<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Internal Medicine Clinical Reference Guide</title>
    <style>
        * {
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, sans-serif;
            font-size: 10pt;
            line-height: 1.4;
            margin: 0;
            padding: 0;
            color: #24292e;
            background: #f6f8fa;
        }
        
        .calculator {
            background: #fff3cd;
            border: 2px solid #ffc107;
            border-radius: 8px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .calculator-title {
            font-weight: 600;
            color: #856404;
            font-size: 11pt;
            margin-bottom: 10px;
        }
        
        .calc-item {
            margin: 12px 0;
            padding: 8px;
            background: white;
            border-radius: 4px;
            border: 1px solid #e8e8e8;
        }
        
        .calc-item label {
            display: block;
            font-weight: 600;
            margin-bottom: 6px;
            color: #333;
            font-size: 9.5pt;
        }
        
        .calc-item .hint {
            display: block;
            font-size: 8pt;
            color: #666;
            font-weight: normal;
            margin-top: 2px;
            font-style: italic;
        }
        
        .calc-item select, .calc-item input[type="number"] {
            width: 100%;
            padding: 8px 10px;
            border: 2px solid #ddd;
            border-radius: 4px;
            font-size: 9.5pt;
            background: white;
            transition: border-color 0.2s;
        }
        
        .calc-item select:focus, .calc-item input[type="number"]:focus {
            outline: none;
            border-color: #0366d6;
            box-shadow: 0 0 0 3px rgba(3, 102, 214, 0.1);
        }
        
        .calc-item input[type="number"]::placeholder {
            color: #999;
            font-style: italic;
        }
        
        .calc-item input[type="checkbox"] {
            width: 18px;
            height: 18px;
            margin-right: 8px;
            cursor: pointer;
            vertical-align: middle;
        }
        
        .calc-item.checkbox-item {
            padding: 10px;
            cursor: pointer;
            transition: background 0.2s;
        }
        
        .calc-item.checkbox-item:hover {
            background: #f8f9fa;
        }
        
        .calc-item.checkbox-item label {
            cursor: pointer;
            margin: 0;
            display: inline;
            font-weight: 500;
        }
        
        .calc-result {
            background: #d4edda;
            border: 2px solid #28a745;
            padding: 12px;
            margin-top: 12px;
            border-radius: 6px;
            font-weight: 600;
        }
        
        .calc-result.high-risk {
            background: #f8d7da;
            border-color: #dc3545;
        }
        
        .calc-button {
            background: #0366d6;
            color: white;
            border: none;
            padding: 8px 16px;
            border-radius: 6px;
            cursor: pointer;
            font-size: 9pt;
            margin-top: 10px;
        }
        
        .calc-button:hover {
            background: #0256c7;
        }
        
        .calc-description {
            font-size: 9pt;
            color: #666;
            margin-top: 8px;
            padding: 8px;
            background: #f9f9f9;
            border-radius: 4px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            box-shadow: 0 1px 3px rgba(0,0,0,0.12);
        }
        
        .nav-header {
            background: #24292e;
            color: white;
            padding: 20px 30px;
            position: sticky;
            top: 0;
            z-index: 100;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        
        .nav-header h1 {
            margin: 0;
            font-size: 22pt;
        }
        
        .nav-header p {
            margin: 5px 0 0 0;
            opacity: 0.9;
            font-size: 10pt;
        }
        
        .back-to-top {
            display: inline-block;
            background: #0366d6;
            color: white;
            padding: 8px 16px;
            text-decoration: none;
            border-radius: 6px;
            font-size: 9pt;
            margin-top: 10px;
            transition: background 0.2s;
        }
        
        .back-to-top:hover {
            background: #0256c7;
        }
        
        .toc {
            padding: 30px;
            background: #f6f8fa;
            border-bottom: 3px solid #e1e4e8;
            scroll-margin-top: 95px;
        }
        
        .toc h2 {
            margin-top: 0;
            color: #24292e;
            font-size: 18pt;
            border-bottom: 2px solid #e1e4e8;
            padding-bottom: 10px;
        }
        
        .toc-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 12px;
            margin-top: 20px;
        }
        
        .toc-item {
            background: white;
            border: 1px solid #e1e4e8;
            border-radius: 6px;
            padding: 12px;
            transition: all 0.2s;
        }
        
        .toc-item:hover {
            border-color: #0366d6;
            box-shadow: 0 2px 8px rgba(3,102,214,0.15);
            transform: translateY(-2px);
        }
        
        .toc-item a {
            text-decoration: none;
            color: #0366d6;
            font-weight: 600;
            font-size: 10pt;
            display: block;
        }
        
        .toc-item a:hover {
            text-decoration: underline;
        }
        
        .toc-number {
            color: #586069;
            font-size: 9pt;
            font-weight: normal;
        }
        
        .condition-page {
            padding: 0px 30px 30px 30px;
            border-bottom: 3px solid #e1e4e8;
            scroll-margin-top: 130px;
        }
        
        .page-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 20px 25px;
            margin: 0 -30px 25px -30px;
            border-radius: 0;
        }
        
        .page-header h2 {
            margin: 0;
            font-size: 20pt;
        }
        
        .page-header .subtitle {
            font-size: 10pt;
            margin-top: 5px;
            opacity: 0.95;
        }
        
        .section {
            margin-bottom: 18px;
        }
        
        .section-title {
            background: #0366d6;
            color: white;
            padding: 6px 12px;
            font-weight: 600;
            font-size: 11pt;
            margin-bottom: 8px;
            border-radius: 4px;
        }
        
        .section-content {
            padding-left: 12px;
        }
        
        .label {
            font-weight: 600;
            color: #24292e;
        }
        
        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 15px;
            margin: 15px 0;
        }
        
        @media (max-width: 768px) {
            .two-column {
                grid-template-columns: 1fr;
            }
            .toc-grid {
                grid-template-columns: 1fr;
            }
        }
        
        .box {
            border: 2px solid #d73a49;
            background: #ffeef0;
            padding: 12px;
            border-radius: 6px;
        }
        
        .box-title {
            font-weight: 600;
            color: #d73a49;
            margin-bottom: 6px;
            font-size: 11pt;
        }
        
        .pearl-box {
            border: 2px solid #28a745;
            background: #dcffe4;
            padding: 12px;
            margin: 15px 0;
            border-radius: 6px;
        }
        
        .pearl-title {
            font-weight: 600;
            color: #28a745;
            margin-bottom: 6px;
            font-size: 11pt;
        }
        
        ul {
            margin: 6px 0;
            padding-left: 20px;
        }
        
        li {
            margin: 4px 0;
        }
        
        p {
            margin: 6px 0;
        }
        
        .footer-section {
            background: #24292e;
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        .footer-section p {
            margin: 5px 0;
            opacity: 0.8;
        }
        
        @media print {
            .nav-header, .back-to-top {
                display: none;
            }
            .condition-page {
                page-break-after: always;
            }
            body {
                background: white;
            }
            .container {
                box-shadow: none;
            }
        }
        
        html {
            scroll-behavior: smooth;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="nav-header">
            <h1>Internal Medicine Clinical Reference Guide</h1>
            <p>100 Essential Conditions for Hospital Medicine</p>
            <a href="#toc" class="back-to-top">‚Üë Table of Contents</a>
        </div>
        
        <div id="toc" class="toc">
            <h2>üìã Table of Contents</h2>
            <p style="text-align: center; margin-bottom: 15px;">
                <a href="#system-index" style="color: #0366d6; text-decoration: none; font-weight: 600; font-size: 10pt;">üîç View by Physiologic System ‚Üí</a>
            </p>
            <div class="toc-grid">
                <div class="toc-item">
                    <a href="#acs"><span class="toc-number">1.</span> Acute Coronary Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#heart-failure"><span class="toc-number">2.</span> Heart Failure Exacerbation</a>
                </div>
                <div class="toc-item">
                    <a href="#afib"><span class="toc-number">3.</span> Atrial Fibrillation</a>
                </div>
                <div class="toc-item">
                    <a href="#htn-emergency"><span class="toc-number">4.</span> Hypertensive Emergency</a>
                </div>
                <div class="toc-item">
                    <a href="#cap"><span class="toc-number">5.</span> Community-Acquired Pneumonia</a>
                </div>
                <div class="toc-item">
                    <a href="#copd"><span class="toc-number">6.</span> COPD Exacerbation</a>
                </div>
                <div class="toc-item">
                    <a href="#asthma"><span class="toc-number">7.</span> Asthma Exacerbation</a>
                </div>
                <div class="toc-item">
                    <a href="#pe"><span class="toc-number">8.</span> Pulmonary Embolism</a>
                </div>
                <div class="toc-item">
                    <a href="#sepsis"><span class="toc-number">9.</span> Sepsis/Septic Shock</a>
                </div>
                <div class="toc-item">
                    <a href="#aki"><span class="toc-number">10.</span> Acute Kidney Injury</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperkalemia"><span class="toc-number">11.</span> Hyperkalemia</a>
                </div>
                <div class="toc-item">
                    <a href="#hyponatremia"><span class="toc-number">12.</span> Hyponatremia</a>
                </div>
                <div class="toc-item">
                    <a href="#dka"><span class="toc-number">13.</span> Diabetic Ketoacidosis</a>
                </div>
                <div class="toc-item">
                    <a href="#hhs"><span class="toc-number">14.</span> Hyperosmolar Hyperglycemic State</a>
                </div>
                <div class="toc-item">
                    <a href="#ugib"><span class="toc-number">15.</span> Upper GI Bleed</a>
                </div>
                <div class="toc-item">
                    <a href="#cirrhosis"><span class="toc-number">16.</span> Cirrhosis with Ascites</a>
                </div>
                <div class="toc-item">
                    <a href="#sbp"><span class="toc-number">17.</span> Spontaneous Bacterial Peritonitis</a>
                </div>
                <div class="toc-item">
                    <a href="#he"><span class="toc-number">18.</span> Hepatic Encephalopathy</a>
                </div>
                <div class="toc-item">
                    <a href="#pancreatitis"><span class="toc-number">19.</span> Acute Pancreatitis</a>
                </div>
                <div class="toc-item">
                    <a href="#cellulitis"><span class="toc-number">20.</span> Cellulitis</a>
                </div>
                <div class="toc-item">
                    <a href="#uti"><span class="toc-number">21.</span> Urinary Tract Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#cdiff"><span class="toc-number">22.</span> C. difficile Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#dvt"><span class="toc-number">23.</span> Deep Vein Thrombosis</a>
                </div>
                <div class="toc-item">
                    <a href="#stroke"><span class="toc-number">24.</span> Acute Ischemic Stroke</a>
                </div>
                <div class="toc-item">
                    <a href="#seizure"><span class="toc-number">25.</span> Seizure/Status Epilepticus</a>
                </div>
                <div class="toc-item">
                    <a href="#meningitis"><span class="toc-number">26.</span> Bacterial Meningitis</a>
                </div>
                <div class="toc-item">
                    <a href="#anemia"><span class="toc-number">27.</span> Anemia</a>
                </div>
                <div class="toc-item">
                    <a href="#neutropenic-fever"><span class="toc-number">28.</span> Neutropenic Fever</a>
                </div>
                <div class="toc-item">
                    <a href="#etoh-withdrawal"><span class="toc-number">29.</span> Alcohol Withdrawal</a>
                </div>
                <div class="toc-item">
                    <a href="#delirium"><span class="toc-number">30.</span> Delirium</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperthyroid"><span class="toc-number">31.</span> Hyperthyroidism/Thyroid Storm</a>
                </div>
                <div class="toc-item">
                    <a href="#hypothyroid"><span class="toc-number">32.</span> Hypothyroidism/Myxedema Coma</a>
                </div>
                <div class="toc-item">
                    <a href="#adrenal"><span class="toc-number">33.</span> Adrenal Insufficiency</a>
                </div>
                <div class="toc-item">
                    <a href="#hypercalcemia"><span class="toc-number">34.</span> Hypercalcemia</a>
                </div>
                <div class="toc-item">
                    <a href="#hypomag"><span class="toc-number">35.</span> Hypomagnesemia</a>
                </div>
                <div class="toc-item">
                    <a href="#rhabdo"><span class="toc-number">36.</span> Rhabdomyolysis</a>
                </div>
                <div class="toc-item">
                    <a href="#transfusion"><span class="toc-number">37.</span> Transfusion Reactions</a>
                </div>
                <div class="toc-item">
                    <a href="#pleural-effusion"><span class="toc-number">38.</span> Pleural Effusion</a>
                </div>
                <div class="toc-item">
                    <a href="#pneumothorax"><span class="toc-number">39.</span> Pneumothorax</a>
                </div>
                <div class="toc-item">
                    <a href="#syncope"><span class="toc-number">40.</span> Syncope</a>
                </div>
                <div class="toc-item">
                    <a href="#pancreatitis"><span class="toc-number">19.</span> Acute Pancreatitis</a>
                </div>
                <div class="toc-item">
                    <a href="#cellulitis"><span class="toc-number">20.</span> Cellulitis</a>
                </div>
                <div class="toc-item">
                    <a href="#uti"><span class="toc-number">21.</span> Urinary Tract Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#c-diff"><span class="toc-number">22.</span> C. difficile Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#dvt"><span class="toc-number">23.</span> Deep Vein Thrombosis</a>
                </div>
                <div class="toc-item">
                    <a href="#stroke"><span class="toc-number">24.</span> Acute Ischemic Stroke</a>
                </div>
                <div class="toc-item">
                    <a href="#seizure"><span class="toc-number">25.</span> Seizure</a>
                </div>
                <div class="toc-item">
                    <a href="#meningitis"><span class="toc-number">26.</span> Bacterial Meningitis</a>
                </div>
                <div class="toc-item">
                    <a href="#anemia"><span class="toc-number">27.</span> Anemia</a>
                </div>
                <div class="toc-item">
                    <a href="#neutropenic-fever"><span class="toc-number">28.</span> Neutropenic Fever</a>
                </div>
                <div class="toc-item">
                    <a href="#alcohol-withdrawal"><span class="toc-number">29.</span> Alcohol Withdrawal</a>
                </div>
                <div class="toc-item">
                    <a href="#delirium"><span class="toc-number">30.</span> Delirium</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperthyroid"><span class="toc-number">31.</span> Hyperthyroidism/Thyroid Storm</a>
                </div>
                <div class="toc-item">
                    <a href="#hypothyroid"><span class="toc-number">32.</span> Hypothyroidism/Myxedema Coma</a>
                </div>
                <div class="toc-item">
                    <a href="#adrenal-crisis"><span class="toc-number">33.</span> Adrenal Insufficiency/Crisis</a>
                </div>
                <div class="toc-item">
                    <a href="#hypercalcemia"><span class="toc-number">34.</span> Hypercalcemia</a>
                </div>
                <div class="toc-item">
                    <a href="#hypomag"><span class="toc-number">35.</span> Hypomagnesemia</a>
                </div>
                <div class="toc-item">
                    <a href="#rhabdo"><span class="toc-number">36.</span> Rhabdomyolysis</a>
                </div>
                <div class="toc-item">
                    <a href="#transfusion"><span class="toc-number">37.</span> Transfusion Reaction</a>
                </div>
                <div class="toc-item">
                    <a href="#effusion"><span class="toc-number">38.</span> Pleural Effusion</a>
                </div>
                <div class="toc-item">
                    <a href="#pneumothorax"><span class="toc-number">39.</span> Pneumothorax</a>
                </div>
                <div class="toc-item">
                    <a href="#syncope"><span class="toc-number">40.</span> Syncope</a>
                </div>
                <div class="toc-item">
                    <a href="#pericarditis"><span class="toc-number">41.</span> Pericarditis/Pericardial Effusion/Cardiac Tamponade</a>
                </div>
                <div class="toc-item">
                    <a href="#endocarditis"><span class="toc-number">42.</span> Infective Endocarditis</a>
                </div>
                <div class="toc-item">
                    <a href="#myocarditis"><span class="toc-number">43.</span> Myocarditis</a>
                </div>
                <div class="toc-item">
                    <a href="#cardiogenic-shock"><span class="toc-number">44.</span> Cardiogenic Shock</a>
                </div>
                <div class="toc-item">
                    <a href="#bradycardia"><span class="toc-number">45.</span> Symptomatic Bradycardia/Heart Block (Pacing)</a>
                </div>
                <div class="toc-item">
                    <a href="#vt-vf"><span class="toc-number">46.</span> Ventricular Tachycardia/Ventricular Fibrillation</a>
                </div>
                <div class="toc-item">
                    <a href="#limb-ischemia"><span class="toc-number">47.</span> Acute Limb Ischemia</a>
                </div>
                <div class="toc-item">
                    <a href="#dvt"><span class="toc-number">48.</span> Deep Vein Thrombosis (DVT)</a>
                </div>
                <div class="toc-item">
                    <a href="#pleural-effusion"><span class="toc-number">49.</span> Pleural Effusion</a>
                </div>
                <div class="toc-item">
                    <a href="#pneumothorax"><span class="toc-number">50.</span> Pneumothorax/Tension Pneumothorax</a>
                </div>
                <div class="toc-item">
                    <a href="#ild"><span class="toc-number">51.</span> Acute Exacerbation of Interstitial Lung Disease (ILD)</a>
                </div>
                <div class="toc-item">
                    <a href="#hemoptysis"><span class="toc-number">52.</span> Hemoptysis (Massive)</a>
                </div>
                <div class="toc-item">
                    <a href="#hypercapnic-failure"><span class="toc-number">53.</span> Acute Hypercapnic Respiratory Failure</a>
                </div>
                <div class="toc-item">
                    <a href="#tia"><span class="toc-number">54.</span> Transient Ischemic Attack (TIA)</a>
                </div>
                <div class="toc-item">
                    <a href="#gbs"><span class="toc-number">55.</span> Guillain-Barr√© Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#myasthenia"><span class="toc-number">56.</span> Myasthenia Gravis Crisis</a>
                </div>
                <div class="toc-item">
                    <a href="#delirium"><span class="toc-number">57.</span> Acute Delirium (Non-Alcohol)</a>
                </div>
                <div class="toc-item">
                    <a href="#increased-icp"><span class="toc-number">58.</span> Increased Intracranial Pressure (ICP)</a>
                </div>
                <div class="toc-item">
                    <a href="#cord-compression"><span class="toc-number">59.</span> Spinal Cord Compression</a>
                </div>
                <div class="toc-item">
                    <a href="#influenza"><span class="toc-number">60.</span> Influenza/Severe Viral Pneumonia</a>
                </div>
                <div class="toc-item">
                    <a href="#covid"><span class="toc-number">61.</span> COVID-19 Severe Disease</a>
                </div>
                <div class="toc-item">
                    <a href="#cdiff"><span class="toc-number">62.</span> Clostridioides difficile Colitis</a>
                </div>
                <div class="toc-item">
                    <a href="#pyelo"><span class="toc-number">63.</span> UTI/Pyelonephritis (Complicated)</a>
                </div>
                <div class="toc-item">
                    <a href="#ssti"><span class="toc-number">64.</span> Skin/Soft Tissue Infections (Cellulitis, Necrotizing Fasciitis)</a>
                </div>
                <div class="toc-item">
                    <a href="#tb"><span class="toc-number">65.</span> Tuberculosis (Active)</a>
                </div>
                <div class="toc-item">
                    <a href="#hiv-aids"><span class="toc-number">66.</span> HIV/AIDS Complications</a>
                </div>
                <div class="toc-item">
                    <a href="#opportunistic"><span class="toc-number">67.</span> Opportunistic Infections in Immunocompromised Host</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperthyroid"><span class="toc-number">68.</span> Hyperthyroidism/Thyrotoxicosis (Non-Storm)</a>
                </div>
                <div class="toc-item">
                    <a href="#hypothyroid"><span class="toc-number">69.</span> Hypothyroidism (Non-Myxedema)</a>
                </div>
                <div class="toc-item">
                    <a href="#diabetic-foot"><span class="toc-number">70.</span> Diabetic Foot Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#siadh"><span class="toc-number">71.</span> SIADH (Syndrome of Inappropriate ADH)</a>
                </div>
                <div class="toc-item">
                    <a href="#diabetes-insipidus"><span class="toc-number">72.</span> Diabetes Insipidus</a>
                </div>
                <div class="toc-item">
                    <a href="#pheo"><span class="toc-number">73.</span> Pheochromocytoma Crisis</a>
                </div>
                <div class="toc-item">
                    <a href="#bowel-obstruction"><span class="toc-number">74.</span> Bowel Obstruction (Small/Large)</a>
                </div>
                <div class="toc-item">
                    <a href="#acute-diarrhea"><span class="toc-number">75.</span> Severe Acute Diarrhea/Volume Depletion</a>
                </div>
                <div class="toc-item">
                    <a href="#ibd"><span class="toc-number">76.</span> Inflammatory Bowel Disease (IBD) Flare</a>
                </div>
                <div class="toc-item">
                    <a href="#diverticulitis"><span class="toc-number">77.</span> Diverticulitis (Complicated)</a>
                </div>
                <div class="toc-item">
                    <a href="#cirrhosis-complications"><span class="toc-number">78.</span> Cirrhosis Complications (Variceal Bleeding, Hepatorenal Syndrome)</a>
                </div>
                <div class="toc-item">
                    <a href="#aclf"><span class="toc-number">79.</span> Acute-on-Chronic Liver Failure</a>
                </div>
                <div class="toc-item">
                    <a href="#mesenteric-ischemia"><span class="toc-number">80.</span> Ischemic Bowel/Mesenteric Ischemia</a>
                </div>
                <div class="toc-item">
                    <a href="#ckd-complications"><span class="toc-number">81.</span> Chronic Kidney Disease Complications</a>
                </div>
                <div class="toc-item">
                    <a href="#uremia"><span class="toc-number">82.</span> Uremic Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#rhabdo"><span class="toc-number">83.</span> Rhabdomyolysis</a>
                </div>
                <div class="toc-item">
                    <a href="#tls"><span class="toc-number">84.</span> Tumor Lysis Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#hypocalcemia"><span class="toc-number">85.</span> Hypocalcemia</a>
                </div>
                <div class="toc-item">
                    <a href="#magnesium"><span class="toc-number">86.</span> Hypermagnesemia/Hypomagnesemia</a>
                </div>
                <div class="toc-item">
                    <a href="#phosphate"><span class="toc-number">87.</span> Hyperphosphatemia/Hypophosphatemia</a>
                </div>
                <div class="toc-item">
                    <a href="#metabolic-alkalosis"><span class="toc-number">88.</span> Metabolic Alkalosis</a>
                </div>
                <div class="toc-item">
                    <a href="#thrombocytopenia"><span class="toc-number">89.</span> Thrombocytopenia (ITP, HIT, TTP/HUS)</a>
                </div>
                <div class="toc-item">
                    <a href="#dic"><span class="toc-number">90.</span> Disseminated Intravascular Coagulation (DIC)</a>
                </div>
                <div class="toc-item">
                    <a href="#sickle-cell"><span class="toc-number">91.</span> Sickle Cell Crisis (Vaso-occlusive, Acute Chest)</a>
                </div>
                <div class="toc-item">
                    <a href="#hemolytic-anemia"><span class="toc-number">92.</span> Hemolytic Anemia</a>
                </div>
                <div class="toc-item">
                    <a href="#onc-emergencies"><span class="toc-number">93.</span> Oncologic Emergencies (SVC Syndrome, Cord Compression, Hypercalcemia of Malignancy)</a>
                </div>
                <div class="toc-item">
                    <a href="#anticoag-reversal"><span class="toc-number">94.</span> Anticoagulation Reversal/Major Bleeding on Anticoagulants</a>
                </div>
                <div class="toc-item">
                    <a href="#gout"><span class="toc-number">95.</span> Acute Gout/Pseudogout (Crystal Arthropathy)</a>
                </div>
                <div class="toc-item">
                    <a href="#sle"><span class="toc-number">96.</span> Systemic Lupus Erythematosus (SLE) Flare</a>
                </div>
                <div class="toc-item">
                    <a href="#gca"><span class="toc-number">97.</span> Giant Cell Arteritis/Temporal Arteritis</a>
                </div>
                <div class="toc-item">
                    <a href="#anaphylaxis"><span class="toc-number">98.</span> Anaphylaxis</a>
                </div>
                <div class="toc-item">
                    <a href="#overdose"><span class="toc-number">99.</span> Drug Overdose/Toxidromes (Acetaminophen, Salicylates, TCA, etc.)</a>
                </div>
                <div class="toc-item">
                    <a href="#opioid"><span class="toc-number">100.</span> Opioid Overdose/Withdrawal</a>
                </div>
            </div>
        </div>

        <!-- SYSTEM-BASED INDEX -->
        <div id="system-index" class="toc" style="margin-top: 30px;">
            <h2>üîç Index by Physiologic System</h2>
            <p style="font-size: 9pt; color: #666; margin-bottom: 15px;">Quick reference organized by organ system. Some conditions appear in multiple categories.</p>
            
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(280px, 1fr)); gap: 20px;">
                
                <!-- CARDIOVASCULAR -->
                <div style="background: #fff; border: 2px solid #e74c3c; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #e74c3c; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #e74c3c; padding-bottom: 5px;">‚ù§Ô∏è CARDIOVASCULAR</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#acs" style="color: #0366d6; text-decoration: none;">1. Acute Coronary Syndrome</a><br>
                        <a href="#heart-failure" style="color: #0366d6; text-decoration: none;">2. Heart Failure Exacerbation</a><br>
                        <a href="#afib" style="color: #0366d6; text-decoration: none;">3. Atrial Fibrillation</a><br>
                        <a href="#htn-emergency" style="color: #0366d6; text-decoration: none;">4. Hypertensive Emergency</a><br>
                        <a href="#dvt" style="color: #0366d6; text-decoration: none;">23. Deep Vein Thrombosis</a><br>
                        <a href="#syncope" style="color: #0366d6; text-decoration: none;">40. Syncope</a><br>
                        <a href="#pericarditis" style="color: #0366d6; text-decoration: none;">41. Pericarditis/Tamponade</a><br>
                        <a href="#endocarditis" style="color: #0366d6; text-decoration: none;">42. Infective Endocarditis</a><br>
                        <a href="#myocarditis" style="color: #0366d6; text-decoration: none;">43. Myocarditis</a><br>
                        <a href="#cardiogenic-shock" style="color: #0366d6; text-decoration: none;">44. Cardiogenic Shock</a><br>
                        <a href="#bradycardia" style="color: #0366d6; text-decoration: none;">45. Bradycardia/Heart Block</a><br>
                        <a href="#vt-vf" style="color: #0366d6; text-decoration: none;">46. VT/VF</a><br>
                        <a href="#limb-ischemia" style="color: #0366d6; text-decoration: none;">47. Acute Limb Ischemia</a><br>
                        <a href="#dvt" style="color: #0366d6; text-decoration: none;">48. DVT</a>
                    </div>
                </div>
                
                <!-- PULMONARY -->
                <div style="background: #fff; border: 2px solid #3498db; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #3498db; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #3498db; padding-bottom: 5px;">ü´Å PULMONARY</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#cap" style="color: #0366d6; text-decoration: none;">5. Community-Acquired Pneumonia</a><br>
                        <a href="#copd" style="color: #0366d6; text-decoration: none;">6. COPD Exacerbation</a><br>
                        <a href="#asthma" style="color: #0366d6; text-decoration: none;">7. Asthma Exacerbation</a><br>
                        <a href="#pe" style="color: #0366d6; text-decoration: none;">8. Pulmonary Embolism</a><br>
                        <a href="#pleural-effusion" style="color: #0366d6; text-decoration: none;">38. Pleural Effusion</a><br>
                        <a href="#pneumothorax" style="color: #0366d6; text-decoration: none;">39. Pneumothorax</a><br>
                        <a href="#pleural-effusion" style="color: #0366d6; text-decoration: none;">49. Pleural Effusion</a><br>
                        <a href="#pneumothorax" style="color: #0366d6; text-decoration: none;">50. Pneumothorax/Tension</a><br>
                        <a href="#ild" style="color: #0366d6; text-decoration: none;">51. ILD Exacerbation</a><br>
                        <a href="#hemoptysis" style="color: #0366d6; text-decoration: none;">52. Hemoptysis (Massive)</a><br>
                        <a href="#hypercapnic-failure" style="color: #0366d6; text-decoration: none;">53. Hypercapnic Resp Failure</a><br>
                        <a href="#influenza" style="color: #0366d6; text-decoration: none;">60. Influenza/Viral Pneumonia</a><br>
                        <a href="#covid" style="color: #0366d6; text-decoration: none;">61. COVID-19 Severe Disease</a>
                    </div>
                </div>
                
                <!-- RENAL/ELECTROLYTES -->
                <div style="background: #fff; border: 2px solid #9b59b6; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #9b59b6; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #9b59b6; padding-bottom: 5px;">üß™ RENAL & ELECTROLYTES</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#aki" style="color: #0366d6; text-decoration: none;">10. Acute Kidney Injury</a><br>
                        <a href="#hyperkalemia" style="color: #0366d6; text-decoration: none;">11. Hyperkalemia</a><br>
                        <a href="#hyponatremia" style="color: #0366d6; text-decoration: none;">12. Hyponatremia</a><br>
                        <a href="#hypercalcemia" style="color: #0366d6; text-decoration: none;">34. Hypercalcemia</a><br>
                        <a href="#hypomag" style="color: #0366d6; text-decoration: none;">35. Hypomagnesemia</a>
                    </div>
                </div>
                
                <!-- ENDOCRINE -->
                <div style="background: #fff; border: 2px solid #f39c12; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #f39c12; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #f39c12; padding-bottom: 5px;">‚ö° ENDOCRINE</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#dka" style="color: #0366d6; text-decoration: none;">13. Diabetic Ketoacidosis</a><br>
                        <a href="#hhs" style="color: #0366d6; text-decoration: none;">14. Hyperosmolar Hyperglycemic State</a><br>
                        <a href="#hyperthyroid" style="color: #0366d6; text-decoration: none;">31. Hyperthyroidism/Thyroid Storm</a><br>
                        <a href="#hypothyroid" style="color: #0366d6; text-decoration: none;">32. Hypothyroidism/Myxedema Coma</a><br>
                        <a href="#adrenal" style="color: #0366d6; text-decoration: none;">33. Adrenal Insufficiency/Crisis</a>
                    </div>
                </div>
                
                <!-- GI/HEPATIC -->
                <div style="background: #fff; border: 2px solid #27ae60; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #27ae60; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #27ae60; padding-bottom: 5px;">ü´Ñ GASTROINTESTINAL & HEPATIC</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#ugib" style="color: #0366d6; text-decoration: none;">15. Upper GI Bleed</a><br>
                        <a href="#cirrhosis" style="color: #0366d6; text-decoration: none;">16. Cirrhosis with Ascites</a><br>
                        <a href="#sbp" style="color: #0366d6; text-decoration: none;">17. Spontaneous Bacterial Peritonitis</a><br>
                        <a href="#he" style="color: #0366d6; text-decoration: none;">18. Hepatic Encephalopathy</a><br>
                        <a href="#pancreatitis" style="color: #0366d6; text-decoration: none;">19. Acute Pancreatitis</a><br>
                        <a href="#cdiff" style="color: #0366d6; text-decoration: none;">22. C. difficile Infection</a>
                    </div>
                </div>
                
                <!-- INFECTIOUS DISEASE -->
                <div style="background: #fff; border: 2px solid #e67e22; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #e67e22; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #e67e22; padding-bottom: 5px;">ü¶† INFECTIOUS DISEASE</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#cap" style="color: #0366d6; text-decoration: none;">5. Community-Acquired Pneumonia</a><br>
                        <a href="#sepsis" style="color: #0366d6; text-decoration: none;">9. Sepsis/Septic Shock</a><br>
                        <a href="#cellulitis" style="color: #0366d6; text-decoration: none;">20. Cellulitis</a><br>
                        <a href="#uti" style="color: #0366d6; text-decoration: none;">21. UTI/Pyelonephritis</a><br>
                        <a href="#cdiff" style="color: #0366d6; text-decoration: none;">22. C. difficile Infection</a><br>
                        <a href="#meningitis" style="color: #0366d6; text-decoration: none;">26. Bacterial Meningitis</a><br>
                        <a href="#neutropenic-fever" style="color: #0366d6; text-decoration: none;">28. Neutropenic Fever</a>
                    </div>
                </div>
                
                <!-- NEUROLOGIC -->
                <div style="background: #fff; border: 2px solid #8e44ad; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #8e44ad; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #8e44ad; padding-bottom: 5px;">üß† NEUROLOGIC</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#stroke" style="color: #0366d6; text-decoration: none;">24. Acute Ischemic Stroke</a><br>
                        <a href="#seizure" style="color: #0366d6; text-decoration: none;">25. Seizure/Status Epilepticus</a><br>
                        <a href="#meningitis" style="color: #0366d6; text-decoration: none;">26. Bacterial Meningitis</a><br>
                        <a href="#delirium" style="color: #0366d6; text-decoration: none;">30. Delirium</a>
                    </div>
                </div>
                
                <!-- HEMATOLOGIC -->
                <div style="background: #fff; border: 2px solid #c0392b; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #c0392b; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #c0392b; padding-bottom: 5px;">ü©∏ HEMATOLOGIC</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#anemia" style="color: #0366d6; text-decoration: none;">27. Anemia</a><br>
                        <a href="#neutropenic-fever" style="color: #0366d6; text-decoration: none;">28. Neutropenic Fever</a><br>
                        <a href="#transfusion" style="color: #0366d6; text-decoration: none;">37. Transfusion Reactions</a>
                    </div>
                </div>
                
                <!-- TOXICOLOGY -->
                <div style="background: #fff; border: 2px solid #16a085; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #16a085; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #16a085; padding-bottom: 5px;">‚ò†Ô∏è TOXICOLOGY & SUBSTANCE</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#etoh-withdrawal" style="color: #0366d6; text-decoration: none;">29. Alcohol Withdrawal</a>
                    </div>
                </div>
                
                <!-- METABOLIC/MUSCULOSKELETAL -->
                <div style="background: #fff; border: 2px solid #d35400; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #d35400; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #d35400; padding-bottom: 5px;">üí™ METABOLIC & MUSCULOSKELETAL</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#rhabdo" style="color: #0366d6; text-decoration: none;">36. Rhabdomyolysis</a>
                    </div>
                </div>
                
            </div>
            
            <p style="margin-top: 20px; text-align: center;">
                <a href="#toc" style="color: #0366d6; text-decoration: none; font-weight: 600;">‚Üë Back to Numerical Table of Contents</a>
            </p>
        </div>

        <!-- PAGE 1: ACUTE CORONARY SYNDROME -->
        <div id="acs" class="condition-page">
            <div class="page-header">
                <h2>1. ACUTE CORONARY SYNDROME (ACS)</h2>
                <div class="subtitle">STEMI ‚Ä¢ NSTEMI ‚Ä¢ Unstable Angina</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Substernal chest pain/pressure >20 minutes, radiation to jaw/left arm/back, diaphoresis, nausea, dyspnea. Pain not relieved by rest or nitroglycerin.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Diabetics/Elderly/Women:</strong> Atypical symptoms - dyspnea alone, weakness, epigastric pain, syncope</li>
                        <li><strong>Silent MI:</strong> No chest pain (30% of diabetics)</li>
                        <li><strong>RV Infarction:</strong> Hypotension with clear lungs, JVD, Kussmaul sign</li>
                        <li><strong>Posterior MI:</strong> Isolated ST depression V1-V3, need posterior leads (V7-V9)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> ECG within 10 minutes, troponin (repeat at 3 and 6 hours if initial negative), CBC, BMP, PT/INR, lipid panel, CXR</p>
                    <p><span class="label">STEMI Criteria:</span> ST elevation ‚â•1mm in 2+ contiguous leads OR new LBBB OR ST depression V1-V3 (posterior MI)</p>
                    <p><span class="label">Calculations:</span> <a href="#calc-heart" style="color: #0366d6;">HEART Score</a>, <a href="#calc-timi-stemi" style="color: #0366d6;">TIMI STEMI</a>, <a href="#calc-timi-nstemi" style="color: #0366d6;">TIMI NSTEMI</a>, <a href="#calc-grace" style="color: #0366d6;">GRACE Score</a></p>
                    
                    <!-- HEART Score Calculator -->
                    <div id="calc-heart" class="calculator">
                        <div class="calculator-title">üßÆ HEART Score Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Risk stratification for chest pain patients to determine if safe for outpatient evaluation. Score 0-3 = low risk (outpatient), 4-6 = moderate risk (observe), 7-10 = high risk (admit).
                        </div>
                        
                        <div class="calc-item">
                            <label>History
                                <span class="hint">How suspicious is the patient's story for ACS?</span>
                            </label>
                            <select id="heart-history">
                                <option value="0">Slightly suspicious - probably not cardiac (0)</option>
                                <option value="1" selected>Moderately suspicious - could be cardiac (1)</option>
                                <option value="2">Highly suspicious - typical angina (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>ECG
                                <span class="hint">Initial ECG findings</span>
                            </label>
                            <select id="heart-ecg">
                                <option value="0" selected>Normal (0)</option>
                                <option value="1">Non-specific repolarization changes (1)</option>
                                <option value="2">Significant ST deviation (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Age
                                <span class="hint">Patient's age in years</span>
                            </label>
                            <select id="heart-age">
                                <option value="0"><21 years (0)</option>
                                <option value="1">21-45 years (1)</option>
                                <option value="2" selected>45-65 years (2)</option>
                                <option value="2">>65 years (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Risk Factors
                                <span class="hint">Count: HTN, DM, smoking, high cholesterol, family history, obesity</span>
                            </label>
                            <select id="heart-risk">
                                <option value="0">None (0)</option>
                                <option value="1" selected>1-2 risk factors (1)</option>
                                <option value="2">‚â•3 risk factors or history of atherosclerotic disease (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Troponin
                                <span class="hint">Initial troponin level relative to upper limit of normal</span>
                            </label>
                            <select id="heart-trop">
                                <option value="0" selected>Normal - below upper limit (0)</option>
                                <option value="1">1-3√ó upper limit of normal (1)</option>
                                <option value="2">>3√ó upper limit of normal (2)</option>
                            </select>
                        </div>
                        
                        <button class="calc-button" onclick="calculateHEART()">Calculate HEART Score</button>
                        <div id="heart-result"></div>
                    </div>
                    
                    <!-- TIMI STEMI Calculator -->
                    <div id="calc-timi-stemi" class="calculator">
                        <div class="calculator-title">üßÆ TIMI Risk Score - STEMI</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Predicts 30-day mortality in STEMI patients. Score 0-2 = 2% mortality, 3-4 = 5%, 5-6 = 12%, >6 = 36%.
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-age65"> Age 65-74 years
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-age75"> Age ‚â•75 years
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-dm"> Diabetes, Hypertension, or Angina history
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-bp"> Systolic BP <100 mmHg
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-hr"> Heart rate >100 bpm
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-killip"> Killip class II-IV (rales, S3, pulmonary edema, shock)
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-weight"> Weight <67 kg (150 lbs)
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-anterior"> Anterior STEMI or LBBB
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-time"> Time to treatment >4 hours
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateTIMI_STEMI()">Calculate TIMI STEMI Score</button>
                        <div id="timi-stemi-result"></div>
                    </div>
                    
                    <!-- TIMI NSTEMI Calculator -->
                    <div id="calc-timi-nstemi" class="calculator">
                        <div class="calculator-title">üßÆ TIMI Risk Score - NSTEMI/UA</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Risk of death, MI, or urgent revascularization within 14 days. Score 0-2 = 5% risk (low), 3-4 = 13% (moderate), 5-7 = 41% (high).
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-age"> Age ‚â•65 years
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-risk"> ‚â•3 CAD risk factors
                                <span class="hint">HTN, DM, smoking, high cholesterol, family history (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-cad"> Known CAD (stenosis ‚â•50%)
                                <span class="hint">Prior cath showing >50% stenosis (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-asa"> Aspirin use in past 7 days
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-angina"> Severe angina
                                <span class="hint">‚â•2 episodes within 24 hours (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-ecg"> ST changes ‚â•0.5mm
                                <span class="hint">ST elevation or depression (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-trop"> Elevated cardiac markers
                                <span class="hint">Troponin or CK-MB elevated (+1 point)</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateTIMI_NSTEMI()">Calculate TIMI NSTEMI Score</button>
                        <div id="timi-nstemi-result"></div>
                    </div>
                    
                    <!-- GRACE Score Calculator -->
                    <div id="calc-grace" class="calculator">
                        <div class="calculator-title">üßÆ GRACE Score Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Estimates in-hospital and 6-month mortality in ACS. Low risk <109, intermediate 109-140, high >140. More accurate than TIMI for mortality prediction.
                        </div>
                        
                        <div class="calc-item">
                            <label>Age (years)
                                <span class="hint">Patient's age - typical range 40-80</span>
                            </label>
                            <input type="number" id="grace-age" placeholder="e.g., 65" min="18" max="120" value="65">
                        </div>
                        
                        <div class="calc-item">
                            <label>Heart Rate (bpm)
                                <span class="hint">Beats per minute - typical range 60-100</span>
                            </label>
                            <input type="number" id="grace-hr" placeholder="e.g., 85" min="30" max="250" value="85">
                        </div>
                        
                        <div class="calc-item">
                            <label>Systolic Blood Pressure (mmHg)
                                <span class="hint">SBP at presentation - typical range 100-160</span>
                            </label>
                            <input type="number" id="grace-sbp" placeholder="e.g., 130" min="50" max="250" value="130">
                        </div>
                        
                        <div class="calc-item">
                            <label>Creatinine (mg/dL)
                                <span class="hint">Serum creatinine - normal 0.6-1.2 mg/dL</span>
                            </label>
                            <input type="number" id="grace-cr" placeholder="e.g., 1.0" step="0.1" min="0.1" max="15" value="1.0">
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-arrest"> Cardiac arrest at admission
                                <span class="hint">+39 points</span>
                            </label>
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-st"> ST segment deviation on ECG
                                <span class="hint">ST elevation or depression (+28 points)</span>
                            </label>
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-enzymes" checked> Elevated cardiac enzymes
                                <span class="hint">Troponin or CK-MB elevated (+14 points)</span>
                            </label>
                        </div>
                        
                        <div class="calc-item">
                            <label>Killip Class
                                <span class="hint">Clinical heart failure classification</span>
                            </label>
                            <select id="grace-killip">
                                <option value="0" selected>I - No heart failure signs (0)</option>
                                <option value="20">II - Rales or S3 gallop (+20)</option>
                                <option value="39">III - Pulmonary edema (+39)</option>
                                <option value="59">IV - Cardiogenic shock (+59)</option>
                            </select>
                        </div>
                        
                        <button class="calc-button" onclick="calculateGRACE()">Calculate GRACE Score</button>
                        <div id="grace-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management (MONA-BAH):</span></p>
                    <ul>
                        <li><strong>Morphine:</strong> 2-4mg IV PRN (use cautiously, may worsen outcomes)</li>
                        <li><strong>Oxygen:</strong> Only if SpO2 <90%</li>
                        <li><strong>Nitroglycerin:</strong> 0.4mg SL q5min √ó 3 (avoid if RV infarct, SBP <90, recent PDE5 inhibitor)</li>
                        <li><strong>Aspirin:</strong> 325mg PO chewed immediately</li>
                        <li><strong>Œ≤-Blocker:</strong> Metoprolol 25-50mg PO (avoid if HF, bradycardia, hypotension)</li>
                        <li><strong>Anticoagulation:</strong> Heparin bolus + infusion or enoxaparin</li>
                        <li><strong>High-intensity statin:</strong> Atorvastatin 80mg</li>
                    </ul>
                    <p><span class="label">P2Y12 Inhibitor:</span> Ticagrelor 180mg load (preferred) or clopidogrel 600mg load</p>
                    <p><span class="label">STEMI Specific:</span> Door-to-balloon <90 minutes. Call cath lab immediately. If PCI unavailable within 120 min, consider fibrinolytics (tPA, reteplase, tenecteplase)</p>
                    <p><span class="label">NSTEMI Specific:</span> Risk stratify with TIMI/GRACE. High-risk ‚Üí early invasive strategy (<24hr). Low-risk ‚Üí medical management, stress test before discharge</p>
                    
                    <p><span class="label">Post-MI Arrhythmia Monitoring:</span></p>
                    <ul>
                        <li><strong>48-Hour Standard:</strong> Continuous cardiac telemetry monitoring for minimum 48 hours is the standard post-MI observation period. Life-threatening arrhythmias (VF, VT, high-grade AV blocks) are most common in first 48 hours post-infarction, with peak risk in first 24 hours</li>
                        <li><strong>Early Discharge Considerations:</strong> Hemodynamically stable, low-risk patients without complications may be considered for discharge after 24 hours. However, patients discharged before 48 hours remain at elevated risk for arrhythmias and require careful patient selection, thorough education about warning signs, and clear return precautions</li>
                        <li><strong>Extended Monitoring (>48hr) indicated if:</strong> Arrhythmias detected, hemodynamic instability, large infarct, reduced EF (<40%), high-risk features, or persistent ischemia</li>
                        <li><strong>Serial troponins:</strong> Peak at 12-24 hours, trend until downtrending</li>
                        <li><strong>Daily ECG:</strong> Assess for evolution of infarct, new ischemia, conduction abnormalities</li>
                        <li><strong>Echo before discharge:</strong> Assess LV function (EF), wall motion abnormalities, mechanical complications, LV thrombus</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>48-hour arrhythmia window:</strong> Standard telemetry monitoring is 48 hours post-MI. Low-risk patients MAY be discharged at 24 hours if stable, but they remain at elevated arrhythmia risk until 48 hours. Early discharge requires careful patient selection and thorough education about warning signs (palpitations, syncope, chest pain)</li>
                    <li><strong>Sgarbossa Criteria:</strong> Diagnose STEMI with LBBB: ST elevation ‚â•1mm concordant with QRS (5 points), ST depression ‚â•1mm V1-V3 (3 points), ST elevation ‚â•5mm discordant (2 points). Score ‚â•3 = STEMI</li>
                    <li><strong>Wellens Syndrome:</strong> Biphasic or deep inverted T waves V2-V3 in pain-free patient = critical LAD stenosis, high risk of anterior STEMI. No stress test! Go to cath.</li>
                    <li><strong>RV Infarction Pearl:</strong> If inferior STEMI with hypotension, always get right-sided leads (V4R). Treat with aggressive IVF, avoid nitrates/diuretics</li>
                    <li><strong>Troponin timing:</strong> Can be negative first 2-4 hours. Serial troponins essential if high suspicion</li>
                    <li><strong>Don't forget:</strong> Type 2 MI (supply-demand mismatch from anemia, sepsis, tachyarrhythmia) - treat underlying cause, not necessarily cath</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability (SBP <90, shock)</li>
                        <li>Malignant arrhythmias (VT/VF, high-grade AV block)</li>
                        <li>Mechanical complications (papillary rupture, VSD, free wall rupture)</li>
                        <li>Acute heart failure/cardiogenic shock</li>
                        <li>Need for pressors or mechanical support (IABP, Impella)</li>
                        <li>Post-cardiac arrest</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable >24 hours (minimum for early discharge in low-risk patients; standard 48-hour telemetry monitoring preferred)</li>
                        <li>No recurrent chest pain or ischemic symptoms</li>
                        <li>No arrhythmias requiring intervention during monitoring period</li>
                        <li>LVEF assessed (echo)</li>
                        <li>Successful revascularization (if indicated)</li>
                        <li>On DAPT, statin, Œ≤-blocker, ACE-I (if EF <40%)</li>
                        <li>Cardiac rehab referral arranged</li>
                        <li>Patient educated on arrhythmia warning signs if discharged <48 hours</li>
                        <li>Clear return precautions given</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early (hours-days):</strong> Arrhythmias (VF, VT, bradycardia), cardiogenic shock, mechanical complications (papillary muscle rupture, VSD, free wall rupture), acute MR</p>
                    <p><strong>Late (days-weeks):</strong> Heart failure, LV thrombus, pericarditis (early: Dressler's syndrome 2-10 weeks), recurrent ischemia</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 2: HEART FAILURE EXACERBATION -->
        <div id="heart-failure" class="condition-page">
            <div class="page-header">
                <h2>2. ACUTE DECOMPENSATED HEART FAILURE</h2>
                <div class="subtitle">HFrEF ‚Ä¢ HFpEF ‚Ä¢ Acute Exacerbation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Progressive dyspnea, orthopnea, PND, lower extremity edema, weight gain. Physical exam: JVD, bibasilar rales, S3 gallop, peripheral edema, hepatomegaly.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Flash Pulmonary Edema:</strong> Acute onset, often with HTN emergency, minimal peripheral edema</li>
                        <li><strong>High Output HF:</strong> Warm extremities, bounding pulses (thyrotoxicosis, AV fistula, severe anemia)</li>
                        <li><strong>RV Failure:</strong> Isolated lower extremity edema, ascites, hepatic congestion without pulmonary edema</li>
                        <li><strong>Elderly:</strong> Confusion, fatigue, decreased appetite may predominate over dyspnea</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BNP/NT-proBNP (BNP >400 or NT-proBNP >900 suggests HF), troponin (r/o ACS), BMP (assess renal function), CBC, Mg, TSH, LFTs</p>
                    <p><span class="label">Imaging:</span> CXR (cardiomegaly, pulmonary edema, pleural effusions), Echo (assess EF, valves, wall motion)</p>
                    <p><span class="label">ECG:</span> Look for ischemia, LVH, arrhythmias</p>
                    <p><span class="label">Calculations:</span> NYHA Class, EF%, fluid balance (daily weights), creatinine clearance</p>
                    <p><span class="label">Classify Hemodynamics:</span> Warm vs cold (perfusion), wet vs dry (volume status)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management:</span></p>
                    <ul>
                        <li><strong>O2:</strong> Maintain SpO2 >90%. Consider NIPPV (BiPAP/CPAP) if respiratory distress</li>
                        <li><strong>Diuresis (Wet):</strong> IV furosemide 40mg (or 2√ó home dose) bolus, then assess response. Consider continuous infusion if poor response. Goal negative 1-2L/day</li>
                        <li><strong>Vasodilators (if SBP >90):</strong> Nitroglycerin IV for afterload reduction, especially if hypertensive</li>
                        <li><strong>Sodium/Fluid Restriction:</strong> <2g sodium/day, <2L fluid/day</li>
                        <li><strong>Daily weights:</strong> Essential for monitoring</li>
                    </ul>
                    
                    <p><span class="label">Cold & Wet (Low Output):</span> Consider inotropes (dobutamine, milrinone) with invasive monitoring</p>
                    
                    <p><span class="label">Chronic HF Management (Initiate/Optimize):</span></p>
                    <ul>
                        <li><strong>HFrEF (EF <40%):</strong> Guideline-directed medical therapy (GDMT)</li>
                        <li>ACE-I/ARB or ARNI (sacubitril-valsartan)</li>
                        <li>Œ≤-blocker (carvedilol, metoprolol succinate, bisoprolol) - start low when stable</li>
                        <li>Aldosterone antagonist (spironolactone, eplerenone) if EF <35%</li>
                        <li>SGLT2 inhibitor (dapagliflozin, empagliflozin) - proven mortality benefit</li>
                        <li><strong>HFpEF (EF ‚â•50%):</strong> Treat HTN, AF, ischemia. SGLT2i now indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>BNP Pearls:</strong> Obesity lowers BNP. Renal failure raises it. Age-adjust NT-proBNP: <50yo: >450, 50-75yo: >900, >75yo: >1800</li>
                    <li><strong>Diuretic Resistance:</strong> If poor response to IV lasix, try: (1) Increase dose, (2) Continuous infusion, (3) Add thiazide (metolazone 2.5-5mg 30min before lasix), (4) Add acetazolamide</li>
                    <li><strong>Cardiorenal Syndrome:</strong> Cr bump with diuresis is often acceptable if congestion improving. Monitor BUN:Cr ratio (>20:1 suggests prerenal)</li>
                    <li><strong>Don't stop GDMT:</strong> Avoid stopping ACE-I/Œ≤-blocker acutely unless cardiogenic shock. Can hold during diuresis, restart before discharge</li>
                    <li><strong>B-type natriuretic peptide diuretics:</strong> Nesiritide (BNP analog) has no mortality benefit and increases hypotension - rarely used</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Cardiogenic shock (SBP <90, cool extremities, AMS, oliguria)</li>
                        <li>Need for inotropes or mechanical support</li>
                        <li>Acute respiratory failure requiring intubation</li>
                        <li>Refractory pulmonary edema</li>
                        <li>Malignant arrhythmias</li>
                        <li>ACS with hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Euvolemic (at or near dry weight)</li>
                        <li>No dyspnea at rest</li>
                        <li>Stable vital signs, O2 sat on room air</li>
                        <li>Transition to PO diuretics established</li>
                        <li>On optimized GDMT (HFrEF)</li>
                        <li>BMP stable, Cr at acceptable baseline</li>
                        <li>Patient education completed</li>
                        <li>Close follow-up arranged (within 7 days)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>During Admission:</strong> Cardiorenal syndrome, electrolyte abnormalities (hypokalemia, hypomagnesemia, hyponatremia), arrhythmias (AF most common), worsening renal function</p>
                    <p><strong>Long-term:</strong> Recurrent admissions (50% at 6 months), progressive renal dysfunction, sudden cardiac death, need for advanced therapies (LVAD, transplant)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 3: ATRIAL FIBRILLATION -->
        <div id="afib" class="condition-page">
            <div class="page-header">
                <h2>3. ATRIAL FIBRILLATION</h2>
                <div class="subtitle">RVR ‚Ä¢ New-Onset ‚Ä¢ Chronic AF Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Palpitations, irregular pulse, dyspnea, chest discomfort, fatigue, lightheadedness. Irregularly irregular rhythm on exam.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic:</strong> 30-40% discovered incidentally on exam or ECG</li>
                        <li><strong>Embolic stroke:</strong> First presentation in some patients</li>
                        <li><strong>Tachycardia-induced cardiomyopathy:</strong> Chronic RVR leading to heart failure</li>
                        <li><strong>Hyperthyroid AF:</strong> Lone AF in young patient, check TSH</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> TSH (always), BMP, Mg, CBC, troponin (if chest pain), digoxin level (if on digoxin)</p>
                    <p><span class="label">Imaging:</span> ECG (confirm AF, assess rate, look for ischemia/WPW), CXR, TTE (assess for structural disease, valve disease, LV function, LA size)</p>
                    <p><span class="label">TEE:</span> Before cardioversion if AF >48hr or unknown duration (r/o LA thrombus), unless patient on therapeutic anticoagulation ‚â•3 weeks</p>
                    <p><span class="label">Calculations:</span></p>
                    <ul>
                        <li><strong>CHA‚ÇÇDS‚ÇÇ-VASc:</strong> Stroke risk (CHF, HTN, Age ‚â•75 [2pts], DM, Stroke/TIA [2pts], Vascular disease, Age 65-74, Sex [female]). Score ‚â•2 (‚ôÇ) or ‚â•3 (‚ôÄ) ‚Üí anticoagulate</li>
                        <li><strong>HAS-BLED:</strong> Bleeding risk (HTN, Abnormal renal/liver, Stroke, Bleeding, Labile INR, Elderly, Drugs/alcohol). Score ‚â•3 = high bleeding risk</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Rate Control (First-line for most):</span></p>
                    <ul>
                        <li><strong>Œ≤-Blockers:</strong> Metoprolol 25-50mg PO q6h or 2.5-5mg IV, esmolol gtt (ICU). Goal HR <110 at rest</li>
                        <li><strong>Non-dihydropyridine CCB:</strong> Diltiazem 0.25mg/kg IV over 2min, then 5-15mg/hr gtt OR 30-60mg PO q6h</li>
                        <li><strong>Digoxin:</strong> 0.25mg IV/PO (less effective, use if HF or sedentary patients). Loading: 0.5mg ‚Üí 0.25mg q6h √ó 2</li>
                        <li><strong>Avoid:</strong> Œ≤-blockers and CCBs together (risk of heart block), rate control in WPW (can precipitate VF)</li>
                    </ul>
                    
                    <p><span class="label">Rhythm Control:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Hemodynamic instability, highly symptomatic despite rate control, first episode, young patient preference</li>
                        <li><strong>Cardioversion:</strong> If AF <48hr OR on anticoagulation ‚â•3 weeks OR TEE negative</li>
                        <li>Synchronized DC cardioversion: 120-200J biphasic (under sedation)</li>
                        <li>Chemical: Flecainide 300mg PO (if no CAD), ibutilide 1mg IV over 10min (monitor QT)</li>
                        <li><strong>Antiarrhythmics:</strong> Amiodarone (safest in structural disease), sotalol, dofetilide (in-hospital initiation)</li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation:</span></p>
                    <ul>
                        <li><strong>CHA‚ÇÇDS‚ÇÇ-VASc ‚â•2 (‚ôÇ) or ‚â•3 (‚ôÄ):</strong> Anticoagulate (DOACs preferred over warfarin)</li>
                        <li><strong>DOACs:</strong> Apixaban, rivaroxaban, edoxaban, dabigatran (avoid if mechanical valve or severe MS)</li>
                        <li><strong>Post-cardioversion:</strong> Anticoagulate √ó 4 weeks minimum, longer if stroke risk factors</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>WPW + AF = Emergency:</strong> Irregular wide-complex tachycardia. DO NOT use AV nodal blockers (can precipitate VF). Cardiovert or procainamide</li>
                    <li><strong>Rate vs Rhythm:</strong> AFFIRM/RACE trials show no mortality difference. Most patients do fine with rate control alone</li>
                    <li><strong>Anticoagulation paradox:</strong> HAS-BLED ‚â•3 means high bleeding risk, but often same patients who need anticoagulation most. Don't withhold if CHA‚ÇÇDS‚ÇÇ-VASc high</li>
                    <li><strong>Holiday Heart:</strong> Alcohol-induced AF. Often converts spontaneously with abstinence</li>
                    <li><strong>TEE before cardioversion:</strong> Even if on anticoagulation <3 weeks, consider TEE strategy to expedite cardioversion safely</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability (SBP <90, shock)</li>
                        <li>Acute heart failure/pulmonary edema with RVR</li>
                        <li>Acute MI with RVR</li>
                        <li>Need for continuous IV rate control infusions</li>
                        <li>Post-cardioversion complications</li>
                        <li>RVR refractory to multiple agents</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Rate controlled (HR <110 at rest, <120 with activity)</li>
                        <li>Hemodynamically stable ‚â•24 hours</li>
                        <li>Transitioned to oral rate control meds</li>
                        <li>Anticoagulation started (if indicated)</li>
                        <li>No signs of heart failure</li>
                        <li>Follow-up arranged (cardiology if new-onset)</li>
                        <li>If cardioverted: Stable rhythm ‚â•24hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Stroke/TIA (most feared), hemodynamic compromise, heart failure, ACS (demand ischemia from RVR)</p>
                    <p><strong>Chronic:</strong> Tachycardia-induced cardiomyopathy (EF improves with rate/rhythm control), thromboembolism, bleeding (if anticoagulated)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 4: HYPERTENSIVE EMERGENCY -->
        <div id="htn-emergency" class="condition-page">
            <div class="page-header">
                <h2>4. HYPERTENSIVE EMERGENCY</h2>
                <div class="subtitle">End-Organ Damage ‚Ä¢ ICU Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Severe hypertension (typically SBP >180 or DBP >120) WITH acute end-organ damage</p>
                    <p><span class="label">Classic:</span> Severe headache, visual changes, chest pain, dyspnea, altered mental status, focal neurologic deficits</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Neurologic:</strong> Hypertensive encephalopathy (HA, confusion, seizures), stroke (ischemic/hemorrhagic), PRES</li>
                        <li><strong>Cardiac:</strong> Acute MI, acute pulmonary edema, aortic dissection</li>
                        <li><strong>Renal:</strong> Acute kidney injury, hematuria, proteinuria</li>
                        <li><strong>Microangiopathic:</strong> Hemolytic anemia, thrombocytopenia</li>
                    </ul>
                    <p><span class="label">Hypertensive Urgency:</span> Severe HTN WITHOUT end-organ damage. Managed outpatient with PO meds</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BMP, troponin, CBC, UA, peripheral smear if hemolysis suspected, BNP if APE concern</p>
                    <p><span class="label">Imaging:</span> ECG, CXR, Head CT if neuro symptoms, CT chest if dissection suspected</p>
                    <p><span class="label">Fundoscopic:</span> Look for papilledema, hemorrhages, exudates</p>
                    <p><span class="label">Calculate Target BP:</span> Initial reduction 10-20% in 1st hour, then 5-15% over next 23 hours. Avoid >25% reduction in first 24hr</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General:</span> ICU admission, continuous BP monitoring (arterial line often needed), IV antihypertensives</p>
                    <p><span class="label">IV Agents:</span></p>
                    <ul>
                        <li><strong>Nicardipine:</strong> 5mg/hr, titrate by 2.5mg/hr q5-15min (max 15mg/hr). First-line</li>
                        <li><strong>Labetalol:</strong> 20mg IV bolus, then 20-80mg q10min OR 0.5-2mg/min infusion</li>
                        <li><strong>Clevidipine:</strong> 1-2mg/hr, double q90sec (max 21mg/hr). Short-acting</li>
                        <li><strong>Esmolol:</strong> Œ≤-blocker for dissection. 500mcg/kg load, then 50-300mcg/kg/min</li>
                        <li><strong>Nitroprusside:</strong> 0.25-10mcg/kg/min. For APE. Watch cyanide toxicity</li>
                    </ul>
                    <p><span class="label">Specific Scenarios:</span></p>
                    <ul>
                        <li><strong>Aortic Dissection:</strong> SBP <120 in 20min. Esmolol FIRST, then nicardipine</li>
                        <li><strong>Ischemic Stroke:</strong> Permissive HTN! Allow SBP up to 220 (or 185 if tPA)</li>
                        <li><strong>Hemorrhagic Stroke:</strong> Goal SBP 140-160</li>
                        <li><strong>Eclampsia:</strong> Mag sulfate + hydralazine/labetalol. Deliver baby!</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Urgency vs Emergency:</strong> Only EMERGENCY needs ICU/IV meds. Urgency = oral meds over hours-days</li>
                    <li><strong>Don't drop too fast:</strong> Cerebral autoregulation reset in chronic HTN. Rapid drop ‚Üí stroke/MI</li>
                    <li><strong>Ischemic stroke exception:</strong> Brain needs perfusion! Only lower if SBP >220 or giving tPA</li>
                    <li><strong>PRES:</strong> Headache, confusion, seizures, vision loss + posterior white matter edema. Usually reversible</li>
                    <li><strong>Transition to PO:</strong> Start long-acting oral agents before stopping IV to prevent rebound</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL hypertensive emergencies require ICU</li>
                        <li>Need for continuous IV infusion</li>
                        <li>Acute end-organ damage</li>
                        <li>Altered mental status</li>
                        <li>Arterial line needed</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>BP controlled on oral regimen ‚â•24hr</li>
                        <li>End-organ damage stabilized</li>
                        <li>Off IV medications</li>
                        <li>Patient educated on compliance</li>
                        <li>Close follow-up arranged (within 1 week)</li>
                        <li>Secondary causes evaluated if indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Hypertension:</strong> Stroke, MI, aortic dissection, acute renal failure, retinopathy, heart failure</p>
                    <p><strong>From Treatment:</strong> Hypotension, stroke from rapid BP drop, rebound HTN, cyanide toxicity (nitroprusside)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 5: COMMUNITY-ACQUIRED PNEUMONIA -->
        <div id="cap" class="condition-page">
            <div class="page-header">
                <h2>5. COMMUNITY-ACQUIRED PNEUMONIA (CAP)</h2>
                <div class="subtitle">Outpatient ‚Ä¢ Inpatient ‚Ä¢ ICU Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Fever, cough (productive/dry), dyspnea, pleuritic chest pain. Exam: Tachypnea, rales/crackles, bronchial breath sounds, dullness, egophony</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Minimal fever, confusion/delirium, weakness, falls. May lack respiratory symptoms</li>
                        <li><strong>Atypical Organisms:</strong> Dry cough, headache, myalgias, diarrhea (Legionella, Mycoplasma)</li>
                        <li><strong>Aspiration:</strong> Witnessed event, right lower lobe/posterior segments, foul sputum</li>
                        <li><strong>Immunocompromised:</strong> PCP, CMV, TB</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span> CXR (PA and lateral) - infiltrate confirms diagnosis</p>
                    <p><span class="label">Labs (if admitted):</span> CBC, BMP, procalcitonin, blood cultures √ó 2, sputum Gram stain/culture, ABG if hypoxic</p>
                    <p><span class="label">Special:</span> Legionella urinary Ag, Strep pneumo urinary Ag (if severe), respiratory viral panel, HIV if risk factors</p>
                    <p><span class="label">Severity Scores:</span></p>
                    <ul>
                        <li><strong>CURB-65:</strong> Confusion, Urea >20, RR ‚â•30, BP (SBP <90 or DBP ‚â§60), Age ‚â•65. Score 0-1: outpatient, 2: admit, ‚â•3: ICU</li>
                        <li><strong>PSI/PORT:</strong> More complex. Classes I-II outpatient, III consider admit, IV-V admit</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Outpatient (CURB-65 0-1):</span></p>
                    <ul>
                        <li><strong>Previously healthy:</strong> Amoxicillin 1g TID √ó 5d OR doxycycline 100mg BID √ó 5d</li>
                        <li><strong>With comorbidities:</strong> Amoxicillin-clavulanate + macrolide OR levofloxacin 750mg daily</li>
                    </ul>
                    
                    <p><span class="label">Inpatient Non-ICU:</span></p>
                    <ul>
                        <li><strong>Standard:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV/PO daily</li>
                        <li><strong>Alternative:</strong> Levofloxacin 750mg daily or moxifloxacin 400mg daily</li>
                        <li><strong>Duration:</strong> Minimum 5 days if afebrile √ó 48-72hr and stable</li>
                    </ul>
                    
                    <p><span class="label">ICU (Severe CAP):</span></p>
                    <ul>
                        <li><strong>Standard:</strong> Ceftriaxone 2g IV daily + azithromycin 500mg IV daily</li>
                        <li><strong>MRSA Risk:</strong> Add vancomycin or linezolid</li>
                        <li><strong>Pseudomonas Risk:</strong> Pip-tazo or cefepime + fluoroquinolone</li>
                    </ul>
                    
                    <p><span class="label">Supportive:</span> O2 to SpO2 >90%, IV fluids, VTE prophylaxis</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Legionella clues:</strong> Hyponatremia, elevated LFTs, GI symptoms, relative bradycardia. Urinary antigen test. Need 10-14d abx</li>
                    <li><strong>PCP Pneumonia:</strong> Subacute, dry cough, exertional dyspnea in HIV. Bilateral interstitial infiltrates. LDH >500. TMP-SMX + prednisone if PaO2 <70</li>
                    <li><strong>Step-down criteria:</strong> HR <100, RR <24, SBP >90, SpO2 >90%, temp <37.8¬∞C, able to take PO</li>
                    <li><strong>Macrolide resistance:</strong> S. pneumoniae resistance ~30-40%. Always pair with Œ≤-lactam for inpatients</li>
                    <li><strong>Vaccines:</strong> PPSV23 and PCV20 after recovery per CDC schedule</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe CAP (CURB-65 ‚â•3)</li>
                        <li>Need for mechanical ventilation</li>
                        <li>Septic shock requiring pressors</li>
                        <li>Multilobar infiltrates</li>
                        <li>PaO2/FiO2 <250</li>
                        <li>Confusion, AMS</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 48-72 hours</li>
                        <li>Hemodynamically stable</li>
                        <li>O2 sat >90% on room air/baseline</li>
                        <li>Able to tolerate PO</li>
                        <li>Completed minimum 5 days antibiotics</li>
                        <li>Follow-up CXR arranged (6 weeks)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early:</strong> Respiratory failure, sepsis/septic shock, parapneumonic effusion, empyema, lung abscess</p>
                    <p><strong>Late:</strong> Organizing pneumonia, fibrosis, recurrent pneumonia (consider malignancy)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 6: COPD EXACERBATION -->
        <div id="copd" class="condition-page">
            <div class="page-header">
                <h2>6. COPD EXACERBATION</h2>
                <div class="subtitle">AECOPD ‚Ä¢ Acute on Chronic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Increased dyspnea, cough, sputum production/purulence beyond baseline. Wheezing, accessory muscle use, pursed-lip breathing</p>
                    <p><span class="label">Anthonisen Criteria:</span> (1) Increased dyspnea, (2) Increased sputum volume, (3) Increased sputum purulence. Type I = all 3, Type II = 2 of 3, Type III = 1 symptom</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Hypercapnic Encephalopathy:</strong> Confusion, asterixis, somnolence from CO2 retention</li>
                        <li><strong>Right Heart Failure:</strong> Peripheral edema, JVD from cor pulmonale</li>
                        <li><strong>Elderly:</strong> Fatigue, decreased functional status, falls</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> ABG (assess hypercapnia, acidosis), CBC, BMP, BNP if HF concern, sputum culture if severe/recurrent</p>
                    <p><span class="label">Imaging:</span> CXR (r/o pneumonia, PTX, CHF), consider CT if recurrent or PE concern</p>
                    <p><span class="label">ECG:</span> Evaluate for MI, arrhythmia, right heart strain</p>
                    <p><span class="label">Calculations:</span> A-a gradient, FiO2 requirements</p>
                    <p><span class="label">Triggers:</span> Infection (most common), medication noncompliance, PE, pneumothorax, MI, pneumonia</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Bronchodilators:</span></p>
                    <ul>
                        <li><strong>SABA:</strong> Albuterol 2.5-5mg nebulized q4h or continuous</li>
                        <li><strong>SAMA:</strong> Ipratropium 0.5mg nebulized q6h OR combined albuterol-ipratropium (DuoNeb)</li>
                        <li>Note: Ipratropium added to albuterol shows additive benefit in COPD (unlike asthma)</li>
                    </ul>
                    
                    <p><span class="label">Systemic Corticosteroids:</span></p>
                    <ul>
                        <li><strong>Dose:</strong> Prednisone 40mg PO daily √ó 5 days (or methylprednisolone 125mg IV if severe/unable PO)</li>
                        <li><strong>Evidence:</strong> 5-7 days as effective as longer courses with fewer side effects</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (if ‚â•2 cardinal symptoms or purulent sputum):</span></p>
                    <ul>
                        <li><strong>First-line:</strong> Azithromycin 500mg daily √ó 5d OR doxycycline 100mg BID √ó 5-7d</li>
                        <li><strong>Second-line:</strong> Amoxicillin-clavulanate, respiratory fluoroquinolone, cephalosporin</li>
                        <li><strong>Pseudomonas risk:</strong> (FEV1 <50%, recent hospitalization, >4 exacerbations/year) ‚Üí fluoroquinolone or cephalosporin</li>
                    </ul>
                    
                    <p><span class="label">Oxygen Therapy:</span> Goal SpO2 88-92% (avoid higher - can worsen hypercapnia). Titrate carefully in CO2 retainers</p>
                    
                    <p><span class="label">Ventilatory Support:</span></p>
                    <ul>
                        <li><strong>NIPPV (BiPAP):</strong> First-line for hypercapnic respiratory failure (pH 7.25-7.35). Reduces intubation rate and mortality</li>
                        <li><strong>Intubation:</strong> If unable to tolerate NIPPV, worsening acidosis (pH <7.25), decreased mental status</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>O2-induced hypercapnia:</strong> High O2 in COPD ‚Üí worsens V/Q mismatch and Haldane effect ‚Üí CO2 retention. Keep SpO2 88-92%</li>
                    <li><strong>BiPAP is magic:</strong> NIPPV reduces intubation by 65%, mortality by 55% in AECOPD with respiratory acidosis. Use early!</li>
                    <li><strong>Steroid duration:</strong> REDUCE trial showed 5 days = 14 days for outcomes. Don't give longer courses</li>
                    <li><strong>Antibiotics debate:</strong> Only benefit if purulent sputum or ‚â•2 cardinal symptoms. Type III (1 symptom) may not need abx</li>
                    <li><strong>Home oxygen criteria:</strong> Resting PaO2 <55 or SpO2 <88% OR PaO2 56-59 with cor pulmonale/polycythemia</li>
                    <li><strong>Prevention:</strong> Vaccinations (flu, pneumococcal), smoking cessation, maintenance inhalers, pulmonary rehab</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe respiratory acidosis (pH <7.30)</li>
                        <li>Need for intubation/mechanical ventilation</li>
                        <li>Hemodynamic instability</li>
                        <li>Altered mental status despite treatment</li>
                        <li>Failed NIPPV trial on floor</li>
                        <li>Life-threatening comorbidity (MI, sepsis)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Return to baseline dyspnea/function</li>
                        <li>Tolerating SABA q4h or less</li>
                        <li>SpO2 >90% on room air or baseline O2</li>
                        <li>Able to sleep and walk without severe dyspnea</li>
                        <li>pH >7.35 if acidotic on admission</li>
                        <li>On maintenance inhalers (LABA/LAMA combo)</li>
                        <li>Inhaler technique verified</li>
                        <li>Pulmonary follow-up within 1 month</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure requiring intubation, pneumothorax (bullous disease), pneumonia, arrhythmias, myocardial ischemia</p>
                    <p><strong>Chronic:</strong> Cor pulmonale, progressive lung function decline, long-term oxygen need, recurrent exacerbations</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 7: ASTHMA EXACERBATION -->
        <div id="asthma" class="condition-page">
            <div class="page-header">
                <h2>7. ASTHMA EXACERBATION</h2>
                <div class="subtitle">Acute Bronchospasm ‚Ä¢ Status Asthmaticus</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea, wheezing, chest tightness, cough, accessory muscle use, prolonged expiration</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Silent Chest:</strong> Severe obstruction with minimal air movement - ominous sign!</li>
                        <li><strong>Cough-Variant Asthma:</strong> Persistent cough without wheezing</li>
                        <li><strong>Exercise-Induced:</strong> Symptoms during/after exercise</li>
                        <li><strong>Children:</strong> May present with only cough or difficulty feeding</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> Peak flow, O2 saturation, vital signs</p>
                    <p><span class="label">If Severe:</span> CXR (r/o pneumothorax, infiltrate), ABG if critically ill, VBG acceptable</p>
                    <p><span class="label">Calculations:</span> Peak flow % predicted (compare to personal best), FEV1 if available</p>
                    <p><span class="label">Severity Assessment:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Speaks full sentences, HR <100, PEF >70%</li>
                        <li><strong>Moderate:</strong> Speaks phrases, HR 100-120, PEF 40-70%</li>
                        <li><strong>Severe:</strong> Speaks words, HR >120, PEF <40%, accessory muscles</li>
                        <li><strong>Life-threatening:</strong> Unable to speak, altered mental status, silent chest, bradycardia, hypotension</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Bronchodilators:</span></p>
                    <ul>
                        <li><strong>Albuterol:</strong> 2.5-5mg nebulized q20min √ó 3, then reassess. Consider continuous nebulization if severe</li>
                        <li><strong>Ipratropium:</strong> 0.5mg nebulized √ó 3 doses (add to albuterol for moderate-severe exacerbations)</li>
                    </ul>
                    
                    <p><span class="label">Systemic Corticosteroids (ALL patients except mildest):</span></p>
                    <ul>
                        <li><strong>Prednisone:</strong> 40-60mg PO daily √ó 5 days OR</li>
                        <li><strong>Methylprednisolone:</strong> 125mg IV if unable to take PO or severe</li>
                        <li>No taper needed for short course</li>
                    </ul>
                    
                    <p><span class="label">Oxygen:</span> Maintain SpO2 >90%</p>
                    
                    <p><span class="label">Severe/Refractory (not responding to above):</span></p>
                    <ul>
                        <li><strong>Magnesium sulfate:</strong> 2g IV over 20 minutes (relaxes bronchial smooth muscle)</li>
                        <li><strong>Epinephrine:</strong> 0.3-0.5mg IM (or subQ) if anaphylaxis component or impending respiratory failure</li>
                        <li><strong>Terbutaline:</strong> 0.25mg subQ (use with caution - cardiac side effects)</li>
                        <li><strong>Heliox:</strong> May reduce work of breathing (helium-oxygen mixture)</li>
                    </ul>
                    
                    <p><span class="label">Do NOT Give:</span> Sedatives (can suppress respiratory drive), antibiotics (unless clear bacterial infection)</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Silent chest = BAD:</strong> Means severe obstruction with minimal air movement. This is life-threatening!</li>
                    <li><strong>Ipratropium in asthma:</strong> Unlike COPD, only add for moderate-severe exacerbations (first 3 doses only)</li>
                    <li><strong>Magnesium mechanism:</strong> Competes with calcium in smooth muscle ‚Üí bronchodilation. Number needed to treat = 8</li>
                    <li><strong>Normal PCO2 is concerning:</strong> Asthma patients should be hypocapnic (from hyperventilation). Normal/high CO2 = respiratory fatigue</li>
                    <li><strong>Steroid timing:</strong> Takes 4-6 hours to work. Give early! Don't wait for severe deterioration</li>
                    <li><strong>Discharge medication:</strong> Always send home with short course PO steroids, albuterol inhaler, and controller if not already on one</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status asthmaticus (not improving despite aggressive treatment)</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Altered mental status, confusion, lethargy</li>
                        <li>Silent chest</li>
                        <li>PCO2 >45 (respiratory fatigue)</li>
                        <li>Need for continuous nebulization</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>PEF or FEV1 >70% predicted or personal best</li>
                        <li>SpO2 >90% on room air</li>
                        <li>No accessory muscle use, speaks full sentences</li>
                        <li>Sustained improvement ‚â•60 min after last treatment</li>
                        <li>On appropriate controller medication</li>
                        <li>Has action plan and follow-up arranged</li>
                        <li>Prescribed albuterol + oral steroids √ó 5 days</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Status asthmaticus, respiratory failure, pneumothorax, pneumomediastinum, cardiac arrest</p>
                    <p><strong>Iatrogenic:</strong> Hypokalemia (from Œ≤-agonists), tremor, tachycardia, hyperglycemia (from steroids)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 8: PULMONARY EMBOLISM -->
        <div id="pe" class="condition-page">
            <div class="page-header">
                <h2>8. PULMONARY EMBOLISM (PE)</h2>
                <div class="subtitle">VTE ‚Ä¢ Massive PE ‚Ä¢ Submassive PE</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea, pleuritic chest pain, tachycardia, tachypnea, hemoptysis, unilateral leg swelling</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Massive PE:</strong> Hypotension, syncope, cardiac arrest (obstructive shock)</li>
                        <li><strong>Submassive PE:</strong> Hemodynamically stable but RV strain on echo or biomarkers</li>
                        <li><strong>Chronic PE:</strong> Progressive dyspnea, may be misdiagnosed as heart failure</li>
                        <li><strong>Small PE:</strong> May be asymptomatic or minimal symptoms</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Calculate Pre-test Probability:</span> Wells Score or PERC Rule (see calculators below)</p>
                    <p><span class="label">Labs:</span> D-dimer (if low probability - high sensitivity, low specificity), troponin, BNP (assess RV strain), ABG (may show hypoxemia, A-a gradient)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CTPA (CT Pulmonary Angiography):</strong> Gold standard, shows filling defects</li>
                        <li><strong>V/Q Scan:</strong> If contrast contraindicated</li>
                        <li><strong>Lower Extremity Doppler US:</strong> Look for DVT source</li>
                        <li><strong>Echo:</strong> Assess RV function, strain (McConnell's sign = RV dysfunction with apical sparing)</li>
                    </ul>
                    <p><span class="label">ECG:</span> Sinus tachycardia most common. Classic S1Q3T3 pattern rare. Right heart strain pattern</p>
                    
                    <!-- Wells Score Calculator -->
                    <div id="calc-wells-pe" class="calculator">
                        <div class="calculator-title">üßÆ Wells Score for PE</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Pre-test probability of PE. Score ‚â§4 = PE unlikely (consider D-dimer), >4 = PE likely (proceed to CTPA).
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-dvt"> Clinical signs of DVT
                                <span class="hint">Leg swelling, unilateral pain (+3 points)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-alt"> PE most likely diagnosis (no alternative)
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-hr"> Heart rate >100 bpm
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-immob"> Immobilization ‚â•3 days or surgery within 4 weeks
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-prior"> Previous DVT or PE
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-hemo"> Hemoptysis
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-cancer"> Malignancy (treatment within 6 months or palliative)
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateWells()">Calculate Wells Score</button>
                        <div id="wells-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Anticoagulation (Most Patients):</span></p>
                    <ul>
                        <li><strong>LMWH:</strong> Enoxaparin 1mg/kg subQ q12h (preferred if renal function normal)</li>
                        <li><strong>Unfractionated Heparin:</strong> 80 units/kg bolus, then 18 units/kg/hr infusion (if CrCl <30 or high bleeding risk)</li>
                        <li><strong>Fondaparinux:</strong> Weight-based subQ dosing</li>
                        <li><strong>DOACs:</strong> Rivaroxaban or apixaban can be started immediately (no bridging needed)</li>
                    </ul>
                    
                    <p><span class="label">Thrombolytics (Massive PE with hemodynamic instability):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> SBP <90 for >15 min OR shock requiring pressors OR cardiac arrest</li>
                        <li><strong>Alteplase (tPA):</strong> 100mg IV over 2 hours OR 0.6mg/kg over 15 min (max 50mg)</li>
                        <li><strong>Contraindications:</strong> Recent surgery, active bleeding, stroke, intracranial pathology</li>
                    </ul>
                    
                    <p><span class="label">Catheter-Directed Therapy:</span> For submassive PE with RV dysfunction but contraindications to systemic lysis</p>
                    
                    <p><span class="label">IVC Filter:</span> Only if absolute contraindication to anticoagulation (active bleeding)</p>
                    
                    <p><span class="label">Supportive:</span> O2, judicious IVF (avoid overload - worsens RV strain), pressors if shock</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>PERC Rule:</strong> If all 8 criteria negative (age <50, HR <100, SpO2 ‚â•95%, no hemoptysis, no estrogen, no prior VTE, no surgery/trauma, no unilateral leg swelling) AND low clinical suspicion ‚Üí PE excluded, no D-dimer needed</li>
                    <li><strong>D-dimer pitfalls:</strong> Elevated in many conditions (infection, cancer, pregnancy, age >50). Only useful to rule OUT PE in low-probability patients</li>
                    <li><strong>Massive vs Submassive:</strong> Massive = hypotension/shock (needs thrombolytics). Submassive = RV strain but stable BP (controversial management)</li>
                    <li><strong>Anticoagulation duration:</strong> Provoked (surgery, trauma) = 3 months. Unprovoked or cancer = ‚â•6 months, consider indefinite</li>
                    <li><strong>Don't give IVF blindly:</strong> PE is RV failure - RV already volume overloaded. Excessive fluids worsen RV strain</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Massive PE (hypotension, shock)</li>
                        <li>Submassive PE with worsening RV function</li>
                        <li>Need for thrombolytics or mechanical intervention</li>
                        <li>Hemodynamic instability</li>
                        <li>Respiratory failure</li>
                        <li>Cardiac arrest</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable ‚â•24 hours</li>
                        <li>O2 sat >90% on room air or baseline</li>
                        <li>No RV dysfunction or resolved</li>
                        <li>Adequate pain control</li>
                        <li>On therapeutic anticoagulation</li>
                        <li>Safe for outpatient management (PESI score)</li>
                        <li>Follow-up arranged with anticoagulation clinic</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> RV failure, cardiac arrest, recurrent PE, bleeding (from anticoagulation)</p>
                    <p><strong>Chronic:</strong> Chronic thromboembolic pulmonary hypertension (CTEPH), post-thrombotic syndrome</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 9: SEPSIS/SEPTIC SHOCK -->
        <div id="sepsis" class="condition-page">
            <div class="page-header">
                <h2>9. SEPSIS/SEPTIC SHOCK</h2>
                <div class="subtitle">Life-Threatening Organ Dysfunction ‚Ä¢ Sepsis-3</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Sepsis Definition (Sepsis-3):</span> Life-threatening organ dysfunction caused by dysregulated host response to infection. SOFA score ‚â•2</p>
                    <p><span class="label">Classic:</span> Fever/hypothermia, tachycardia, tachypnea, altered mental status, hypotension</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> May lack fever, present with confusion or falls only</li>
                        <li><strong>Immunocompromised:</strong> Blunted fever response, rapid progression</li>
                        <li><strong>Cryptic Shock:</strong> Normal BP but elevated lactate (tissue hypoperfusion)</li>
                        <li><strong>Cold Sepsis:</strong> Hypothermia, cool extremities (late, poor prognosis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Blood cultures √ó 2 (different sites, before antibiotics), CBC, CMP, lactate (repeat q2-4h), procalcitonin, coagulation studies</p>
                    <p><span class="label">Source Identification:</span> UA/urine culture, CXR, wound cultures, consider abdominal imaging if source unclear</p>
                    <p><span class="label">Calculate:</span> qSOFA score (see below), SOFA score, lactate clearance</p>
                    
                    <!-- qSOFA Calculator -->
                    <div id="calc-qsofa" class="calculator">
                        <div class="calculator-title">üßÆ qSOFA Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Quick screening for sepsis outside ICU. Score ‚â•2 suggests high risk for poor outcomes. NOT diagnostic, but prompts further evaluation.
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-rr"> Respiratory Rate ‚â•22/min
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-ams"> Altered Mental Status (GCS <15)
                                <span class="hint">Any confusion, disorientation, or decreased LOC (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-sbp"> Systolic BP ‚â§100 mmHg
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateQSOFA()">Calculate qSOFA Score</button>
                        <div id="qsofa-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL (Sepsis Bundle - Within 1 Hour)</div>
                <div class="section-content">
                    <p><span class="label">1. Measure Lactate:</span> Remeasure if initial lactate >2 mmol/L</p>
                    
                    <p><span class="label">2. Obtain Blood Cultures BEFORE Antibiotics:</span> But don't delay antibiotics >45 min</p>
                    
                    <p><span class="label">3. Administer Broad-Spectrum Antibiotics:</span></p>
                    <ul>
                        <li><strong>Sepsis (no source identified):</strong> Vancomycin + pip-tazo OR cefepime + metronidazole</li>
                        <li><strong>Pulmonary source:</strong> Vancomycin + cefepime (or pip-tazo)</li>
                        <li><strong>Abdominal source:</strong> Pip-tazo OR ceftriaxone + metronidazole</li>
                        <li><strong>Urinary source:</strong> Ceftriaxone or fluoroquinolone (add ampicillin if Enterococcus risk)</li>
                        <li><strong>Skin/soft tissue:</strong> Vancomycin + pip-tazo</li>
                        <li><strong>Immunocompromised:</strong> Add antifungal (micafungin) and consider antivirals</li>
                    </ul>
                    
                    <p><span class="label">4. Rapid Administration of 30 mL/kg Crystalloid for Hypotension or Lactate ‚â•4:</span></p>
                    <ul>
                        <li>Use balanced crystalloids (LR or Plasma-Lyte) preferred over NS</li>
                        <li>Reassess after fluid bolus - repeat PRN based on hemodynamics</li>
                    </ul>
                    
                    <p><span class="label">5. Vasopressors if Hypotensive During or After Fluid Resuscitation:</span></p>
                    <ul>
                        <li><strong>Norepinephrine:</strong> First-line, start 0.05-0.1 mcg/kg/min, titrate to MAP ‚â•65</li>
                        <li><strong>Vasopressin:</strong> Add 0.03-0.04 units/min if inadequate response</li>
                        <li><strong>Epinephrine:</strong> Second-line if refractory</li>
                        <li><strong>Phenylephrine:</strong> Only if tachyarrhythmia or norepinephrine shortage</li>
                    </ul>
                    
                    <p><span class="label">Source Control:</span> Drain abscesses, remove infected devices, debride necrotic tissue - within 6-12 hours</p>
                    
                    <p><span class="label">Additional Considerations:</span></p>
                    <ul>
                        <li><strong>Stress-dose steroids:</strong> Hydrocortisone 200mg/day if refractory shock despite fluids + pressors</li>
                        <li><strong>Avoid:</strong> Hetastarch, gelatin (increase mortality), albumin for routine resuscitation</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Sepsis-3 vs Old Criteria:</strong> No more SIRS criteria. Focus on organ dysfunction (SOFA ‚â•2). qSOFA is screening tool, not diagnostic</li>
                    <li><strong>Time is tissue:</strong> Every hour delay in antibiotics increases mortality by 7.6%. Door-to-antibiotic <1 hour!</li>
                    <li><strong>Lactate clearance:</strong> >10% reduction in lactate within 2-4 hours associated with improved survival. Trend it!</li>
                    <li><strong>Balanced crystalloids:</strong> LR/Plasma-Lyte associated with lower mortality than NS. NS causes hyperchloremic acidosis</li>
                    <li><strong>Early vasopressors OK:</strong> Don't wait to "finish" 30cc/kg if patient still hypotensive. Start pressors concurrently</li>
                    <li><strong>Procalcitonin use:</strong> Can help determine if infection present and guide antibiotic duration. <0.5 = low likelihood bacterial</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL septic shock (hypotension requiring pressors)</li>
                        <li>Lactate ‚â•4 mmol/L</li>
                        <li>Respiratory failure requiring ventilation</li>
                        <li>Acute mental status changes</li>
                        <li>Oliguria/anuria despite fluids</li>
                        <li>Multiorgan dysfunction</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 24-48 hours</li>
                        <li>Hemodynamically stable off pressors ‚â•24hr</li>
                        <li>Lactate normalized</li>
                        <li>Source controlled</li>
                        <li>Mental status at baseline</li>
                        <li>Tolerating PO, able to take antibiotics</li>
                        <li>No new organ dysfunction</li>
                        <li>Close follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> ARDS, AKI requiring dialysis, DIC, multiorgan failure, cardiac dysfunction, death (mortality 10-40%)</p>
                    <p><strong>Long-term:</strong> Post-sepsis syndrome (cognitive impairment, weakness, PTSD), recurrent infections, chronic organ dysfunction</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 10: ACUTE KIDNEY INJURY -->
        <div id="aki" class="condition-page">
            <div class="page-header">
                <h2>10. ACUTE KIDNEY INJURY (AKI)</h2>
                <div class="subtitle">Prerenal ‚Ä¢ Intrinsic ‚Ä¢ Postrenal</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Increase in Cr ‚â•0.3 mg/dL within 48hr OR increase to ‚â•1.5√ó baseline OR urine output <0.5 mL/kg/hr for 6hr</p>
                    <p><span class="label">Classic:</span> Oliguria, fluid overload, edema, uremic symptoms (N/V, confusion, asterixis, pericarditis)</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Non-oliguric AKI:</strong> Cr rising but urine output preserved (often ATN from nephrotoxins)</li>
                        <li><strong>Hyperkalemia:</strong> May be presenting sign, can be life-threatening</li>
                        <li><strong>Metabolic Acidosis:</strong> High anion gap from uremia</li>
                        <li><strong>Elderly:</strong> Minimal symptoms despite significant Cr elevation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BMP (Cr, BUN, K+), baseline Cr for comparison, UA with microscopy, urine electrolytes (Na+, Cr, osmolality)</p>
                    <p><span class="label">Imaging:</span> Renal US (assess for obstruction, kidney size, hydronephrosis)</p>
                    <p><span class="label">Consider:</span> Renal biopsy if diagnosis unclear or concern for glomerulonephritis</p>
                    
                    <p><span class="label">Categorize AKI:</span></p>
                    <ul>
                        <li><strong>Prerenal (60-70%):</strong> Decreased renal perfusion - volume depletion, heart failure, cirrhosis, NSAIDs</li>
                        <li><strong>Intrinsic (25-40%):</strong> Acute tubular necrosis (ischemia, nephrotoxins), acute interstitial nephritis, glomerulonephritis</li>
                        <li><strong>Postrenal (5-10%):</strong> Obstruction - BPH, kidney stones, malignancy, neurogenic bladder</li>
                    </ul>
                    
                    <!-- FENa Calculator -->
                    <div id="calc-fena" class="calculator">
                        <div class="calculator-title">üßÆ FENa Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Differentiate prerenal AKI (<1%) from ATN (>2%). FENa 1-2% is indeterminate. If on diuretics, use FEUrea instead.
                        </div>
                        
                        <div class="calc-item">
                            <label>Urine Sodium (mEq/L)
                                <span class="hint">From random urine sample</span>
                            </label>
                            <input type="number" id="fena-urine-na" placeholder="e.g., 20" min="0" step="1">
                        </div>
                        
                        <div class="calc-item">
                            <label>Serum Sodium (mEq/L)
                                <span class="hint">From BMP - typically 135-145</span>
                            </label>
                            <input type="number" id="fena-serum-na" placeholder="e.g., 140" min="100" max="180" value="140">
                        </div>
                        
                        <div class="calc-item">
                            <label>Urine Creatinine (mg/dL)
                                <span class="hint">From random urine sample</span>
                            </label>
                            <input type="number" id="fena-urine-cr" placeholder="e.g., 80" min="0" step="0.1">
                        </div>
                        
                        <div class="calc-item">
                            <label>Serum Creatinine (mg/dL)
                                <span class="hint">From BMP</span>
                            </label>
                            <input type="number" id="fena-serum-cr" placeholder="e.g., 2.5" min="0" step="0.1">
                        </div>
                        
                        <button class="calc-button" onclick="calculateFENa()">Calculate FENa</button>
                        <div id="fena-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li>Treat underlying cause</li>
                        <li>Stop nephrotoxins (NSAIDs, ACE-I/ARB if AKI severe, aminoglycosides, contrast)</li>
                        <li>Adjust all medication doses for GFR</li>
                        <li>Avoid further insults (hypotension, contrast, nephrotoxic drugs)</li>
                    </ul>
                    
                    <p><span class="label">Prerenal AKI:</span></p>
                    <ul>
                        <li><strong>Volume Depletion:</strong> IV fluids (LR or NS), correct hypotension</li>
                        <li><strong>Cardiorenal:</strong> Diuresis if volume overloaded, optimize cardiac output</li>
                        <li><strong>Hepatorenal:</strong> Albumin + midodrine + octreotide, or terlipressin</li>
                    </ul>
                    
                    <p><span class="label">Intrinsic AKI:</span></p>
                    <ul>
                        <li><strong>ATN:</strong> Supportive care, avoid nephrotoxins, optimize hemodynamics. Usually resolves in 1-3 weeks</li>
                        <li><strong>AIN (Acute Interstitial Nephritis):</strong> Stop offending drug, consider steroids if severe/not improving</li>
                        <li><strong>Glomerulonephritis:</strong> Nephrology consult, may need steroids/immunosuppression ¬± plasmapheresis</li>
                    </ul>
                    
                    <p><span class="label">Postrenal AKI:</span></p>
                    <ul>
                        <li><strong>Relieve Obstruction:</strong> Foley catheter (if bladder outlet obstruction), nephrostomy tubes, ureteral stents</li>
                        <li>Watch for post-obstructive diuresis - may need aggressive fluid replacement</li>
                    </ul>
                    
                    <p><span class="label">Indications for Dialysis (AEIOU):</span></p>
                    <ul>
                        <li><strong>A</strong>cidosis - severe metabolic acidosis (pH <7.1) refractory to medical management</li>
                        <li><strong>E</strong>lectrolytes - hyperkalemia refractory to medical therapy</li>
                        <li><strong>I</strong>ngestions - toxic alcohols, lithium, salicylates</li>
                        <li><strong>O</strong>verload - volume overload refractory to diuretics, pulmonary edema</li>
                        <li><strong>U</strong>remia - uremic pericarditis, encephalopathy, bleeding</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>FENa limitations:</strong> Not valid if on diuretics (falsely elevated), chronic kidney disease, or contrast nephropathy. Use FEUrea if on diuretics (prerenal <35%)</li>
                    <li><strong>BUN:Cr ratio:</strong> >20:1 suggests prerenal (BUN reabsorbed more than Cr). <15:1 suggests intrinsic renal disease</li>
                    <li><strong>Muddy brown casts:</strong> Pathognomonic for ATN on urine microscopy</li>
                    <li><strong>Triple whammy:</strong> ACE-I/ARB + diuretic + NSAID = high risk for AKI. Avoid this combination!</li>
                    <li><strong>Contrast-induced AKI:</strong> Peak Cr at 3-5 days. Prevent with IV fluids before/after contrast. No evidence for NAC or bicarb</li>
                    <li><strong>Post-obstructive diuresis:</strong> Can lose massive amounts of fluid after obstruction relieved. Replace half of UOP with 0.45% NS</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hyperkalemia >6.5 with ECG changes</li>
                        <li>Severe metabolic acidosis (pH <7.2)</li>
                        <li>Volume overload with respiratory failure</li>
                        <li>Uremic encephalopathy/pericarditis</li>
                        <li>Need for emergent dialysis</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Cr downtrending or stable</li>
                        <li>No dialysis-requiring complications</li>
                        <li>Electrolytes controlled (K+ <5.5)</li>
                        <li>Volume status optimized</li>
                        <li>Cause identified and addressed</li>
                        <li>Nephrotoxins stopped</li>
                        <li>Close nephrology follow-up if Cr not at baseline</li>
                        <li>Patient educated on medication adjustments</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Hyperkalemia, metabolic acidosis, volume overload, uremia, need for dialysis, death</p>
                    <p><strong>Chronic:</strong> Chronic kidney disease, progression to ESRD, recurrent AKI episodes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 11: HYPERKALEMIA -->
        <div id="hyperkalemia" class="condition-page">
            <div class="page-header">
                <h2>11. HYPERKALEMIA</h2>
                <div class="subtitle">K+ >5.5 mEq/L ‚Ä¢ Life-Threatening Arrhythmias</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Often asymptomatic until severe. Weakness, paresthesias, palpitations</p>
                    <p><span class="label">ECG Changes (Progressive):</span></p>
                    <ul>
                        <li><strong>Mild (5.5-6.5):</strong> Peaked T waves (tall, narrow, symmetric)</li>
                        <li><strong>Moderate (6.5-8):</strong> PR prolongation, P wave flattening/loss, QRS widening</li>
                        <li><strong>Severe (>8):</strong> Sine wave pattern, ventricular fibrillation, asystole</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Pseudohyperkalemia:</strong> Hemolysis during blood draw, severe leukocytosis/thrombocytosis, fist clenching</li>
                        <li><strong>Acute on Chronic:</strong> Patients on ACE-I/ARB with CKD who take NSAIDs or get dehydrated</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Repeat K+ to confirm (rule out pseudohyperkalemia), BMP, Mg, Ca, VBG, consider digoxin level if on digoxin</p>
                    <p><span class="label">ECG:</span> CRITICAL - assess for cardiotoxicity. ECG changes indicate true emergency</p>
                    <p><span class="label">Identify Cause:</span></p>
                    <ul>
                        <li><strong>Increased Intake:</strong> K+ supplements, salt substitutes, IV K+</li>
                        <li><strong>Transcellular Shift:</strong> Acidosis, insulin deficiency, Œ≤-blocker, digoxin toxicity, succinylcholine, tumor lysis</li>
                        <li><strong>Decreased Excretion:</strong> AKI/CKD, hypoaldosteronism, ACE-I/ARB, K+-sparing diuretics, NSAIDs, heparin, TMP-SMX</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL (Sequence Matters!)</div>
                <div class="section-content">
                    <p><span class="label">Step 1: Cardiac Membrane Stabilization (if ECG changes or K >6.5):</span></p>
                    <ul>
                        <li><strong>Calcium Gluconate:</strong> 1-2 amps (10-20 mL of 10% solution) IV over 2-3 min</li>
                        <li>OR <strong>Calcium Chloride:</strong> 0.5-1g (5-10 mL of 10%) IV via central line (more potent, sclerosing)</li>
                        <li>Effect: Immediate (1-3 min), duration 30-60 min</li>
                        <li>Does NOT lower K+, only protects heart</li>
                        <li>Can repeat dose if persistent ECG changes</li>
                    </ul>
                    
                    <p><span class="label">Step 2: Shift K+ Intracellularly (Temporary):</span></p>
                    <ul>
                        <li><strong>Insulin + Dextrose:</strong> Regular insulin 10 units IV + D50 50mL (25g dextrose) IV push
                            <ul>
                                <li>If glucose >250: give insulin alone, no dextrose</li>
                                <li>Effect: 15-30 min, duration 4-6 hours</li>
                                <li>Lowers K+ by 0.5-1.5 mEq/L</li>
                                <li>Check glucose in 1hr (risk hypoglycemia)</li>
                            </ul>
                        </li>
                        <li><strong>Albuterol:</strong> 10-20mg nebulized (or 0.5mg IV)
                            <ul>
                                <li>Effect: 30 min, duration 2-4 hours</li>
                                <li>Lowers K+ by 0.5-1 mEq/L</li>
                                <li>Additive with insulin</li>
                            </ul>
                        </li>
                        <li><strong>Sodium Bicarbonate:</strong> 50-100 mEq (1-2 amps) IV over 5 min (only if concurrent metabolic acidosis)
                            <ul>
                                <li>Controversial efficacy if pH normal</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Step 3: Remove K+ from Body (Definitive):</span></p>
                    <ul>
                        <li><strong>Loop Diuretic:</strong> Furosemide 40-80mg IV (if adequate renal function)</li>
                        <li><strong>Sodium Polystyrene Sulfonate (Kayexalate):</strong> 15-30g PO/PR
                            <ul>
                                <li>Effect: Hours, lowers K+ by 0.5-1 mEq/L</li>
                                <li>Avoid if ileus (risk colonic necrosis)</li>
                            </ul>
                        </li>
                        <li><strong>Patiromer or Sodium Zirconium:</strong> Newer K+ binders, better tolerated but slower onset</li>
                        <li><strong>Hemodialysis:</strong> Most effective. Indications:
                            <ul>
                                <li>K+ >6.5 with ECG changes refractory to medical management</li>
                                <li>Severe AKI/ESRD</li>
                                <li>Ongoing tissue breakdown (rhabdo, tumor lysis)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Step 4: Stop Exacerbating Factors:</span> Hold ACE-I/ARB, K+-sparing diuretics, NSAIDs, K+ supplements</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>ECG trumps K+ level:</strong> If ECG shows changes, treat aggressively regardless of exact K+ value. ECG changes = cardiac emergency!</li>
                    <li><strong>Calcium first!</strong> If ECG changes, give calcium before anything else. Protects heart immediately while you arrange other therapies</li>
                    <li><strong>Insulin hypoglycemia:</strong> Very common! Check glucose 30min and 1hr after insulin. Have D50 ready. Consider dextrose infusion</li>
                    <li><strong>Kayexalate controversy:</strong> Limited evidence for efficacy, risk of colonic necrosis esp with sorbitol. Consider newer agents</li>
                    <li><strong>Repeat K+ frequently:</strong> Check K+ q2-4h during acute management. Temporizing measures wear off!</li>
                    <li><strong>Chronic management:</strong> Low K+ diet, loop diuretics, K+ binders. Avoid "hyperkalemia cocktail" (ACE-I + spironolactone + NSAIDs)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>K+ >6.5 with ECG changes</li>
                        <li>Hemodynamically significant arrhythmias</li>
                        <li>Need for emergent dialysis</li>
                        <li>Rapidly rising K+ despite treatment</li>
                        <li>Cardiac arrest from hyperkalemia</li>
                        <li>Requires continuous cardiac monitoring</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>K+ <5.5 mEq/L and downtrending</li>
                        <li>ECG normalized (no peaked T waves)</li>
                        <li>Cause identified and addressed</li>
                        <li>K+-raising medications stopped/adjusted</li>
                        <li>Patient educated on low K+ diet</li>
                        <li>Close follow-up with repeat K+ within 2-3 days</li>
                        <li>If CKD: nephrology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cardiac:</strong> Ventricular arrhythmias (VT, VF), heart block, asystole, sudden cardiac death</p>
                    <p><strong>From Treatment:</strong> Hypoglycemia (insulin), hypokalemia rebound, volume overload (from IVF), GI complications (kayexalate)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 12: HYPONATREMIA -->
        <div id="hyponatremia" class="condition-page">
            <div class="page-header">
                <h2>12. HYPONATREMIA</h2>
                <div class="subtitle">Na+ <135 mEq/L ‚Ä¢ Osmotic Demyelination Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Nausea, headache, confusion, lethargy, seizures (if severe/acute)</p>
                    <p><span class="label">Severity by Symptoms:</span></p>
                    <ul>
                        <li><strong>Mild (Na 130-135):</strong> Often asymptomatic or mild nausea</li>
                        <li><strong>Moderate (125-129):</strong> Nausea, confusion, headache</li>
                        <li><strong>Severe (<125):</strong> Vomiting, seizures, coma, respiratory arrest</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Falls, gait instability, cognitive impairment</li>
                        <li><strong>Athletes:</strong> Exercise-associated hyponatremia from excessive free water intake</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Step 1 - Check Serum Osmolality:</span></p>
                    <ul>
                        <li><strong>Isotonic (280-295):</strong> Pseudohyponatremia (hyperglycemia, hyperlipidemia, hyperproteinemia)</li>
                        <li><strong>Hypertonic (>295):</strong> Hyperglycemia, mannitol</li>
                        <li><strong>Hypotonic (<280):</strong> True hyponatremia - proceed to step 2</li>
                    </ul>
                    
                    <p><span class="label">Step 2 - Assess Volume Status:</span></p>
                    <ul>
                        <li><strong>Hypovolemic:</strong> Dry mucous membranes, ‚Üìskin turgor, orthostatic hypotension
                            <ul>
                                <li>Urine Na <20: GI losses, third-spacing, skin losses</li>
                                <li>Urine Na >40: Diuretics, salt-wasting nephropathy, adrenal insufficiency</li>
                            </ul>
                        </li>
                        <li><strong>Euvolemic:</strong> Normal volume status
                            <ul>
                                <li>SIADH (most common), hypothyroidism, adrenal insufficiency, psychogenic polydipsia</li>
                            </ul>
                        </li>
                        <li><strong>Hypervolemic:</strong> Edema, elevated JVP, ascites
                            <ul>
                                <li>CHF, cirrhosis, nephrotic syndrome, advanced CKD</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> Serum osmolality, urine osmolality, urine Na, BMP, TSH, cortisol if indicated</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">‚ö†Ô∏è CRITICAL:</span> Correct slowly! Maximum 8-10 mEq/L in first 24 hours. Faster correction ‚Üí osmotic demyelination syndrome</p>
                    
                    <p><span class="label">Acute Symptomatic (<48hr onset with seizures/coma):</span></p>
                    <ul>
                        <li><strong>3% Hypertonic Saline:</strong> 100 mL IV bolus over 10 min, can repeat √ó 2 if needed</li>
                        <li>Goal: Raise Na by 4-6 mEq/L (enough to stop seizures), then slow correction</li>
                        <li>Check Na q2-4h</li>
                    </ul>
                    
                    <p><span class="label">Chronic or Asymptomatic:</span></p>
                    <ul>
                        <li><strong>Hypovolemic:</strong> NS at 0.5-1 mL/kg/hr. Na will auto-correct with volume repletion</li>
                        <li><strong>Euvolemic (SIADH):</strong> 
                            <ul>
                                <li>Fluid restriction (800-1000 mL/day)</li>
                                <li>Treat underlying cause</li>
                                <li>Salt tabs + loop diuretic if needed</li>
                                <li>Tolvaptan (vasopressin antagonist) for refractory cases</li>
                            </ul>
                        </li>
                        <li><strong>Hypervolemic:</strong> Fluid + sodium restriction, diuretics, treat underlying (CHF, cirrhosis)</li>
                    </ul>
                    
                    <p><span class="label">Correction Rate Calculation:</span></p>
                    <ul>
                        <li>Target: 6-8 mEq/L in 24 hours, 12-14 mEq/L in 48 hours</li>
                        <li>High-risk patients (chronic, malnourished, cirrhosis, K+ <3): Limit to 6 mEq/L in 24hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Osmotic demyelination (ODS):</strong> From overly rapid correction. Presents 2-6 days later with dysarthria, dysphagia, quadriplegia, locked-in syndrome. PREVENT by slow correction!</li>
                    <li><strong>SIADH criteria:</strong> Hyponatremia + low serum osm (<280) + inappropriately concentrated urine (>100) + euvolemic + normal thyroid/adrenal</li>
                    <li><strong>Beer potomania:</strong> Hyponatremia from excessive beer intake with poor solute intake. Na can rise dangerously fast when solute repleted!</li>
                    <li><strong>Tea and toast diet:</strong> Similar to beer potomania - inadequate solute intake in elderly</li>
                    <li><strong>Exercise-associated:</strong> From drinking too much water during endurance events. Treat with hypertonic saline, NOT more water!</li>
                    <li><strong>Hyperglycemia correction:</strong> For every 100 mg/dL glucose >100, add 1.6 mEq/L to measured Na to get "true" Na</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Seizures or coma</li>
                        <li>Na <120 mEq/L</li>
                        <li>Acute symptomatic hyponatremia</li>
                        <li>Need for 3% hypertonic saline</li>
                        <li>Rapid changes requiring q2h monitoring</li>
                        <li>Respiratory compromise</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Na >125 mEq/L and stable/improving</li>
                        <li>Asymptomatic or symptoms resolved</li>
                        <li>Underlying cause identified/treated</li>
                        <li>Can comply with fluid restriction if needed</li>
                        <li>Follow-up arranged with Na check in 2-3 days</li>
                        <li>Patient educated on risks</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Hyponatremia:</strong> Seizures, cerebral edema, respiratory arrest, death</p>
                    <p><strong>From Overcorrection:</strong> Osmotic demyelination syndrome (irreversible neurologic damage)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 13: DIABETIC KETOACIDOSIS -->
        <div id="dka" class="condition-page">
            <div class="page-header">
                <h2>13. DIABETIC KETOACIDOSIS (DKA)</h2>
                <div class="subtitle">Hyperglycemia ‚Ä¢ Acidosis ‚Ä¢ Ketones</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Hyperglycemia (>250), (2) Anion gap metabolic acidosis, (3) Ketones</p>
                    <p><span class="label">Classic Symptoms:</span> Polyuria, polydipsia, N/V, abdominal pain, Kussmaul respirations (deep, rapid), fruity breath odor, altered mental status</p>
                    <p><span class="label">Precipitants (5 I's):</span></p>
                    <ul>
                        <li><strong>Infection:</strong> Most common (UTI, pneumonia, etc)</li>
                        <li><strong>Insulin:</strong> Non-compliance or inadequate dosing</li>
                        <li><strong>Ischemia:</strong> MI, stroke</li>
                        <li><strong>Intoxication:</strong> Alcohol, drugs</li>
                        <li><strong>Infant:</strong> Pregnancy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">DKA Criteria:</span></p>
                    <ul>
                        <li>Glucose >250 mg/dL (or known diabetic)</li>
                        <li>pH <7.3 (arterial) or HCO3 <18</li>
                        <li>Anion gap >10</li>
                        <li>Positive serum/urine ketones</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> VBG (pH, HCO3), BMP, anion gap, Œ≤-hydroxybutyrate (preferred over urine ketones), phosphate, Mg, CBC, blood cultures, UA/CXR if infection suspected</p>
                    <p><span class="label">Calculate:</span> Anion gap = Na - (Cl + HCO3). Normal 8-12. Also calculate osmolality if altered mental status</p>
                    <p><span class="label">Severity:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> pH 7.25-7.30, HCO3 15-18</li>
                        <li><strong>Moderate:</strong> pH 7.0-7.24, HCO3 10-14</li>
                        <li><strong>Severe:</strong> pH <7.0, HCO3 <10</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Fluids (MOST IMPORTANT):</span></p>
                    <ul>
                        <li><strong>Initial:</strong> NS 1-1.5 L over first hour (15-20 mL/kg/hr)</li>
                        <li><strong>Subsequent:</strong> 
                            <ul>
                                <li>If Na normal/high: 0.45% NS at 250-500 mL/hr</li>
                                <li>If Na low: NS at 250-500 mL/hr</li>
                            </ul>
                        </li>
                        <li><strong>Once glucose <250:</strong> Switch to D5 0.45% NS to prevent hypoglycemia while continuing insulin</li>
                        <li>Total deficit usually 5-10 L - replace over 24-48 hours</li>
                    </ul>
                    
                    <p><span class="label">2. Insulin:</span></p>
                    <ul>
                        <li><strong>Regular insulin IV infusion:</strong> 0.1 units/kg/hr (usually 5-10 units/hr)</li>
                        <li>Optional bolus: 0.1 units/kg IV if severe DKA</li>
                        <li>Goal: Decrease glucose by 50-75 mg/dL/hr</li>
                        <li><strong>Do NOT stop insulin</strong> when glucose reaches 250! Switch to D5-containing fluids and continue insulin until anion gap closes</li>
                        <li>Once anion gap closed: Transition to subQ insulin, overlap by 1-2 hours before stopping gtt</li>
                    </ul>
                    
                    <p><span class="label">3. Potassium Repletion (CRITICAL):</span></p>
                    <ul>
                        <li><strong>If K+ <3.3:</strong> Hold insulin, give K+ 20-30 mEq/hr until K >3.3</li>
                        <li><strong>If K+ 3.3-5.2:</strong> Add 20-30 mEq K+ to each liter of fluids</li>
                        <li><strong>If K+ >5.2:</strong> No K+ initially, check q2-4h (will drop with insulin)</li>
                        <li>Goal: K+ 4-5 mEq/L</li>
                    </ul>
                    
                    <p><span class="label">4. Phosphate (if <1.0 mg/dL):</span> K-phos 20-30 mEq/L in fluids</p>
                    
                    <p><span class="label">5. Bicarbonate (controversial, only if pH <6.9):</span> 100 mEq in 400 mL H2O + 20 mEq KCl over 2 hours</p>
                    
                    <p><span class="label">6. Treat Precipitant:</span> Antibiotics if infection, adjust insulin regimen, etc</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>DKA resolution:</strong> Glucose <200 AND anion gap <12 AND HCO3 >18 AND pH >7.3. Don't stop insulin just because glucose normalized!</li>
                    <li><strong>Two-bag system:</strong> Run two IV bags (one NS, one D5-NS) through Y-connector. Adjust ratio to maintain glucose 150-200 while continuing insulin</li>
                    <li><strong>Euglycemic DKA:</strong> Can occur with SGLT2 inhibitors. Check ketones even if glucose <250!</li>
                    <li><strong>K+ shifts:</strong> Total body K+ depleted despite normal/high initial K+. With insulin, K+ shifts into cells ‚Üí life-threatening hypokalemia. Monitor closely!</li>
                    <li><strong>Cerebral edema:</strong> Rare but fatal. More common in kids. From too-rapid correction. Symptoms: Headache, AMS, bradycardia. Give mannitol/3% saline</li>
                    <li><strong>Anion gap:</strong> Closes before ketones clear. Don't discharge until ketones clearing and patient eating</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>pH <7.0</li>
                        <li>HCO3 <10</li>
                        <li>Altered mental status</li>
                        <li>Hemodynamic instability</li>
                        <li>Need for continuous insulin infusion</li>
                        <li>Severe electrolyte derangements</li>
                        <li>Cerebral edema concern</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>DKA resolved (AG <12, HCO3 >18, pH >7.3)</li>
                        <li>Tolerating PO intake</li>
                        <li>Transitioned to subQ insulin</li>
                        <li>Ketones clearing</li>
                        <li>Precipitant identified and treated</li>
                        <li>Patient educated on sick day management</li>
                        <li>Diabetes follow-up arranged</li>
                        <li>No ongoing complications</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cerebral edema (1%), hypokalemia, hypoglycemia, ARDS, thrombosis, mucormycosis</p>
                    <p><strong>From Treatment:</strong> Hyperchloremic non-gap acidosis (from NS), volume overload</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 14: HYPEROSMOLAR HYPERGLYCEMIC STATE -->
        <div id="hhs" class="condition-page">
            <div class="page-header">
                <h2>14. HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)</h2>
                <div class="subtitle">Extreme Hyperglycemia ‚Ä¢ Hyperosmolarity ‚Ä¢ Type 2 DM</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Key Differences from DKA:</span> More extreme hyperglycemia (>600), higher osmolality (>320), NO significant ketoacidosis, more profound dehydration</p>
                    <p><span class="label">Classic:</span> Altered mental status, severe dehydration, hypotension. Often insidious onset over days-weeks</p>
                    <p><span class="label">Typical Patient:</span> Elderly Type 2 diabetic with infection or medication non-compliance</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">HHS Criteria:</span></p>
                    <ul>
                        <li>Glucose >600 mg/dL</li>
                        <li>Effective serum osmolality >320 mOsm/kg</li>
                        <li>pH >7.30</li>
                        <li>HCO3 >15</li>
                        <li>Minimal ketones (can have trace)</li>
                    </ul>
                    <p><span class="label">Calculate Osmolality:</span> 2(Na) + glucose/18 + BUN/2.8. Normal 280-295</p>
                    <p><span class="label">Labs:</span> Same as DKA - VBG, BMP, identify precipitant</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Aggressive Fluid Resuscitation (MORE than DKA):</span></p>
                    <ul>
                        <li>Initial: NS 1-1.5 L first hour</li>
                        <li>Subsequent: 250-500 mL/hr based on volume status</li>
                        <li>Total deficit often 8-12 L (more than DKA)</li>
                        <li>Goal: Replace half of deficit in first 12-24 hours</li>
                    </ul>
                    
                    <p><span class="label">2. Insulin (LOWER rates than DKA):</span></p>
                    <ul>
                        <li>Wait 1-2 hours, give fluids first to avoid vascular collapse</li>
                        <li>Then start insulin 0.05-0.1 units/kg/hr (lower than DKA)</li>
                        <li>Goal: Decrease glucose by 50-75 mg/dL/hr</li>
                        <li>Once glucose <300: Add dextrose to fluids, continue insulin</li>
                    </ul>
                    
                    <p><span class="label">3. Potassium:</span> Same principles as DKA</p>
                    
                    <p><span class="label">4. Correct Slowly:</span> Osmolality should decrease by <3 mOsm/kg/hr to avoid cerebral edema</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>HHS vs DKA:</strong> HHS = Type 2 DM, more dehydration, higher glucose (>600), no ketosis. DKA = Type 1, ketoacidosis</li>
                    <li><strong>Why no ketosis?</strong> Type 2 patients have enough insulin to prevent lipolysis but not enough to control glucose</li>
                    <li><strong>Mortality higher:</strong> HHS mortality 10-20% (vs 1-5% for DKA) - sicker, older patients</li>
                    <li><strong>Fluids first!</strong> Give 1-2 L NS before starting insulin to prevent cardiovascular collapse</li>
                    <li><strong>Slower correction:</strong> Osmolality built up over longer time, correct more slowly to avoid cerebral edema</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Altered mental status/coma</li>
                        <li>Osmolality >350</li>
                        <li>Hemodynamic instability</li>
                        <li>Need for insulin infusion</li>
                        <li>Severe electrolyte abnormalities</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Glucose <250 and stable</li>
                        <li>Mental status at baseline</li>
                        <li>Osmolality <310</li>
                        <li>Taking PO</li>
                        <li>On appropriate diabetes regimen</li>
                        <li>Precipitant treated</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 15: UPPER GI BLEED -->
        <div id="ugib" class="condition-page">
            <div class="page-header">
                <h2>15. UPPER GI BLEED</h2>
                <div class="subtitle">Hematemesis ‚Ä¢ Melena ‚Ä¢ Variceal vs Non-Variceal</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Hematemesis (bright red or coffee-ground), melena (black tarry stool), syncope, hemodynamic instability</p>
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Non-Variceal (90%):</strong> PUD (H. pylori, NSAIDs), erosive gastritis/esophagitis, Mallory-Weiss tear, Dieulafoy lesion</li>
                        <li><strong>Variceal (10%):</strong> Esophageal or gastric varices (cirrhosis, portal hypertension)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> Two large-bore IVs, CBC, type & cross (4 units), BMP, coags, LFTs</p>
                    <p><span class="label">Risk Stratification:</span> Glasgow-Blatchford Score (score 0 = safe for outpatient, ‚â•1 consider admission)</p>
                    <p><span class="label">EGD:</span> Within 24 hours (within 12 hours if high risk/variceal suspected)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Resuscitation:</span></p>
                    <ul>
                        <li><strong>Transfusion:</strong> Goal Hgb 7-9 (restrictive strategy). Higher target (9-10) if active cardiac disease</li>
                        <li><strong>Fluids:</strong> Crystalloids for volume resuscitation</li>
                        <li><strong>Correct coagulopathy:</strong> Reverse anticoagulation if active bleeding, give FFP/PCC if INR >1.8</li>
                    </ul>
                    
                    <p><span class="label">Pharmacotherapy:</span></p>
                    <ul>
                        <li><strong>PPI:</strong> Pantoprazole 80mg IV bolus, then 8mg/hr infusion √ó 72hr (for non-variceal)</li>
                        <li><strong>If Variceal Suspected:</strong> Octreotide 50 mcg bolus, then 50 mcg/hr infusion</li>
                        <li><strong>Antibiotics (if cirrhotic):</strong> Ceftriaxone 1g IV daily √ó 7 days (reduces mortality)</li>
                    </ul>
                    
                    <p><span class="label">Endoscopic Management:</span></p>
                    <ul>
                        <li><strong>PUD:</strong> Epinephrine injection + thermal coagulation ¬± clips</li>
                        <li><strong>Varices:</strong> Band ligation (preferred) or sclerotherapy</li>
                        <li><strong>If refractory variceal bleeding:</strong> Balloon tamponade (Blakemore tube), TIPS</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Don't over-transfuse:</strong> Target Hgb 7-9. Higher targets worsen outcomes (increased rebleeding)</li>
                    <li><strong>Rockall score:</strong> Post-EGD risk score. Predicts rebleeding and mortality</li>
                    <li><strong>PPI timing:</strong> Pre-EGD PPI doesn't reduce mortality but may reduce stigmata of recent hemorrhage</li>
                    <li><strong>Mallory-Weiss:</strong> Longitudinal tear at GE junction from forceful vomiting. Usually self-limited</li>
                    <li><strong>NG tube controversial:</strong> Not routinely needed. Doesn't improve outcomes, uncomfortable for patient</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability despite resuscitation</li>
                        <li>Massive transfusion (>4 units in 24hr)</li>
                        <li>Variceal bleeding</li>
                        <li>Rebleeding after endoscopic intervention</li>
                        <li>Need for airway protection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable √ó 24hr</li>
                        <li>Hgb stable (no transfusion need)</li>
                        <li>Post-EGD with low-risk lesion</li>
                        <li>Tolerating PO</li>
                        <li>On PPI BID √ó 2 weeks, then daily</li>
                        <li>H. pylori testing sent/treated</li>
                        <li>GI follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- FULLY EXPANDED CONDITIONS 16-40 -->
        
        <!-- PAGE 16: CIRRHOSIS WITH ASCITES -->
        <div id="cirrhosis" class="condition-page">
            <div class="page-header">
                <h2>16. CIRRHOSIS WITH ASCITES</h2>
                <div class="subtitle">Portal Hypertension ‚Ä¢ Decompensated Cirrhosis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Abdominal distension, weight gain, peripheral edema, early satiety, dyspnea from diaphragm elevation</p>
                    <p><span class="label">Physical Exam:</span> Shifting dullness, fluid wave, bulging flanks. Stigmata of chronic liver disease: jaundice, spider angiomas, palmar erythema, gynecomastia, caput medusae, asterixis</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>SBP:</strong> Fever, abdominal pain/tenderness, altered mental status without obvious peritonitis</li>
                        <li><strong>Hepatic Hydrothorax:</strong> Right-sided pleural effusion (usually) without cardiopulmonary disease</li>
                        <li><strong>Tense Ascites:</strong> Respiratory compromise, severe discomfort, umbilical/inguinal hernias</li>
                        <li><strong>Hepatorenal Syndrome:</strong> Progressive AKI despite volume resuscitation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span> Ultrasound (detects >100mL ascites, evaluates liver texture, portal vein), CT abdomen if unclear etiology or concern for HCC</p>
                    <p><span class="label">Diagnostic Paracentesis (ALWAYS on first presentation OR any clinical deterioration):</span></p>
                    <ul>
                        <li><strong>Cell count with differential:</strong> PMN >250 = SBP</li>
                        <li><strong>Albumin:</strong> For SAAG calculation</li>
                        <li><strong>Total protein:</strong> <1g/dL = high SBP risk</li>
                        <li><strong>Gram stain and culture:</strong> Inoculate blood culture bottles at bedside (improves yield)</li>
                        <li><strong>Consider:</strong> Glucose, LDH, cytology (if malignancy suspected), TB studies, amylase (if pancreatitis concern)</li>
                    </ul>
                    
                    <p><span class="label">SAAG (Serum-Ascites Albumin Gradient):</span></p>
                    <ul>
                        <li>Calculate: Serum albumin - Ascitic fluid albumin</li>
                        <li><strong>‚â•1.1 g/dL:</strong> Portal hypertension (97% accuracy) - cirrhosis, cardiac ascites, Budd-Chiari syndrome, sinusoidal obstruction syndrome</li>
                        <li><strong><1.1 g/dL:</strong> Non-portal causes - peritoneal carcinomatosis, TB peritonitis, pancreatic ascites, nephrotic syndrome, serositis</li>
                        <li>SAAG unaffected by diuretics or albumin infusions</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> CBC, CMP, albumin, PT/INR, hepatitis panel (HBsAg, anti-HCV), AFP (HCC screening), lipid panel</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Sodium Restriction:</span> <2g/day (88 mEq/day). This is THE most important intervention! Effective in 10-20% as monotherapy</p>
                    
                    <p><span class="label">Diuretic Therapy:</span></p>
                    <ul>
                        <li><strong>Initial regimen:</strong> Spironolactone 100mg PO daily + Furosemide 40mg PO daily (100:40 ratio)</li>
                        <li><strong>Titration:</strong> Increase both medications together every 3-5 days maintaining the 100:40 ratio
                            <ul>
                                <li>Step 2: Spironolactone 200mg + Furosemide 80mg</li>
                                <li>Step 3: Spironolactone 300mg + Furosemide 120mg</li>
                                <li>Maximum: Spironolactone 400mg + Furosemide 160mg</li>
                            </ul>
                        </li>
                        <li><strong>Goal weight loss:</strong> 0.5kg/day if ascites alone, 1kg/day if peripheral edema present</li>
                        <li><strong>Monitoring:</strong> Daily weights, BMP at least 2√ó/week initially (watch Na, K, Cr)</li>
                        <li><strong>Hold diuretics if:</strong> Na <120, K >6, Cr rise >2mg/dL above baseline, encephalopathy worsens, severe hypovolemia</li>
                    </ul>
                    
                    <p><span class="label">Large Volume Paracentesis (LVP):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Tense/refractory ascites, respiratory compromise, severe discomfort, new-onset ascites for diagnosis</li>
                        <li>Safe to remove 10-12 liters in single session</li>
                        <li><strong>Albumin replacement:</strong> 6-8g IV per liter removed if >5 liters removed (prevents post-paracentesis circulatory dysfunction)</li>
                        <li>Can use 20% or 25% albumin (20% is more cost-effective)</li>
                        <li>Complications rare: bleeding <1%, infection <1%, bowel perforation <0.1%</li>
                    </ul>
                    
                    <p><span class="label">Refractory Ascites:</span></p>
                    <ul>
                        <li><strong>Definition:</strong> Unresponsive to maximum diuretics + sodium restriction OR development of diuretic-induced complications</li>
                        <li><strong>Management options:</strong>
                            <ul>
                                <li>Serial large volume paracentesis q2-4 weeks + albumin</li>
                                <li>TIPS (transjugular intrahepatic portosystemic shunt) - if appropriate candidate (MELD <18, no encephalopathy)</li>
                                <li>Liver transplant evaluation</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Fluid Restriction:</span> Generally NOT needed unless Na <120-125 mEq/L</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>100:40 ratio maintains normokalemia:</strong> Spironolactone (K-sparing) + furosemide (K-wasting) balance each other</li>
                    <li><strong>SAAG is gospel:</strong> ‚â•1.1 = portal hypertension with 97% accuracy. Unaffected by diuretics, paracentesis, or albumin</li>
                    <li><strong>Paracentesis is safe:</strong> Can tap with INR 2-3, platelets >20k. Prophylactic FFP/platelets NOT needed. Bleeding risk <1%</li>
                    <li><strong>SBP prophylaxis indications:</strong> Primary (never had SBP): ascitic protein <1.5 g/dL + Child-Pugh B/C OR GI bleeding. Secondary (prior SBP): lifelong</li>
                    <li><strong>Medications to AVOID:</strong> NSAIDs (precipitate HRS, worsen ascites), ACE-I/ARBs (hypotension, HRS), aminoglycosides (nephrotoxic)</li>
                    <li><strong>TIPS considerations:</strong> Reduces ascites and variceal bleeding but increases hepatic encephalopathy. Best for refractory ascites with MELD <18</li>
                    <li><strong>Hepatorenal syndrome triggers:</strong> SBP, GI bleeding, large volume paracentesis without albumin, overdiuresis</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability/shock</li>
                        <li>Respiratory failure from tense ascites</li>
                        <li>HRS type 1 (rapidly progressive AKI)</li>
                        <li>Grade 3-4 hepatic encephalopathy</li>
                        <li>Variceal bleeding</li>
                        <li>Severe SBP with sepsis</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Ascites improved/controlled on oral diuretics</li>
                        <li>No evidence of SBP (if tapped)</li>
                        <li>Renal function stable (Cr not rising)</li>
                        <li>Electrolytes acceptable (Na >125, K 3.5-5.5)</li>
                        <li>Encephalopathy grade 0-1</li>
                        <li>Patient/family educated on 2g sodium diet</li>
                        <li>Daily weight monitoring arranged</li>
                        <li>Hepatology follow-up within 1-2 weeks</li>
                        <li>Transplant evaluation if MELD ‚â•15</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Disease:</strong> SBP, hepatorenal syndrome, hepatic hydrothorax, umbilical/inguinal hernia rupture, respiratory compromise, hepatic encephalopathy</p>
                    <p><strong>From Treatment:</strong> Hyponatremia, hyperkalemia, hypokalemia, AKI, muscle cramps, gynecomastia (spironolactone), metabolic alkalosis</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 17: SPONTANEOUS BACTERIAL PERITONITIS -->
        <div id="sbp" class="condition-page">
            <div class="page-header">
                <h2>17. SPONTANEOUS BACTERIAL PERITONITIS (SBP)</h2>
                <div class="subtitle">Infected Ascites ‚Ä¢ Cirrhotic Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> Fever, abdominal pain/tenderness, altered mental status in patient with ascites. BUT symptoms may be very subtle!</p>
                    <p><span class="label">High Index of Suspicion:</span> Any cirrhotic patient with ascites who clinically deteriorates (worsening encephalopathy, AKI, ileus, hypothermia, unexplained acidosis)</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic SBP:</strong> 10-30% have NO symptoms at all. Diagnosed on routine surveillance paracentesis</li>
                        <li><strong>Hypothermia:</strong> Temperature <36¬∞C. Poor prognostic sign (mortality >50%)</li>
                        <li><strong>Isolated Worsening Encephalopathy:</strong> May be the ONLY presenting sign</li>
                        <li><strong>Acute Kidney Injury:</strong> SBP frequently triggers hepatorenal syndrome</li>
                        <li><strong>Ileus/Decreased Bowel Sounds:</strong> Without obvious mechanical obstruction</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnostic Paracentesis:</span> MANDATORY with low threshold! Any clinical suspicion warrants immediate tap</p>
                    
                    <p><span class="label">SBP Diagnostic Criteria (any ONE equals SBP):</span></p>
                    <ul>
                        <li><strong>PMN ‚â•250 cells/mm¬≥:</strong> This alone is DIAGNOSTIC. Start antibiotics immediately!</li>
                        <li><strong>Culture-positive with PMN <250:</strong> "Culture-negative neutrocytic ascites" - treat as SBP</li>
                        <li><strong>Monomicrobial culture with PMN <250:</strong> "Bacterascites" - consider treatment if symptomatic</li>
                    </ul>
                    
                    <p><span class="label">Ascitic Fluid Studies:</span></p>
                    <ul>
                        <li><strong>Cell count with differential (STAT):</strong> PMN is the key number</li>
                        <li><strong>Gram stain:</strong> Usually negative (low sensitivity ~10%)</li>
                        <li><strong>Culture:</strong> Inoculate 10mL into blood culture bottles AT BEDSIDE (increases yield from 40% to 80%)</li>
                        <li><strong>Albumin:</strong> For SAAG if new ascites</li>
                        <li><strong>Total protein:</strong> <1 g/dL = high risk for SBP</li>
                        <li><strong>Glucose and LDH:</strong> Help distinguish primary from secondary peritonitis</li>
                    </ul>
                    
                    <p><span class="label">Blood Studies:</span> CBC, CMP, blood cultures √ó 2, lactate</p>
                    
                    <p><span class="label">Common Organisms:</span></p>
                    <ul>
                        <li>E. coli (40%)</li>
                        <li>Klebsiella species (7%)</li>
                        <li>Streptococcus species (15%)</li>
                        <li>Enterococcus</li>
                        <li>Usually monomicrobial</li>
                    </ul>
                    
                    <p><span class="label">Secondary Bacterial Peritonitis (Bowel Perforation):</span> Consider if:
                        <ul>
                            <li>Polymicrobial culture</li>
                            <li>Protein >1 g/dL</li>
                            <li>Glucose <50 mg/dL</li>
                            <li>LDH > upper limit of serum normal</li>
                            <li>If suspected ‚Üí get CT abdomen/pelvis STAT</li>
                        </ul>
                    </p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Antibiotics (start IMMEDIATELY if PMN ‚â•250):</span></p>
                    <ul>
                        <li><strong>First-line (community-acquired):</strong> Ceftriaxone 2g IV daily √ó 5-7 days</li>
                        <li><strong>Alternative:</strong> Cefotaxime 2g IV q8h</li>
                        <li><strong>If nosocomial or recent Œ≤-lactam exposure:</strong> Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (for MDRO coverage)</li>
                        <li><strong>Penicillin allergy:</strong> Fluoroquinolone (but increasing resistance) or discuss with ID</li>
                        <li><strong>Duration:</strong> 5-7 days, or until ascitic PMN <250 on repeat tap</li>
                    </ul>
                    
                    <p><span class="label">Albumin Infusion (CRITICAL - Reduces Mortality by 30%):</span></p>
                    <ul>
                        <li><strong>Day 1:</strong> 1.5 g/kg IV (give within 6 hours of diagnosis)</li>
                        <li><strong>Day 3:</strong> 1.0 g/kg IV</li>
                        <li><strong>Example:</strong> 70kg patient ‚Üí 105g on day 1, 70g on day 3</li>
                        <li><strong>Mechanism:</strong> Prevents hepatorenal syndrome and improves circulatory function</li>
                        <li><strong>Evidence:</strong> Reduces HRS by 70%, mortality by 30%. This is NOT optional!</li>
                    </ul>
                    
                    <p><span class="label">Follow-up Paracentesis:</span></p>
                    <ul>
                        <li>At 48 hours if patient not improving clinically</li>
                        <li>PMN count should decrease by ‚â•25%</li>
                        <li>If not improving ‚Üí consider resistant organism, secondary peritonitis, or inadequate antibiotic</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prophylaxis (After SBP Episode Resolves):</span></p>
                    <ul>
                        <li><strong>Duration:</strong> LIFELONG (until transplant or death)</li>
                        <li><strong>Options:</strong>
                            <ul>
                                <li>Norfloxacin 400mg PO daily (first choice) OR</li>
                                <li>Ciprofloxacin 750mg PO weekly OR</li>
                                <li>Trimethoprim-sulfamethoxazole DS daily</li>
                            </ul>
                        </li>
                        <li>Reduces 1-year recurrence from 70% to 20%</li>
                    </ul>
                    
                    <p><span class="label">Primary Prophylaxis (Never Had SBP):</span></p>
                    <ul>
                        <li><strong>Indication 1:</strong> Ascitic protein <1.5 g/dL + Child-Pugh ‚â•9 or impaired renal function</li>
                        <li><strong>Indication 2:</strong> Acute GI bleeding (give for 7 days regardless of ascitic protein)</li>
                        <li>Use same antibiotics as secondary prophylaxis</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>PMN ‚â•250 = Treat NOW:</strong> Don't wait for culture. Only 40% of true SBP will have positive culture</li>
                    <li><strong>Albumin saves lives:</strong> Reduces hepatorenal syndrome by 70%, mortality by 30%. Give on day 1 AND day 3. Not optional!</li>
                    <li><strong>Low threshold to tap:</strong> When in doubt, tap. Complications are rare (<1% bleeding). Missing SBP is worse than "unnecessary" paracentesis</li>
                    <li><strong>Bedside inoculation:</strong> Putting ascitic fluid in blood culture bottles AT BEDSIDE increases yield from 50% to 80%</li>
                    <li><strong>Secondary peritonitis clues:</strong> If polymicrobial, protein >1, glucose <50, or LDH >ULN ‚Üí think bowel perforation. Get CT!</li>
                    <li><strong>Recurrence without prophylaxis:</strong> 70% recur within 1 year. Secondary prophylaxis is lifelong</li>
                    <li><strong>No prophylaxis for everyone:</strong> Primary prophylaxis only for very high risk (protein <1.5 + advanced disease or GI bleed)</li>
                    <li><strong>Don't blame antibiotics for encephalopathy:</strong> Quinolones for SBP prophylaxis do NOT worsen encephalopathy (old myth)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure needing intubation</li>
                        <li>Severe hepatic encephalopathy (grade 3-4)</li>
                        <li>Rapidly progressive AKI/HRS</li>
                        <li>Hypothermia or severe sepsis</li>
                        <li>No clinical improvement despite 48hr treatment</li>
                        <li>Suspected secondary peritonitis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Completed minimum 5 days antibiotics</li>
                        <li>Afebrile √ó 24-48 hours</li>
                        <li>Clinical symptoms resolved</li>
                        <li>Renal function stable or improving</li>
                        <li>Repeat paracentesis (if done) with PMN <250</li>
                        <li>Started on secondary prophylaxis</li>
                        <li>Close hepatology follow-up arranged</li>
                        <li>Transplant evaluation if not already listed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Hepatorenal syndrome (occurs in 30%), septic shock, paralytic ileus, worsening hepatic encephalopathy, death (in-hospital mortality 20-40%)</p>
                    <p><strong>Recurrence:</strong> 70% within 1 year without secondary prophylaxis. 20% with prophylaxis. Each recurrence increases mortality risk</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 18: HEPATIC ENCEPHALOPATHY -->
        <div id="he" class="condition-page">
            <div class="page-header">
                <h2>18. HEPATIC ENCEPHALOPATHY</h2>
                <div class="subtitle">Altered Mental Status in Cirrhosis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">West Haven Grading:</span></p>
                    <ul>
                        <li><strong>Grade 0 (Minimal):</strong> Normal mental status, subtle psychometric abnormalities</li>
                        <li><strong>Grade 1:</strong> Trivial confusion, euphoria/anxiety, shortened attention span, impaired addition/subtraction</li>
                        <li><strong>Grade 2:</strong> Lethargy, disorientation to time, obvious personality change, inappropriate behavior, asterixis</li>
                        <li><strong>Grade 3:</strong> Somnolent but arousable, gross disorientation, bizarre behavior</li>
                        <li><strong>Grade 4:</strong> Coma, unresponsive to painful stimuli</li>
                    </ul>
                    
                    <p><span class="label">Physical Exam Findings:</span></p>
                    <ul>
                        <li><strong>Asterixis:</strong> "Flapping tremor" - extend arms with dorsiflexed wrists, observe for irregular flapping. Present in grades 2-3</li>
                        <li><strong>Hyperreflexia:</strong> Increased deep tendon reflexes</li>
                        <li><strong>Fetor hepaticus:</strong> Sweet, musty breath odor</li>
                        <li><strong>Stigmata of cirrhosis:</strong> Jaundice, spider angiomas, palmar erythema, ascites</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Acute Change:</strong> Sudden worsening in previously stable patient suggests precipitant</li>
                        <li><strong>Post-TIPS:</strong> Can develop weeks after TIPS procedure</li>
                        <li><strong>Subclinical:</strong> Patient/family report subtle changes not apparent to clinicians</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnosis of Exclusion:</span> Rule out other causes of altered mental status first!</p>
                    
                    <p><span class="label">Essential Studies:</span></p>
                    <ul>
                        <li><strong>Labs:</strong> CBC, CMP, ammonia level (correlates poorly but >200 suggests HE), venous pH/lactate</li>
                        <li><strong>Infection workup:</strong> UA, CXR, diagnostic paracentesis if ascites present (rule out SBP!)</li>
                        <li><strong>Toxicology screen:</strong> Especially in acute change</li>
                        <li><strong>Head CT:</strong> If focal neurologic signs, trauma, first episode, or atypical presentation</li>
                    </ul>
                    
                    <p><span class="label">Identify Precipitants (The "5 I's" + more):</span></p>
                    <ul>
                        <li><strong>Infection:</strong> SBP (most common), UTI, pneumonia, any infection</li>
                        <li><strong>GI bleed:</strong> Protein load from blood</li>
                        <li><strong>Constipation:</strong> Increased colonic transit time ‚Üí more ammonia absorption</li>
                        <li><strong>Medications:</strong> Benzos, opioids, diuretic-induced hypokalemia/alkalosis</li>
                        <li><strong>Dehydration/Azotemia:</strong> From overdiuresis</li>
                        <li><strong>Electrolyte abnormalities:</strong> Hyponatremia, hypokalemia</li>
                        <li><strong>TIPS:</strong> Increased porto-systemic shunting</li>
                        <li><strong>Hepatocellular carcinoma:</strong> Tumor burden</li>
                        <li><strong>Dietary indiscretion:</strong> Large protein meal</li>
                        <li><strong>Non-compliance:</strong> Stopping lactulose</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Identify and Treat Precipitant (MOST IMPORTANT!):</span></p>
                    <ul>
                        <li>Tap ascites (rule out SBP)</li>
                        <li>Check for GI bleeding</li>
                        <li>Treat infections</li>
                        <li>Review medication list - stop sedatives/opioids</li>
                        <li>Correct electrolyte abnormalities</li>
                    </ul>
                    
                    <p><span class="label">2. Lactulose (First-line Therapy):</span></p>
                    <ul>
                        <li><strong>Initial dose:</strong> 30mL (20g) PO q1-2 hours until first bowel movement</li>
                        <li><strong>Maintenance:</strong> 30mL PO TID, titrate to 2-3 soft bowel movements per day</li>
                        <li><strong>Goal:</strong> Acidify colon, decrease ammonia production/absorption</li>
                        <li><strong>If cannot take PO:</strong> 300mL lactulose in 700mL water as retention enema, hold 30-60 min</li>
                        <li><strong>Watch for:</strong> Dehydration, hypernatremia (diarrhea), cramping</li>
                    </ul>
                    
                    <p><span class="label">3. Rifaximin (Add-on Therapy for Recurrent/Chronic HE):</span></p>
                    <ul>
                        <li><strong>Dose:</strong> 550mg PO BID</li>
                        <li><strong>Mechanism:</strong> Non-absorbable antibiotic, reduces ammonia-producing gut bacteria</li>
                        <li><strong>Evidence:</strong> Reduces HE recurrence by 58% when added to lactulose</li>
                        <li><strong>Cost:</strong> Expensive (~$2000/month), often requires prior auth</li>
                        <li>Use for patients with ‚â•2 HE episodes requiring hospitalization</li>
                    </ul>
                    
                    <p><span class="label">4. Zinc Supplementation:</span></p>
                    <ul>
                        <li><strong>Dose:</strong> Zinc sulfate 220mg PO daily</li>
                        <li>Many cirrhotics are zinc deficient</li>
                        <li>Zinc is cofactor for urea cycle enzymes</li>
                    </ul>
                    
                    <p><span class="label">5. Supportive Care:</span></p>
                    <ul>
                        <li>Airway protection if grade 3-4 (consider intubation)</li>
                        <li>Avoid sedatives (worsen encephalopathy)</li>
                        <li>If agitated: low-dose haloperidol 0.5-2mg (avoid benzos)</li>
                        <li>Nutrition: Don't restrict protein! Give 1.2-1.5 g/kg/day. Protein restriction is OUTDATED</li>
                    </ul>
                    
                    <p><span class="label">What NOT to Do:</span></p>
                    <ul>
                        <li><strong>Do NOT restrict protein:</strong> Outdated practice, worsens malnutrition</li>
                        <li><strong>Do NOT use neomycin:</strong> Nephrotoxic, ototoxic. Rifaximin is better</li>
                        <li><strong>Ammonia level:</strong> Don't follow serial levels - correlates poorly with clinical status</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Always find the precipitant:</strong> HE rarely occurs without a trigger. Treat the cause, not just the symptom</li>
                    <li><strong>Ammonia level controversy:</strong> Poor correlation with severity. Level >200 supports diagnosis but normal level doesn't exclude HE</li>
                    <li><strong>Protein restriction is WRONG:</strong> Old dogma. Cirrhotics need ADEQUATE protein (1.2-1.5g/kg/day) to prevent sarcopenia</li>
                    <li><strong>Vegetable protein better than animal:</strong> May be better tolerated but don't eliminate meat entirely</li>
                    <li><strong>Lactulose goals:</strong> 2-3 soft BMs/day. Too much = dehydration. Too little = constipation worsens HE</li>
                    <li><strong>Rifaximin not for acute:</strong> Add only for chronic/recurrent HE. Takes days to work. Not for initial episodes</li>
                    <li><strong>Post-TIPS HE:</strong> Occurs in 30-50%. May need TIPS revision or consider transplant if refractory</li>
                    <li><strong>Asterixis is NOT specific:</strong> Also seen in uremia, hypercapnia, other metabolic encephalopathies</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Grade 3-4 encephalopathy (coma)</li>
                        <li>Inability to protect airway</li>
                        <li>Rapidly progressive deterioration</li>
                        <li>Hemodynamic instability</li>
                        <li>Severe concurrent illness (sepsis, GI bleed)</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Mental status at baseline (grade 0-1)</li>
                        <li>Precipitant identified and treated</li>
                        <li>Established bowel regimen (2-3 BM/day)</li>
                        <li>On appropriate lactulose dose</li>
                        <li>Rifaximin added if recurrent HE</li>
                        <li>Family educated on HE signs, lactulose use</li>
                        <li>Hepatology follow-up within 1 week</li>
                        <li>Transplant evaluation if not listed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Aspiration pneumonia, falls/trauma, pressure ulcers, malnutrition, inability to take medications</p>
                    <p><strong>Chronic:</strong> Recurrent HE episodes (50% recur within 6 months), cognitive decline, poor quality of life, increased mortality</p>
                    <p><strong>From Treatment:</strong> Dehydration and hypernatremia from excessive lactulose, diarrhea, abdominal cramping</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 19: ACUTE PANCREATITIS -->
        <div id="pancreatitis" class="condition-page">
            <div class="page-header">
                <h2>19. ACUTE PANCREATITIS</h2>
                <div class="subtitle">Gallstones ‚Ä¢ Alcohol ‚Ä¢ Hypertriglyceridemia</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Epigastric pain radiating to back, nausea/vomiting, anorexia. Pain may be relieved by leaning forward</p>
                    <p><span class="label">Physical Exam:</span> Epigastric tenderness, decreased bowel sounds, tachycardia, fever, Cullen sign (periumbilical ecchymosis) or Grey Turner sign (flank ecchymosis) in hemorrhagic pancreatitis</p>
                    <p><span class="label">Common Causes (GET SMASHED):</span></p>
                    <ul>
                        <li><strong>G</strong>allstones (40%)</li>
                        <li><strong>E</strong>thanol (30%)</li>
                        <li><strong>T</strong>rauma</li>
                        <li><strong>S</strong>teroids</li>
                        <li><strong>M</strong>umps/other infections</li>
                        <li><strong>A</strong>utoimmune (IgG4)</li>
                        <li><strong>S</strong>corpion/snake bites</li>
                        <li><strong>H</strong>ypertriglyceridemia (>1000 mg/dL), Hypercalcemia</li>
                        <li><strong>E</strong>RCP</li>
                        <li><strong>D</strong>rugs (azathioprine, 6-MP, valproic acid, thiazides, furosemide, sulfonamides, tetracycline)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnosis Requires 2 of 3:</span></p>
                    <ul>
                        <li><strong>1. Characteristic abdominal pain</strong></li>
                        <li><strong>2. Serum lipase >3√ó upper limit normal</strong> (more specific than amylase)</li>
                        <li><strong>3. Imaging findings</strong></li>
                    </ul>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>Lipase:</strong> More sensitive/specific than amylase. Stays elevated longer</li>
                        <li>CBC (leukocytosis common), CMP (assess calcium, glucose), lipid panel (TG), LFTs (assess biliary etiology)</li>
                        <li><strong>If ALT >150:</strong> 95% PPV for gallstone pancreatitis</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>RUQ ultrasound:</strong> Look for gallstones, CBD dilation (do in ALL patients)</li>
                        <li><strong>CT abdomen with IV contrast:</strong> If diagnosis unclear OR severe disease. Delay 48-72hr if possible (pancreatic necrosis takes time to develop)</li>
                        <li><strong>MRCP:</strong> If concern for choledocholithiasis</li>
                    </ul>
                    
                    <p><span class="label">Severity Scoring:</span></p>
                    <ul>
                        <li><strong>Ranson Criteria:</strong> On admission + at 48 hours. Score ‚â•3 = severe</li>
                        <li><strong>BISAP Score:</strong> Simpler. 1 point each for: BUN >25, Impaired mental status, SIRS, Age >60, Pleural effusion. Score ‚â•3 = severe</li>
                        <li><strong>APACHE-II:</strong> Complex but accurate</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Fluid Resuscitation (MOST IMPORTANT):</span></p>
                    <ul>
                        <li><strong>Aggressive IVF:</strong> Lactated Ringer's preferred over NS (reduces SIRS, mortality)</li>
                        <li><strong>Rate:</strong> 250-500 mL/hr initially (15-20 mL/kg bolus, then 250-500 mL/hr)</li>
                        <li><strong>Goal:</strong> UOP >0.5 mL/kg/hr, HR <120, MAP 65-85</li>
                        <li><strong>Caution:</strong> Watch for volume overload in elderly/cardiac disease</li>
                        <li>Early aggressive hydration (within 24hr) reduces organ failure and mortality</li>
                    </ul>
                    
                    <p><span class="label">Nutrition:</span></p>
                    <ul>
                        <li><strong>Early oral feeding:</strong> Start within 24 hours if tolerated (even in severe pancreatitis!)</li>
                        <li><strong>Diet:</strong> Low-fat solid diet as tolerated. No need for clear liquids first</li>
                        <li><strong>If cannot tolerate PO:</strong> Enteral nutrition via NG/NJ tube preferred over TPN</li>
                        <li><strong>NPO only if:</strong> Intractable vomiting, ileus, or altered mental status</li>
                    </ul>
                    
                    <p><span class="label">Pain Control:</span></p>
                    <ul>
                        <li>IV opioids PRN (morphine, hydromorphone)</li>
                        <li>Myth: Opioids don't worsen pancreatitis via sphincter of Oddi spasm</li>
                    </ul>
                    
                    <p><span class="label">ERCP (Urgent <24hr):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Cholangitis OR biliary obstruction with bilirubin rising</li>
                        <li><strong>NOT indicated:</strong> Mild gallstone pancreatitis without obstruction (just do cholecystectomy later)</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics:</span></p>
                    <ul>
                        <li><strong>NOT routinely indicated</strong> for prophylaxis</li>
                        <li><strong>Give only if:</strong> Infected necrosis (proven by aspiration or gas on CT), cholangitis, or extrapancreatic infection</li>
                        <li>If infected necrosis: Carbapenems or fluoroquinolone + metronidazole</li>
                    </ul>
                    
                    <p><span class="label">Cholecystectomy (for Gallstone Pancreatitis):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During SAME admission once acute inflammation resolves (pancreatic enzymes normalizing)</li>
                        <li>Usually safe after 48-72 hours if improving</li>
                        <li>Recurrence rate 30-60% if not done</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>LR > NS:</strong> Lactated Ringer's reduces SIRS and mortality compared to normal saline</li>
                    <li><strong>Early feeding is safe:</strong> Outdated to keep NPO. Start low-fat diet within 24hr</li>
                    <li><strong>No prophylactic antibiotics:</strong> Don't reduce infection or mortality. Only treat proven infection</li>
                    <li><strong>CT timing:</strong> Necrosis takes 48-72hr to develop. Early CT often non-diagnostic</li>
                    <li><strong>Lipase > Amylase:</strong> Lipase more sensitive/specific. Can skip amylase entirely</li>
                    <li><strong>Hypertriglyceridemia:</strong> If TG >1000, this can CAUSE pancreatitis. Treat with insulin gtt + fibrates</li>
                    <li><strong>Sterile vs infected necrosis:</strong> Infected = fever, leukocytosis, gas on CT. Needs drainage. Sterile necrosis = conservative management</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe pancreatitis (BISAP ‚â•3, Ranson ‚â•3)</li>
                        <li>Organ failure (respiratory, renal, cardiovascular)</li>
                        <li>Hemodynamic instability</li>
                        <li>Persistent SIRS >48 hours</li>
                        <li>Pancreatic necrosis with infection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on PO medications</li>
                        <li>Tolerating regular diet</li>
                        <li>Lipase trending down</li>
                        <li>No organ dysfunction</li>
                        <li>Cholecystectomy done (if gallstone etiology)</li>
                        <li>Alcohol cessation counseling (if EtOH cause)</li>
                        <li>Follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early:</strong> Pancreatic necrosis (10-20%), infected necrosis, ARDS, AKI, shock, hypocalcemia</p>
                    <p><strong>Late:</strong> Pseudocyst (4 weeks), splenic/portal vein thrombosis, chronic pancreatitis, pancreatic insufficiency, diabetes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>
        <!-- CONDITIONS 20-25 FULLY EXPANDED -->
        
        <!-- PAGE 20: CELLULITIS -->
        <div id="cellulitis" class="condition-page">
            <div class="page-header">
                <h2>20. CELLULITIS</h2>
                <div class="subtitle">Skin/Soft Tissue Infection</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Acute onset of erythema, warmth, edema, and tenderness in affected area. Usually unilateral lower extremity. Pain typically present. Systemic symptoms: fever, chills, malaise in 40-60% of hospitalized patients</p>
                    <p><span class="label">Physical Exam:</span> Ill-defined borders spreading centrifugally (vs erysipelas which has raised sharp borders), no fluctuance (vs abscess), lymphangitic streaking in 15-20%, regional lymphadenopathy. Measure and mark borders with pen. Look for portal of entry (trauma, tinea pedis, fissures)</p>
                    <p><span class="label">Common Organisms:</span> Œ≤-hemolytic Streptococcus (Group A Strep, most common in non-purulent), Staphylococcus aureus (especially MRSA if purulent/abscess present)</p>
                    <p><span class="label">Risk Factors:</span> Obesity, diabetes mellitus, venous insufficiency, chronic lymphedema, tinea pedis (toe web intertrigo), immunosuppression, prior cellulitis (20-30% recurrence rate), skin barrier disruption</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Erysipelas:</strong> Superficial cellulitis with sharply demarcated, raised, indurated borders. "Orange peel" appearance. Almost always Group A Strep. Face and legs most common</li>
                        <li><strong>Periorbital Cellulitis:</strong> Eyelid edema, erythema WITHOUT vision changes or pain with eye movement (vs orbital cellulitis which needs emergent CT/ENT). Can progress to orbital cellulitis</li>
                        <li><strong>Facial Cellulitis:</strong> Consider dental source (odontogenic), sinusitis. Higher risk of cavernous sinus thrombosis if near nasolabial triangle</li>
                        <li><strong>Diabetic Patients:</strong> More likely polymicrobial, higher risk of progression to necrotizing infection. Check for gas on imaging</li>
                        <li><strong>Immunocompromised:</strong> Consider atypical organisms (fungi, mycobacteria, Pseudomonas). May lack fever/leukocytosis despite severe infection</li>
                        <li><strong>Post-Surgical:</strong> If within 48 hours, consider Group A Strep (rapidly progressive, very painful). If days later, S. aureus more likely</li>
                        <li><strong>Water Exposure:</strong> Vibrio vulnificus (salt water), Aeromonas (fresh water) - both can cause necrotizing fasciitis. Ask about water exposure!</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Based on appearance - culture/biopsy rarely needed for typical cellulitis. Positive predictive value of clinical diagnosis >70% by experienced clinicians</p>
                    
                    <p><span class="label">Labs (Obtain if systemic symptoms or severe):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common (WBC >12k in 50%), left shift. Leukopenia concerning for overwhelming sepsis</li>
                        <li><strong>Blood Cultures:</strong> Low yield (<5% positive) but obtain if: fever >38.5¬∞C, hypotension, immunocompromised, suspected bacteremia, failed outpatient therapy</li>
                        <li><strong>ESR/CRP:</strong> Elevated but non-specific. Can be useful if diagnosis uncertain or to follow treatment response</li>
                        <li><strong>BMP:</strong> If systemic toxicity (assess renal function before vancomycin/aminoglycosides)</li>
                        <li><strong>Lactate:</strong> If concern for sepsis or necrotizing infection</li>
                    </ul>
                    
                    <p><span class="label">Imaging (NOT routinely needed):</span></p>
                    <ul>
                        <li><strong>Ultrasound:</strong> Can differentiate cellulitis from abscess. "Cobblestoning" of subcutaneous tissue seen in cellulitis. Can identify fluid collections needing drainage</li>
                        <li><strong>CT with IV contrast:</strong> If necrotizing fasciitis suspected (gas in tissues, fascial involvement), deep abscess, osteomyelitis concern</li>
                        <li><strong>MRI:</strong> Gold standard for osteomyelitis, deep space infections, necrotizing fasciitis. Use if diagnosis unclear and high clinical suspicion</li>
                        <li><strong>X-ray:</strong> Can identify foreign body, subcutaneous gas (necrotizing infection), osteomyelitis (after 2 weeks)</li>
                    </ul>
                    
                    <p><span class="label">Culture/Biopsy (Consider if):</span></p>
                    <ul>
                        <li>Purulent drainage present ‚Üí Send for culture & sensitivity (guides antibiotic de-escalation)</li>
                        <li>Failed initial therapy</li>
                        <li>Immunocompromised (atypical organisms)</li>
                        <li>Penetrating trauma or water exposure (atypical organisms)</li>
                        <li>Punch biopsy/aspiration: Low yield (20-40% positive), painful, generally not recommended for uncomplicated cellulitis</li>
                    </ul>
                    
                    <p><span class="label">Mark Borders:</span> Draw around erythema with marker, date/time. Essential for tracking progression/regression. Take photo for documentation</p>
                    
                    <p><span class="label">Differential Diagnosis to Consider:</span></p>
                    <ul>
                        <li><strong>Stasis Dermatitis:</strong> Bilateral, chronic, hyperpigmentation, varicose veins. Often misdiagnosed as cellulitis</li>
                        <li><strong>DVT:</strong> Asymmetric edema but typically no erythema. Get duplex if uncertain</li>
                        <li><strong>Contact Dermatitis:</strong> Pruritic, vesicular, bilateral distribution, exposure history</li>
                        <li><strong>Necrotizing Fasciitis:</strong> Pain out of proportion, hemorrhagic bullae, crepitus, systemic toxicity, rapid progression</li>
                        <li><strong>Gout/Pseudogout:</strong> Acute monoarticular arthritis, usually joint-based</li>
                        <li><strong>Lipodermatosclerosis:</strong> Chronic, indurated, inverted champagne bottle appearance of lower leg</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Key Decision: Purulent vs Non-Purulent</span></p>
                    <ul>
                        <li><strong>Non-Purulent:</strong> No drainable abscess, no purulent discharge ‚Üí Target Streptococcus, NO MRSA coverage needed</li>
                        <li><strong>Purulent:</strong> Abscess, furuncle, carbuncle, purulent drainage ‚Üí MUST cover MRSA</li>
                    </ul>
                    
                    <p><span class="label">Non-Purulent Cellulitis (No Abscess/Furuncle) - Streptococcal Coverage:</span></p>
                    <ul>
                        <li><strong>Mild (Outpatient):</strong>
                            <ul>
                                <li>Cephalexin 500mg PO QID √ó 5-10 days (first-line)</li>
                                <li>Dicloxacillin 500mg PO QID √ó 5-10 days</li>
                                <li>Amoxicillin-clavulanate 875mg BID √ó 5-10 days</li>
                            </ul>
                        </li>
                        <li><strong>Moderate (Inpatient/Observation):</strong>
                            <ul>
                                <li>Cefazolin 1-2g IV q8h (excellent Strep/MSSA coverage)</li>
                                <li>Ceftriaxone 1-2g IV q24h (good for once-daily dosing)</li>
                            </ul>
                        </li>
                        <li><strong>PCN Allergy (Non-anaphylaxis):</strong>
                            <ul>
                                <li>Cephalosporins safe if non-IgE mediated reaction (~98% safe)</li>
                            </ul>
                        </li>
                        <li><strong>Severe PCN Allergy (Anaphylaxis):</strong>
                            <ul>
                                <li>Clindamycin 600mg IV q8h OR 300-450mg PO TID (covers Strep/MSSA, not MRSA reliably)</li>
                                <li>Doxycycline 100mg PO/IV BID</li>
                                <li>Levofloxacin 750mg PO/IV daily (avoid if other options available)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Purulent Cellulitis (WITH Abscess/Drainage) - MRSA Coverage Required:</span></p>
                    <ul>
                        <li><strong>Mild (Outpatient):</strong>
                            <ul>
                                <li>TMP-SMX DS 1-2 tabs PO BID √ó 5-10 days (excellent MRSA coverage)</li>
                                <li>Doxycycline 100mg PO BID √ó 5-10 days</li>
                                <li>Clindamycin 300-450mg PO TID √ó 5-10 days (if local resistance <10%)</li>
                            </ul>
                        </li>
                        <li><strong>Moderate-Severe (Inpatient):</strong>
                            <ul>
                                <li>Vancomycin 15-20mg/kg IV q8-12h (goal trough 15-20 for complicated infections)</li>
                                <li>Daptomycin 4mg/kg IV q24h (skin infections, not if pulmonary involvement)</li>
                                <li>Linezolid 600mg PO/IV BID (excellent bioavailability, reserve for VRE risk)</li>
                            </ul>
                        </li>
                        <li><strong>I&D (Incision & Drainage):</strong> Drain abscess if present. Send purulent material for culture & sensitivity. I&D alone may be sufficient for small abscesses <5cm without surrounding cellulitis</li>
                    </ul>
                    
                    <p><span class="label">Severe/Complicated Cellulitis:</span></p>
                    <ul>
                        <li><strong>Septic/Toxic appearance:</strong> Vancomycin 15-20mg/kg IV q8-12h + Pip-tazo 3.375g IV q6h</li>
                        <li><strong>Necrotizing Fasciitis Concern:</strong> Vancomycin + Pip-tazo + Clindamycin 900mg IV q8h (clindamycin inhibits toxin production). IMMEDIATE surgical consultation</li>
                        <li><strong>Immunocompromised:</strong> Broader coverage - consider Vancomycin + Cefepime or Vancomycin + Meropenem</li>
                        <li><strong>Water Exposure:</strong>
                            <ul>
                                <li>Salt water (Vibrio): Doxycycline 100mg IV BID + Ceftriaxone 1g IV q24h</li>
                                <li>Fresh water (Aeromonas): Ceftriaxone + Ciprofloxacin 400mg IV q12h</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Diabetes:</strong> Lower threshold to admit. Check for gas on imaging. Consider broader coverage if severe or neuropathy present</li>
                        <li><strong>Cirrhosis:</strong> Higher risk of Vibrio if shellfish exposure. Consider ceftriaxone + doxycycline</li>
                        <li><strong>Neutropenic:</strong> Cefepime or meropenem + vancomycin. Consider antifungal if not improving</li>
                        <li><strong>Bite Wounds:</strong>
                            <ul>
                                <li>Human/Animal: Amoxicillin-clavulanate 875mg BID OR Ampicillin-sulbactam 3g IV q6h</li>
                                <li>PCN allergic: Doxycycline + Metronidazole OR Moxifloxacin</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Adjunct Measures:</span></p>
                    <ul>
                        <li><strong>Elevation:</strong> Keep affected limb elevated above heart level. CRITICAL for reducing edema and speeding recovery</li>
                        <li><strong>Analgesia:</strong> NSAIDs (ibuprofen 600mg q6h) or acetaminophen 1g q6h. NSAIDs have anti-inflammatory benefit</li>
                        <li><strong>Treat Underlying Conditions:</strong>
                            <ul>
                                <li>Tinea pedis: Topical antifungal (terbinafine cream BID √ó 2 weeks)</li>
                                <li>Venous insufficiency: Compression stockings after acute infection resolves</li>
                                <li>Edema: Diuretics if appropriate, elevation, compression</li>
                            </ul>
                        </li>
                        <li><strong>Wound Care:</strong> Keep clean and dry. Gentle cleansing with soap and water. No need for topical antibiotics</li>
                    </ul>
                    
                    <p><span class="label">Duration of Therapy:</span></p>
                    <ul>
                        <li><strong>Standard:</strong> 5-10 days typical. Minimum 5 days if rapidly improving</li>
                        <li><strong>Severe:</strong> 10-14 days if slow response, extensive disease, or immunocompromised</li>
                        <li><strong>Transition to PO:</strong> When afebrile >24hr, improving cellulitis, tolerating PO, stable vitals</li>
                        <li><strong>Response Time:</strong> Expect improvement within 48-72 hours. Erythema may initially expand first 24-48hr despite appropriate antibiotics (inflammatory response). If not improving by 72hr, re-evaluate</li>
                    </ul>
                    
                    <p><span class="label">Recurrent Cellulitis Prevention:</span></p>
                    <ul>
                        <li><strong>‚â•2 episodes/year or ‚â•3 lifetime:</strong> Consider prophylaxis</li>
                        <li>Penicillin VK 250mg PO BID OR Erythromycin 250mg PO BID (indefinitely or seasonally)</li>
                        <li>Address predisposing factors: Treat tinea pedis aggressively, compression for lymphedema/venous insufficiency, good skin hygiene</li>
                        <li>Patient education: Early recognition and treatment at first sign reduces hospitalizations</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>MRSA coverage ONLY if purulent:</strong> Overuse of vancomycin drives resistance. Non-purulent cellulitis = Œ≤-lactam monotherapy. Don't reflexively add vanc!</li>
                    <li><strong>Mark borders religiously:</strong> Date and time your marking. Simple intervention that objectively tracks progression/regression and improves clinical decision-making</li>
                    <li><strong>Elevation is NOT optional:</strong> Elevating the affected limb above heart level significantly speeds recovery by reducing venous congestion and edema. It's as important as antibiotics!</li>
                    <li><strong>Recurrent cellulitis screening questions:</strong> Ask about tinea pedis (toe web maceration = portal of entry), lymphedema, venous insufficiency. Treating these reduces recurrence dramatically</li>
                    <li><strong>Purpura = NOT cellulitis:</strong> If non-blanching purpura present, think necrotizing fasciitis, meningococcemia, septic emboli, vasculitis. Blanching erythema = cellulitis</li>
                    <li><strong>Pain out of proportion = Surgical Emergency:</strong> If pain is much worse than exam findings suggest, think necrotizing fasciitis. Also: hemorrhagic bullae, crepitus, "wooden" induration, rapid progression, systemic toxicity ‚Üí STAT surgical consult + broad antibiotics + clindamycin</li>
                    <li><strong>Initial expansion doesn't mean failure:</strong> Cellulitis commonly gets worse in first 24-48 hours despite appropriate antibiotics due to inflammatory response. Don't panic and broaden coverage unless systemic symptoms worsen</li>
                    <li><strong>Stasis dermatitis masquerader:</strong> #1 cellulitis mimic. Clues: Bilateral (cellulitis usually unilateral), chronic course, hyperpigmentation, varicose veins, hemosiderin deposition, pruritus > pain. Don't treat with antibiotics!</li>
                    <li><strong>LRINEC score for necrotizing fasciitis:</strong> CRP, WBC, Hgb, Na, Cr, glucose. Score ‚â•6 ‚Üí 50% PPV for NF. Score ‚â•8 ‚Üí 75% PPV. But don't wait for lab results if clinical suspicion high!</li>
                    <li><strong>Blood cultures low yield:</strong> Only 5% positive in cellulitis, but still obtain if fever >38.5¬∞C or concern for bacteremia. Don't withhold antibiotics waiting for culture results</li>
                    <li><strong>Prophylaxis pearls:</strong> For recurrent cellulitis (‚â•2/year), continuous penicillin prophylaxis reduces recurrence by 50%. But address underlying causes first (tinea pedis treatment, compression, lymphedema therapy)</li>
                    <li><strong>Failed therapy checklist:</strong> Wrong diagnosis (stasis dermatitis, DVT)? Inadequate coverage (MRSA not covered)? Abscess needing drainage? Underlying osteomyelitis? Deep space infection? Non-infectious cause?</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Necrotizing fasciitis suspected or confirmed (pain out of proportion, crepitus, bullae, "wooden" feel)</li>
                        <li>Septic shock (SBP <90 despite fluids, lactate >4)</li>
                        <li>Rapidly progressive cellulitis despite IV antibiotics (expanding >5cm/hr)</li>
                        <li>Compartment syndrome (tense compartment, pain with passive stretch, paresthesias, pulselessness)</li>
                        <li>Streptococcal toxic shock syndrome (hypotension + multi-organ dysfunction)</li>
                        <li>Airway compromise (facial/neck cellulitis, Ludwig's angina)</li>
                        <li>Need for vasopressors or aggressive resuscitation</li>
                        <li>Hemodynamic instability with failed floor management</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 24 hours (Temp <38¬∞C)</li>
                        <li>Hemodynamically stable (SBP >90, HR <110)</li>
                        <li>Erythema/edema clearly improving (borders regressing)</li>
                        <li>Pain controlled on oral analgesics</li>
                        <li>Tolerating PO intake and oral antibiotics</li>
                        <li>No evidence of abscess requiring drainage</li>
                        <li>No concern for necrotizing infection</li>
                        <li>Adequate home support for elevation/wound care</li>
                        <li>Close follow-up arranged within 2-3 days</li>
                        <li>Patient educated on: limb elevation, signs of worsening, medication adherence</li>
                        <li>If diabetes: glucose controlled, good perfusion to affected area</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Local Complications:</strong> Abscess formation (fluctuance, purulent drainage - needs I&D), necrotizing fasciitis (pain out of proportion, bullae, crepitus, rapid progression), compartment syndrome (increased pressure in fascial compartment - surgical emergency), lymphangitis (red streaking), chronic lymphedema (after repeated episodes), post-infectious scarring/hyperpigmentation</p>
                    <p><strong>Systemic Complications:</strong> Bacteremia/sepsis (5-10% of hospitalized patients), septic shock, endocarditis (especially MRSA bacteremia), osteomyelitis (if bone involvement), septic arthritis (if joint nearby), glomerulonephritis (post-Streptococcal), toxic shock syndrome (Strep or Staph toxins)</p>
                    <p><strong>Treatment-Related:</strong> Antibiotic-associated diarrhea, C. difficile infection, drug allergy/rash, nephrotoxicity (vancomycin, aminoglycosides), red man syndrome (vancomycin infusion reaction), thrombophlebitis (IV site)</p>
                    <p><strong>Recurrence:</strong> 20-30% recurrence rate, higher with lymphedema. Monitor for: inadequately treated portal of entry (tinea pedis), unaddressed edema/venous insufficiency, immunosuppression</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 21: UTI/PYELONEPHRITIS -->
        <div id="uti" class="condition-page">
            <div class="page-header">
                <h2>21. URINARY TRACT INFECTION / PYELONEPHRITIS</h2>
                <div class="subtitle">Cystitis ‚Ä¢ Pyelonephritis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Cystitis (Lower UTI):</span> Acute onset of dysuria, urinary frequency, urgency, suprapubic pain/pressure, hematuria (gross or microscopic). NO fever (Temp <38¬∞C) or flank pain. Symptoms typically develop over hours to 1-2 days</p>
                    <p><span class="label">Pyelonephritis (Upper UTI):</span> Fever >38.5¬∞C, rigors, unilateral flank/back pain, costovertebral angle (CVA) tenderness on exam, nausea/vomiting. Often accompanied by dysuria and frequency. Can progress to sepsis</p>
                    <p><span class="label">Complicated UTI Definition:</span> Structural/functional abnormality of GU tract, instrumentation, immunosuppression, pregnancy, males, indwelling catheter, recent antimicrobial use, diabetes, renal transplant, hospital-acquired. Higher risk of treatment failure and complications</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly Patients:</strong> May present with altered mental status, confusion, falls, functional decline, or generalized weakness WITHOUT classic UTI symptoms. Fever often absent or blunted. Dysuria may not be reported. High index of suspicion needed</li>
                        <li><strong>Diabetic Patients:</strong> Higher risk of emphysematous pyelonephritis (gas-forming infection - E. coli, Klebsiella), papillary necrosis, perinephric abscess. Worse outcomes, longer treatment needed. May have poor glucose control as only manifestation</li>
                        <li><strong>Pregnancy:</strong> 20-30% of untreated asymptomatic bacteriuria progresses to pyelonephritis. Pyelonephritis can trigger preterm labor, low birth weight. Must screen ALL pregnant women and treat asymptomatic bacteriuria. Higher risk of recurrence during pregnancy</li>
                        <li><strong>Men (Any Age):</strong> Almost always complicated UTI. Assume prostatic involvement until proven otherwise. Need 7-14 days of treatment. Evaluate for structural abnormalities, BPH, prostatitis. First UTI in young man = red flag for anatomic defect</li>
                        <li><strong>Catheter-Associated (CAUTI):</strong> New fever, flank pain, suprapubic pain, altered mental status in catheterized patient. Often polymicrobial. Pyuria alone is NOT diagnostic (50% of catheterized patients have asymptomatic pyuria). Need symptoms to treat</li>
                        <li><strong>Perinephric/Renal Abscess:</strong> Persistent fever despite 48-72 hours appropriate antibiotics. Unilateral flank pain, palpable flank mass. Risk factors: diabetes, IV drug use, renal stones, obstruction. CT diagnostic. May need percutaneous or surgical drainage</li>
                        <li><strong>Xanthogranulomatous Pyelonephritis:</strong> Rare chronic infection causing granulomatous destruction of kidney. Mimics renal mass on imaging. Presents with persistent flank pain, fever, weight loss. Kidney non-functional, requires nephrectomy</li>
                        <li><strong>Emphysematous Pyelonephritis:</strong> Life-threatening gas-forming infection. 90% diabetics. Presents with severe sepsis, CVA tenderness. CT shows gas in renal parenchyma. High mortality (20-40%). Requires IV antibiotics + possible nephrectomy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Urinalysis (Essential for ALL):</span></p>
                    <ul>
                        <li><strong>Pyuria:</strong> >10 WBC/hpf highly suggestive. >5 WBC/hpf = abnormal. Absence of pyuria makes UTI unlikely (95% NPV)</li>
                        <li><strong>Bacteriuria:</strong> Any bacteria on unspun urine microscopy = ‚â•10^5 CFU/mL</li>
                        <li><strong>Leukocyte Esterase:</strong> Sensitive (75-96%) but less specific. Produced by WBCs. Can be false positive with contamination</li>
                        <li><strong>Nitrites:</strong> Highly specific (90-100%) but only 50% sensitive. Many uropathogens (Enterococcus, Staph saprophyticus, Pseudomonas) don't produce nitrites. Requires bacteria in bladder ‚â•4 hours</li>
                        <li><strong>Hematuria:</strong> Present in 40-60% of UTIs but non-specific</li>
                        <li><strong>WBC Casts:</strong> Pathognomonic for pyelonephritis (indicates renal parenchymal involvement). Differentiates from cystitis</li>
                    </ul>
                    
                    <p><span class="label">Urine Culture & Sensitivity (When to Send):</span></p>
                    <ul>
                        <li><strong>ALWAYS send before antibiotics if:</strong> Pyelonephritis, complicated UTI, pregnant, recent antibiotic use, healthcare-associated, symptoms >7 days, recurrent UTI, immunocompromised</li>
                        <li><strong>NOT needed for:</strong> Uncomplicated cystitis in young women (treat empirically)</li>
                        <li><strong>Collection:</strong> Mid-stream clean catch (not catheter unless catheter present <2 hours). First morning void best</li>
                        <li><strong>Interpretation:</strong>
                            <ul>
                                <li>‚â•10^5 CFU/mL = diagnostic for cystitis</li>
                                <li>‚â•10^4 CFU/mL = diagnostic for pyelonephritis</li>
                                <li>‚â•10^2 CFU/mL = diagnostic if catheter specimen</li>
                                <li>Multiple organisms = contamination (repeat culture)</li>
                            </ul>
                        </li>
                        <li><strong>Common Organisms:</strong> E. coli (75-95%), Klebsiella pneumoniae (5-10%), Proteus mirabilis (5%), Enterococcus (5%), Staphylococcus saprophyticus (5-15% in young women)</li>
                    </ul>
                    
                    <p><span class="label">Blood Cultures:</span></p>
                    <ul>
                        <li><strong>Obtain if:</strong> Pyelonephritis with sepsis/hemodynamic instability, immunocompromised, persistent fever despite 48-72hr of antibiotics, concern for bacteremia</li>
                        <li>Positive in 15-25% of hospitalized pyelonephritis patients</li>
                        <li>Usually same organism as urine culture</li>
                    </ul>
                    
                    <p><span class="label">Additional Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common in pyelonephritis (WBC often 12-20k with left shift). Leukopenia suggests severe sepsis</li>
                        <li><strong>BMP:</strong> Assess renal function (baseline Cr), check for AKI. Evaluate electrolytes</li>
                        <li><strong>Pregnancy test:</strong> ALL women of childbearing age (ectopic can present as flank pain, UTI changes management in pregnancy)</li>
                        <li><strong>Lactate:</strong> If sepsis suspected (goal <2, elevated suggests tissue hypoperfusion)</li>
                    </ul>
                    
                    <p><span class="label">Imaging (NOT routine, but obtain if):</span></p>
                    <ul>
                        <li><strong>CT Abdomen/Pelvis WITH IV Contrast (Test of Choice):</strong>
                            <ul>
                                <li>No clinical improvement after 48-72 hours of appropriate antibiotics</li>
                                <li>Sepsis/septic shock</li>
                                <li>Immunocompromised (evaluate for abscess)</li>
                                <li>Concern for urinary obstruction (hydronephrosis, stones)</li>
                                <li>Recurrent pyelonephritis (>2 episodes)</li>
                                <li>Men with pyelonephritis (evaluate for anatomic abnormality)</li>
                                <li>Suspected emphysematous pyelonephritis (gas in tissues)</li>
                                <li>Suspected perinephric/renal abscess</li>
                            </ul>
                        </li>
                        <li><strong>Renal Ultrasound:</strong> First-line if pregnant or contraindication to IV contrast. Can detect hydronephrosis (obstruction) but less sensitive for abscess than CT. Good for assessing kidney size/echogenicity</li>
                        <li><strong>KUB X-ray:</strong> Limited utility. Can identify radiopaque stones (calcium) but misses 10-20% of stones</li>
                    </ul>
                    
                    <p><span class="label">Special Diagnostic Considerations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic Bacteriuria (ASB):</strong> Positive culture (‚â•10^5 CFU/mL) WITHOUT symptoms. Very common in elderly, catheterized patients. <strong>DO NOT TREAT</strong> except in pregnancy or before urologic procedures. Treatment causes antibiotic resistance without benefit</li>
                        <li><strong>Sterile Pyuria:</strong> WBCs in urine but negative culture. Differential: TB (send AFB culture √ó 3), fungal infection, interstitial nephritis, appendicitis, recent antibiotic use, urethritis (chlamydia, gonorrhea), kidney stones</li>
                        <li><strong>Catheter-Associated UTI Diagnosis:</strong> Catheterized patient with fever (>38¬∞C) OR new onset suprapubic pain OR flank pain OR altered mental status WITHOUT other source PLUS positive culture ‚â•10^3 CFU/mL. Pyuria alone is NOT diagnostic</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Uncomplicated Cystitis (Healthy Non-Pregnant Women):</span></p>
                    <ul>
                        <li><strong>First-Line Options:</strong>
                            <ul>
                                <li>Nitrofurantoin monohydrate/macrocrystals 100mg PO BID √ó 5 days (preferred)</li>
                                <li>TMP-SMX DS (160/800mg) PO BID √ó 3 days (only if local E. coli resistance <20%)</li>
                            </ul>
                        </li>
                        <li><strong>Second-Line Options:</strong>
                            <ul>
                                <li>Fosfomycin 3g PO √ó single dose (convenient but slightly lower cure rate ~90%)</li>
                                <li>Pivmecillinam 400mg PO TID √ó 3-5 days (not available in US)</li>
                            </ul>
                        </li>
                        <li><strong>When Œ≤-lactams Necessary:</strong>
                            <ul>
                                <li>Amoxicillin-clavulanate 875/125mg PO BID √ó 5-7 days</li>
                                <li>Cefpodoxime 100mg PO BID √ó 5-7 days</li>
                                <li>Less effective than nitrofurantoin/TMP-SMX - use only if alternatives unavailable</li>
                            </ul>
                        </li>
                        <li><strong>AVOID Fluoroquinolones:</strong> Reserve for pyelonephritis due to serious adverse effects (C. diff, tendon rupture, neuropathy) and resistance concerns</li>
                        <li><strong>Contraindications:</strong>
                            <ul>
                                <li>Nitrofurantoin: CrCl <30 mL/min, pregnancy at term (risk of hemolytic anemia in newborn), G6PD deficiency</li>
                                <li>TMP-SMX: Pregnancy (especially 1st trimester - neural tube defects), severe sulfa allergy, CrCl <15</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Acute Pyelonephritis - Outpatient (Mild, Tolerates PO, Reliable):</span></p>
                    <ul>
                        <li><strong>Fluoroquinolone (if local resistance <10%):</strong>
                            <ul>
                                <li>Ciprofloxacin 500mg PO BID √ó 7 days OR 1000mg XR daily √ó 7 days</li>
                                <li>Levofloxacin 750mg PO daily √ó 5 days</li>
                                <li>Can give single dose ceftriaxone 1g IM in ED before starting oral quinolone</li>
                            </ul>
                        </li>
                        <li><strong>If Fluoroquinolone Resistance or Contraindicated:</strong>
                            <ul>
                                <li>Ceftriaxone 1g IM/IV √ó 1 dose, THEN oral step-down based on culture susceptibility</li>
                                <li>If susceptible: TMP-SMX DS BID √ó 14 days OR Amoxicillin-clavulanate 875mg BID √ó 10-14 days</li>
                                <li>Cefpodoxime 200mg PO BID √ó 10-14 days (if susceptible)</li>
                            </ul>
                        </li>
                        <li><strong>Duration:</strong> 7-14 days depending on agent and clinical response. Fluoroquinolones 5-7 days, Œ≤-lactams 10-14 days</li>
                    </ul>
                    
                    <p><span class="label">Acute Pyelonephritis - Inpatient (Toxic, Septic, Unable to Tolerate PO):</span></p>
                    <ul>
                        <li><strong>Moderate Severity:</strong>
                            <ul>
                                <li>Ceftriaxone 1-2g IV q24h (excellent E. coli, Klebsiella, Proteus coverage)</li>
                                <li>Ciprofloxacin 400mg IV q12h OR Levofloxacin 750mg IV q24h</li>
                            </ul>
                        </li>
                        <li><strong>Severe/Septic/Complicated:</strong>
                            <ul>
                                <li>Cefepime 2g IV q8h (broader than ceftriaxone, covers Pseudomonas)</li>
                                <li>Piperacillin-tazobactam 3.375g IV q6h or 4.5g IV q8h</li>
                            </ul>
                        </li>
                        <li><strong>If Gram-Positive Cocci on Culture:</strong> Add Ampicillin 2g IV q4h (for Enterococcus - VRE risk if amp-resistant)</li>
                        <li><strong>ESBL Risk Factors Present:</strong> Previous ESBL infection, recent hospitalization, healthcare exposure, international travel, chronic care facility resident
                            <ul>
                                <li>Ertapenem 1g IV q24h OR Meropenem 1g IV q8h</li>
                                <li>Avoid cephalosporins/fluoroquinolones if ESBL confirmed</li>
                            </ul>
                        </li>
                        <li><strong>Transition to Oral:</strong> When afebrile √ó 24 hours, improved symptoms, tolerating PO, hemodynamically stable
                            <ul>
                                <li>Ciprofloxacin 500mg BID or Levofloxacin 750mg daily</li>
                                <li>TMP-SMX DS BID (if susceptible)</li>
                                <li>Amoxicillin-clavulanate 875mg BID (if susceptible)</li>
                            </ul>
                        </li>
                        <li><strong>Total Duration:</strong> 7-14 days
                            <ul>
                                <li>7 days if uncomplicated, rapid response to treatment</li>
                                <li>10-14 days if complicated, bacteremia, slow response, immunocompromised, male</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Complicated UTI/Urosepsis:</span></p>
                    <ul>
                        <li><strong>Broad-Spectrum Initial Coverage:</strong>
                            <ul>
                                <li>Pip-tazo 4.5g IV q6h OR Cefepime 2g IV q8h</li>
                                <li>If MRSA suspected (skin breakdown, recent healthcare): ADD Vancomycin 15-20mg/kg IV q8-12h</li>
                                <li>If critically ill: Meropenem 1g IV q8h (covers ESBL, Pseudomonas)</li>
                            </ul>
                        </li>
                        <li><strong>De-escalate Based on Cultures:</strong> Narrow to organism-specific therapy once susceptibilities available</li>
                        <li><strong>Duration:</strong> 10-14 days minimum. Extend if slow response, abscess, obstruction</li>
                        <li><strong>Source Control:</strong> Remove catheters if possible. Drain abscesses. Relieve obstruction (nephrostomy, stent)</li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Pregnancy:</strong>
                            <ul>
                                <li><strong>Screen ALL pregnant women</strong> for ASB at 12-16 weeks (treat if positive)</li>
                                <li>Cystitis: Nitrofurantoin 100mg BID √ó 5-7 days (avoid at term) OR Amoxicillin-clavulanate 875mg BID √ó 5-7 days OR Cephalexin 500mg QID √ó 5-7 days</li>
                                <li>Pyelonephritis: <strong>ADMIT</strong> - Ceftriaxone 1-2g IV q24h until afebrile √ó 24-48hr, then Cephalexin 500mg QID √ó 10-14 days total</li>
                                <li><strong>AVOID:</strong> Fluoroquinolones (cartilage toxicity), TMP in 1st trimester (neural tube defects), nitrofurantoin at term</li>
                            </ul>
                        </li>
                        <li><strong>Men (Always Complicated):</strong>
                            <ul>
                                <li>Assume prostatic involvement</li>
                                <li>Fluoroquinolone √ó 10-14 days (penetrates prostate): Ciprofloxacin 500mg BID or Levofloxacin 750mg daily</li>
                                <li>Alternative: TMP-SMX DS BID √ó 14 days (if susceptible)</li>
                                <li>If severe: Start IV (ceftriaxone, cefepime), transition to PO quinolone</li>
                                <li>Urology referral for: recurrent UTI, first UTI in young man, concern for obstruction</li>
                            </ul>
                        </li>
                        <li><strong>Catheter-Associated UTI (CAUTI):</strong>
                            <ul>
                                <li><strong>Remove or replace catheter</strong> if possible before starting antibiotics</li>
                                <li>Often polymicrobial, resistant organisms (Pseudomonas, Enterococcus, Candida)</li>
                                <li>Empiric: Ceftriaxone 1g IV daily OR Ciprofloxacin 400mg IV q12h</li>
                                <li>If severe: Cefepime or Pip-tazo (Pseudomonas coverage)</li>
                                <li>Duration: 7 days if catheter removed, 10-14 days if catheter remains in place</li>
                                <li>De-escalate based on cultures</li>
                            </ul>
                        </li>
                        <li><strong>Renal Impairment:</strong>
                            <ul>
                                <li>Avoid nitrofurantoin if CrCl <30 (inadequate levels)</li>
                                <li>Dose-adjust fluoroquinolones, Œ≤-lactams based on CrCl</li>
                                <li>TMP-SMX: Avoid if CrCl <15</li>
                            </ul>
                        </li>
                        <li><strong>Elderly/Nursing Home:</strong>
                            <ul>
                                <li>Do NOT treat asymptomatic bacteriuria</li>
                                <li>If symptomatic: Consider atypical presentations (AMS, falls)</li>
                                <li>Higher resistance rates - obtain culture before treating</li>
                                <li>Lower threshold to admit (dehydration, frailty, poor PO intake)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Recurrent UTI Management (‚â•2 in 6 months or ‚â•3 in 12 months):</span></p>
                    <ul>
                        <li><strong>Non-Antibiotic Strategies:</strong>
                            <ul>
                                <li>Increase fluid intake (2-3 L/day)</li>
                                <li>Void after intercourse</li>
                                <li>Avoid spermicides, diaphragms</li>
                                <li>Cranberry products (modest benefit - 500-1500mg proanthocyanidins daily)</li>
                                <li>D-mannose 2g daily (prevents E. coli adhesion)</li>
                                <li>Vaginal estrogen cream (post-menopausal women) - Estradiol 0.5g intravaginally 2x/week</li>
                            </ul>
                        </li>
                        <li><strong>Antibiotic Prophylaxis:</strong>
                            <ul>
                                <li><strong>Continuous:</strong> TMP-SMX SS (40/200mg) daily OR Nitrofurantoin 50-100mg daily at bedtime</li>
                                <li><strong>Post-coital:</strong> Single dose TMP-SMX SS or nitrofurantoin 50-100mg within 2 hours of intercourse</li>
                                <li><strong>Self-start therapy:</strong> Patient-initiated 3-day course at first symptom if reliable patient</li>
                            </ul>
                        </li>
                        <li><strong>Further Workup:</strong> Consider urologic evaluation (cystoscopy, renal US) if: recurrent pyelonephritis, hematuria, men, young children, suspicion of anatomic abnormality</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pyuria alone is NOT infection:</strong> 30-50% of catheterized patients have asymptomatic pyuria. Need SYMPTOMS to diagnose and treat CAUTI. Don't treat labs, treat patients!</li>
                    <li><strong>Asymptomatic bacteriuria - DON'T treat (with 2 exceptions):</strong> Treating ASB in elderly, catheterized, or diabetic patients drives resistance without benefit. ONLY treat in pregnancy or before urologic procedures. This is one of the most common antibiotic stewardship errors</li>
                    <li><strong>E. coli is the usual suspect:</strong> Causes 75-95% of community-acquired UTIs. Klebsiella, Proteus, Enterococcus are next. If unusual organism (Pseudomonas, Staph aureus), think catheter, recent healthcare exposure, or structural abnormality</li>
                    <li><strong>Men = complicated until proven otherwise:</strong> Almost all UTIs in men involve prostate. Need 10-14 days treatment (vs 3-5 days women). First UTI in young man = red flag for anatomic abnormality (posterior urethral valves, etc) - needs urologic workup</li>
                    <li><strong>Nitrofurantoin doesn't work for pyelonephritis:</strong> Doesn't achieve therapeutic levels in renal parenchyma or blood. Excellent for cystitis only. Using for pyelo = treatment failure</li>
                    <li><strong>Emphysematous pyelonephritis = life-threatening:</strong> Gas in kidney on CT. 90% in diabetics. E. coli or Klebsiella ferment glucose ‚Üí gas production. High mortality (20-40%). Needs IV antibiotics ¬± nephrectomy if refractory. Never miss this on imaging!</li>
                    <li><strong>WBC casts are pathognomonic for pyelonephritis:</strong> If WBC casts on UA = renal parenchymal involvement (vs cystitis which is bladder only). This finding confirms pyelonephritis diagnosis</li>
                    <li><strong>Post-treatment UA not needed:</strong> If symptoms resolve, don't recheck UA/culture. Pyuria can persist for weeks after successful treatment. Only reculture if persistent symptoms. "Test of cure" is symptom resolution, not negative UA</li>
                    <li><strong>Pregnancy ASB MUST be treated:</strong> 30% of untreated ASB in pregnancy progresses to pyelonephritis ‚Üí preterm labor. Screen ALL pregnant women at 12-16 weeks and treat positive cultures even if asymptomatic. This is the ONLY population where ASB treatment is indicated</li>
                    <li><strong>Fluoroquinolone resistance is rising:</strong> E. coli resistance now 20-30% in many areas. Check local antibiogram. If resistance >10%, avoid empiric quinolones for pyelonephritis - use ceftriaxone instead</li>
                    <li><strong>Perinephric abscess if fever persists despite antibiotics:</strong> Still febrile after 48-72 hours of appropriate antibiotics? Get CT - look for abscess. Abscess >3cm usually needs percutaneous drainage. Antibiotics alone often insufficient</li>
                    <li><strong>Recurrent UTI red flags needing urologic evaluation:</strong> Recurrent pyelonephritis, men, young children, painless hematuria, suspicion of stones/obstruction/anatomic defect. These need cystoscopy and/or imaging to find underlying cause</li>
                    <li><strong>Sterile pyuria differential:</strong> WBCs but negative culture = TB (get AFB culture √ó 3), partially treated UTI, urethritis (STI - test for chlamydia/gonorrhea), interstitial nephritis (NSAIDs, antibiotics), kidney stones, appendicitis, fungal infection (Candida in catheterized/diabetics)</li>
                    <li><strong>Nitrites are specific but not sensitive:</strong> If positive = infection. But 50% of UTIs are nitrite-negative because many organisms (Enterococcus, Staph saprophyticus, Pseudomonas, Acinetobacter) don't convert nitrate to nitrite. Don't rule out UTI based on negative nitrites alone</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Urosepsis with septic shock (SBP <90 despite fluids, lactate >4, requiring pressors)</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Severe sepsis with multi-organ dysfunction (AKI, AMS, coagulopathy)</li>
                        <li>Obstructive uropathy with sepsis (needs emergent decompression)</li>
                        <li>Perinephric or renal abscess with hemodynamic instability</li>
                        <li>Emphysematous pyelonephritis with shock (may need nephrectomy)</li>
                        <li>Papillary necrosis with obstruction and sepsis</li>
                        <li>Fournier's gangrene (necrotizing perineal infection - surgical emergency)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 24-48 hours (temperature <38¬∞C)</li>
                        <li>Hemodynamically stable (SBP >100, HR <100)</li>
                        <li>Tolerating PO intake without nausea/vomiting</li>
                        <li>Pain controlled on oral analgesics</li>
                        <li>Able to take oral antibiotics and reliable for adherence</li>
                        <li>Improving leukocytosis (if initially elevated, downtrending WBC)</li>
                        <li>Stable or improving renal function (if AKI, Cr trending toward baseline)</li>
                        <li>No evidence of obstruction requiring intervention (if imaging done)</li>
                        <li>No abscess, or abscess drained and improving</li>
                        <li>Urine culture results available and organism susceptible to oral agent</li>
                        <li>Patient educated on: completing full antibiotic course, adequate hydration (2-3 L/day), return precautions</li>
                        <li>PCP follow-up arranged within 1 week (urology if recurrent, male, or anatomic concern)</li>
                        <li>Plan for repeat culture if: pregnant, recurrent infection, initial blood culture positive</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early Complications (Hours-Days):</strong> Sepsis/septic shock (15-25% of hospitalized pyelonephritis), bacteremia with metastatic seeding (endocarditis, vertebral osteomyelitis, septic arthritis), acute kidney injury (from sepsis, obstruction, or bilateral pyelonephritis), urinary retention (from UTI-induced detrusor dysfunction), severe hematuria (can cause clot retention requiring continuous bladder irrigation)</p>
                    <p><strong>Late Complications (Days-Weeks):</strong> Perinephric abscess (persistent fever >72hr despite antibiotics, needs CT diagnosis and drainage), intrarenal abscess, emphysematous pyelonephritis (diabetics - gas-forming infection, 20-40% mortality, may need nephrectomy), renal papillary necrosis (diabetics, sickle cell disease, analgesic abuse - presents with flank pain, hematuria, AKI), chronic pyelonephritis with renal scarring (recurrent infections ‚Üí CKD), xanthogranulomatous pyelonephritis (rare chronic granulomatous destruction of kidney)</p>
                    <p><strong>Treatment-Related Complications:</strong> C. difficile infection (fluoroquinolones highest risk), antibiotic-associated diarrhea, allergic reactions (rash, anaphylaxis), tendon rupture (fluoroquinolones - Achilles tendon), peripheral neuropathy (fluoroquinolones - can be irreversible), QT prolongation (fluoroquinolones, especially if other QT drugs), photosensitivity (fluoroquinolones), pulmonary fibrosis (nitrofurantoin with chronic use >6 months), hemolytic anemia (nitrofurantoin in G6PD deficiency)</p>
                    <p><strong>Pregnancy-Related:</strong> Preterm labor and delivery (pyelonephritis), low birth weight, intrauterine growth restriction, maternal sepsis, respiratory failure (ARDS from pyelonephritis in pregnancy)</p>
                    <p><strong>Recurrence:</strong> 25-30% recurrence within 6 months if underlying factors not addressed (kidney stones, obstruction, vesicoureteral reflux, anatomic abnormality, poor hygiene, sexual activity with spermicide use, post-menopausal atrophic vaginitis, BPH in men, neurogenic bladder, immunosuppression)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGES 22-25 streamlined to fit tokens, can expand later -->
        
        <div id="cdiff" class="condition-page">
            <div class="page-header">
                <h2>22. C. DIFFICILE INFECTION (CDI)</h2>
                <div class="subtitle">Clostridioides difficile ‚Ä¢ Antibiotic-Associated Diarrhea ‚Ä¢ Pseudomembranous Colitis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> ‚â•3 unformed (loose or watery) stools in 24 hours in setting of recent antibiotic exposure (typically within past 3 months). Crampy abdominal pain, low-grade fever. Diarrhea is NOT bloody in most cases. Leukocytosis often pronounced (WBC 15-30k)</p>
                    <p><span class="label">Physical Exam:</span> Diffuse abdominal tenderness (worse in left lower quadrant), abdominal distension, hyperactive bowel sounds. If peritoneal signs present ‚Üí concerning for toxic megacolon or perforation</p>
                    
                    <p><span class="label">Risk Factors:</span></p>
                    <ul>
                        <li><strong>Antibiotic exposure:</strong> #1 risk factor. Highest risk: clindamycin, fluoroquinolones, cephalosporins, carbapenems. Even single dose can trigger. Usually within 3 months but can be up to 3 years</li>
                        <li><strong>Healthcare exposure:</strong> Hospitalization, nursing home, recent admission</li>
                        <li><strong>Advanced age:</strong> >65 years (decreased immunity, increased exposure)</li>
                        <li><strong>Medications:</strong> PPIs (impair gastric acid barrier), H2 blockers, chemotherapy</li>
                        <li><strong>Immunosuppression:</strong> IBD, transplant, malignancy, HIV</li>
                        <li><strong>GI surgery/manipulation:</strong> Recent abdominal surgery, NG tube, PEG tube</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Severe CDI:</strong> WBC ‚â•15k, Cr ‚â•1.5√ó baseline. Presents with high fever (>38.5¬∞C), severe abdominal pain, hypotension. May have minimal diarrhea (ileus develops)</li>
                        <li><strong>Fulminant CDI (2-3% of cases):</strong> Hypotension requiring pressors, shock, ileus, megacolon, perforation, multi-organ failure. WBC >35k or <2k (leukemoid reaction or leukopenia both bad signs). High mortality (30-50%)</li>
                        <li><strong>Toxic Megacolon:</strong> Abdominal distension, absent bowel sounds, peritoneal signs. Colon >6cm on imaging. Life-threatening - requires surgical evaluation</li>
                        <li><strong>Elderly Patients:</strong> May present with only altered mental status, functional decline, or minimal diarrhea. Lower threshold for testing</li>
                        <li><strong>IBD Patients:</strong> Difficult to distinguish from IBD flare. C. diff superinfection in 5-10% of IBD hospitalizations. Always test IBD patients with worsening symptoms</li>
                        <li><strong>Community-Acquired CDI:</strong> No recent healthcare or antibiotic exposure (15-25% of cases). Often younger, healthier patients. Associated with PPI use, outpatient antibiotics</li>
                        <li><strong>Asymptomatic Carriage:</strong> 3-15% of healthy adults, 20-40% of hospitalized patients colonized without symptoms. Do NOT test or treat asymptomatic patients (even if formed stool sent for testing comes back positive)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">When to Test:</span> ONLY test patients with ‚â•3 unformed stools in 24 hours. Do NOT test formed stools or asymptomatic patients (high false positive rate from colonization)</p>
                    
                    <p><span class="label">Diagnostic Testing (Multi-Step Algorithm Preferred):</span></p>
                    <ul>
                        <li><strong>NAAT (Nucleic Acid Amplification Test/PCR):</strong>
                            <ul>
                                <li>Detects toxin genes (tcdB). Most sensitive test (>95%)</li>
                                <li>Problem: Can't distinguish active infection from colonization</li>
                                <li>If positive ‚Üí need clinical correlation (symptoms + risk factors)</li>
                            </ul>
                        </li>
                        <li><strong>EIA for Toxins A/B:</strong>
                            <ul>
                                <li>Detects actual toxins in stool. High specificity (>95%) but poor sensitivity (60-80%)</li>
                                <li>If positive ‚Üí definite infection (can start treatment)</li>
                                <li>If negative ‚Üí doesn't rule out (may need NAAT or repeat testing)</li>
                            </ul>
                        </li>
                        <li><strong>GDH (Glutamate Dehydrogenase) Antigen:</strong>
                            <ul>
                                <li>Screening test. Sensitive but not specific (detects organism, not toxin)</li>
                                <li>If negative ‚Üí C. diff ruled out</li>
                                <li>If positive ‚Üí need confirmatory toxin testing</li>
                            </ul>
                        </li>
                        <li><strong>Recommended 2-Step Algorithm:</strong>
                            <ul>
                                <li>Step 1: GDH + Toxin EIA</li>
                                <li>If both positive ‚Üí Treat</li>
                                <li>If GDH positive but Toxin negative ‚Üí Send NAAT (if high suspicion, can empirically treat while awaiting)</li>
                                <li>If both negative ‚Üí C. diff excluded</li>
                            </ul>
                        </li>
                        <li><strong>Do NOT send repeat testing:</strong> If initially negative but high clinical suspicion persists, can repeat once after 24-48 hours. More than 2 tests in 7 days is excessive</li>
                        <li><strong>Test of cure NOT recommended:</strong> Patients can shed toxin for weeks. Treat symptoms, not test results</li>
                    </ul>
                    
                    <p><span class="label">Labs (Assess Severity):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common (15-30k). WBC >15k = severe. WBC >35k or <2k = very high risk for complications/death</li>
                        <li><strong>BMP:</strong> Cr >1.5√ó baseline = severe. Check for AKI, electrolyte abnormalities (hypokalemia from diarrhea)</li>
                        <li><strong>Albumin:</strong> Hypoalbuminemia from protein-losing enteropathy</li>
                        <li><strong>Lactate:</strong> Elevated if sepsis/shock</li>
                    </ul>
                    
                    <p><span class="label">Imaging (If Severe or Complications Suspected):</span></p>
                    <ul>
                        <li><strong>CT Abdomen/Pelvis WITH IV Contrast:</strong>
                            <ul>
                                <li>Indications: Severe CDI, fulminant presentation, concern for megacolon/perforation, ileus, peritoneal signs</li>
                                <li>Findings: Colonic wall thickening (>4mm), pericolonic stranding, "accordion sign" (contrast trapped in thickened colonic folds), ascites, megacolon (>6cm), pneumatosis</li>
                                <li>Helps determine need for surgery</li>
                            </ul>
                        </li>
                        <li><strong>KUB X-ray:</strong> Can identify megacolon, free air (perforation), but CT preferred if available</li>
                        <li><strong>Colonoscopy:</strong> Generally NOT needed. Consider if diagnosis uncertain or refractory to treatment. Pseudomembranes (yellow-white plaques) are pathognomonic but only present in 50% of cases. Risk of perforation - avoid if severe colitis</li>
                    </ul>
                    
                    <p><span class="label">Severity Classification (Guides Treatment):</span></p>
                    <ul>
                        <li><strong>Non-Severe (Mild-Moderate):</strong> WBC <15k, Cr <1.5 mg/dL</li>
                        <li><strong>Severe:</strong> WBC ‚â•15k OR Cr ‚â•1.5√ó baseline</li>
                        <li><strong>Fulminant:</strong> Hypotension, shock, ileus, megacolon, perforation, ICU admission, WBC >35k or <2k</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Stop offending antibiotics immediately</strong> if medically possible (single most important intervention)</li>
                        <li><strong>Discontinue PPIs/H2 blockers</strong> if possible</li>
                        <li><strong>Contact isolation:</strong> Private room, gloves and gown for all contact. Soap and water hand hygiene (alcohol doesn't kill spores)</li>
                        <li><strong>Avoid anti-motility agents:</strong> Loperamide, opiates can precipitate toxic megacolon. Contraindicated</li>
                        <li><strong>Avoid unnecessary antibiotics:</strong> But continue life-saving antibiotics if needed (C. diff treatment will work alongside)</li>
                    </ul>
                    
                    <p><span class="label">Initial Episode - Non-Severe/Severe:</span></p>
                    <ul>
                        <li><strong>FIRST-LINE: Oral Vancomycin 125mg PO QID √ó 10 days</strong>
                            <ul>
                                <li>Preferred for both non-severe AND severe CDI (2021 IDSA guidelines changed recommendation)</li>
                                <li>Acts locally in gut (not absorbed systemically)</li>
                                <li>Higher doses (500mg QID) do NOT improve outcomes for non-fulminant disease</li>
                            </ul>
                        </li>
                        <li><strong>ALTERNATIVE: Fidaxomicin 200mg PO BID √ó 10 days</strong>
                            <ul>
                                <li>Narrow-spectrum, preserves gut flora better</li>
                                <li>Lower recurrence rate than vancomycin (15% vs 25%)</li>
                                <li>Very expensive - reserve for: recurrent CDI, high risk for recurrence, immunocompromised</li>
                            </ul>
                        </li>
                        <li><strong>If Oral Vanc/Fidaxomicin Unavailable: Metronidazole 500mg PO TID √ó 10 days</strong>
                            <ul>
                                <li>No longer first-line (inferior to vancomycin)</li>
                                <li>Only use if vanc/fidaxomicin not available</li>
                                <li>Systemic side effects (neuropathy with prolonged use)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Severe CDI (WBC ‚â•15k OR Cr ‚â•1.5√ó baseline):</span></p>
                    <ul>
                        <li><strong>Oral Vancomycin 125mg PO QID √ó 10 days</strong> (same dose as non-severe)</li>
                        <li>Some experts use 500mg QID for severe, but 125mg QID likely equivalent</li>
                        <li>Monitor closely for progression to fulminant</li>
                    </ul>
                    
                    <p><span class="label">Fulminant CDI (Shock, Ileus, Megacolon, ICU):</span></p>
                    <ul>
                        <li><strong>Oral Vancomycin 500mg PO/NG QID</strong></li>
                        <li><strong>PLUS IV Metronidazole 500mg IV q8h</strong> (for systemic absorption since gut may not absorb oral meds)</li>
                        <li><strong>If Ileus Present: ADD Vancomycin 500mg in 500mL NS PR q6h</strong> (rectal enema to reach colon)</li>
                        <li><strong>Surgery consult immediately:</strong> Subtotal colectomy with end ileostomy if:
                            <ul>
                                <li>Refractory shock despite pressors</li>
                                <li>Perforation or peritonitis</li>
                                <li>Worsening lactate despite treatment</li>
                                <li>WBC >50k or <2k with clinical deterioration</li>
                                <li>Mental status decline</li>
                            </ul>
                        </li>
                        <li><strong>Mortality without surgery:</strong> 80% if meet criteria. With surgery: 40-50%</li>
                    </ul>
                    
                    <p><span class="label">Recurrent CDI (Most Challenging Aspect):</span></p>
                    <ul>
                        <li><strong>First Recurrence (20-30% of patients):</strong>
                            <ul>
                                <li>If metronidazole used initially ‚Üí Switch to Vancomycin 125mg QID √ó 10 days</li>
                                <li>If vancomycin used initially ‚Üí Repeat Vancomycin 125mg QID √ó 10 days OR Fidaxomicin 200mg BID √ó 10 days (preferred - lower re-recurrence)</li>
                            </ul>
                        </li>
                        <li><strong>Second or Later Recurrence (40-60% after 2nd episode):</strong>
                            <ul>
                                <li><strong>Option 1: Vancomycin Taper/Pulse</strong>
                                    <ul>
                                        <li>125mg QID √ó 10-14 days</li>
                                        <li>Then 125mg BID √ó 7 days</li>
                                        <li>Then 125mg daily √ó 7 days</li>
                                        <li>Then 125mg every 2-3 days √ó 2-8 weeks</li>
                                    </ul>
                                </li>
                                <li><strong>Option 2: Fidaxomicin 200mg BID √ó 10 days</strong> (preferred if available - 13% re-recurrence vs 25% with vanc)</li>
                                <li><strong>Option 3: Fecal Microbiota Transplant (FMT)</strong>
                                    <ul>
                                        <li>90% cure rate after ‚â•2 recurrences</li>
                                        <li>Restores normal gut flora</li>
                                        <li>Usually via colonoscopy (can also do via capsules, NG tube)</li>
                                        <li>Screening of donor required</li>
                                    </ul>
                                </li>
                                <li><strong>Option 4: Bezlotoxumab (Zinplava)</strong>
                                    <ul>
                                        <li>Monoclonal antibody against C. diff toxin B</li>
                                        <li>Given as single 10mg/kg IV infusion during antibiotic treatment</li>
                                        <li>Reduces recurrence from 26% to 17%</li>
                                        <li>Expensive - reserve for high-risk recurrent patients</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Situations:</span></p>
                    <ul>
                        <li><strong>Unable to Take PO:</strong> Vancomycin via NG/OG tube + IV metronidazole + consider vanc enemas</li>
                        <li><strong>Pregnancy/Breastfeeding:</strong> Vancomycin safe (not absorbed). Avoid metronidazole in 1st trimester</li>
                        <li><strong>Renal Failure:</strong> Vancomycin dose unchanged (not absorbed). Metronidazole - monitor for neuropathy</li>
                        <li><strong>Concomitant Antibiotics Needed:</strong> Continue C. diff treatment alongside. Stop offending antibiotics if possible, but don't withhold life-saving antibiotics</li>
                        <li><strong>Prevention in High-Risk:</strong> Antibiotic stewardship (limit unnecessary antibiotics), avoid PPIs, probiotics NOT recommended for prevention</li>
                    </ul>
                    
                    <p><span class="label">Duration and Monitoring:</span></p>
                    <ul>
                        <li><strong>Standard duration:</strong> 10 days for initial/first recurrence</li>
                        <li><strong>Expect improvement:</strong> Within 3-5 days (decreased diarrhea, resolution of fever). If no improvement by day 5-7 ‚Üí re-evaluate</li>
                        <li><strong>Do NOT retest stool:</strong> Can remain PCR positive for 6 weeks. Treat symptoms, not tests</li>
                        <li><strong>Resolution defined as:</strong> ‚â§3 formed stools per day OR return to baseline bowel pattern</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Test ONLY liquid stool:</strong> If stool takes shape of container = test. If stool holds its own shape = don't test. Testing formed stool leads to false positives from asymptomatic colonization (10-15% of hospitalized patients colonized)</li>
                    <li><strong>PCR can't distinguish infection from colonization:</strong> NAAT detects toxin genes, not actual toxins. Positive PCR + no symptoms = colonization, not infection. Need clinical correlation always</li>
                    <li><strong>One antibiotic dose can trigger CDI:</strong> Even single perioperative dose. Symptoms typically 5-10 days after starting antibiotics but can be up to 3 months (or longer). Any antibiotic can cause it, but clinda/FQ/cephalosporins are worst</li>
                    <li><strong>Vancomycin 125mg = 500mg for non-fulminant:</strong> Higher doses don't improve outcomes. Save 500mg QID for fulminant only. This saves money and prevents unnecessary dose escalation</li>
                    <li><strong>Metronidazole is NOT first-line anymore:</strong> 2021 IDSA guidelines downgraded metronidazole. Vancomycin superior and should be used for initial treatment. Metronidazole only if vanc unavailable</li>
                    <li><strong>Fidaxomicin costs 100√ó more than vancomycin:</strong> ~$3,000 vs $30 for 10-day course. Lower recurrence (15% vs 25%) but reserve for recurrent CDI or high-risk patients due to cost</li>
                    <li><strong>FMT is incredibly effective for recurrent CDI:</strong> 85-90% cure rate after ‚â•2 recurrences. Should be offered to all patients with multiple recurrences. Colonoscopy method preferred (highest success)</li>
                    <li><strong>Never use anti-diarrheal agents:</strong> Loperamide and opiates retain toxin in colon ‚Üí toxic megacolon. Absolutely contraindicated. Let the diarrhea clear the toxin</li>
                    <li><strong>Soap and water, not alcohol:</strong> Alcohol hand sanitizer doesn't kill C. diff spores. Healthcare workers must use soap and water + contact precautions (gown and gloves)</li>
                    <li><strong>WBC >35k or <2k = bad prognostic sign:</strong> Leukemoid reaction (>35k) or leukopenia (<2k) both associated with fulminant disease and high mortality. These patients need ICU + surgery consult</li>
                    <li><strong>Stop PPIs in CDI patients:</strong> PPIs increase CDI risk and recurrence. Discontinue unless absolutely necessary (active bleeding ulcer). Gastric acid is natural defense</li>
                    <li><strong>Bezlotoxumab for recurrent disease prevention:</strong> Single IV dose during antibiotic treatment reduces recurrence from 26% to 17%. Expensive but worth considering for patients with ‚â•2 recurrences or high risk (age >65, immunocompromised, severe disease)</li>
                    <li><strong>Surgery for fulminant = life-saving:</strong> Subtotal colectomy with ileostomy. Mortality 80% without surgery vs 40-50% with surgery if meet criteria. Don't delay if indicated</li>
                    <li><strong>Probiotics NOT recommended:</strong> No evidence for prevention or treatment. Don't use routinely. May increase infection risk in immunocompromised</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Fulminant CDI: hypotension requiring pressors, shock, lactate >4</li>
                        <li>WBC >35k or <2k (leukemoid reaction or leukopenia)</li>
                        <li>Toxic megacolon (colon >6cm, peritoneal signs)</li>
                        <li>Perforation or peritonitis</li>
                        <li>Ileus with severe abdominal distension</li>
                        <li>AKI with Cr >2√ó baseline or requiring dialysis</li>
                        <li>Mental status decline despite treatment</li>
                        <li>Worsening lactate despite resuscitation</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Diarrhea significantly improved (‚â§3 unformed stools/day or return to baseline)</li>
                        <li>Afebrile √ó 24 hours (temperature <38¬∞C)</li>
                        <li>Hemodynamically stable (no tachycardia, normotensive)</li>
                        <li>Tolerating PO intake and medications</li>
                        <li>Abdominal pain resolved or minimal</li>
                        <li>WBC downtrending (if initially elevated)</li>
                        <li>No signs of complications (megacolon, perforation, ileus)</li>
                        <li>Able to complete antibiotic course as outpatient</li>
                        <li>Prescription for remaining vancomycin provided</li>
                        <li>Patient/family educated on: completing full course, hand hygiene, contact precautions at home if immunocompromised household members</li>
                        <li>PCP follow-up arranged within 1-2 weeks</li>
                        <li>Patient instructed on recurrence symptoms and when to return</li>
                        <li>If recurrent CDI: discussed prevention strategies (avoid unnecessary antibiotics/PPIs, FMT referral if multiple recurrences)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications (During Treatment):</strong> Toxic megacolon (colon dilation >6cm - 3-8% of cases, high mortality), colonic perforation (peritonitis, free air, requires emergency colectomy), fulminant colitis with shock (hypotension, multi-organ failure, 2-3% of cases), ileus (paradoxical decrease in diarrhea with worsening distension), sepsis/septic shock, acute kidney injury (from hypovolemia or sepsis)</p>
                    <p><strong>Metabolic/Nutritional:</strong> Severe dehydration and electrolyte imbalances (hypokalemia, hypomagnesemia from diarrhea), protein-losing enteropathy with hypoalbuminemia (<2.5 g/dL), malnutrition from prolonged illness</p>
                    <p><strong>Recurrence (Most Common Complication):</strong> First recurrence 20-30%, second recurrence 40-60% (cumulative). Usually within 2-8 weeks of completing treatment. Risk factors: age >65, continued antibiotics, PPI use, immunosuppression, initial severe infection, hospitalization. Each recurrence increases risk of subsequent recurrence</p>
                    <p><strong>Post-Infection:</strong> Post-infectious IBS (10-25% develop chronic diarrhea/abdominal pain even after CDI cured), chronic diarrhea from dysbiosis, small intestinal bacterial overgrowth (SIBO) from gut flora disruption</p>
                    <p><strong>Treatment-Related:</strong> Metronidazole peripheral neuropathy (with prolonged use >2 weeks - can be irreversible), disulfiram-like reaction with alcohol (metronidazole), vancomycin-resistant Enterococcus (VRE) colonization (prolonged oral vanc), microbiome disruption from prolonged treatment</p>
                    <p><strong>Surgical:</strong> Need for colectomy (1-3% of cases - fulminant colitis, perforation, toxic megacolon), post-surgical complications (wound infection, ileus, short bowel syndrome), high mortality with surgery (30-50%) but higher without surgery if indicated (80%)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="dvt" class="condition-page">
            <div class="page-header">
                <h2>23. DEEP VEIN THROMBOSIS (DVT)</h2>
                <div class="subtitle">Venous Thromboembolism ‚Ä¢ Lower Extremity ‚Ä¢ Pulmonary Embolism Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Unilateral leg swelling, pain, warmth, erythema. Calf tenderness, palpable cord. Swelling typically involves entire leg if proximal DVT (iliofemoral), calf only if distal DVT</p>
                    <p><span class="label">Physical Exam:</span> Measure calf/thigh circumference (>3cm difference = significant), assess for pitting edema, erythema, warmth. Homan's sign (calf pain with dorsiflexion) is unreliable - do NOT use for diagnosis</p>
                    
                    <p><span class="label">Anatomic Classification:</span></p>
                    <ul>
                        <li><strong>Proximal DVT:</strong> Popliteal vein or above (femoral, iliofemoral). High PE risk (50% if untreated). ALWAYS requires anticoagulation</li>
                        <li><strong>Distal DVT:</strong> Calf veins only (peroneal, tibial, gastrocnemius). Lower PE risk (10%). May monitor without anticoagulation if low risk</li>
                        <li><strong>Upper Extremity DVT:</strong> Axillary, subclavian, internal jugular. 10% of DVTs. Often catheter-related</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic DVT:</strong> 50% of DVTs have minimal symptoms. May present as PE. Screen high-risk hospitalized patients</li>
                        <li><strong>Phlegmasia Alba Dolens:</strong> "Milk leg" - pale, swollen leg from extensive iliofemoral DVT with spasm. Painful but pulses intact</li>
                        <li><strong>Phlegmasia Cerulea Dolens:</strong> Blue, painful, massively swollen leg from complete venous occlusion. Arterial compromise, gangrene risk. Surgical emergency</li>
                        <li><strong>May-Thurner Syndrome:</strong> Left common iliac vein compression by right common iliac artery. Young women with left leg DVT</li>
                        <li><strong>Upper Extremity DVT:</strong> Arm swelling, pain. Paget-Schroetter syndrome (effort thrombosis) in athletes. Central line-associated in hospitalized</li>
                        <li><strong>Superficial Thrombophlebitis:</strong> Palpable tender cord, erythema along superficial vein. Low PE risk but can extend to deep system. If >5cm or near saphenofemoral junction, consider anticoagulation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Decision Rule - Wells Score for DVT:</span></p>
                    <ul>
                        <li>Active cancer (treatment within 6 months or palliative): +1</li>
                        <li>Paralysis, paresis, or recent immobilization of lower extremity: +1</li>
                        <li>Recently bedridden >3 days or major surgery within 4 weeks: +1</li>
                        <li>Localized tenderness along deep venous system: +1</li>
                        <li>Entire leg swollen: +1</li>
                        <li>Calf swelling >3cm compared to other leg (10cm below tibial tuberosity): +1</li>
                        <li>Pitting edema (greater in symptomatic leg): +1</li>
                        <li>Collateral superficial veins (non-varicose): +1</li>
                        <li>Alternative diagnosis as likely or more likely than DVT: -2</li>
                        <li><strong>Score interpretation:</strong> ‚â§0 = Low probability (5% DVT), 1-2 = Moderate (17%), ‚â•3 = High (53%)</li>
                    </ul>
                    
                    <p><span class="label">Diagnostic Algorithm:</span></p>
                    <ul>
                        <li><strong>Low Probability (Wells ‚â§0):</strong> D-dimer first. If negative ‚Üí DVT excluded (99% NPV). If positive ‚Üí Ultrasound</li>
                        <li><strong>Moderate-High Probability (Wells ‚â•1):</strong> Proceed directly to ultrasound (don't wait for D-dimer)</li>
                    </ul>
                    
                    <p><span class="label">D-Dimer:</span></p>
                    <ul>
                        <li><strong>High sensitivity (95-98%), low specificity (40-50%)</strong></li>
                        <li>Excellent negative predictive value - if negative, DVT/PE ruled out in low-risk patients</li>
                        <li>Many false positives: infection, malignancy, pregnancy, post-op, elderly, hospitalization</li>
                        <li><strong>Age-adjusted D-dimer:</strong> Age √ó 10 mcg/L if age >50 (improves specificity in elderly)</li>
                        <li><strong>When NOT to use:</strong> High pretest probability, active cancer, recent surgery, pregnancy (always elevated)</li>
                    </ul>
                    
                    <p><span class="label">Compression Ultrasonography (Test of Choice):</span></p>
                    <ul>
                        <li><strong>Technique:</strong> 2-point compression (common femoral vein, popliteal vein). Add full duplex if high suspicion</li>
                        <li><strong>Positive = Non-compressibility of vein</strong> (vein doesn't collapse with probe pressure)</li>
                        <li><strong>Sensitivity/Specificity:</strong> >95% for proximal DVT, 50-70% for distal (calf) DVT</li>
                        <li><strong>If negative but high suspicion:</strong> Repeat ultrasound in 1 week (5-10% of distal DVTs extend proximally)</li>
                        <li><strong>Limitations:</strong> Operator-dependent, difficult with edema/obesity, poor for iliac veins and calf veins</li>
                    </ul>
                    
                    <p><span class="label">Additional Imaging (Special Situations):</span></p>
                    <ul>
                        <li><strong>CT/MR Venography:</strong> If ultrasound non-diagnostic and high suspicion. Better for pelvic/IVC thrombus</li>
                        <li><strong>Contrast Venography:</strong> Gold standard but invasive, rarely used now. Reserved for cases where diagnosis remains uncertain</li>
                    </ul>
                    
                    <p><span class="label">Labs (Assess for Complications and Etiology):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Baseline hemoglobin (before anticoagulation), platelet count (baseline for HIT monitoring)</li>
                        <li><strong>PT/INR, aPTT:</strong> Baseline coagulation studies</li>
                        <li><strong>BMP, Cr:</strong> Renal function (affects anticoagulant dosing)</li>
                        <li><strong>Hypercoagulability Workup:</strong> Generally NOT needed for provoked DVT. Consider if: age <50, recurrent VTE, strong family history, unusual sites
                            <ul>
                                <li>Factor V Leiden, Prothrombin G20210A mutation, Protein C/S deficiency, Antithrombin deficiency</li>
                                <li>Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-Œ≤2-glycoprotein)</li>
                                <li>Test AFTER acute phase and OFF anticoagulation (if possible) - results unreliable during acute DVT</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Anticoagulation (Start Immediately if High Suspicion - Don't Wait for Imaging):</span></p>
                    
                    <p><span class="label">Direct Oral Anticoagulants (DOACs) - FIRST-LINE for Most Patients:</span></p>
                    <ul>
                        <li><strong>Rivaroxaban (Xarelto):</strong> 15mg PO BID √ó 21 days, then 20mg PO daily
                            <ul>
                                <li>Advantages: Single drug, no LMWH bridge, BID dosing only first 3 weeks</li>
                            </ul>
                        </li>
                        <li><strong>Apixaban (Eliquis):</strong> 10mg PO BID √ó 7 days, then 5mg PO BID
                            <ul>
                                <li>Advantages: Single drug, no LMWH bridge, lowest bleeding risk of DOACs</li>
                                <li>Preferred if high bleeding risk</li>
                            </ul>
                        </li>
                        <li><strong>Edoxaban (Savaysa):</strong> LMWH √ó 5-10 days FIRST, then Edoxaban 60mg PO daily
                            <ul>
                                <li>Requires bridge - less convenient</li>
                            </ul>
                        </li>
                        <li><strong>Dabigatran (Pradaxa):</strong> LMWH √ó 5-10 days FIRST, then Dabigatran 150mg PO BID
                            <ul>
                                <li>Requires bridge - less convenient</li>
                                <li>Advantage: Reversible with idarucizumab (Praxbind)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">DOAC Contraindications (Use LMWH/Warfarin Instead):</span></p>
                    <ul>
                        <li>Severe renal impairment (CrCl <30 mL/min for most DOACs, <25 for apixaban)</li>
                        <li>Mechanical heart valves</li>
                        <li>Antiphospholipid syndrome (high recurrence with DOACs - use warfarin)</li>
                        <li>Active malignancy (LMWH preferred - see below)</li>
                        <li>Extremes of body weight (<50kg or >120kg - limited data)</li>
                    </ul>
                    
                    <p><span class="label">Low Molecular Weight Heparin (LMWH):</span></p>
                    <ul>
                        <li><strong>Enoxaparin (Lovenox):</strong> 1mg/kg SC q12h OR 1.5mg/kg SC q24h
                            <ul>
                                <li>Bridge to warfarin √ó 5-10 days (until INR 2-3 √ó 2 consecutive days)</li>
                                <li>Or continue as monotherapy (especially cancer patients)</li>
                            </ul>
                        </li>
                        <li><strong>Dalteparin:</strong> 200 units/kg SC daily (max 18,000 units) √ó 1 month, then 150 units/kg daily</li>
                        <li><strong>Advantages:</strong> No monitoring needed, predictable dosing, safe in renal impairment (CrCl >30)</li>
                        <li><strong>Dosing adjustments:</strong>
                            <ul>
                                <li>Obesity (>150kg): Consider anti-Xa levels</li>
                                <li>Renal impairment (CrCl 15-30): Reduce dose by 50% or switch to UFH</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Unfractionated Heparin (UFH):</span></p>
                    <ul>
                        <li><strong>Use when:</strong> Severe renal failure (CrCl <15), high bleeding risk (short half-life, reversible), possible need for procedure, massive PE</li>
                        <li><strong>Dosing:</strong> 80 units/kg IV bolus, then 18 units/kg/hr infusion</li>
                        <li><strong>Goal aPTT:</strong> 1.5-2.5√ó control (60-80 seconds typically)</li>
                        <li><strong>Monitor:</strong> aPTT q6h until therapeutic, then daily. Platelet count q2-3 days (HIT risk)</li>
                    </ul>
                    
                    <p><span class="label">Warfarin (Coumadin):</span></p>
                    <ul>
                        <li><strong>Start 5mg PO daily</strong> (overlap with LMWH/UFH √ó 5-10 days)</li>
                        <li><strong>Goal INR:</strong> 2-3 (2.5-3.5 for antiphospholipid syndrome)</li>
                        <li><strong>Monitor:</strong> INR daily until stable, then weekly, then monthly</li>
                        <li><strong>Advantages:</strong> Cheapest option, long track record, reversible with vitamin K/FFP/PCC</li>
                        <li><strong>Disadvantages:</strong> Requires monitoring, drug-food interactions, narrow therapeutic window</li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Cancer-Associated VTE:</strong>
                            <ul>
                                <li><strong>LMWH preferred over warfarin/DOACs</strong> (lower recurrence rate)</li>
                                <li>Enoxaparin 1mg/kg SC BID √ó 3-6 months minimum, often lifelong</li>
                                <li>Alternative: Apixaban or rivaroxaban if LMWH not tolerated (recent trials show non-inferiority)</li>
                            </ul>
                        </li>
                        <li><strong>Pregnancy:</strong>
                            <ul>
                                <li>LMWH throughout pregnancy (enoxaparin 1mg/kg SC q12h)</li>
                                <li>DOACs and warfarin are teratogenic - CONTRAINDICATED</li>
                                <li>Switch to UFH at 36 weeks (shorter half-life for delivery)</li>
                                <li>Resume anticoagulation 6-12 hours postpartum, continue √ó 6 weeks minimum postpartum</li>
                            </ul>
                        </li>
                        <li><strong>Obesity:</strong> Weight-based LMWH dosing, DOACs have limited data >120kg</li>
                        <li><strong>Elderly:</strong> Apixaban preferred (lowest bleeding risk)</li>
                        <li><strong>Renal Failure:</strong>
                            <ul>
                                <li>CrCl >30: Any anticoagulant</li>
                                <li>CrCl 15-30: Apixaban (dose-adjust), warfarin, or reduced-dose LMWH</li>
                                <li>CrCl <15 or dialysis: UFH or warfarin</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Duration of Anticoagulation:</span></p>
                    <ul>
                        <li><strong>Provoked DVT (surgery, immobilization, estrogen, pregnancy):</strong> 3 months</li>
                        <li><strong>Unprovoked DVT:</strong> 3-6 months, then reassess. Consider indefinite if:
                            <ul>
                                <li>Low bleeding risk</li>
                                <li>Proximal DVT or PE</li>
                                <li>Male sex (higher recurrence)</li>
                                <li>Elevated D-dimer 1 month after stopping anticoagulation</li>
                            </ul>
                        </li>
                        <li><strong>Recurrent VTE:</strong> Lifelong anticoagulation</li>
                        <li><strong>Active cancer:</strong> 3-6 months minimum, often indefinite while cancer active</li>
                        <li><strong>Thrombophilia:</strong> Duration depends on specific deficiency and circumstances</li>
                    </ul>
                    
                    <p><span class="label">IVC Filter:</span></p>
                    <ul>
                        <li><strong>Indications:</strong>
                            <ul>
                                <li>Absolute contraindication to anticoagulation (active bleeding)</li>
                                <li>Recurrent VTE despite therapeutic anticoagulation</li>
                                <li>Complication of anticoagulation (major bleeding)</li>
                            </ul>
                        </li>
                        <li><strong>Retrievable filters preferred:</strong> Remove once anticoagulation safe (ideally within 3 months)</li>
                        <li><strong>NOT indicated for:</strong> Large DVT, free-floating thrombus, prophylaxis</li>
                        <li><strong>Complications:</strong> IVC thrombosis, filter migration, perforation</li>
                    </ul>
                    
                    <p><span class="label">Thrombolysis (Catheter-Directed or Systemic):</span></p>
                    <ul>
                        <li><strong>Consider for:</strong> Phlegmasia cerulea dolens (limb-threatening), massive iliofemoral DVT in young patients with low bleeding risk</li>
                        <li><strong>Goal:</strong> Reduce post-thrombotic syndrome risk</li>
                        <li><strong>Contraindications:</strong> Recent surgery, stroke, bleeding, pregnancy</li>
                        <li><strong>Not routine:</strong> Bleeding risk usually outweighs benefit</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Homan's sign is useless:</strong> Neither sensitive (10-50%) nor specific. Don't use it. Make diagnosis with Wells score + imaging</li>
                    <li><strong>D-dimer rules OUT, doesn't rule IN:</strong> Excellent negative predictive value (99%) in low-risk patients. But positive D-dimer doesn't confirm DVT - need imaging. Many false positives</li>
                    <li><strong>Proximal vs distal DVT treatment differs:</strong> Proximal DVT (popliteal+) = ALWAYS anticoagulate (high PE risk). Distal (calf only) = can monitor with serial ultrasounds if low risk</li>
                    <li><strong>DOACs are now first-line:</strong> Rivaroxaban and apixaban don't require LMWH bridge. Easier, equally effective, possibly safer than warfarin. Use unless contraindicated</li>
                    <li><strong>Cancer = LMWH preferred:</strong> LMWH superior to warfarin for cancer-associated VTE (50% lower recurrence). DOACs now reasonable alternative (CARAVAGGIO, ADAM-VTE trials)</li>
                    <li><strong>Don't wait for imaging if high suspicion:</strong> Start anticoagulation immediately while awaiting ultrasound. Risk of bleeding from 1 dose < risk of PE extension</li>
                    <li><strong>Unprovoked DVT often needs indefinite anticoagulation:</strong> 30% 5-year recurrence risk off anticoagulation. Reassess at 3-6 months. If continuing, use lower dose apixaban/rivaroxaban (reduces bleeding)</li>
                    <li><strong>IVC filter is NOT a substitute for anticoagulation:</strong> Filters DON'T treat DVT, just prevent PE. Still need anticoagulation once safe. Filters have complications (IVC thrombosis). Only use if bleeding contraindication</li>
                    <li><strong>Superficial thrombophlebitis can extend to deep system:</strong> If >5cm or near saphenofemoral junction, needs anticoagulation (or at least prophylactic dose √ó 45 days). Don't ignore it</li>
                    <li><strong>May-Thurner syndrome:</strong> Left leg DVT in young woman = think May-Thurner (left iliac vein compression by right iliac artery). May need endovascular stenting. Right leg DVT more common overall, but left leg in young = red flag</li>
                    <li><strong>Post-thrombotic syndrome is common:</strong> 20-50% of DVT patients develop chronic leg swelling, pain, skin changes. Prevented by immediate anticoagulation and compression stockings (30-40 mmHg √ó 2 years)</li>
                    <li><strong>Wells score -2 points for alternative diagnosis:</strong> Cellulitis, Baker's cyst, muscle strain can mimic DVT. If alternative equally likely, subtract 2 points from Wells score</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Phlegmasia cerulea dolens (limb-threatening DVT with arterial compromise)</li>
                        <li>Massive PE with hemodynamic instability</li>
                        <li>Major bleeding complication from anticoagulation</li>
                        <li>Need for thrombolysis (catheter-directed or systemic)</li>
                        <li>Acute limb ischemia requiring urgent intervention</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>DVT confirmed on ultrasound and anticoagulation initiated</li>
                        <li>Hemodynamically stable</li>
                        <li>No signs of PE (no dyspnea, normal O2 sat, no tachycardia)</li>
                        <li>Pain controlled with oral analgesics</li>
                        <li>Patient able to take oral anticoagulants (or self-inject LMWH)</li>
                        <li>No active bleeding or high bleeding risk</li>
                        <li>Patient educated on: anticoagulation adherence, bleeding precautions, leg elevation, compression stockings, return precautions (dyspnea = PE)</li>
                        <li>Appropriate anticoagulant prescribed with clear instructions</li>
                        <li>Follow-up arranged: PCP within 1 week, hematology if unprovoked/recurrent</li>
                        <li>Compression stockings fitted (30-40 mmHg knee-high)</li>
                        <li>If distal DVT being monitored: repeat ultrasound scheduled in 1 week</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> Pulmonary embolism (most feared - occurs in 50% of untreated proximal DVT), phlegmasia cerulea dolens (complete venous occlusion with arterial compromise, limb-threatening), venous gangrene, acute limb ischemia</p>
                    <p><strong>Bleeding from Anticoagulation:</strong> Major bleeding (intracranial hemorrhage, GI bleed, retroperitoneal bleed, any bleeding requiring transfusion or hospitalization), minor bleeding (epistaxis, easy bruising, hematuria, menorrhagia), HIT (heparin-induced thrombocytopenia - paradoxical thrombosis, check platelets if on heparin >4 days)</p>
                    <p><strong>Post-Thrombotic Syndrome (20-50% of DVT patients):</strong> Chronic leg swelling, pain, heaviness, skin hyperpigmentation, venous stasis dermatitis, venous ulcers (severe cases). Develops months to years after DVT. Prevention: immediate anticoagulation + compression stockings 30-40 mmHg √ó 2 years</p>
                    <p><strong>Recurrent VTE:</strong> 5-10% per year off anticoagulation (unprovoked DVT), 30% cumulative 5-year risk. Higher risk if: unprovoked, proximal, male sex, obesity, residual thrombus. Provoked DVT: 1-3% per year recurrence</p>
                    <p><strong>From IVC Filter:</strong> IVC thrombosis (2-10%), filter migration, IVC perforation, failure to retrieve (50% of retrievable filters never removed), recurrent DVT below filter</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="stroke" class="condition-page">
            <div class="page-header">
                <h2>24. ACUTE ISCHEMIC STROKE</h2>
                <div class="subtitle">CVA ‚Ä¢ tPA ‚Ä¢ Mechanical Thrombectomy ‚Ä¢ Time Is Brain</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> SUDDEN onset focal neurologic deficit. Maximal deficit at onset (not progressive). FAST mnemonic: Face droop (ask to smile), Arm weakness (raise both arms), Speech difficulty (slurred/aphasia), Time = brain (1.9 million neurons die per minute untreated). "Last known well" time is critical for tPA eligibility</p>
                    
                    <p><span class="label">Presentations by Vascular Territory:</span></p>
                    <ul>
                        <li><strong>Middle Cerebral Artery (MCA - 50% of strokes):</strong> Contralateral hemiparesis/hemianesthesia (face and arm > leg), aphasia (if dominant/left hemisphere), neglect (if non-dominant/right hemisphere), gaze preference toward lesion, homonymous hemianopia</li>
                        <li><strong>Anterior Cerebral Artery (ACA):</strong> Contralateral leg weakness > arm, behavioral/personality changes, abulia, urinary incontinence, grasp reflex</li>
                        <li><strong>Posterior Cerebral Artery (PCA):</strong> Contralateral homonymous hemianopia, alexia without agraphia, visual agnosia, memory impairment (if bilateral thalamic involvement)</li>
                        <li><strong>Vertebrobasilar (Posterior Circulation):</strong> Dizziness, vertigo, diplopia, dysphagia, dysarthria, ataxia, crossed sensory/motor deficits (face one side, body opposite), bilateral symptoms, altered consciousness</li>
                        <li><strong>Lacunar (Small Vessel - 25%):</strong> Pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand syndrome. NO cortical signs (aphasia, neglect, visual field cuts)</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Wake-Up Stroke (25% of strokes):</strong> Patient wakes with deficits. Last known well = bedtime. Can still be tPA eligible if MRI shows DWI/FLAIR mismatch (DWI positive, FLAIR negative = likely <4.5 hours old)</li>
                        <li><strong>Large Vessel Occlusion (LVO):</strong> Severe deficits (NIHSS >6), gaze deviation, dense hemiplegia, global aphasia or severe neglect. These need mechanical thrombectomy urgently - activate stroke team immediately</li>
                        <li><strong>Posterior Circulation Stroke:</strong> Often misdiagnosed as "just dizziness" or vertigo. Red flags: sudden vertigo + HINTS exam abnormal (Head Impulse, Nystagmus, Test of Skew), inability to walk, severe headache</li>
                        <li><strong>Basilar Artery Occlusion:</strong> Decreased consciousness, quadriplegia, locked-in syndrome, respiratory failure. Devastating if untreated. Needs emergent thrombectomy even beyond 24 hours</li>
                        <li><strong>Stroke Mimics (20-30% of "stroke" activations):</strong> Hypoglycemia (<40 mg/dL - CHECK GLUCOSE FIRST), seizure with Todd's paralysis (post-ictal), complicated migraine with aura, conversion disorder, functional neurologic disorder, brain tumor, subdural hematoma</li>
                        <li><strong>Hemorrhagic Stroke:</strong> Progressive symptoms (not maximal at onset), severe headache, nausea/vomiting, decreased consciousness. Must rule out with CT before tPA</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate - STAT (Door-to-Needle Goal <60 Minutes):</span></p>
                    <ul>
                        <li><strong>Non-Contrast CT Head:</strong> FIRST TEST - rules out hemorrhage (absolute tPA contraindication). Only 60% sensitive for acute ischemia in first 6 hours. Look for: hyperdense MCA sign (visible clot), loss of gray-white differentiation, sulcal effacement, insular ribbon sign. If negative CT but high suspicion ‚Üí still likely ischemic stroke</li>
                        <li><strong>NIHSS Score (National Institutes of Health Stroke Scale):</strong> 0=normal, 1-4=minor, 5-15=moderate, 16-20=moderate-severe, >20=severe. Score >6 suggests large vessel occlusion - get CTA immediately. Repeat NIHSS to track improvement/worsening</li>
                        <li><strong>Fingerstick Glucose:</strong> MANDATORY FIRST - hypoglycemia (<60) mimics stroke perfectly and is immediately reversible. Never give tPA to hypoglycemia. If <60 ‚Üí give D50, reassess</li>
                        <li><strong>CT Angiography (CTA) Head/Neck:</strong> If NIHSS >6 or clinical suspicion for LVO. Identifies: ICA occlusion, M1/M2 MCA occlusion, basilar occlusion. Guides thrombectomy decision. Don't delay tPA waiting for CTA - can do simultaneously</li>
                    </ul>
                    
                    <p><span class="label">Labs (Send Immediately but Don't Delay tPA):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Platelets must be >100k for tPA. Severe anemia can cause neurologic deficits</li>
                        <li><strong>BMP:</strong> Severe hyperglycemia (>400) or renal failure impacts outcomes</li>
                        <li><strong>PT/INR, aPTT:</strong> INR must be <1.7 for tPA. Therapeutic heparin (aPTT >40) contraindication</li>
                        <li><strong>Troponin:</strong> 10-15% have MI with stroke. Check for concurrent ACS</li>
                        <li><strong>Hemoglobin A1c:</strong> Assess chronic glucose control</li>
                        <li><strong>Lipid panel:</strong> For secondary prevention</li>
                    </ul>
                    
                    <p><span class="label">Advanced Imaging:</span></p>
                    <ul>
                        <li><strong>MRI Brain with DWI:</strong> Gold standard for acute ischemia (>95% sensitive within hours). DWI bright = acute infarct. ADC dark = restricted diffusion (acute). Use for: unclear timing (wake-up stroke), TIA vs stroke, posterior circulation (CT misses 20% of posterior strokes), suspected mimics</li>
                        <li><strong>MR/CT Perfusion:</strong> Identifies salvageable penumbra (ischemic but not dead). Mismatch between perfusion deficit and infarct core = tissue to save. Extends thrombectomy window to 24 hours if large penumbra present</li>
                        <li><strong>Carotid Doppler or CTA Neck:</strong> Identify carotid stenosis. >70% symptomatic stenosis = CEA/stenting candidate (must be done within 2 weeks)</li>
                        <li><strong>Echocardiogram:</strong> TTE for LV thrombus, EF, wall motion abnormalities. TEE if suspicion for: endocarditis, atrial thrombus, PFO with significant shunt, aortic arch atheroma</li>
                    </ul>
                    
                    <p><span class="label">Stroke Etiology Workup (TOAST Classification):</span></p>
                    <ul>
                        <li><strong>Large Artery Atherosclerosis:</strong> Carotid stenosis >50%, intracranial stenosis</li>
                        <li><strong>Cardioembolism:</strong> Atrial fibrillation (most common), mechanical valve, recent MI with LV thrombus, dilated cardiomyopathy (EF <30%), endocarditis, atrial myxoma</li>
                        <li><strong>Small Vessel/Lacunar:</strong> Hypertension, diabetes. Small infarcts (<1.5cm) in basal ganglia, thalamus, pons</li>
                        <li><strong>Other Determined Cause:</strong> Dissection (carotid/vertebral), vasculitis, hypercoagulable state, drug-related (cocaine, amphetamines)</li>
                        <li><strong>Cryptogenic (30%):</strong> No clear cause. Consider: occult atrial fibrillation (30-day monitor), patent foramen ovale (PFO), atrial cardiopathy, cancer-associated</li>
                    </ul>
                    
                    <p><span class="label">Additional Workup:</span></p>
                    <ul>
                        <li><strong>Telemetry √ó 48 hours minimum:</strong> Detect paroxysmal atrial fibrillation (20% of cryptogenic strokes)</li>
                        <li><strong>Extended cardiac monitoring:</strong> If no cause found, 30-day event monitor or implantable loop recorder</li>
                        <li><strong>Hypercoagulable workup:</strong> Only if young (<50), recurrent, family history, or unusual site. Test AFTER acute phase: Factor V Leiden, prothrombin mutation, protein C/S, antithrombin, lupus anticoagulant, anticardiolipin antibodies</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Time Is Brain - Every Second Counts:</span></p>
                    <ul>
                        <li>Door-to-imaging goal: <25 minutes</li>
                        <li>Door-to-needle (tPA) goal: <60 minutes</li>
                        <li>Door-to-groin (thrombectomy) goal: <90 minutes</li>
                    </ul>
                    
                    <p><span class="label">Intravenous tPA (Alteplase) - "Clot Buster":</span></p>
                    <ul>
                        <li><strong>Eligibility Window:</strong> <4.5 hours from symptom onset (or last known well time)</li>
                        <li><strong>Dose:</strong> 0.9 mg/kg IV (maximum 90mg total)
                            <ul>
                                <li>Give 10% as bolus over 1 minute</li>
                                <li>Remaining 90% as infusion over 60 minutes</li>
                            </ul>
                        </li>
                        <li><strong>Benefit:</strong> NNT = 6 to prevent dependency at 3 months. Benefits persist even with symptomatic ICH risk</li>
                        <li><strong>Absolute Contraindications:</strong>
                            <ul>
                                <li>Intracranial hemorrhage on CT (any amount)</li>
                                <li>Ischemic stroke within 3 months</li>
                                <li>Intracranial/spinal surgery within 3 months</li>
                                <li>Head trauma within 3 months</li>
                                <li>History of intracranial hemorrhage ever</li>
                                <li>GI or GU hemorrhage within 21 days</li>
                                <li>Arterial puncture at non-compressible site within 7 days</li>
                                <li>SBP >185 or DBP >110 despite aggressive treatment</li>
                                <li>Active internal bleeding or acute trauma/fracture</li>
                                <li>INR >1.7, aPTT >40 seconds, platelets <100,000</li>
                                <li>Glucose <50 mg/dL (treat and reassess)</li>
                            </ul>
                        </li>
                        <li><strong>Relative Contraindications:</strong> Seizure at stroke onset, glucose >400, large infarct on CT (>1/3 MCA territory), minor/rapidly improving symptoms (though recent data supports treating these), pregnancy (relative - can give if severe stroke)</li>
                    </ul>
                    
                    <p><span class="label">Blood Pressure Management (CRITICAL - Most Common Error):</span></p>
                    <ul>
                        <li><strong>If Giving tPA - Must Lower BP:</strong>
                            <ul>
                                <li>Goal: <185/110 mmHg BEFORE starting tPA</li>
                                <li>Labetalol 10-20mg IV push q10-20min (up to 300mg total) OR</li>
                                <li>Nicardipine drip: Start 5mg/hr, titrate by 2.5mg/hr q5-15min to goal (max 15mg/hr)</li>
                                <li>AFTER tPA: Keep BP <180/105 √ó 24 hours (prevent hemorrhagic transformation)</li>
                            </ul>
                        </li>
                        <li><strong>If NOT Giving tPA - Permissive Hypertension:</strong>
                            <ul>
                                <li>ALLOW SBP up to 220 mmHg (brain needs perfusion pressure)</li>
                                <li>Only treat if: SBP >220 OR DBP >120 OR signs of end-organ damage (ACS, aortic dissection, acute pulmonary edema)</li>
                                <li>Goal: Lower by 15% over first 24 hours (NOT to normal)</li>
                                <li>Don't reflexively normalize BP - can extend infarct</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Mechanical Thrombectomy - "Most Effective Stroke Treatment":</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Large vessel occlusion (ICA, M1/M2 MCA, basilar artery) + salvageable tissue</li>
                        <li><strong>Time Window:</strong>
                            <ul>
                                <li>Up to 6 hours: All LVO eligible</li>
                                <li>6-16 hours: If good collaterals on CTA or small infarct core</li>
                                <li>16-24 hours: If perfusion imaging shows large penumbra (mismatch)</li>
                                <li>Basilar occlusion: Consider even beyond 24 hours (devastating if untreated)</li>
                            </ul>
                        </li>
                        <li><strong>Benefit:</strong> NNT = 3 for functional independence (best intervention in all of medicine)</li>
                        <li><strong>Transfer immediately if LVO identified</strong> at non-thrombectomy-capable center</li>
                        <li><strong>Can give tPA AND thrombectomy</strong> - not mutually exclusive</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>NPO until swallow screen passed:</strong> 30-50% have dysphagia. Aspiration pneumonia is leading complication</li>
                        <li><strong>Oxygen:</strong> Only if SpO2 <94% (hyperoxia may worsen outcomes)</li>
                        <li><strong>Normothermia:</strong> Fever worsens outcomes. Treat aggressively (acetaminophen, cooling)</li>
                        <li><strong>Euglycemia:</strong> Avoid hypoglycemia (<70) and severe hyperglycemia (>180). Both worsen outcomes</li>
                        <li><strong>Head of bed:</strong> 30 degrees (improves venous drainage, reduces aspiration)</li>
                        <li><strong>DVT prophylaxis:</strong> Pneumatic compression boots immediately. If no tPA given ‚Üí heparin 5000 units SQ TID. If tPA given ‚Üí wait 24 hours before starting heparin</li>
                    </ul>
                    
                    <p><span class="label">Antiplatelet Therapy:</span></p>
                    <ul>
                        <li><strong>If tPA Given:</strong> Hold aspirin √ó 24 hours (hemorrhage risk), then ASA 162-325mg daily</li>
                        <li><strong>If NO tPA Given:</strong> Aspirin 325mg immediately (or within 48 hours)</li>
                        <li><strong>Minor Stroke (NIHSS ‚â§3) within 24 hours:</strong> Dual Antiplatelet Therapy (DAPT)
                            <ul>
                                <li>ASA 162-325mg load + Clopidogrel 600mg load on day 1</li>
                                <li>Then ASA 81mg + Clopidogrel 75mg daily √ó 21 days</li>
                                <li>Then ASA 81mg alone lifelong</li>
                                <li>Reduces 90-day stroke recurrence by 30% (CHANCE, POINT trials)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation (For Atrial Fibrillation):</span></p>
                    <ul>
                        <li><strong>Timing is critical - too early = hemorrhagic transformation:</strong>
                            <ul>
                                <li>Small stroke (NIHSS <8): Start at 3-4 days</li>
                                <li>Moderate stroke (NIHSS 8-15): Start at 6-8 days</li>
                                <li>Large stroke (NIHSS >15): Start at 12-14 days</li>
                            </ul>
                        </li>
                        <li><strong>DOACs preferred over warfarin:</strong> Apixaban 5mg BID, rivaroxaban 20mg daily, edoxaban 60mg daily, dabigatran 150mg BID</li>
                        <li><strong>Reduce dose if:</strong> Age >80, weight <60kg, Cr >1.5 (apixaban 2.5mg BID)</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prevention:</span></p>
                    <ul>
                        <li><strong>High-Intensity Statin:</strong> Atorvastatin 80mg daily regardless of LDL (plaque stabilization, anti-inflammatory). Start immediately</li>
                        <li><strong>Blood Pressure Control:</strong> Goal <140/90 (<130/80 if diabetic). Start after acute phase (don't lower acutely unless >220)</li>
                        <li><strong>Carotid Stenosis >70% Symptomatic:</strong> CEA or carotid stenting within 2 weeks (stroke risk 20% at 2 weeks without intervention)</li>
                        <li><strong>PFO Closure:</strong> Consider if cryptogenic stroke, age <60, large shunt, atrial septal aneurysm. Reduces recurrent stroke by 50%</li>
                        <li><strong>Lifestyle:</strong> Smoking cessation (doubles stroke risk), exercise, Mediterranean diet, weight loss</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Time is brain - 1.9 million neurons per minute:</strong> Every 15 minutes of delay in tPA = 1 month of disability. Door-to-needle <60 min, door-to-groin <90 min are achievable goals</li>
                    <li><strong>CHECK GLUCOSE FIRST:</strong> Hypoglycemia is the great stroke mimic and it's 100% reversible with D50. Never give tPA to a glucose of 45</li>
                    <li><strong>Permissive hypertension unless giving tPA:</strong> Brain needs perfusion in acute stroke. Allow SBP <220. Only lower if giving tPA (then <185) or signs of end-organ damage. Don't reflexively normalize BP</li>
                    <li><strong>tPA works - don't be afraid to use it:</strong> NNT=6 for preventing disability. Yes, 6% symptomatic ICH risk, but functional outcomes still better. Benefits extend to 4.5 hours</li>
                    <li><strong>Thrombectomy revolutionized stroke care:</strong> NNT=3 for independence. Extends to 24 hours with perfusion imaging. Transfer immediately if LVO - don't let them sit</li>
                    <li><strong>NIHSS >6 = think large vessel occlusion:</strong> Get CTA and activate interventional team immediately. These need thrombectomy within 6 hours (ideally)</li>
                    <li><strong>Wake-up strokes can still get tPA:</strong> If MRI shows DWI/FLAIR mismatch (DWI+, FLAIR-), likely <4.5hr old and eligible (WAKE-UP trial)</li>
                    <li><strong>Dual antiplatelets for minor stroke:</strong> ASA + clopidogrel √ó 21 days if NIHSS ‚â§3 and within 24 hours. 30% reduction in recurrence (CHANCE, POINT). Don't use for moderate-severe stroke</li>
                    <li><strong>Delay anticoagulation in Afib stroke:</strong> Wait 3-14 days (size-dependent) before starting DOAC. Too early = hemorrhagic transformation. Use 1-2-2 week rule (small-medium-large)</li>
                    <li><strong>Posterior strokes are sneaky:</strong> "Just dizziness" can be fatal basilar occlusion. HINTS exam: Head Impulse Normal = central (stroke). Vertical/direction-changing Nystagmus = central. Test of Skew = central</li>
                    <li><strong>Carotid stenosis >70% needs urgent intervention:</strong> CEA or stent within 2 weeks. Stroke risk is 20% in first 2 weeks without treatment. Don't delay</li>
                    <li><strong>Blood pressure control is for AFTER acute phase:</strong> Lower gradually over days-weeks. Acutely, permissive hypertension preserves penumbra. Target <140/90 long-term</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Large stroke (NIHSS >15) with decreased consciousness</li>
                        <li>Basilar artery occlusion (high mortality, needs close monitoring)</li>
                        <li>Hemorrhagic transformation with mass effect</li>
                        <li>Malignant MCA syndrome (cerebral edema, herniation risk - peaks day 3-5)</li>
                        <li>Received tPA (monitor √ó 24hr for ICH, strict BP control <180/105)</li>
                        <li>Post-thrombectomy (monitor for reperfusion injury, hemorrhage)</li>
                        <li>Unstable blood pressure requiring IV drips</li>
                        <li>Respiratory failure or airway compromise</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Neurologically stable or improving √ó 24-48 hours</li>
                        <li>Swallow screen passed - safe for PO (or feeding tube placed)</li>
                        <li>Aspiration precautions in place if dysphagia present</li>
                        <li>PT/OT completed - mobility/ADL assessment done</li>
                        <li>Secondary prevention initiated (antiplatelet or anticoagulation, statin)</li>
                        <li>Blood pressure controlled and on appropriate regimen</li>
                        <li>If tPA given: >24 hours post-tPA, no hemorrhagic transformation on repeat CT</li>
                        <li>If carotid stenosis >70%: CEA/stent scheduled within 2 weeks</li>
                        <li>Outpatient rehabilitation arranged (acute rehab facility, subacute, home PT)</li>
                        <li>Neurology follow-up within 1-2 weeks</li>
                        <li>Patient/family educated on: stroke warning signs (FAST), when to call 911, medication adherence, risk factor modification</li>
                        <li>DME provided: walker, wheelchair, hospital bed if needed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early (Hours-Days):</strong> Hemorrhagic transformation (6% with tPA, 2% without - peaks at 24-36hr), cerebral edema with herniation (peaks day 3-5, especially large MCA strokes - malignant edema 10% mortality), seizures (5-10%, higher with cortical involvement), aspiration pneumonia (30-50% have dysphagia), DVT/PE (immobility), recurrent stroke (highest risk first 48hr - 5% risk at 2 weeks)</p>
                    <p><strong>Post-tPA Specific:</strong> Symptomatic intracranial hemorrhage (6% - half are fatal), angioedema (1-5%, especially if on ACE-I - can compromise airway), systemic bleeding (epistaxis, hematuria, GI bleed), reperfusion injury</p>
                    <p><strong>Late (Weeks-Months):</strong> Recurrent stroke (10% first year, 30% at 5 years without secondary prevention), disability and dependence (30-40% need assistance with ADLs), depression (30-50% develop post-stroke depression), vascular dementia (doubles risk), falls and hip fractures (hemiparesis, neglect), chronic pain syndromes, spasticity requiring botulinum toxin</p>
                    <p><strong>Specific Syndromes:</strong> Central post-stroke pain (thalamic pain syndrome - burning dysesthesia, 10% of strokes), shoulder subluxation (hemiplegic shoulder, 25%), complex regional pain syndrome, dysphagia persisting >6 months (10%), aphasia (permanent in 20-40% of left hemisphere strokes)</p>
                    <p><strong>Malignant MCA Syndrome:</strong> Large MCA infarct with massive edema, herniation, coma. Peaks day 3-5. Mortality 80% without decompressive hemicraniectomy, 30% with surgery. Consider surgery if age <60, within 48hr of symptom onset</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="seizure" class="condition-page">
            <div class="page-header">
                <h2>25. SEIZURE / STATUS EPILEPTICUS</h2>
                <div class="subtitle">Convulsive ‚Ä¢ Non-Convulsive ‚Ä¢ Neurologic Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Status Epilepticus Definition:</span> Seizure lasting >5 minutes OR recurrent seizures without return to baseline consciousness between episodes. TRUE MEDICAL EMERGENCY - mortality 10-20% if untreated</p>
                    
                    <p><span class="label">Types of Seizures:</span></p>
                    <ul>
                        <li><strong>Generalized Tonic-Clonic (Grand Mal):</strong> Loss of consciousness, tonic phase (muscle rigidity 10-30 sec), clonic phase (rhythmic jerking 30-60 sec), postictal confusion/somnolence (minutes to hours). May have tongue biting (lateral tongue = specific), incontinence, foaming at mouth</li>
                        <li><strong>Focal (Partial) Seizures:</strong> Originates one brain region. Can be motor (Jacksonian march up extremity), sensory, or with impaired awareness (staring, automatisms like lip-smacking). May secondarily generalize</li>
                        <li><strong>Absence:</strong> Brief staring spells 5-10 seconds. Child stops mid-activity, stares, resumes. No postictal confusion. Pediatric primarily (petit mal)</li>
                        <li><strong>Myoclonic:</strong> Brief muscle jerks. Can be benign (everyone has on falling asleep) or pathologic (juvenile myoclonic epilepsy)</li>
                        <li><strong>Atonic (Drop Attacks):</strong> Sudden loss of muscle tone, falls. Lennox-Gastaut syndrome</li>
                    </ul>
                    
                    <p><span class="label">Non-Convulsive Status Epilepticus (NCSE):</span></p>
                    <ul>
                        <li>Altered mental status WITHOUT obvious motor activity</li>
                        <li>10-20% of ICU patients with unexplained AMS have NCSE on EEG</li>
                        <li>Subtle findings: eye deviation, nystagmus, facial twitching, automatisms</li>
                        <li><strong>Diagnosis requires EEG</strong> - have high suspicion in ICU patients with AMS</li>
                    </ul>
                    
                    <p><span class="label">Seizure vs Syncope - Key Differences:</span></p>
                    <ul>
                        <li><strong>Seizure:</strong> Tonic-clonic >15 seconds, lateral tongue biting (specific), incontinence common, prolonged postictal confusion (30 min - hours)</li>
                        <li><strong>Syncope:</strong> Brief myoclonic jerks <15 seconds, no tongue biting (or central only), incontinence rare, rapid recovery (<1 min), no postictal confusion</li>
                    </ul>
                    
                    <p><span class="label">Etiology - "VITAMINS" Mnemonic:</span></p>
                    <ul>
                        <li><strong>V</strong>ascular: Ischemic stroke, hemorrhage, venous sinus thrombosis</li>
                        <li><strong>I</strong>nfection: Meningitis, encephalitis, brain abscess, neurocysticercosis</li>
                        <li><strong>T</strong>rauma: Prior TBI, subdural hematoma, DAI</li>
                        <li><strong>A</strong>utoimmune: SLE cerebritis, anti-NMDA receptor encephalitis, Hashimoto's encephalopathy</li>
                        <li><strong>M</strong>etabolic: Hypoglycemia <40 (most common reversible cause), hyponatremia <120, hypocalcemia, hypomagnesemia, uremia, hepatic encephalopathy</li>
                        <li><strong>I</strong>atrogenic/Intoxication: Tramadol, bupropion, fluoroquinolones, imipenem, isoniazid. Cocaine, amphetamines. WITHDRAWAL: alcohol, benzodiazepines, baclofen</li>
                        <li><strong>N</strong>eoplasm: Primary brain tumor, metastases (lung, breast, melanoma, renal)</li>
                        <li><strong>S</strong>tructural: Remote stroke, prior TBI, congenital malformation, mesial temporal sclerosis</li>
                    </ul>
                    
                    <p><span class="label">First Seizure Workup Approach:</span></p>
                    <ul>
                        <li><strong>Provoked Seizure:</strong> Clear reversible cause (metabolic, infection, drug). Treat cause, may not need chronic AED. Recurrence risk low if cause corrected</li>
                        <li><strong>Unprovoked Seizure:</strong> No identifiable acute cause. 40-50% recurrence risk. Consider starting AED after first unprovoked seizure, especially if: abnormal MRI, abnormal EEG, nocturnal seizure, focal seizure</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate Bedside:</span></p>
                    <ul>
                        <li><strong>Fingerstick Glucose:</strong> FIRST TEST - hypoglycemia (<40) causes seizures and is immediately reversible with D50. Never miss this</li>
                        <li><strong>Accucheck if on floor:</strong> While waiting for labs</li>
                    </ul>
                    
                    <p><span class="label">Labs (STAT):</span></p>
                    <ul>
                        <li><strong>BMP:</strong> Sodium (<120 causes seizures), calcium, magnesium, glucose, BUN/Cr (uremia)</li>
                        <li><strong>CBC:</strong> Infection, anemia</li>
                        <li><strong>LFTs:</strong> Hepatic encephalopathy</li>
                        <li><strong>Toxicology Screen:</strong> Cocaine, amphetamines, PCP</li>
                        <li><strong>Alcohol Level:</strong> If suspect withdrawal</li>
                        <li><strong>Anti-Epileptic Drug (AED) Levels:</strong> If known epileptic (phenytoin, valproate, carbamazepine). Levetiracetam levels not clinically useful</li>
                        <li><strong>Serum Prolactin:</strong> Peaks 10-20 min after seizure, normal by 60 min. >3√ó baseline supports seizure (but normal doesn't rule out). Not routinely needed</li>
                        <li><strong>CK:</strong> Rhabdomyolysis common after prolonged seizure (CK >1000 in 50%)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Non-Contrast CT Head:</strong> FIRST imaging - rules out bleed, mass, stroke. Get immediately if: first seizure, trauma, focal deficits, immunocompromised, persistent AMS</li>
                        <li><strong>MRI Brain:</strong> More sensitive for: hippocampal sclerosis, cortical dysplasia, small tumors, encephalitis, posterior reversible encephalopathy syndrome (PRES). Get within 24-48hr for first seizure</li>
                    </ul>
                    
                    <p><span class="label">Lumbar Puncture:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Fever, immunocompromised, concern for meningitis/encephalitis, first seizure with no clear cause</li>
                        <li><strong>Get CT first if:</strong> Focal deficits, papilledema, immunocompromised (to rule out mass/herniation risk)</li>
                        <li><strong>Send:</strong> Cell count, glucose, protein, Gram stain, culture, HSV PCR, consider autoimmune encephalitis panel</li>
                    </ul>
                    
                    <p><span class="label">EEG (Electroencephalogram):</span></p>
                    <ul>
                        <li><strong>Routine EEG (30 min):</strong> All first-time seizure patients. Identifies: epileptiform discharges (spikes, sharp waves), focal slowing (structural lesion), generalized slowing (encephalopathy). Yield increases if done within 24-48 hours</li>
                        <li><strong>Continuous EEG Monitoring:</strong>
                            <ul>
                                <li>Status epilepticus (confirms cessation after treatment)</li>
                                <li>Unexplained AMS in ICU (r/o non-convulsive status)</li>
                                <li>Burst suppression monitoring (if on pentobarbital/propofol for refractory status)</li>
                            </ul>
                        </li>
                        <li><strong>Limitations:</strong> Single EEG only captures epileptiform activity in 50% of epileptics. Repeat EEG or prolonged monitoring increases yield to 80-90%</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Active Seizure Management (Non-Status):</span></p>
                    <ul>
                        <li>Position on SIDE (prevent aspiration)</li>
                        <li>Protect from injury (pad head, move objects away)</li>
                        <li>Do NOT restrain</li>
                        <li>Do NOT place anything in mouth (can break teeth, cause aspiration)</li>
                        <li>Supplemental O2 via NC or face mask</li>
                        <li>Establish IV access</li>
                        <li>Most seizures self-terminate in 1-3 minutes</li>
                        <li><strong>If seizure >5 minutes ‚Üí STATUS EPILEPTICUS ‚Üí Start treatment algorithm</strong></li>
                    </ul>
                    
                    <p><span class="label">STATUS EPILEPTICUS TREATMENT ALGORITHM (Time-Sensitive!):</span></p>
                    
                    <p><strong>STAGE 1 (0-5 minutes): First-Line Benzodiazepines</strong></p>
                    <ul>
                        <li><strong>Lorazepam (Ativan):</strong> 4mg IV over 2 minutes. Repeat once if continued seizure after 5 min (max 8mg)
                            <ul>
                                <li>Preferred over diazepam (longer duration of action)</li>
                                <li>Success rate: 60-80%</li>
                            </ul>
                        </li>
                        <li><strong>OR Midazolam (Versed):</strong> 10mg IM (if no IV access - absorbed well IM)
                            <ul>
                                <li>Alternative: 0.2mg/kg IV (typical 10-15mg)</li>
                                <li>Faster onset than lorazepam</li>
                                <li>IM route as effective as IV lorazepam in prehospital setting</li>
                            </ul>
                        </li>
                        <li><strong>OR Diazepam (Valium):</strong> 10mg IV or 20mg PR (rectal gel - useful prehospital/nursing home)
                            <ul>
                                <li>Rapid onset but shorter duration than lorazepam</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>STAGE 2 (5-20 minutes): Second-Line Anti-Epileptic Drugs (If Benzos Fail)</strong></p>
                    <p>Choose ONE of the following:</p>
                    <ul>
                        <li><strong>Levetiracetam (Keppra):</strong> 60 mg/kg IV over 10 min (max 4500mg, typical dose 3000-4500mg)
                            <ul>
                                <li>Advantages: No drug interactions, safe profile, no cardiac monitoring needed, preferred by many</li>
                                <li>Disadvantages: May be slightly less effective than fosphenytoin (debated)</li>
                                <li>Side effects: Minimal. Rare psychiatric symptoms</li>
                            </ul>
                        </li>
                        <li><strong>Fosphenytoin:</strong> 20 PE/kg IV at max rate 150 PE/min (typical 1500-2000 PE, takes 10-15 min)
                            <ul>
                                <li>Advantages: Long track record, effective</li>
                                <li>Disadvantages: Cardiac monitoring required (bradycardia, hypotension, arrhythmias), purple glove syndrome, drug interactions (induces CYP450), can't use in heart block</li>
                                <li>Slower infusion if elderly or cardiac disease</li>
                                <li>Check ECG before and during infusion</li>
                            </ul>
                        </li>
                        <li><strong>Valproate (Depacon):</strong> 40 mg/kg IV over 10 min (max 3000mg)
                            <ul>
                                <li>Advantages: Well-tolerated, no cardiac effects</li>
                                <li>Disadvantages: Contraindicated in pregnancy (teratogenic), liver disease, pancreatitis history. Hyperammonemia, thrombocytopenia</li>
                            </ul>
                        </li>
                        <li><strong>Phenobarbital:</strong> 15 mg/kg IV at 50-100 mg/min
                            <ul>
                                <li>Advantages: Effective, cheap</li>
                                <li>Disadvantages: Sedation, respiratory depression (have airway equipment ready), long half-life</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>STAGE 3 (20-40 minutes): Refractory Status Epilepticus</strong></p>
                    <ul>
                        <li>If seizure continues despite 2 first-line agents ‚Üí REFRACTORY status</li>
                        <li><strong>Intubate for airway protection</strong> (will need continuous sedation)</li>
                        <li><strong>ICU admission</strong></li>
                        <li><strong>Continuous EEG monitoring</strong></li>
                        <li><strong>Choose continuous infusion:</strong>
                            <ul>
                                <li><strong>Midazolam:</strong> 0.2 mg/kg bolus, then 0.05-2 mg/kg/hr infusion
                                    <ul>
                                        <li>First-line for refractory status (preferred by most)</li>
                                        <li>Titrate to seizure cessation on EEG or burst suppression</li>
                                    </ul>
                                </li>
                                <li><strong>Propofol:</strong> 1-2 mg/kg bolus, then 20-200 mcg/kg/min (2-10 mg/kg/hr)
                                    <ul>
                                        <li>Rapid on/off</li>
                                        <li>Watch for propofol infusion syndrome (rhabdo, metabolic acidosis, cardiac arrest) if >48hr or high doses</li>
                                        <li>Check CK, lactate, triglycerides daily</li>
                                    </ul>
                                </li>
                                <li><strong>Pentobarbital:</strong> 5-15 mg/kg load over 1hr, then 0.5-10 mg/kg/hr
                                    <ul>
                                        <li>Most effective but most side effects</li>
                                        <li>Severe hypotension (need pressors), ileus</li>
                                        <li>Reserved for super-refractory status</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li><strong>Goal:</strong> Seizure suppression on EEG. Some aim for burst suppression (flat periods between bursts)</li>
                        <li><strong>Duration:</strong> 24-48 hours, then attempt to wean. If seizures recur ‚Üí another 24 hours</li>
                    </ul>
                    
                    <p><span class="label">Starting Maintenance Anti-Epileptic Drug (After First Unprovoked Seizure):</span></p>
                    <ul>
                        <li><strong>Levetiracetam (Keppra):</strong> 500mg BID, increase to 1000-1500mg BID
                            <ul>
                                <li>FIRST-LINE for most patients</li>
                                <li>No drug interactions, no monitoring needed</li>
                                <li>Side effects: Irritability, depression (10-15%)</li>
                            </ul>
                        </li>
                        <li><strong>Lamotrigine (Lamictal):</strong> Start 25mg daily, slow titration
                            <ul>
                                <li>Must titrate SLOWLY (increase by 25mg every 2 weeks)</li>
                                <li>Fast titration ‚Üí Stevens-Johnson syndrome risk</li>
                                <li>Good for generalized epilepsy, well-tolerated</li>
                                <li>Final dose: 200-400mg daily (divided BID)</li>
                            </ul>
                        </li>
                        <li><strong>Lacosamide (Vimpat):</strong> 50mg BID, increase to 200-400mg daily
                            <ul>
                                <li>Good for focal seizures</li>
                                <li>Side effects: Dizziness, ataxia, PR interval prolongation (check ECG)</li>
                            </ul>
                        </li>
                        <li><strong>Older Options (More Side Effects/Interactions):</strong>
                            <ul>
                                <li>Phenytoin: Gingival hyperplasia, hirsutism, CYP450 inducer, narrow therapeutic window</li>
                                <li>Carbamazepine: Hyponatremia (SIADH), aplastic anemia (rare), CYP450 inducer</li>
                                <li>Valproate: Weight gain, hair loss, tremor, hepatotoxicity, teratogenic</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Considerations:</span></p>
                    <ul>
                        <li><strong>Provoked Seizures (Reversible Cause):</strong>
                            <ul>
                                <li>Alcohol withdrawal: Benzos (lorazepam, diazepam), thiamine</li>
                                <li>Hyponatremia: Correct slowly (risk of osmotic demyelination). If <120 with seizure, can give 100mL 3% saline bolus</li>
                                <li>Hypoglycemia: D50 50mL IV push</li>
                                <li>Hypocalcemia: Calcium gluconate 1-2g IV</li>
                                <li>Isoniazid overdose: Pyridoxine (vitamin B6) gram-for-gram match to INH dose</li>
                            </ul>
                        </li>
                        <li><strong>Pregnancy (Eclampsia):</strong> Magnesium sulfate 4-6g IV load, then 1-2g/hr. If seizures continue ‚Üí lorazepam</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Status epilepticus = >5 minutes, not 30:</strong> Old definition was 30 min. Now ANY seizure >5 min = status. Start treatment aggressively - every minute increases risk of refractory status and permanent neuronal injury</li>
                    <li><strong>Benzos first, AED second:</strong> Don't skip benzos and go straight to fosphenytoin. Benzos stop 60-80% of seizures. Give lorazepam 4mg IV immediately</li>
                    <li><strong>Midazolam IM if no IV access:</strong> 10mg IM works as well as IV lorazepam. Don't delay trying to get IV - give IM midazolam immediately</li>
                    <li><strong>Non-convulsive status is common in ICU:</strong> 10-20% of unexplained AMS in ICU is NCSE on EEG. Have low threshold for continuous EEG monitoring</li>
                    <li><strong>Levetiracetam is now first-line AED:</strong> Safer, fewer interactions than phenytoin. Equally effective for status epilepticus (ESETT trial). Start with keppra for most patients</li>
                    <li><strong>Provoked seizures may not need chronic AED:</strong> If clear reversible cause (alcohol withdrawal, severe hyponatremia <120, hypoglycemia <40), treat the cause. May not need lifelong AED</li>
                    <li><strong>Check glucose ALWAYS:</strong> Hypoglycemia causes seizures and is immediately reversible with D50. Never miss this - it's the most treatable cause</li>
                    <li><strong>Lateral tongue bite is specific for seizure:</strong> Central tongue bite can happen with any loss of consciousness (syncope, head trauma). LATERAL tongue bite is specific for tonic-clonic seizure</li>
                    <li><strong>Propofol infusion syndrome is real:</strong> Rhabdomyolysis, metabolic acidosis, cardiac arrest. Risk with >48hr use or high doses (>80 mcg/kg/min). Check CK, lactate, triglycerides daily</li>
                    <li><strong>Don't start multiple AEDs simultaneously:</strong> Use monotherapy first. Only add second AED if inadequate seizure control on max tolerated dose of first. Polypharmacy increases side effects and interactions</li>
                    <li><strong>First unprovoked seizure has 40-50% recurrence risk:</strong> Consider starting AED, especially if: abnormal MRI, abnormal EEG, nocturnal seizure, patient has high-risk occupation (pilot, driver)</li>
                    <li><strong>Todd's paralysis mimics stroke:</strong> Post-ictal focal weakness lasting 24-48 hours. MRI/CT normal. Resolves completely. Don't give tPA for this</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status epilepticus (seizure >5 min or recurrent without baseline recovery)</li>
                        <li>Refractory status requiring continuous infusion (midazolam, propofol, pentobarbital)</li>
                        <li>Intubated for airway protection</li>
                        <li>Multiple seizures without return to baseline</li>
                        <li>Non-convulsive status on EEG requiring continuous monitoring</li>
                        <li>Hypoxia or respiratory compromise from seizure</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>No seizures √ó 24-48 hours</li>
                        <li>Back to neurologic baseline (or new baseline established if stroke/bleed)</li>
                        <li>Anti-epileptic drug started (if unprovoked seizure or epilepsy)</li>
                        <li>AED levels checked if applicable (phenytoin, valproate, carbamazepine)</li>
                        <li>Provoking factors addressed/corrected (alcohol withdrawal treated, electrolytes normalized)</li>
                        <li>Safe to drive per state law (typically 3-12 months seizure-free required - varies by state)</li>
                        <li>Fall precautions at home if recurrent seizure risk</li>
                        <li>Neurology follow-up arranged within 1-2 weeks</li>
                        <li>Patient educated on: taking AED daily (don't miss doses), avoiding seizure triggers (sleep deprivation, alcohol), seizure precautions (no swimming alone, no heights, caution with driving), when to call 911 (seizure >5 min)</li>
                        <li>MRI completed or scheduled (if first seizure)</li>
                        <li>EEG completed or scheduled</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Seizure Activity:</strong> Aspiration pneumonia (30-50% if prolonged seizure or decreased consciousness), rhabdomyolysis (CK >1000 in 50% of status epilepticus, can cause AKI), acute kidney injury (from rhabdomyolysis, hypotension), lactic acidosis (from muscle activity), hyperthermia (from muscle activity, increases neuronal injury), posterior shoulder dislocation (tonic phase - anterior more common in most trauma but posterior in seizures), vertebral compression fractures (from violent muscle contractions), oral trauma (tongue biting, broken teeth)</p>
                    <p><strong>From Status Epilepticus:</strong> Permanent neuronal injury if >30 minutes (excitotoxicity from glutamate), cerebral edema, Todd's paralysis (post-ictal focal weakness lasting 24-48hr, mimics stroke), cognitive impairment, development of refractory epilepsy, death (10-20% mortality for status epilepticus)</p>
                    <p><strong>From Treatment:</strong> Respiratory depression (benzodiazepines, barbiturates - have airway equipment ready), hypotension (propofol, phenytoin, barbiturates), propofol infusion syndrome (rhabdo, acidosis, cardiac arrest after >48hr high-dose propofol), cardiac arrhythmias (phenytoin - especially if infused too fast), purple glove syndrome (phenytoin extravasation causing limb ischemia), hepatotoxicity (valproate), thrombocytopenia (valproate), hyponatremia (carbamazepine causing SIADH), Steven-Johnson syndrome (lamotrigine if titrated too fast, carbamazepine)</p>
                    <p><strong>Psychosocial:</strong> Loss of driving privileges (state-dependent, typically 3-12 months seizure-free required), job limitations (can't be pilot, commercial driver, work at heights), stigma, depression (30% of epileptics), medication non-adherence (leading cause of breakthrough seizures)</p>
                    <p><strong>SUDEP (Sudden Unexpected Death in Epilepsy):</strong> 1 in 1000 epilepsy patients per year. Higher risk if: poorly controlled seizures, generalized tonic-clonic, young age, non-adherence to AEDs, nocturnal seizures. Mechanism: likely cardiac arrhythmia or respiratory arrest during seizure</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- CONDITIONS 26-40 - Complete but streamlined for token efficiency -->
        
        <!-- CONDITION 26: BACTERIAL MENINGITIS - EXPANDED -->
        <div id="meningitis" class="condition-page">
            <div class="page-header">
                <h2>26. BACTERIAL MENINGITIS</h2>
                <div class="subtitle">CNS Emergency ‚Ä¢ Give Antibiotics BEFORE LP ‚Ä¢ Dexamethasone</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad (44% have all 3):</span> Fever + headache + nuchal rigidity. 95% have ‚â•2 of: fever, headache, stiff neck, altered mental status</p>
                    <p><span class="label">Physical Exam:</span> Nuchal rigidity (passive neck flexion causes resistance), Kernig sign (hip flexed 90¬∞ then extend knee ‚Üí pain/resistance), Brudzinski sign (neck flexion ‚Üí involuntary hip flexion), jolt accentuation (turning head worsens HA). Altered MS 69%, focal deficits 10-30%, seizures 20-30%, papilledema rare (<1%). Petechial/purpuric rash = N. meningitidis</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly/Immunocompromised:</strong> Subtle - only AMS, weakness, falls. May lack fever/meningismus. Low threshold for LP</li>
                        <li><strong>Listeria (>50yo, pregnant, immunocompromised):</strong> More indolent. May have rhombencephalitis (brainstem - ataxia, CN palsies). Unpasteurized dairy/deli meats</li>
                        <li><strong>Meningococcemia:</strong> Fulminant - petechiae/purpura, shock, DIC, multi-organ failure. Health-to-death <24hr. Waterhouse-Friderichsen (adrenal hemorrhage)</li>
                        <li><strong>Post-neurosurgery/VP shunt:</strong> Healthcare-associated (S. aureus, coag-neg Staph, Pseudomonas). Fever + HA = shunt infection until proven otherwise</li>
                        <li><strong>Partially treated:</strong> Prior antibiotics (even 1-2 doses oral) sterilize CSF culture but leave inflammatory profile. Use PCR. Treat as bacterial</li>
                        <li><strong>Chronic meningitis (>4 weeks):</strong> TB, fungal (Cryptococcus in HIV), Lyme, syphilis, malignancy. Lymphocytic CSF</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">CRITICAL PRINCIPLE:</span> <strong>DO NOT DELAY ANTIBIOTICS for LP or CT!</strong> Door-to-antibiotic <1 hour improves outcomes. Antibiotics before LP don't affect yield if LP within 2-4 hours</p>
                    
                    <p><span class="label">CT Head BEFORE LP if:</span> Immunocompromised, history CNS disease, new seizure (<1 week), papilledema, GCS ‚â§10, focal deficit. Algorithm: Give antibiotics ‚Üí CT ‚Üí LP. If mass effect on CT, discuss LP with neurology</p>
                    
                    <p><span class="label">LP Procedure:</span> Lateral (measure OP) or sitting. L3-L4 or L4-L5. Opening pressure with manometer (normal 10-20 cm H2O, bacterial >25). Collect 4 tubes: (1) Gram/culture/PCR, (2) glucose/protein, (3) cell count/diff, (4) hold for extras. Traumatic tap: subtract 1 WBC per 700 RBCs</p>
                    
                    <p><span class="label">CSF Interpretation - Bacterial vs Viral:</span></p>
                    <ul>
                        <li><strong>Bacterial:</strong> WBC >1000 (often >5000), PMN >80%, glucose <40 or <50% serum, protein >200 (often >1000), opening pressure >25</li>
                        <li><strong>Viral:</strong> WBC 10-500, lymphs >50%, glucose normal (>45), protein 50-100</li>
                        <li><strong>Normal:</strong> WBC 0-5, glucose 50-80, protein 15-45</li>
                    </ul>
                    
                    <p><span class="label">CSF Studies:</span> Cell count/diff, glucose (+ simultaneous serum glucose for ratio), protein, Gram stain (60-90% positive depending on organism), culture (gold standard, 24-48hr), PCR/BioFire FilmArray (rapid ~1hr, detects S. pneumo, N. meningitidis, H. flu, Listeria, viruses - helpful when antibiotics given before LP), CSF lactate (>4 mmol/L = bacterial, 95% sens/spec). Add AFB/TB PCR, fungal culture, Crypto Ag, VDRL, Lyme if chronic presentation</p>
                    
                    <p><span class="label">Blood Studies:</span> Cultures √ó 2 (positive 50-80%), CBC (leukocytosis, bands, thrombocytopenia if DIC), BMP (hyponatremia from SIADH common), coags if DIC suspected, lactate, serum glucose (for CSF ratio), procalcitonin (>0.5 suggests bacterial)</p>
                    
                    <p><span class="label">Common Pathogens by Age:</span></p>
                    <ul>
                        <li><strong>Adults <50yo:</strong> S. pneumoniae (50%), N. meningitidis (25%), rarely H. influenzae</li>
                        <li><strong>Adults ‚â•50yo:</strong> S. pneumoniae, Listeria, gram-negatives (E. coli, Klebsiella)</li>
                        <li><strong>Post-neurosurgery/shunt:</strong> S. aureus/epidermidis, Pseudomonas, Acinetobacter</li>
                        <li><strong>Immunocompromised:</strong> Listeria, gram-negatives, Cryptococcus, TB</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC ANTIBIOTICS (START IMMEDIATELY, Within 1 Hour):</span></p>
                    <ul>
                        <li><strong>Adults <50yo, immunocompetent:</strong> Vancomycin 15-20 mg/kg IV q8-12h + Ceftriaxone 2g IV q12h (or Cefotaxime 2g q4-6h). Covers S. pneumo (including resistant), N. meningitidis, H. flu</li>
                        <li><strong>Adults ‚â•50yo OR immunocompromised OR alcoholism:</strong> Add Ampicillin 2g IV q4h for Listeria coverage. Triple therapy: Vanc + Ceftriaxone + Ampicillin</li>
                        <li><strong>Post-neurosurgery/VP shunt:</strong> Vancomycin + Cefepime 2g IV q8h (or Meropenem 2g q8h) for Pseudomonas coverage</li>
                        <li><strong>Severe PCN allergy:</strong> Vancomycin + Moxifloxacin 400mg IV daily. Can use Aztreonam + Moxifloxacin if needed</li>
                    </ul>
                    
                    <p><span class="label">DEXAMETHASONE:</span> 10mg IV q6h √ó 4 days. MUST give BEFORE or WITH first antibiotic dose (not after). Reduces mortality/hearing loss in pneumococcal meningitis. Discontinue if organism not S. pneumoniae</p>
                    
                    <p><span class="label">Targeted Therapy (once organism/sensitivities known):</span></p>
                    <ul>
                        <li><strong>S. pneumoniae PCN-sensitive (MIC <0.06):</strong> Penicillin G 4 million units IV q4h. If resistant: continue Vanc + Ceftriaxone. Duration 10-14 days. Continue dexamethasone √ó 4d</li>
                        <li><strong>N. meningitidis:</strong> Ceftriaxone 2g IV q12h √ó 7 days (or Penicillin G if sensitive). Droplet precautions √ó 24hr after antibiotics. Chemoprophylaxis close contacts: Cipro 500mg PO √ó 1 or Ceftriaxone 250mg IM √ó 1</li>
                        <li><strong>Listeria:</strong> Ampicillin 2g IV q4h + Gentamicin 5-7 mg/kg IV daily √ó 21 days (synergy). TMP-SMX 5 mg/kg IV q8h if PCN allergy. Don't use ceftriaxone (no Listeria coverage)</li>
                        <li><strong>H. influenzae:</strong> Ceftriaxone 2g IV q12h √ó 7-10 days</li>
                        <li><strong>Pseudomonas:</strong> Cefepime 2g IV q8h or Meropenem 2g IV q8h √ó 21 days. Consider intrathecal/intraventricular aminoglycoside if refractory</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>ICP management:</strong> Elevate HOB 30¬∞, avoid hypotonic fluids, treat fever/pain aggressively. If severe ‚ÜëICP: Mannitol 0.25-1 g/kg IV or 3% saline bolus. Neurosurgery for ventriculostomy if hydrocephalus</li>
                        <li><strong>Seizures:</strong> Treat acutely (lorazepam 2-4mg IV). Prophylactic AEDs not recommended unless seizure occurred. Load levetiracetam if recurrent</li>
                        <li><strong>SIADH (common):</strong> Fluid restrict 1-1.5 L/day. Hypertonic saline if severe symptomatic hyponatremia (Na <120, seizures, severe AMS)</li>
                        <li><strong>Isolation:</strong> Droplet precautions for N. meningitidis until 24hr after antibiotics. Standard precautions for other organisms</li>
                    </ul>
                    
                    <p><span class="label">Repeat LP at 48hr if:</span> Persistent fever, worsening neurologic status, concern for resistant organism. Should see ‚ÜìWBC, ‚Üìprotein, sterile cultures</p>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Antibiotics before LP saves lives:</strong> Every hour delay increases mortality. If high suspicion, give empiric antibiotics immediately - don't wait. Diagnostic yield minimally affected if LP within 2-4 hours</li>
                    <li><strong>Classic triad is the minority:</strong> Only 44% have fever + HA + stiff neck. 95% have ‚â•2 of: fever, HA, stiff neck, AMS. Don't wait for "classic" presentation</li>
                    <li><strong>Dexamethasone timing critical:</strong> BEFORE or WITH first antibiotic (not after). Reduces mortality/hearing loss in pneumococcal. Don't forget it!</li>
                    <li><strong>Low CSF glucose = bacterial:</strong> CSF glucose <40 or <50% serum highly specific for bacterial meningitis. Viral/aseptic has normal glucose</li>
                    <li><strong>PCR is game-changer:</strong> BioFire results ~1hr vs 24-48hr culture. Helpful when antibiotics given before LP. High sensitivity/specificity</li>
                    <li><strong>Listeria loves extremes:</strong> Neonates, elderly >50, pregnant, immunocompromised. MUST add ampicillin empirically - ceftriaxone doesn't cover Listeria</li>
                    <li><strong>Meningococcus kills fast:</strong> Petechial rash + shock = urgent antibiotics + ICU + prophylaxis contacts (Cipro 500mg √ó 1). Health-to-death <24hr</li>
                    <li><strong>Shunt infection = neurosurgery consult:</strong> Fever + HA in VP shunt = infection until proven otherwise. Often coag-neg Staph. Needs vancomycin + shunt removal/externalization</li>
                    <li><strong>Hearing screen everyone:</strong> 30% get hearing loss with pneumococcal meningitis. Audiology screening before discharge + follow-up mandatory</li>
                    <li><strong>Normal CT doesn't rule out ‚ÜëICP:</strong> CT may be normal even with elevated ICP from meningitis. Only delays LP if mass effect/shift. Give antibiotics first!</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>GCS <12 or rapidly declining mental status</li>
                        <li>Hemodynamic instability requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Refractory or recurrent seizures</li>
                        <li>Signs of increased ICP (Cushing triad, papilledema)</li>
                        <li>Need for ICP monitoring or ventriculostomy</li>
                        <li>Meningococcemia with septic shock/DIC</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile >24-48 hours off antibiotics</li>
                        <li>Clinical improvement (HA resolving, AMS cleared, ambulating)</li>
                        <li>Tolerating PO intake</li>
                        <li>Neurologic exam stable or improved</li>
                        <li>Completed appropriate IV antibiotic duration (7-21d depending on organism)</li>
                        <li>CSF sterilized if repeat LP performed</li>
                        <li>Hearing screen performed (audiology follow-up arranged)</li>
                        <li>Close outpatient follow-up with ID/neurology</li>
                        <li>No complications requiring ongoing inpatient management</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Neurologic:</strong> Seizures (20-30% - treat acutely, consider prophylaxis if recurrent), stroke (15% from vasculitis/venous thrombosis), brain abscess, subdural empyema, ventriculitis, cerebral edema with herniation, hydrocephalus (communicating or obstructive requiring VP shunt), cranial nerve palsies (CN VI, VII, VIII most common - especially hearing loss)</p>
                    <p><strong>Systemic Complications:</strong> Septic shock (especially meningococcemia), DIC with bleeding, ARDS requiring mechanical ventilation, multi-organ failure, adrenal crisis (Waterhouse-Friderichsen syndrome in meningococcemia), SIADH with severe hyponatremia</p>
                    <p><strong>Long-term Sequelae:</strong> Sensorineural hearing loss (30% with S. pneumoniae - permanent, requires hearing aids/cochlear implants), cognitive impairment (memory, executive function), motor deficits/hemiparesis, post-infectious epilepsy, hydrocephalus requiring permanent shunt</p>
                    <p><strong>Mortality:</strong> Overall 15-20%. S. pneumoniae 20-30%, N. meningitidis 5-10%, Listeria 20-30%, gram-negatives 20-40%. Poor prognostic factors: elderly, delayed treatment, GCS <10, seizures, shock, focal deficits</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 27: ANEMIA - EXPANDED -->
        <div id="anemia" class="condition-page">
            <div class="page-header">
                <h2>27. ANEMIA</h2>
                <div class="subtitle">Microcytic ‚Ä¢ Normocytic ‚Ä¢ Macrocytic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">General Symptoms (severity depends on acuity and degree):</span> Fatigue, weakness, dyspnea on exertion, dizziness, headache, tinnitus, palpitations, chest pain (angina if severe anemia + CAD). Pallor (conjunctivae, palmar creases), tachycardia, systolic flow murmur, orthostatic hypotension if acute blood loss</p>
                    
                    <p><span class="label">Alternate Presentations by Etiology:</span></p>
                    <ul>
                        <li><strong>Iron Deficiency:</strong> Koilonychia (spoon nails), glossitis, angular cheilitis, pica (ice chips/starch/dirt craving), restless leg syndrome, dysphagia (Plummer-Vinson syndrome with esophageal webs)</li>
                        <li><strong>B12 Deficiency:</strong> Neurologic symptoms - paresthesias (glove-stocking), ataxia, decreased proprioception/vibratory sense, dementia, psychiatric changes. Glossitis (beefy red tongue). Subacute combined degeneration of spinal cord (dorsal columns + lateral corticospinal tracts)</li>
                        <li><strong>Folate Deficiency:</strong> Similar to B12 but NO neurologic symptoms. Glossitis, diarrhea. Often in alcoholics, malnutrition</li>
                        <li><strong>Hemolysis:</strong> Jaundice (‚Üëunconjugated bilirubin), dark urine (hemoglobinuria), splenomegaly. If intravascular: hemoglobinuria, hemosiderinuria. If extravascular: splenomegaly, gallstones (pigmented)</li>
                        <li><strong>Acute Blood Loss:</strong> Tachycardia, hypotension, orthostatic changes, melena/hematochezia (GI bleed), hematemesis, vaginal bleeding. Hgb may be normal initially (takes hours for equilibration)</li>
                        <li><strong>Anemia of Chronic Disease:</strong> Underlying inflammatory condition (RA, IBD, malignancy, CKD). Usually mild-moderate anemia (Hgb 9-11)</li>
                        <li><strong>Thalassemia:</strong> Mild microcytic anemia often asymptomatic. Family history Mediterranean/Asian descent. Splenomegaly if thalassemia major</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Initial Labs:</span> CBC with differential, reticulocyte count (assess bone marrow response), peripheral smear, iron studies, B12/folate, LDH/haptoglobin/bilirubin (if hemolysis suspected)</p>
                    
                    <p><span class="label">Approach by MCV (Mean Corpuscular Volume):</span></p>
                    
                    <p><strong>MICROCYTIC (MCV <80 fL) - "TAILS":</strong></p>
                    <ul>
                        <li><strong>Thalassemia:</strong> Hgb electrophoresis (‚ÜëHbA2 in Œ≤-thal trait), family hx, ethnicity. MCV often <75, RBC count elevated despite low Hgb (RBC >5 million). RDW normal. Mentzer index (MCV/RBC count) <13 suggests thalassemia</li>
                        <li><strong>Anemia of chronic disease:</strong> Ferritin elevated (>100) or normal, TIBC low, transferrin saturation low-normal. Inflammatory markers elevated (CRP, ESR). Look for underlying chronic condition</li>
                        <li><strong>Iron deficiency:</strong> Ferritin <30 ng/mL (most specific). Serum iron low, TIBC elevated, transferrin saturation <20%. RDW elevated. Peripheral smear: hypochromic microcytic cells, pencil cells. Investigate source of blood loss (GI workup if no obvious source)</li>
                        <li><strong>Lead poisoning:</strong> Basophilic stippling on smear, elevated blood lead level. Occupational exposure, pica</li>
                        <li><strong>Sideroblastic anemia:</strong> Ring sideroblasts on bone marrow. Elevated ferritin, normal/high iron. Causes: alcohol, isoniazid, lead, copper deficiency, myelodysplasia</li>
                    </ul>
                    
                    <p><strong>NORMOCYTIC (MCV 80-100 fL):</strong></p>
                    <ul>
                        <li><strong>Check reticulocyte count to distinguish:</strong></li>
                        <li><strong>Elevated reticulocyte count (>2-3%) = Appropriate Response:</strong>
                            <ul>
                                <li><strong>Acute blood loss:</strong> Obvious source (GI bleed, trauma, surgery, menorrhagia). Hgb may be normal initially</li>
                                <li><strong>Hemolysis:</strong> Elevated LDH, low haptoglobin, elevated indirect bilirubin, +/- hemoglobinuria. Smear: schistocytes (TTP, HUS, DIC, mechanical valves), spherocytes (autoimmune, hereditary spherocytosis), sickle cells, bite cells (G6PD). Coombs test for autoimmune hemolytic anemia</li>
                            </ul>
                        </li>
                        <li><strong>Low reticulocyte count (<2%) = Inadequate Response:</strong>
                            <ul>
                                <li><strong>Anemia of chronic disease/inflammation:</strong> Ferritin normal/high, low TIBC. Underlying chronic illness (CKD, cancer, infection, autoimmune)</li>
                                <li><strong>CKD:</strong> Low EPO production. Cr elevated, usually Hgb 9-11. Start EPO if Hgb <10</li>
                                <li><strong>Bone marrow failure:</strong> Pancytopenia (‚ÜìWBC, ‚Üìplatelets, ‚ÜìRBC). Aplastic anemia, myelodysplasia, leukemia, myelofibrosis. Needs bone marrow biopsy</li>
                                <li><strong>Early iron/B12/folate deficiency:</strong> May be normocytic before becoming micro/macrocytic. Check iron studies, B12, folate</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>MACROCYTIC (MCV >100 fL):</strong></p>
                    <ul>
                        <li><strong>B12 deficiency:</strong> B12 <200 pg/mL (or <300 if high clinical suspicion). Elevated methylmalonic acid and homocysteine (more sensitive). Hypersegmented neutrophils on smear. Causes: pernicious anemia (anti-IF antibodies), malabsorption (Crohn's, celiac, gastric bypass), strict vegan diet, metformin</li>
                        <li><strong>Folate deficiency:</strong> Folate <2 ng/mL. Elevated homocysteine but normal methylmalonic acid. No neurologic symptoms (vs B12). Causes: poor diet (alcoholics, elderly), malabsorption, medications (methotrexate, phenytoin, TMP-SMX), pregnancy/lactation (increased demand)</li>
                        <li><strong>Alcohol:</strong> Direct marrow suppression. Often with folate deficiency. MCV 100-110. Elevated GGT, AST>ALT</li>
                        <li><strong>Hypothyroidism:</strong> Check TSH. MCV usually 100-110</li>
                        <li><strong>Medications:</strong> Hydroxyurea, zidovudine (AZT), azathioprine, 5-FU, methotrexate</li>
                        <li><strong>Myelodysplastic syndrome (MDS):</strong> Elderly, refractory anemia, dysplastic cells on smear, cytopenias. Bone marrow biopsy shows dysplasia. Risk of transformation to AML</li>
                        <li><strong>Reticulocytosis:</strong> Young RBCs are larger. If brisk hemolysis/blood loss with appropriate reticulocyte response, MCV may be elevated</li>
                    </ul>
                    
                    <p><span class="label">Additional Workup for Specific Situations:</span></p>
                    <ul>
                        <li><strong>GI workup if iron deficiency with no obvious source:</strong> EGD + colonoscopy to evaluate for occult GI bleeding (gastritis, ulcer, colon cancer, AVM). Celiac serologies. H. pylori testing</li>
                        <li><strong>Hemolysis workup:</strong> Coombs (direct antiglobulin test) for autoimmune hemolytic anemia. G6PD level (if bite cells, acute hemolysis after oxidative stress). Osmotic fragility (hereditary spherocytosis). PNH flow cytometry if intravascular hemolysis</li>
                        <li><strong>Bone marrow biopsy if:</strong> Pancytopenia, suspected malignancy (leukemia, lymphoma, myeloma), unexplained anemia, MDS suspected</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Transfusion Thresholds:</span></p>
                    <ul>
                        <li><strong>Stable, no CAD:</strong> Transfuse if Hgb <7 g/dL (restrictive strategy)</li>
                        <li><strong>CAD or high cardiac risk:</strong> Transfuse if Hgb <8 g/dL</li>
                        <li><strong>Acute MI/ACS:</strong> Transfuse if Hgb <10 g/dL (some say <8, controversial - individualize)</li>
                        <li><strong>Symptomatic (dyspnea, angina, orthostasis):</strong> Transfuse regardless of Hgb if symptomatic</li>
                        <li><strong>Chronic anemia:</strong> Often tolerate lower Hgb (compensatory mechanisms). Treat underlying cause, transfuse only if symptomatic or Hgb <7</li>
                        <li><strong>Each unit pRBC raises Hgb by ~1 g/dL</strong> (or Hct by ~3%)</li>
                    </ul>
                    
                    <p><span class="label">Specific Treatments by Etiology:</span></p>
                    
                    <p><strong>Iron Deficiency:</strong></p>
                    <ul>
                        <li><strong>Oral iron (first-line):</strong> Ferrous sulfate 325mg PO TID (65mg elemental iron per tablet). Take on empty stomach with vitamin C (enhances absorption). Common SE: constipation, dark stools, nausea. Response in 2-4 weeks (‚Üëreticulocytes), full repletion 3-6 months. Continue 3 months after Hgb normalized to replete stores</li>
                        <li><strong>IV iron (if oral intolerance, malabsorption, CKD, need rapid repletion):</strong> Iron sucrose 200mg IV √ó 5 doses or Ferric carboxymaltose 750mg IV √ó 2 doses or Iron dextran (test dose required). Risk: anaphylaxis (rare with newer formulations), hypophosphatemia</li>
                        <li><strong>Treat underlying cause:</strong> GI bleeding (PPI for ulcer, colonoscopy for polyp/cancer removal), menorrhagia (NSAIDs, OCPs, IUD, ablation)</li>
                    </ul>
                    
                    <p><strong>B12 Deficiency:</strong></p>
                    <ul>
                        <li><strong>Cyanocobalamin 1000 mcg IM daily √ó 7 days, then weekly √ó 4 weeks, then monthly lifelong</strong> (if pernicious anemia or malabsorption)</li>
                        <li><strong>Oral B12 1000-2000 mcg daily:</strong> Alternative if dietary deficiency or mild malabsorption (compliance issue - less reliable)</li>
                        <li><strong>Neurologic symptoms may be irreversible if prolonged deficiency:</strong> Treat urgently</li>
                        <li><strong>NEVER give folate without B12</strong> in macrocytic anemia - can worsen B12 neuropathy!</li>
                    </ul>
                    
                    <p><strong>Folate Deficiency:</strong></p>
                    <ul>
                        <li><strong>Folic acid 1mg PO daily √ó 1-4 months</strong> until replete</li>
                        <li><strong>Treat underlying cause:</strong> Alcohol cessation, improve diet</li>
                        <li><strong>Pregnancy:</strong> All women of childbearing age should take 400-800 mcg daily (prevent neural tube defects)</li>
                    </ul>
                    
                    <p><strong>Anemia of Chronic Disease:</strong></p>
                    <ul>
                        <li><strong>Treat underlying condition</strong> (control inflammation, treat cancer, manage CKD)</li>
                        <li><strong>If concurrent iron deficiency</strong> (ferritin <100 in setting of inflammation): IV iron (oral poorly absorbed)</li>
                        <li><strong>EPO (erythropoietin):</strong> If CKD with Hgb <10, or cancer-related anemia. Epoetin alfa 50-100 units/kg SC 3√ó/week. Target Hgb 10-11 (don't overcorrect - ‚Üëthrombosis risk). Requires adequate iron stores</li>
                    </ul>
                    
                    <p><strong>Hemolytic Anemia:</strong></p>
                    <ul>
                        <li><strong>Autoimmune (warm AIHA):</strong> Prednisone 1mg/kg daily, taper over weeks-months. If refractory: Rituximab, IVIG, splenectomy. Folic acid 1mg daily (increased RBC turnover)</li>
                        <li><strong>Cold agglutinin disease:</strong> Avoid cold exposure. Rituximab. Don't transfuse unless life-threatening (can worsen hemolysis)</li>
                        <li><strong>G6PD deficiency:</strong> Avoid oxidative triggers (sulfa drugs, dapsone, antimalarials, fava beans). Supportive care, transfuse if severe</li>
                        <li><strong>TTP:</strong> URGENT plasmapheresis (see TTP section)</li>
                    </ul>
                    
                    <p><strong>Thalassemia:</strong></p>
                    <ul>
                        <li><strong>Trait (minor):</strong> No treatment needed. Avoid unnecessary iron supplementation. Genetic counseling</li>
                        <li><strong>Major:</strong> Chronic transfusions (maintain Hgb >9-10), iron chelation (deferoxamine, deferasirox) to prevent iron overload. Splenectomy if hypersplenism. Bone marrow transplant curative</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>MCV is your roadmap:</strong> Microcytic ‚Üí think iron/thalassemia/chronic disease. Normocytic ‚Üí check retic count (high = bleeding/hemolysis, low = bone marrow problem). Macrocytic ‚Üí B12/folate/alcohol/hypothyroid</li>
                    <li><strong>Ferritin <30 = iron deficiency:</strong> Most specific test. But ferritin is acute phase reactant - may be falsely normal/elevated with inflammation. If ferritin 30-100 with chronic disease, still suspect iron deficiency</li>
                    <li><strong>RDW helps distinguish:</strong> High RDW = iron deficiency (mixed cell sizes). Normal RDW = thalassemia, chronic disease (uniform small cells)</li>
                    <li><strong>Thalassemia has HIGH RBC count:</strong> Despite low Hgb/MCV, RBC count often >5 million (vs iron deficiency with low RBC count). Mentzer index <13 suggests thalassemia</li>
                    <li><strong>B12 deficiency causes neuro symptoms, folate doesn't:</strong> Paresthesias, ataxia, dementia = B12. Never give folate without checking B12 first in macrocytic anemia - can worsen neuropathy!</li>
                    <li><strong>Acute blood loss: Hgb lags:</strong> Initial Hgb may be normal because both RBCs and plasma lost equally. Takes hours for equilibration. Treat based on clinical status (hypotension, tachycardia)</li>
                    <li><strong>Hemolysis triad:</strong> Elevated LDH + low haptoglobin + elevated indirect bilirubin. If all three present, hemolysis confirmed. Then figure out cause (Coombs, smear)</li>
                    <li><strong>Restrictive transfusion saves lives:</strong> Transfuse <7 in stable patients (or <8 if CAD). Overtransfusion increases mortality, volume overload, immunosuppression</li>
                    <li><strong>Each unit pRBC raises Hgb ~1 g/dL:</strong> Don't transfuse more than needed. Reassess after each unit</li>
                    <li><strong>Iron pills cause constipation/GI upset:</strong> Take with food if intolerant (absorption slightly decreased but better than not taking). Try every-other-day dosing (absorption actually better). Black stools are expected</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Hemodynamic instability (hypotension, tachycardia unresponsive to fluids/transfusion)</li>
                        <li>Active massive hemorrhage requiring massive transfusion protocol</li>
                        <li>Severe symptomatic anemia (Hgb <5-6) with angina, AMS, respiratory distress</li>
                        <li>TTP/HUS with neurologic changes or renal failure</li>
                        <li>Severe autoimmune hemolytic anemia with rapid decompensation</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable</li>
                        <li>Hgb stable or improving</li>
                        <li>No active bleeding</li>
                        <li>Tolerating PO intake (including iron/B12 if applicable)</li>
                        <li>Underlying cause identified and treated (or plan in place)</li>
                        <li>Appropriate outpatient follow-up arranged (PCP, hematology, GI)</li>
                        <li>Patient educated on medications, dietary recommendations</li>
                        <li>Transfusion reactions ruled out if transfused</li>
                        <li>Safe for discharge from functional standpoint</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> High-output heart failure (severe chronic anemia - Hgb <6-7 with inadequate compensation), angina/MI (demand ischemia from anemia in patient with CAD), syncope, falls (orthostasis, weakness), transfusion reactions (see transfusion section)</p>
                    <p><strong>From Iron Deficiency:</strong> Restless leg syndrome (improves with iron repletion), cognitive impairment (especially children), increased risk infection (impaired immune function), pica complications (lead poisoning from paint chips, bowel obstruction)</p>
                    <p><strong>From B12 Deficiency:</strong> Irreversible neurologic damage (subacute combined degeneration - ataxia, spasticity, paresthesias), dementia, depression, increased homocysteine ‚Üí thrombosis risk</p>
                    <p><strong>From Treatment:</strong> Iron overload (chronic transfusions - hemochromatosis, cardiac/liver damage, requires chelation), transfusion reactions, infection from immunosuppression (rituximab, steroids for AIHA)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 28: NEUTROPENIC FEVER - EXPANDED -->
        <div id="neutropenic-fever" class="condition-page">
            <div class="page-header">
                <h2>28. NEUTROPENIC FEVER</h2>
                <div class="subtitle">Oncologic Emergency ‚Ä¢ Empiric Antibiotics Within 1 Hour</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Single oral temperature ‚â•38.3¬∞C (101¬∞F) OR temperature ‚â•38¬∞C (100.4¬∞F) for ‚â•1 hour WITH absolute neutrophil count (ANC) <500 cells/¬µL OR ANC expected to decline to <500 within 48 hours</p>
                    <p><span class="label">Calculation:</span> ANC = WBC √ó (% neutrophils + % bands) / 100</p>
                    
                    <p><span class="label">Typical Presentation:</span> Fever may be ONLY sign of infection (neutropenic patients lack inflammatory response - no pus, minimal symptoms). Subtle findings: mild hypotension, tachycardia, confusion. Absence of fever does NOT rule out infection</p>
                    
                    <p><span class="label">Common Sources (often no clear source found 50-60%):</span></p>
                    <ul>
                        <li><strong>GI tract (most common):</strong> Oral mucositis, esophagitis, typhlitis (cecal inflammation), C. diff, perirectal abscess</li>
                        <li><strong>Lungs:</strong> Pneumonia (bacterial, fungal - Aspergillus, PCP)</li>
                        <li><strong>Skin/soft tissue:</strong> Cellulitis, catheter site infection, perirectal abscess</li>
                        <li><strong>Bloodstream:</strong> Catheter-related bloodstream infection (CRBSI - coag-neg Staph, S. aureus)</li>
                        <li><strong>Urinary tract:</strong> Less common (neutrophils needed for pyuria - may have negative UA despite UTI)</li>
                        <li><strong>Sinusitis:</strong> Especially if prolonged neutropenia (fungal - Mucor, Aspergillus)</li>
                    </ul>
                    
                    <p><span class="label">Alternate/High-Risk Presentations:</span></p>
                    <ul>
                        <li><strong>Septic shock:</strong> Hypotension, tachycardia, AMS, lactate elevation. Requires urgent resuscitation + antibiotics</li>
                        <li><strong>Typhlitis (neutropenic enterocolitis):</strong> RLQ pain, diarrhea, distension. CT shows bowel wall thickening cecum/ascending colon. High mortality if perforation. Needs surgical consult</li>
                        <li><strong>Perirectal abscess:</strong> Severe perianal pain, tenderness. Often NO fluctuance (neutropenic - can't form pus). Needs exam under anesthesia + drainage + antibiotics</li>
                        <li><strong>Invasive fungal infection (if prolonged neutropenia >7-10 days):</strong> Persistent fever despite antibiotics. Aspergillus (pulmonary nodules, halo sign on CT), Candida (bloodstream, hepatosplenic candidiasis), Mucormycosis (sinusitis, black eschar)</li>
                        <li><strong>Atypical pneumonia:</strong> PCP (HIV/lymphoma), CMV, viral (RSV, influenza)</li>
                        <li><strong>CNS infection:</strong> Headache, AMS, focal deficits. Listeria, Aspergillus, Toxoplasma, Cryptococcus</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs (STAT):</span></p>
                    <ul>
                        <li><strong>CBC with differential:</strong> Confirm ANC. Trend daily. Platelets (thrombocytopenia common)</li>
                        <li><strong>Blood cultures √ó 2 sets:</strong> One from EACH lumen of central line (if present) + peripheral. Label which lumen. Positive in 20-30%</li>
                        <li><strong>CMP:</strong> Renal function (for antibiotic dosing), electrolytes, LFTs</li>
                        <li><strong>Lactate:</strong> If concern for sepsis</li>
                        <li><strong>UA with culture:</strong> Even if UA negative (neutropenia ‚Üí may not have WBCs in urine despite UTI)</li>
                        <li><strong>Stool culture, C. diff if diarrhea</strong></li>
                        <li><strong>Procalcitonin:</strong> May help distinguish bacterial vs non-bacterial (not routinely recommended)</li>
                        <li><strong>Fungal markers if prolonged fever (>4-7 days) or high risk:</strong> Serum (1‚Üí3)-Œ≤-D-glucan (Candida, Aspergillus, PCP), Galactomannan (Aspergillus), Cryptococcal antigen</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Chest X-ray:</strong> All patients. But CXR may be normal early (neutropenia ‚Üí no infiltrate). If negative but respiratory symptoms, get CT chest</li>
                        <li><strong>CT Chest (if respiratory symptoms, hypoxia, or persistent fever):</strong> More sensitive for pneumonia, fungal nodules. Look for: infiltrates, nodules, halo sign (Aspergillus), cavitation</li>
                        <li><strong>CT Abdomen/Pelvis (if abdominal pain or no clear source):</strong> Evaluate for typhlitis, abscess, colitis</li>
                        <li><strong>CT Sinuses (if sinus symptoms, especially prolonged neutropenia):</strong> Rule out invasive fungal sinusitis</li>
                    </ul>
                    
                    <p><span class="label">Other Studies:</span></p>
                    <ul>
                        <li><strong>Respiratory viral panel (if respiratory symptoms):</strong> Influenza, RSV, COVID</li>
                        <li><strong>Lumbar puncture (if CNS symptoms):</strong> After platelets >50k. CSF for cell count, protein, glucose, Gram stain, culture, Crypto Ag, fungal culture</li>
                        <li><strong>Skin biopsy (if skin lesions):</strong> Culture and histology. Rule out disseminated fungal (Fusarium, Mucor)</li>
                    </ul>
                    
                    <p><span class="label">Risk Stratification (MASCC Score - guides inpatient vs outpatient, intensity):</span></p>
                    <ul>
                        <li><strong>MASCC Score ‚â•21:</strong> Low risk (mortality <5%). May consider outpatient management in select patients</li>
                        <li><strong>MASCC Score <21:</strong> High risk (mortality >20%). Requires inpatient management + aggressive treatment</li>
                        <li><strong>High-risk features:</strong> Prolonged neutropenia (>7 days expected), ANC <100, hemodynamic instability, pneumonia, mucositis grade 3-4, neurologic changes, abdominal pain, renal/liver dysfunction, age >60</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC ANTIBIOTICS (START WITHIN 1 HOUR):</span></p>
                    
                    <p><strong>Initial Monotherapy (Preferred):</strong></p>
                    <ul>
                        <li><strong>Cefepime 2g IV q8h</strong> (antipseudomonal cephalosporin, preferred)</li>
                        <li><strong>OR Piperacillin-Tazobactam 4.5g IV q6h</strong> (broader spectrum)</li>
                        <li><strong>OR Meropenem 1g IV q8h</strong> (if PCN allergy or resistant organisms suspected)</li>
                        <li>Monotherapy covers: Pseudomonas, E. coli, Klebsiella, Enterobacter, Proteus, Staph (not MRSA), Strep</li>
                    </ul>
                    
                    <p><strong>ADD Vancomycin 15-20 mg/kg IV q8-12h if:</strong></p>
                    <ul>
                        <li>Central line/catheter infection suspected (erythema, tenderness at site)</li>
                        <li>Severe mucositis (oral, esophageal, GI - ‚ÜëStrep viridans, Enterococcus risk)</li>
                        <li>Hemodynamic instability/septic shock</li>
                        <li>Skin/soft tissue infection</li>
                        <li>Known MRSA colonization</li>
                        <li>Pneumonia (cover MRSA)</li>
                    </ul>
                    
                    <p><strong>ADD Antifungal Coverage if:</strong></p>
                    <ul>
                        <li><strong>Persistent fever >4-7 days despite broad-spectrum antibiotics</strong> (empiric antifungal)</li>
                        <li><strong>Clinical/radiographic evidence of invasive fungal infection:</strong> Pulmonary nodules, halo sign, sinusitis</li>
                        <li><strong>Positive fungal markers:</strong> Œ≤-D-glucan, galactomannan</li>
                        <li><strong>Options:</strong> Micafungin 100mg IV daily (Candida), Voriconazole 6mg/kg q12h √ó 2 then 4mg/kg q12h (Aspergillus), Liposomal Amphotericin B 3-5mg/kg IV daily (broad spectrum, if refractory)</li>
                    </ul>
                    
                    <p><strong>Special Situations:</strong></p>
                    <ul>
                        <li><strong>Perirectal abscess/typhlitis:</strong> Pip-tazo + Vancomycin (or Meropenem + Vanc). Metronidazole 500mg IV q8h if extensive bowel involvement. Surgical consult</li>
                        <li><strong>PCP suspected (HIV, lymphoma):</strong> TMP-SMX 5mg/kg IV q8h. Prednisone if severe (PaO2 <70 or A-a gradient >35)</li>
                        <li><strong>Viral respiratory infection (influenza):</strong> Oseltamivir 75mg PO BID √ó 5d if within 48hr symptom onset (or longer if immunocompromised)</li>
                        <li><strong>HSV/VZV (mucositis, vesicular rash):</strong> Acyclovir 5-10mg/kg IV q8h</li>
                    </ul>
                    
                    <p><span class="label">Duration of Antibiotics:</span></p>
                    <ul>
                        <li><strong>If source identified:</strong> Treat for appropriate duration (7-14 days typical)</li>
                        <li><strong>If NO source, clinically improving, afebrile >48hr:</strong> Continue until ANC >500 (at least 7 days total)</li>
                        <li><strong>If persistent fever but stable:</strong> Continue antibiotics until ANC >500 or until fungal workup complete</li>
                        <li><strong>Do NOT stop antibiotics just because fever persists</strong> - fever may persist due to tumor, drugs, blood products, non-bacterial causes</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>G-CSF (filgrastim 5 mcg/kg SC daily):</strong> Consider if high-risk (MASCC <21, pneumonia, septic shock, invasive fungal, prolonged neutropenia expected >7-10 days). Shortens duration neutropenia. NOT needed routinely low-risk patients</li>
                        <li><strong>Fluid resuscitation:</strong> NS boluses if hypotensive. Early aggressive hydration improves outcomes</li>
                        <li><strong>Avoid rectal temps/exams, suppositories, enemas:</strong> Risk of bacteremia from mucosal trauma</li>
                        <li><strong>Transfusion support:</strong> pRBCs if Hgb <7-8, platelets if <10k (or <50k if bleeding/procedure)</li>
                        <li><strong>Oral care:</strong> Chlorhexidine or salt/soda rinses QID. Pain control (opiates if severe mucositis)</li>
                        <li><strong>Isolate patient:</strong> Private room, hand hygiene, avoid fresh flowers/plants (fungal spores), low-microbial diet controversial</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Door-to-antibiotic <1 hour saves lives:</strong> Mortality increases 18% for each hour delay. Don't wait for cultures - empiric antibiotics immediately</li>
                    <li><strong>Fever may be only sign:</strong> Neutropenic patients can't mount inflammatory response. No pus, minimal symptoms despite severe infection. Low threshold to treat</li>
                    <li><strong>ANC <100 is very high risk:</strong> "Profound neutropenia." Mortality >20%. Need aggressive treatment, GCSF, close monitoring</li>
                    <li><strong>Persistent fever >4-7 days ‚Üí add antifungal:</strong> Empiric coverage for invasive fungal (Aspergillus, Candida). Don't wait for positive cultures/markers</li>
                    <li><strong>Don't forget perirectal exam:</strong> But be gentle! Perirectal abscess common, may not have fluctuance. Severe tenderness = likely abscess. Needs drainage</li>
                    <li><strong>CXR can be falsely negative:</strong> Neutropenia ‚Üí no infiltrate despite pneumonia. If respiratory symptoms, get CT chest even if CXR normal</li>
                    <li><strong>Mucositis = add vancomycin:</strong> Oral/GI mucositis ‚Üërisk Strep viridans bacteremia. Must add vancomycin to empiric regimen</li>
                    <li><strong>Typhlitis is surgical emergency:</strong> RLQ pain + fever + neutropenia = typhlitis until proven otherwise. CT shows cecal wall thickening. High mortality if perforation. Surgical consult urgently</li>
                    <li><strong>Don't remove central line unless CRBSI confirmed:</strong> Lines are precious in chemo patients. Can treat through line unless Staph aureus, Candida, or persistent bacteremia</li>
                    <li><strong>GCSF shortens duration:</strong> Use if high-risk (MASCC <21). Shortens neutropenia by ~2-3 days, reduces infection complications. NOT needed routinely</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Multi-organ dysfunction (renal failure, hepatic failure)</li>
                        <li>Hemodynamic instability despite fluid resuscitation</li>
                        <li>Profound neutropenia (ANC <100) with sepsis</li>
                        <li>Typhlitis with concern for perforation</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile >24-48 hours off antibiotics (or on PO antibiotics if continued)</li>
                        <li>Hemodynamically stable</li>
                        <li>ANC recovering (>200-500 and rising)</li>
                        <li>No evidence of active infection requiring IV therapy</li>
                        <li>Able to tolerate PO intake</li>
                        <li>Close outpatient follow-up arranged (oncology within 48-72hr)</li>
                        <li>Patient education on infection precautions, when to return</li>
                        <li>Low-risk by MASCC score if outpatient management planned</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Infectious Complications:</strong> Septic shock (mortality 30-50%), invasive fungal infection (Aspergillus pneumonia, disseminated candidiasis - high mortality), typhlitis with perforation (requires surgery, high mortality), perirectal abscess with necrotizing fasciitis, catheter-related bloodstream infection (S. aureus, Candida - may require line removal), PCP pneumonia with respiratory failure</p>
                    <p><strong>Non-Infectious:</strong> Tumor lysis syndrome (especially with treatment of hematologic malignancies), mucositis (severe pain, inability to eat/swallow, TPN required), bleeding (thrombocytopenia), VTE (hypercoagulable from cancer), drug toxicity (nephrotoxicity, hepatotoxicity from antibiotics/antifungals)</p>
                    <p><strong>Mortality:</strong> Overall 5-20% depending on risk factors. Low-risk (MASCC ‚â•21) <5%, High-risk (MASCC <21) >20%. Mortality higher if: ANC <100, septic shock, pneumonia, invasive fungal infection, age >60</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 29: ALCOHOL WITHDRAWAL - EXPANDED -->
        <div id="etoh-withdrawal" class="condition-page">
            <div class="page-header">
                <h2>29. ALCOHOL WITHDRAWAL</h2>
                <div class="subtitle">CIWA-Ar Protocol ‚Ä¢ Delirium Tremens ‚Ä¢ Thiamine BEFORE Glucose</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Timeline of Symptoms:</span></p>
                    <ul>
                        <li><strong>Minor withdrawal (6-12 hours after last drink):</strong> Tremor, anxiety, agitation, diaphoresis, nausea/vomiting, headache, insomnia, mild tachycard ia, mild hypertension</li>
                        <li><strong>Withdrawal seizures (12-48 hours):</strong> Generalized tonic-clonic, typically brief (<2 min), single or clustered (2-4 seizures), self-limited. If prolonged or focal ‚Üí think other cause (structural lesion, infection)</li>
                        <li><strong>Alcoholic hallucinosis (12-24 hours):</strong> Visual, auditory, or tactile hallucinations WITH intact orientation (patient knows hallucinations aren't real). No autonomic instability. Benign, self-limited</li>
                        <li><strong>Delirium Tremens/DTs (48-72 hours, can be up to 7-10 days):</strong> Life-threatening. Severe autonomic instability (tachycardia >120, hypertension, hyperthermia >38.5¬∞C, profound diaphoresis), delirium (disoriented, agitated, hallucinations), tremor. Mortality 5-15% if untreated, <1-5% with treatment</li>
                    </ul>
                    
                    <p><span class="label">Risk Factors for Severe Withdrawal/DTs:</span> History of DTs/severe withdrawal, concurrent illness (pneumonia, pancreatitis, trauma), advanced age, multiple prior detoxifications (kindling phenomenon), prolonged heavy drinking, abrupt cessation, metabolic abnormalities (‚ÜìK, ‚ÜìMg, ‚ÜìPO4)</p>
                    
                    <p><span class="label">Alternate/Complicated Presentations:</span></p>
                    <ul>
                        <li><strong>Occult withdrawal in hospitalized patients:</strong> Admitted for other reason (trauma, surgery, infection), develops withdrawal 24-72hr into admission. High suspicion if unexplained tachycardia, hypertension, agitation</li>
                        <li><strong>Concurrent Wernicke encephalopathy:</strong> Acute thiamine deficiency. Triad: confusion, ataxia, ophthalmoplegia (nystagmus, gaze palsy). Often only 1-2 of triad present. Needs urgent IV thiamine BEFORE glucose</li>
                        <li><strong>Co-ingestion:</strong> Benzodiazepines (may mask withdrawal initially then rebound), opioids (can have concurrent withdrawal), stimulants (confound tachycardia/hypertension assessment)</li>
                        <li><strong>Hepatic encephalopathy mimicking DTs:</strong> Both have AMS, but HE has asterixis, elevated ammonia, slower onset. Can coexist</li>
                        <li><strong>Seizure complications:</strong> Status epilepticus (rare but life-threatening), aspiration pneumonia, traumatic injury from fall</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Based on history, timeline, CIWA-Ar score. No specific diagnostic test</p>
                    
                    <p><span class="label">CIWA-Ar Score (Clinical Institute Withdrawal Assessment - Alcohol, revised):</span></p>
                    <p>10-item scale, max score 67. Assess q1-2h initially:</p>
                    <ul>
                        <li>Nausea/vomiting (0-7)</li>
                        <li>Tremor (0-7)</li>
                        <li>Paroxysmal sweats (0-7)</li>
                        <li>Anxiety (0-7)</li>
                        <li>Agitation (0-7)</li>
                        <li>Tactile disturbances (0-7)</li>
                        <li>Auditory disturbances (0-7)</li>
                        <li>Visual disturbances (0-7)</li>
                        <li>Headache (0-7)</li>
                        <li>Orientation/clouding of sensorium (0-4)</li>
                    </ul>
                    <p><strong>Interpretation:</strong> <8 = minimal withdrawal, 8-15 = moderate, >15 = severe, >20 = very severe (high DT risk)</p>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>BMP:</strong> Hypokalemia, hypomagnesemia, hypophosphatemia common. Anion gap metabolic acidosis (lactic acidosis, ketoacidosis). Renal function</li>
                        <li><strong>CBC:</strong> Macrocytosis (MCV >100), thrombocytopenia. Leukocytosis if infection</li>
                        <li><strong>LFTs:</strong> Elevated AST>ALT (2:1 ratio), GGT elevated. Assess for cirrhosis, hepatitis</li>
                        <li><strong>Albumin, INR:</strong> Synthetic liver function (low albumin, elevated INR = advanced liver disease)</li>
                        <li><strong>Magnesium, phosphate:</strong> Correct deficiencies (affect seizure threshold, cardiac arrhythmias)</li>
                        <li><strong>Thiamine level:</strong> Usually not sent (takes days, unreliable). Just give empiric thiamine</li>
                        <li><strong>Ethanol level:</strong> Helpful to know if still intoxicated vs pure withdrawal. But low/negative ethanol doesn't rule out withdrawal</li>
                        <li><strong>Lipase, troponin if abdominal pain/chest pain:</strong> Pancreatitis and ACS common in alcoholics</li>
                        <li><strong>Ammonia if concern for hepatic encephalopathy</strong></li>
                        <li><strong>Blood cultures if fever:</strong> Rule out infection (pneumonia, SBP, bacteremia)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT Head (if first seizure, focal seizure, persistent AMS, focal neurologic deficit, head trauma):</strong> Rule out ICH, subdural, stroke, mass</li>
                        <li><strong>CXR:</strong> Aspiration pneumonia common (especially post-seizure), eval for other pulmonary pathology</li>
                        <li><strong>EEG (if prolonged seizure or concern for non-convulsive status):</strong> Withdrawal seizures are brief, self-limited. If prolonged ‚Üí other etiology</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Benzodiazepines (Cornerstone of Treatment):</span></p>
                    
                    <p><strong>CIWA-Ar Protocol (Symptom-Triggered):</strong></p>
                    <ul>
                        <li><strong>Assess CIWA-Ar q1-2h (or q4h if stable/asleep)</strong></li>
                        <li><strong>If CIWA ‚â•8:</strong> Lorazepam 2-4mg IV/PO OR Diazepam 10-20mg IV/PO OR Chlordiazepoxide 50-100mg PO</li>
                        <li><strong>Reassess 1 hour after dose, repeat if CIWA still ‚â•8</strong></li>
                        <li><strong>Goal:</strong> CIWA <8, patient calm but arousable</li>
                        <li><strong>IV preferred if severe withdrawal, NPO, vomiting, or poor absorption</strong></li>
                    </ul>
                    
                    <p><strong>Fixed-Dose Protocol (if CIWA not feasible - ICU, intubated):</strong></p>
                    <ul>
                        <li><strong>Lorazepam 2mg IV q6h scheduled + 2mg q1h PRN breakthrough</strong></li>
                        <li><strong>OR Diazepam 10mg IV q6h scheduled + 10mg q1h PRN</strong></li>
                        <li><strong>Taper over 3-5 days once stable</strong></li>
                    </ul>
                    
                    <p><strong>Choice of Benzodiazepine:</strong></p>
                    <ul>
                        <li><strong>Lorazepam (Ativan):</strong> Intermediate-acting. No active metabolites. Safe in liver disease. Predictable IM absorption. PREFERRED if: liver disease, elderly, need IM route</li>
                        <li><strong>Diazepam (Valium):</strong> Long-acting, active metabolites (smoother withdrawal, less breakthrough). Preferred by some for DTs. Accumulates in liver disease. PREFERRED if: normal liver function, severe withdrawal/DTs</li>
                        <li><strong>Chlordiazepoxide (Librium):</strong> Long-acting, PO only. Good for mild-moderate withdrawal outpatient. NOT for severe/DTs</li>
                    </ul>
                    
                    <p><span class="label">Delirium Tremens (DTs) - Aggressive Management:</span></p>
                    <ul>
                        <li><strong>ICU admission</strong></li>
                        <li><strong>High-dose benzodiazepines:</strong> Lorazepam 2-4mg IV q10-15min or Diazepam 10-20mg IV q10-15min until symptoms controlled. May need 100s of mg/day</li>
                        <li><strong>Phenobarbital (if refractory to benzos):</strong> Phenobarbital 130-260mg IV q15-20min (max 10-15 mg/kg loading dose) then 30-60mg IV q6-8h maintenance. Synergistic with benzos, works on different GABA receptor</li>
                        <li><strong>Propofol/dexmedetomidine infusion (if refractory, intubated):</strong> Propofol 20-80 mcg/kg/min, Dexmedetomidine 0.2-1.5 mcg/kg/hr. Adjuncts, not replacements for benzos</li>
                        <li><strong>Avoid antipsychotics (haloperidol) as monotherapy:</strong> Lower seizure threshold, don't treat withdrawal. Can use low-dose as adjunct for hallucinations if needed (haloperidol 0.5-2mg)</li>
                        <li><strong>Aggressive supportive care:</strong> IVF, cooling for hyperthermia, electrolyte repletion</li>
                    </ul>
                    
                    <p><span class="label">Thiamine & Nutritional Repletion (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Thiamine 100mg IV daily √ó 3-5 days, then 100mg PO daily</strong></li>
                        <li><strong>MUST give thiamine BEFORE glucose</strong> (glucose depletes thiamine, can precipitate Wernicke encephalopathy)</li>
                        <li><strong>If concern for Wernicke:</strong> Thiamine 500mg IV TID √ó 3 days (higher dose)</li>
                        <li><strong>Folic acid 1mg PO daily</strong></li>
                        <li><strong>Multivitamin daily</strong></li>
                        <li><strong>Magnesium repletion:</strong> Mag sulfate 2-4g IV (or Mag oxide 400-800mg PO TID). Recheck and replete until >2 mg/dL. Hypomagnesemia ‚Üìefficacy of benzos, ‚Üëseizure risk</li>
                        <li><strong>Phosphate repletion:</strong> K-phos or NaPhos based on K level. Goal >2.5 mg/dL</li>
                        <li><strong>Potassium repletion:</strong> 40-80 mEq IV (if <3.5). Recheck q4-6h until >3.5</li>
                    </ul>
                    
                    <p><span class="label">Seizure Management:</span></p>
                    <ul>
                        <li><strong>Acute seizure:</strong> Lorazepam 2-4mg IV (treat seizure + withdrawal). Usually self-limited</li>
                        <li><strong>NO prophylactic AEDs:</strong> Benzodiazepines prevent seizures. AEDs (phenytoin, levetiracetam) don't prevent withdrawal seizures</li>
                        <li><strong>If status epilepticus or prolonged seizure:</strong> Standard status protocol (lorazepam, then phenytoin/fosphenytoin or levetiracetam loading)</li>
                        <li><strong>Replete magnesium aggressively</strong> (low Mg lowers seizure threshold)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Hydration:</strong> NS 100-150 mL/hr (many patients volume depleted). Monitor for volume overload if cirrhosis/cardiomyopathy</li>
                        <li><strong>Cooling for hyperthermia:</strong> Ice packs, cooling blanket. Acetaminophen (avoid NSAIDs if cirrhosis/varices)</li>
                        <li><strong>Aspiration precautions:</strong> NPO if AMS, HOB elevated, monitor for pneumonia</li>
                        <li><strong>Restraints only if necessary:</strong> Can worsen agitation, rhabdomyolysis. Verbal de-escalation, sitter, adequate sedation preferred</li>
                        <li><strong>Treat concurrent conditions:</strong> Pancreatitis, pneumonia, GI bleed common</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Thiamine BEFORE glucose:</strong> Glucose depletes thiamine stores, can precipitate Wernicke encephalopathy (irreversible). Always give thiamine first in alcoholic patients</li>
                    <li><strong>Withdrawal seizures are 12-48hr, self-limited:</strong> If seizure <12hr (still intoxicated?) or >48hr (other cause?), broaden differential. No need for AED prophylaxis - benzos prevent withdrawal seizures</li>
                    <li><strong>DTs peak 48-72hr:</strong> Life-threatening. Autonomic storm (tachy, HTN, fever, diaphoresis) + delirium. Needs ICU, massive doses of benzos. Mortality 5-15% if untreated</li>
                    <li><strong>Magnesium is key:</strong> Hypomagnesemia lowers seizure threshold, reduces benzo efficacy. Aggressively replete Mg until >2 mg/dL</li>
                    <li><strong>CIWA doesn't work if intubated/ICU:</strong> Need fixed-dose protocol. CIWA requires patient cooperation</li>
                    <li><strong>Phenobarbital for refractory DTs:</strong> If benzos failing (which is rare), add phenobarbital. Different GABA receptor, synergistic. Works when benzos don't</li>
                    <li><strong>Don't confuse with hepatic encephalopathy:</strong> Both have AMS in alcoholic. HE has asterixis, elevated ammonia, responds to lactulose/rifaximin. Can coexist. If unsure, treat both</li>
                    <li><strong>Occult withdrawal in hospital:</strong> Patient admitted for trauma/surgery/infection, becomes unexplained tachy/HTN/agitated 24-72hr later. Think withdrawal, check alcohol history</li>
                    <li><strong>Restraints worsen outcomes:</strong> Increase agitation, rhabdomyolysis, aspiration. Use adequate sedation instead. Chemical > physical restraint</li>
                    <li><strong>Can't oversedatewith benzos in withdrawal:</strong> Respiratory drive preserved until massive doses. Goal is calm but arousable. Don't underdose - prevents DTs</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Delirium tremens (autonomic instability + delirium)</li>
                        <li>Refractory withdrawal requiring high-dose benzos or phenobarbital</li>
                        <li>Seizures (especially if recurrent or status epilepticus)</li>
                        <li>Severe agitation requiring intubation for airway protection</li>
                        <li>Hemodynamic instability, severe hypertension</li>
                        <li>Concurrent critical illness (sepsis, GI bleed, pancreatitis)</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>CIWA <8-10 for >24 hours</li>
                        <li>Stable vital signs off benzodiazepines</li>
                        <li>No seizure activity</li>
                        <li>Tolerating PO intake</li>
                        <li>Ambulating safely</li>
                        <li>Completed thiamine/vitamin repletion (or on PO regimen)</li>
                        <li>Substance use treatment/counseling initiated or arranged</li>
                        <li>Outpatient follow-up arranged (PCP, addiction medicine)</li>
                        <li>Safe discharge environment</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> Delirium tremens (mortality 5-15% if untreated), seizures (aspiration, trauma, status epilepticus), Wernicke encephalopathy (irreversible if not treated - ataxia, confusion, ophthalmoplegia ‚Üí Korsakoff syndrome with permanent memory impairment), aspiration pneumonia, rhabdomyolysis (from agitation, seizures, restraints - can cause AKI)</p>
                    <p><strong>Cardiovascular:</strong> Arrhythmias (especially if hypokalemia/hypomagnesemia), cardiomyopathy exacerbation (alcoholic CMP), hypertensive crisis, MI (demand ischemia from tachycardia)</p>
                    <p><strong>From Underlying Alcoholism:</strong> GI bleed (varices, gastritis, Mallory-Weiss), pancreatitis, hepatic encephalopathy, hepatorenal syndrome, coagulopathy (low platelets, elevated INR), infections (pneumonia, SBP)</p>
                    <p><strong>From Treatment:</strong> Over-sedation with respiratory depression (rare with benzos alone), paradoxical agitation, delirium from benzodiazepines</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITIONS 30-39: COMPREHENSIVE BUT STREAMLINED -->

<!-- CONDITION 30: DELIRIUM -->
        <div id="delirium" class="condition-page">
            <div class="page-header">
                <h2>30. DELIRIUM</h2>
                <div class="subtitle">Acute Confusional State ‚Ä¢ CAM Criteria ‚Ä¢ Treat Underlying Cause</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION & DIAGNOSIS</div>
                <div class="section-content">
                    <p><span class="label">CAM Criteria (Confusion Assessment Method) - ALL required:</span></p>
                    <ul>
                        <li><strong>(1) Acute onset + fluctuating course:</strong> Symptoms developed acutely (hours-days), wax/wane throughout day</li>
                        <li><strong>(2) Inattention:</strong> Difficulty focusing, easily distracted, can't follow conversation</li>
                        <li><strong>PLUS EITHER:</strong> (3) Disorganized thinking (rambling, illogical) OR (4) Altered level of consciousness (hyperalert, lethargic, stuporous)</li>
                    </ul>
                    
                    <p><span class="label">Types:</span> Hyperactive (25% - agitated, combative, hallucinations), Hypoactive (25% - lethargic, withdrawn, often missed), Mixed (50%)</p>
                    
                    <p><span class="label">Common Causes - "I WATCH DEATH":</span> Infections, Withdrawal, Acute metabolic, Trauma/CNS, Hypoxia, Deficiencies (B12, thiamine), Endocrine, Acute vascular, Toxins/drugs, Heavy metals</p>
                    
                    <p><span class="label">High-Risk Medications (Avoid):</span> Anticholinergics (diphenhydramine, TCAs), benzodiazepines (paradoxical), opioids, H2 blockers, corticosteroids, dopamine agonists</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">WORKUP & TREATMENT</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> CBC, CMP, UA/culture, blood cultures if fever, TSH, B12, drug screen, ammonia if liver disease, ABG if hypoxia</p>
                    <p><span class="label">Imaging:</span> CT head if focal signs, fall, anticoagulated, new-onset</p>
                    <p><span class="label">LP if:</span> Fever + AMS with no clear source (meningitis/encephalitis)</p>
                    
                    <p><span class="label">Non-Pharmacologic (FIRST-LINE):</span></p>
                    <ul>
                        <li>Reorient frequently (clocks, calendars, familiar objects)</li>
                        <li>Normalize sleep-wake cycle (lights on during day, dark/quiet at night)</li>
                        <li>Early mobilization (PT/OT daily)</li>
                        <li>Sensory aids (glasses, hearing aids)</li>
                        <li>Avoid restraints (worsen delirium)</li>
                        <li>Family/sitter presence</li>
                    </ul>
                    
                    <p><span class="label">Pharmacologic (ONLY if severe agitation, danger to self/others):</span></p>
                    <ul>
                        <li><strong>Haloperidol 0.5-2mg IV/PO q4-6h PRN</strong> (low-dose). Avoid if QTc >500, Parkinson's, Lewy body dementia</li>
                        <li><strong>Quetiapine 25-50mg PO q12h</strong> (if hyperactive, sundowning). Better for elderly</li>
                        <li><strong>Avoid benzodiazepines</strong> (except alcohol/benzo withdrawal)</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Delirium vs Dementia:</strong> Delirium = acute onset (hours-days), fluctuating, inattention. Dementia = chronic (months-years), stable throughout day, memory loss predominates</li>
                    <li><strong>Hypoactive delirium often missed:</strong> Quiet, withdrawn, "pleasantly confused." Worse outcomes than hyperactive. Screen all elderly admissions with CAM</li>
                    <li><strong>Anticholinergics are enemy #1:</strong> Diphenhydramine, TCAs, scopolamine, first-gen antihistamines. Avoid in elderly</li>
                    <li><strong>Restraints worsen delirium:</strong> Increase agitation, prolong delirium, cause injury. Use sitters, reorientation instead</li>
                    <li><strong>Every delirious patient needs infection workup:</strong> UTI, pneumonia, bacteremia most common. Even if afebrile</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Severe agitation refractory to medications</li>
                        <li>Respiratory compromise requiring intubation for airway protection</li>
                        <li>Hemodynamic instability</li>
                        <li>Concern for life-threatening cause (meningitis, severe sepsis)</li>
                    </ul>
                </div>
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Delirium resolved or significantly improved</li>
                        <li>Underlying cause identified and treated</li>
                        <li>Safe functional status (ambulation, ADLs)</li>
                        <li>Medication reconciliation (d/c deliriogenic meds)</li>
                        <li>Adequate support at discharge (may need rehab/SNF)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Falls, aspiration, pressure ulcers, prolonged hospitalization (‚ÜëLOS by 5-10 days), functional decline</p>
                    <p><strong>Long-term:</strong> Persistent cognitive impairment (30-40%), increased mortality (11% at 1 month), institutionalization, progression to dementia</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 31-35: ENDOCRINE EMERGENCIES (Condensed) -->
        
        <div id="hyperthyroid" class="condition-page">
            <div class="page-header">
                <h2>31. HYPERTHYROIDISM / THYROID STORM</h2>
                <div class="subtitle">Graves ‚Ä¢ Toxic Adenoma ‚Ä¢ Storm = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Presentation:</span> Weight loss despite ‚Üëappetite, tremor, palpitations/AFib, heat intolerance, diarrhea, anxiety, proximal weakness. Graves: exophthalmos, pretibial myxedema, diffuse goiter</p>
                    <p><span class="label">Storm (Life-Threatening):</span> Fever >40¬∞C (104¬∞F), severe tachycardia (>140), AMS, agitation/psychosis, heart failure, vomiting/diarrhea. Burch-Wartofsky score ‚â•45 = storm. Mortality 10-20%</p>
                    <p><span class="label">Labs:</span> TSH suppressed (<0.01), Free T4 elevated (>1.8), Free T3 elevated. TSI/TRAb positive (Graves). Radioiodine uptake scan if etiology unclear</p>
                    
                    <p><span class="label">Storm Treatment (Order Matters!):</span></p>
                    <ol>
                        <li><strong>Œ≤-blocker FIRST:</strong> Propranolol 60-80mg PO q4-6h (or 1mg IV q10min) OR Esmolol infusion. Blocks peripheral T4‚ÜíT3 conversion + controls symptoms</li>
                        <li><strong>Thionamide (1hr after Œ≤-blocker):</strong> PTU 600mg PO load then 200mg q6h OR Methimazole 20mg q6h. PTU preferred (blocks T4‚ÜíT3 conversion)</li>
                        <li><strong>Iodine (1hr AFTER thionamide):</strong> SSKI 5 drops PO q6h OR Lugol's solution 10 drops q8h. Blocks thyroid hormone release. Must give after thionamide (prevents iodine from being used for hormone synthesis)</li>
                        <li><strong>Steroid:</strong> Hydrocortisone 100mg IV q8h (blocks T4‚ÜíT3, treats possible adrenal insufficiency)</li>
                        <li><strong>Supportive:</strong> Cooling (acetaminophen, cooling blanket - NOT aspirin, displaces T4 from binding proteins), IVF, treat precipitant</li>
                    </ol>
                    
                    <p><span class="label">Outpatient Hyperthyroidism:</span> Methimazole 10-20mg daily (first-line) OR PTU 50mg TID (if pregnant 1st trimester, intolerant to methimazole). Propranolol 20-40mg TID for symptoms. Definitive: Radioiodine ablation or thyroidectomy after euthyroid</p>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Order matters in storm:</strong> Œ≤-blocker first, thionamide 1hr later, iodine 1hr after that. Wrong order = worsened storm</li>
                    <li><strong>Iodine without thionamide = bad:</strong> Provides substrate for more hormone synthesis. Always give thionamide first</li>
                    <li><strong>PTU in pregnancy 1st trimester:</strong> Methimazole causes aplasia cutis. Switch to methimazole 2nd/3rd trimester</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="hypothyroid" class="condition-page">
            <div class="page-header">
                <h2>32. HYPOTHYROIDISM / MYXEDEMA COMA</h2>
                <div class="subtitle">Severe Hypothyroidism ‚Ä¢ Rare but Lethal</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Chronic Hypothyroidism:</span> Fatigue, weight gain, cold intolerance, constipation, hair loss, dry skin, bradycardia, delayed DTRs, periorbital edema. Labs: TSH elevated (>10), Free T4 low (<0.8)</p>
                    <p><span class="label">Treatment Outpatient:</span> Levothyroxine 1.6 mcg/kg/day PO (typical 75-125 mcg daily). Start 25-50 mcg if elderly/>65yo or CAD (risk MI from increased demand). Recheck TSH 6-8 weeks, titrate to normal TSH</p>
                    
                    <p><span class="label">Myxedema Coma (Emergency, Mortality 30-60%):</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Profound hypothermia (<95¬∞F), severe bradycardia (<50), hypoventilation (‚ÜìCO2 drive, respiratory failure), hyponatremia, hypoglycemia, AMS‚Üícoma, non-pitting edema, pericardial/pleural effusions</li>
                        <li><strong>Precipitants:</strong> Infection, MI, stroke, hypothermia, sedatives/narcotics, surgery</li>
                        <li><strong>Diagnosis:</strong> Clinical + TSH elevated (>20), Free T4 very low. Don't wait for labs - treat empirically if high suspicion</li>
                    </ul>
                    
                    <p><span class="label">Myxedema Coma Treatment:</span></p>
                    <ul>
                        <li><strong>T4 (levothyroxine) 200-400 mcg IV load</strong> then 100 mcg IV daily. Larger, slower onset but safer</li>
                        <li><strong>PLUS T3 (liothyronine) 10 mcg IV q8h:</strong> Faster onset (hours vs days). Use both T4+T3</li>
                        <li><strong>Hydrocortisone 100mg IV q8h:</strong> Rule out adrenal insufficiency (can coexist). Give steroids BEFORE thyroid hormone (thyroid hormone can precipitate crisis if AI present)</li>
                        <li><strong>Supportive:</strong> Passive rewarming (NOT active - can cause vascular collapse), mechanical ventilation if respiratory failure, hypertonic saline if severe hyponatremia (usually improves with treatment), treat precipitant (infection)</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Steroid BEFORE thyroid hormone in crisis:</strong> Prevents adrenal crisis from increased cortisol metabolism</li>
                    <li><strong>Passive rewarming only:</strong> Active rewarming (warm blankets, heating) causes peripheral vasodilation ‚Üí cardiovascular collapse</li>
                    <li><strong>Hyponatremia improves with treatment:</strong> Due to SIADH from hypothyroidism. Don't over correct</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="adrenal" class="condition-page">
            <div class="page-header">
                <h2>33. ADRENAL INSUFFICIENCY / CRISIS</h2>
                <div class="subtitle">Primary (Addison's) ‚Ä¢ Secondary ‚Ä¢ Crisis = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Chronic AI Presentation:</span> Fatigue, weight loss, hypotension, hyponatremia, hypoglycemia. PRIMARY (Addison's) ALSO has: hyperkalemia, hyperpigmentation (‚ÜëACTH stimulates melanocytes), salt craving. SECONDARY: no hyperK/hyperpigmentation</p>
                    
                    <p><span class="label">Adrenal Crisis (Emergency):</span> Shock (refractory hypotension), abdominal pain/vomiting (mimics acute abdomen), fever, severe dehydration, AMS/confusion. Precipitants: Infection, surgery, trauma, stopping steroids abruptly</p>
                    
                    <p><span class="label">Diagnosis:</span></p>
                    <ul>
                        <li><strong>Random cortisol:</strong> <3 mcg/dL = AI, >18 = excludes, 3-18 = indeterminate (do stim test)</li>
                        <li><strong>Cosyntropin stimulation test:</strong> Give cosyntropin 250 mcg IV, check cortisol at 30 and 60 min. Normal: cortisol >18-20. Abnormal: <18 = AI</li>
                        <li><strong>DON'T WAIT for test in crisis - treat empirically!</strong> Can do test later</li>
                        <li><strong>Distinguish primary vs secondary:</strong> ACTH level. Primary: ACTH >100 (pituitary trying to stimulate failed adrenals). Secondary: ACTH <10 (pituitary failure)</li>
                    </ul>
                    
                    <p><span class="label">Crisis Treatment (DON'T DELAY):</span></p>
                    <ul>
                        <li><strong>Hydrocortisone 100mg IV bolus immediately,</strong> then 50-100mg IV q6-8h (or 200mg/24hr continuous infusion)</li>
                        <li><strong>Aggressive IVF:</strong> NS 1-2L rapidly, then 200-300 mL/hr. Patients profoundly volume depleted</li>
                        <li><strong>Dextrose if hypoglycemic:</strong> D50 1-2 amps IV</li>
                        <li><strong>Treat precipitant:</strong> Antibiotics if infection, stress-dose steroids perioperatively</li>
                        <li><strong>NO fludrocortisone initially:</strong> High-dose hydrocortisone has mineralocorticoid activity. Add fludrocortisone once stable on oral therapy</li>
                    </ul>
                    
                    <p><span class="label">Chronic Replacement (After Crisis):</span></p>
                    <ul>
                        <li><strong>Hydrocortisone 15-25mg/day divided BID-TID</strong> (give 2/3 AM, 1/3 afternoon - mimic diurnal rhythm)</li>
                        <li><strong>Fludrocortisone 0.1mg PO daily if PRIMARY</strong> (mineralocorticoid replacement). Not needed if secondary</li>
                        <li><strong>Stress dosing:</strong> Double-triple dose for illness, surgery. Fever/infection: double dose. Major surgery: hydrocortisone 100mg IV q8h √ó 24-48hr</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Don't wait to treat crisis:</strong> If suspected, give hydrocortisone 100mg IV immediately. Can do cosyntropin test after (use dexamethasone 4mg if need test, doesn't interfere)</li>
                    <li><strong>Hyperkalemia + hyponatremia = PRIMARY:</strong> Aldosterone deficiency. Secondary AI has normal K (aldosterone intact)</li>
                    <li><strong>Hyperpigmentation = PRIMARY:</strong> ‚ÜëACTH stimulates melanocytes. Look: knuckles, palmar creases, scars, mucous membranes</li>
                    <li><strong>Most common cause chronic AI:</strong> Iatrogenic (stopping steroids abruptly after chronic use). Need slow taper</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="hypercalcemia" class="condition-page">
            <div class="page-header">
                <h2>34. HYPERCALCEMIA</h2>
                <div class="subtitle">"Stones, Bones, Groans, Psychiatric Overtones"</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Symptoms:</span> Mild (Ca 10.5-12): Often asymptomatic. Moderate-Severe (Ca >12): Polyuria/polydipsia (nephrogenic DI), constipation, nausea/vomiting, weakness, confusion, lethargy, shortened QT interval. Very severe (>14): AMS, coma, arrhythmias</p>
                    
                    <p><span class="label">Causes (90% are these 2):</span></p>
                    <ul>
                        <li><strong>Primary hyperparathyroidism:</strong> Outpatient, mild-moderate (Ca 10.5-11.5). PTH elevated or "inappropriately normal" with high Ca. Adenoma usually. Treatment: Parathyroidectomy if symptomatic</li>
                        <li><strong>Malignancy:</strong> Inpatient, moderate-severe (Ca >12). PTH suppressed (<20). Mechanisms: PTHrP (squamous cell, renal, breast), osteolytic mets (multiple myeloma, breast), calcitriol production (lymphoma). Treatment: Treat cancer, aggressive hydration, bisphosphonates</li>
                        <li><strong>Other:</strong> Granulomatous disease (sarcoid, TB - ‚Üëcalcitriol), meds (thiazides, lithium, vitamin D intoxication), immobilization</li>
                    </ul>
                    
                    <p><span class="label">Treatment (Severe Hypercalcemia Ca >12-14):</span></p>
                    <ol>
                        <li><strong>IV Fluids:</strong> NS 200-300 mL/hr (goal UOP 100-150 mL/hr). Rehydrate (hypercalcemia causes dehydration from nephrogenic DI). Works in hours, lowers Ca 1-3 mg/dL. FIRST-LINE</li>
                        <li><strong>Calcitonin 4 units/kg subQ or IM q12h:</strong> Rapid onset (4-6hr), modest effect (‚ÜìCa 1-2 mg/dL). Tachyphylaxis in 48-72hr. Use as bridge while waiting for bisphosphonate</li>
                        <li><strong>Bisphosphonates (MOST effective):</strong> Pamidronate 60-90mg IV over 2-4hr OR Zoledronic acid 4mg IV over 15min. Onset 2-4 days, peak 5-7 days, lasts weeks. Lowers Ca 2-3 mg/dL. Dose-adjust if CrCl <30</li>
                        <li><strong>Dialysis:</strong> If refractory, severe renal failure, or Ca >18. Rapidly effective</li>
                        <li><strong>Avoid thiazides, lithium, vitamin D/calcium supplements</strong></li>
                    </ol>
                    
                    <p><span class="label">Special Cases:</span></p>
                    <ul>
                        <li><strong>Granulomatous (sarcoid):</strong> Prednisone 20-40mg daily (‚Üìcalcitriol production)</li>
                        <li><strong>Lymphoma:</strong> Treat malignancy, steroids help</li>
                        <li><strong>Vitamin D intoxication:</strong> Stop vitamin D, steroids, fluids, bisphosphonates</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>PTH tells you the cause:</strong> PTH elevated/normal = hyperparathyroidism. PTH suppressed = malignancy or other</li>
                    <li><strong>Outpatient vs inpatient:</strong> Outpatient mild hypercalcemia = hyperparathyroidism. Inpatient severe = malignancy</li>
                    <li><strong>Calcitonin is bridge:</strong> Works fast (hours) but tachyphylaxis (stops working after 2-3 days). Use while waiting for bisphosphonate to kick in</li>
                    <li><strong>Bisphosphonates most effective:</strong> But slow (2-4 days). Lasts weeks. Don't give if AKI (wait for rehydration)</li>
                    <li><strong>Furosemide does NOT help:</strong> Old teaching. Causes dehydration, worsens. Only if volume overload</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="hypomag" class="condition-page">
            <div class="page-header">
                <h2>35. HYPOMAGNESEMIA</h2>
                <div class="subtitle">Mg <1.5 ‚Ä¢ Often With HypoK/HypoCa</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Causes:</span> GI losses (diarrhea, malabsorption), renal losses (diuretics - loops/thiazides, PPIs, aminoglycosides, cisplatin, amphotericin), alcohol, DKA, refeeding syndrome, chronic PPI use</p>
                    <p><span class="label">Symptoms:</span> Often asymptomatic until Mg <1. Tremor, muscle fasciculations, weakness, tetany (Trousseau/Chvostek signs), seizures, arrhythmias (torsades de pointes, afib, PVCs), personality changes. Refractory hypokalemia/hypocalcemia (Mg needed for K/Ca homeostasis)</p>
                    <p><span class="label">ECG:</span> Prolonged QT, widened QRS, peaked T waves, torsades de pointes</p>
                    
                    <p><span class="label">Treatment:</span></p>
                    <ul>
                        <li><strong>Asymptomatic/Mild (Mg >1):</strong> Magnesium oxide 400-800mg PO BID-TID (poorly absorbed, causes diarrhea). OR Mag glycinate/citrate better tolerated</li>
                        <li><strong>Moderate (Mg <1) or Symptomatic:</strong> Magnesium sulfate 2g IV over 15-30min, repeat q6h until Mg >1.5. Then transition to PO</li>
                        <li><strong>Severe/Life-Threatening (Torsades, seizure, tetany):</strong> Magnesium sulfate 2-4g IV over 10-15min, then continuous infusion 1-2g/hr. Monitor DTRs (loss = hypermagnesemia). Cardiac monitor</li>
                        <li><strong>Replete K and Ca simultaneously:</strong> Won't normalize until Mg corrected. Check all three, replete together</li>
                        <li><strong>Monitor serum Mg q6-12h</strong> during repletion. Goal >1.5-2 mg/dL</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Refractory hypokalemia = check Mg:</strong> Can't fix K until Mg replete. Mg needed for K channel function</li>
                    <li><strong>Hypocalcemia with Mg deficiency:</strong> Mg needed for PTH secretion/action. Replete Mg first, Ca will follow</li>
                    <li><strong>Torsades de pointes:</strong> 2g Mg IV over 1-2min (even if Mg normal). First-line treatment</li>
                    <li><strong>Monitor DTRs:</strong> Loss of reflexes = hypermagnesemia (>4-5). Stop infusion if DTRs lost</li>
                    <li><strong>PPI-induced hypomagnesemia:</strong> Chronic PPI use (months-years) ‚Üí severe hypomagnesemia. Stop PPI, switch to H2 blocker</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITIONS 36-39: Final Four -->

        <div id="rhabdo" class="condition-page">
            <div class="page-header">
                <h2>36. RHABDOMYOLYSIS</h2>
                <div class="subtitle">CK >1000 ‚Ä¢ Myoglobinuria ‚Ä¢ AKI Risk</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Causes - "CRAMPS":</span> Crush injury/trauma, Recreational drugs (cocaine, PCP, MDMA, amphetamines), Alcohol/Anesthetics (malignant hyperthermia, NMS), Meds (statins, fibrates, colchicine), Prolonged immobilization/seizures, Strenuous exercise, Heat stroke, Infections (influenza, HIV)</p>
                    <p><span class="label">Classic Triad (only 10% have all 3):</span> Myalgias, weakness, dark urine (tea/cola-colored from myoglobinuria)</p>
                    <p><span class="label">Presentation:</strong> Muscle pain/tenderness/swelling, weakness, dark urine. May have compartment syndrome (tense compartments, pain out of proportion, 5 P's). Severe: AKI, hyperkalemia, arrhythmias</p>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CK (creatine kinase):</strong> >1000 (often >5000, can be >100,000). Peak 24-36hr, normalize in 3-5 days. Trend daily</li>
                        <li><strong>Urine:</strong> Dipstick positive for blood (myoglobin cross-reacts) but NO RBCs on microscopy. Urine myoglobin (rarely sent, not needed)</li>
                        <li><strong>BMP:</strong> AKI (Cr rising), hyperkalemia (released from muscle - LIFE-THREATENING), hypocalcemia early (Ca deposits in necrotic muscle), hypercalcemia late (resorption), hyperphosphatemia (released from muscle), elevated anion gap (lactate)</li>
                        <li><strong>ABG:</strong> Metabolic acidosis</li>
                        <li><strong>Check:</strong> LDH, AST/ALT (elevated from muscle, not liver), uric acid (elevated)</li>
                    </ul>
                    
                    <p><span class="label">Treatment (Aggressive IVF is Key):</span></p>
                    <ul>
                        <li><strong>IV Fluids:</strong> NS 200-300 mL/hr (or 1-1.5 L/hr if severe). Goal: UOP >200-300 mL/hr (flush myoglobin before it precipitates in tubules). Continue until CK downtrending <5000 AND Cr improving</li>
                        <li><strong>Monitor:</strong> Strict I/Os, UOP hourly, daily CK/BMP/Ca/Phos, cardiac telemetry (hyperK risk)</li>
                        <li><strong>Alkalinize urine (controversial, not routinely recommended):</strong> Some add NaHCO3 to IVF (3 amps in 1L D5W at 200 mL/hr) to maintain urine pH >6.5 (prevents myoglobin precipitation). But no proven benefit, risks volume overload/alkalosis</li>
                        <li><strong>Avoid:</strong> NSAIDs, nephrotoxins</li>
                        <li><strong>Hyperkalemia:</strong> Treat aggressively (insulin/dextrose, calcium, kayexalate, dialysis if severe)</li>
                        <li><strong>Hypocalcemia (early):</strong> DO NOT treat unless symptomatic (seizures, tetany, long QT). Repleting Ca can worsen later hypercalcemia</li>
                        <li><strong>Dialysis if:</strong> Severe AKI (oliguric, Cr >5-6), refractory hyperkalemia, severe acidosis, volume overload</li>
                        <li><strong>Compartment syndrome:</strong> Ortho/surgery consult URGENTLY. Fasciotomy if pressures >30 mmHg</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>IVF, IVF, IVF:</strong> Aggressive volume expansion is treatment. Prevents AKI by flushing myoglobin. Goal UOP >200 mL/hr</li>
                    <li><strong>Hyperkalemia kills:</strong> Released from necrotic muscle. Check K q6-12h initially. Cardiac monitor. Treat aggressively</li>
                    <li><strong>Don't treat early hypocalcemia:</strong> Ca deposits in muscle. Later, gets resorbed ‚Üí hypercalcemia. Treating early worsens late</li>
                    <li><strong>Dipstick + but no RBCs = myoglobinuria:</strong> Myoglobin cross-reacts with hemoglobin on dipstick. Microscopy negative for RBCs</li>
                    <li><strong>Statin-induced rhabdo:</strong> Risk factors: Asian, elderly, CKD, drug interactions (gemfibrozil, azoles, macrolides). Check CK before starting if high risk</li>
                    <li><strong>Compartment syndrome:</strong> Tense compartment, pain out of proportion, pain with passive stretch. Pressures >30 mmHg. SURGICAL EMERGENCY - fasciotomy</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="transfusion" class="condition-page">
            <div class="page-header">
                <h2>37. TRANSFUSION REACTIONS</h2>
                <div class="subtitle">Acute Hemolytic ‚Ä¢ TRALI ‚Ä¢ TACO ‚Ä¢ Febrile</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Acute Hemolytic (ABO Incompatibility) - WORST:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Within minutes of transfusion</li>
                        <li><strong>Symptoms:</strong> Fever, chills, back/chest/flank pain, dyspnea, hypotension, hemoglobinuria (red/dark urine), DIC, AKI. IF INTUBATED: unexplained fever, hypotension, hemoglobinuria, oozing from surgical sites</li>
                        <li><strong>Cause:</strong> Clerical error (wrong blood to wrong patient). ABO antibodies lyse donor RBCs</li>
                        <li><strong>Treatment:</strong> STOP transfusion immediately! Maintain UOP >100 mL/hr (IVF, diuretics, alkalinize urine). Pressors if shock. Check: Coombs (DAT), LDH, haptoglobin, bilirubin, coags (DIC screen). Send blood bag + patient blood back to blood bank</li>
                    </ul>
                    
                    <p><span class="label">Febrile Non-Hemolytic (FNHTR) - Most Common:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During or within 4hr of transfusion</li>
                        <li><strong>Symptoms:</strong> Fever (>1¬∞C rise or >38¬∞C), chills, rigors. No hemolysis</li>
                        <li><strong>Cause:</strong> Recipient antibodies against donor WBCs/platelets, or cytokines released from donor WBCs</li>
                        <li><strong>Treatment:</strong> STOP transfusion. Check hemolysis labs (rule out hemolytic). If negative, give acetaminophen, can cautiously resume transfusion slowly. Prevent: Leukoreduced blood for future transfusions, pre-med with acetaminophen</li>
                    </ul>
                    
                    <p><span class="label">TRALI (Transfusion-Related Acute Lung Injury):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Within 6hr of transfusion</li>
                        <li><strong>Symptoms:</strong> Acute hypoxemia, dyspnea, bilateral infiltrates on CXR (looks like ARDS), fever, hypotension. Normal CVP/PCWP (vs TACO)</li>
                        <li><strong>Cause:</strong> Donor antibodies against recipient WBCs ‚Üí capillary leak, non-cardiogenic pulmonary edema</li>
                        <li><strong>Treatment:</strong> Supportive - O2, may need intubation/mechanical ventilation. Diuretics NOT helpful (not volume overload). Usually resolves 48-96hr</li>
                    </ul>
                    
                    <p><span class="label">TACO (Transfusion-Associated Circulatory Overload):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During or within 6hr</li>
                        <li><strong>Symptoms:</strong> Dyspnea, tachycardia, hypertension, JVD, pulmonary edema, bilateral crackles. Elevated BNP/NT-proBNP</li>
                        <li><strong>Cause:</strong> Volume overload (especially in CHF, renal failure, elderly)</li>
                        <li><strong>Treatment:</strong> Slow/stop transfusion. Diuretics (furosemide 20-40mg IV). O2, upright position. Prevent: Slow transfusion rate (<1 unit per 2-4hr), furosemide between units if high risk</li>
                    </ul>
                    
                    <p><span class="label">Allergic:</span></p>
                    <ul>
                        <li><strong>Mild (urticaria):</strong> Stop transfusion, antihistamine (diphenhydramine 25-50mg). Can resume if improves. Pre-med with antihistamine for future</li>
                        <li><strong>Severe (anaphylaxis):</strong> Angioedema, bronchospasm, hypotension. STOP transfusion. Epinephrine 0.3-0.5mg IM, antihistamines, steroids, IVF, pressors. Washed RBCs for future (removes plasma proteins)</li>
                    </ul>
                    
                    <p><span class="label">Delayed Hemolytic (Days to Weeks):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> 3-10 days post-transfusion</li>
                        <li><strong>Symptoms:</strong> Unexplained fever, jaundice, falling Hgb, dark urine. Less severe than acute hemolytic</li>
                        <li><strong>Cause:</strong> Anamnestic antibody response (patient previously sensitized, antibody level low ‚Üí transfusion boosts antibody production)</li>
                        <li><strong>Labs:</strong> Positive DAT, elevated bilirubin, LDH, low haptoglobin</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>STOP transfusion first:</strong> For ANY reaction (except very mild urticaria). Check vitals, send hemolysis labs, notify blood bank</li>
                    <li><strong>Acute hemolytic is clerical error:</strong> Wrong blood to wrong patient. Double-check patient ID before transfusion. Devastating complication</li>
                    <li><strong>TRALI vs TACO:</strong> Both have pulmonary edema within 6hr. TRALI = hypotension, normal CVP. TACO = hypertension, JVD, elevated BNP. TRALI = supportive, TACO = diuretics</li>
                    <li><strong>Febrile reaction most common:</strong> Benign. Rule out hemolysis (check labs), then acetaminophen, resume transfusion. Prevent with leukoreduced blood</li>
                    <li><strong>Pre-med selectively:</strong> Acetaminophen if prior febrile reactions. Diphenhydramine if prior allergic. NOT routinely for everyone</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="pleural-effusion" class="condition-page">
            <div class="page-header">
                <h2>38. PLEURAL EFFUSION</h2>
                <div class="subtitle">Transudate vs Exudate ‚Ä¢ Light's Criteria</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Presentation:</span> Dyspnea, pleuritic chest pain, cough. Exam: Decreased breath sounds, dullness to percussion, decreased tactile fremitus</p>
                    <p><span class="label">CXR:</span> Blunted costophrenic angle (requires ~200 mL). Lateral decubitus view (layering confirms free-flowing fluid). If loculated, doesn't layer</p>
                    <p><span class="label">Ultrasound:</span> More sensitive than CXR (detects 50 mL). Guides thoracentesis</p>
                    
                    <p><span class="label">Light's Criteria (Exudate if ‚â•1 of 3):</span></p>
                    <ul>
                        <li>Pleural fluid protein / Serum protein >0.5</li>
                        <li>Pleural fluid LDH / Serum LDH >0.6</li>
                        <li>Pleural fluid LDH >2/3 upper limit of normal serum LDH</li>
                    </ul>
                    <p><strong>Sensitivity 98%, Specificity 80%.</strong> Misclassifies ~20% transudates as exudates (especially if on diuretics). If clinically transudate but meets Light's, calculate serum-albumin gradient: Serum albumin - Pleural albumin >1.2 = transudate</p>
                    
                    <p><span class="label">Transudate (‚ÜìCapillary Hydrostatic Pressure or ‚ÜìOncotic Pressure):</span></p>
                    <ul>
                        <li><strong>CHF (most common):</strong> Bilateral, symmetric. Treat CHF (diuretics). Thoracentesis only if asymmetric, fever, or not responding to diuresis</li>
                        <li><strong>Cirrhosis/Hepatic hydrothorax:</strong> Usually right-sided. Treat ascites (diuretics, TIPS if refractory)</li>
                        <li><strong>Nephrotic syndrome:</strong> Hypoalbuminemia (<2.5), proteinuria >3.5 g/day</li>
                        <li><strong>PE:</strong> Can be transudate OR exudate. If high suspicion, get CTPA</li>
                    </ul>
                    
                    <p><span class="label">Exudate (Inflammation, Infection, Malignancy):</span></p>
                    <ul>
                        <li><strong>Pneumonia/Parapneumonic:</strong> Most common exudate. Thoracentesis if fluid >10mm on lateral decubitus or loculated. Simple parapneumonic: pH >7.2, glucose >60, LDH <1000, negative Gram/culture ‚Üí antibiotics alone. Complicated: pH <7.2, glucose <60, LDH >1000, or positive Gram/culture ‚Üí chest tube drainage</li>
                        <li><strong>Empyema:</strong> Pus in pleural space. Frank pus, positive Gram stain/culture, pH <7.2, glucose <40. Needs chest tube + antibiotics +/- VATS/surgery</li>
                        <li><strong>Malignancy:</strong> Lung cancer, breast, lymphoma, ovarian. Often bloody, exudative. Cytology positive in 60%. Thoracentesis for diagnosis + symptom relief. Pleurodesis if recurrent</li>
                        <li><strong>TB:</strong> Lymphocytic predominance (>50%), elevated ADA (>40 U/L), positive AFB culture (50-80% if also send pleural biopsy). Pleural biopsy for culture + histology (granulomas)</li>
                        <li><strong>PE:</strong> 1/3 transudates, 2/3 exudates. Often bloody. If suspected, get CTPA</li>
                        <li><strong>Pancreatitis:</strong> Left-sided, elevated pleural fluid amylase (>serum)</li>
                    </ul>
                    
                    <p><span class="label">Send Pleural Fluid for:</span></p>
                    <ul>
                        <li><strong>Always:</strong> pH, protein, LDH, cell count/diff, Gram stain, culture (aerobic/anaerobic)</li>
                        <li><strong>If concern for malignancy:</strong> Cytology (3 samples ‚Üëyield)</li>
                        <li><strong>If suspect TB:</strong> AFB smear/culture, ADA, pleural biopsy</li>
                        <li><strong>If bloody:</strong> Hematocrit (Hct >50% of serum Hct = hemothorax)</li>
                        <li><strong>If concern for pancreatitis, esophageal rupture:</strong> Amylase</li>
                        <li><strong>If milky appearance:</strong> Triglycerides (>110 = chylothorax)</li>
                    </ul>
                    
                    <p><span class="label">Treatment:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause</strong></li>
                        <li><strong>Therapeutic thoracentesis:</strong> If symptomatic (dyspnea). Remove 1-1.5L max at a time (risk re-expansion pulmonary edema if >1.5L). Repeatthorax as needed</li>
                        <li><strong>Chest tube:</strong> If empyema, complicated parapneumonic, hemothorax</li>
                        <li><strong>Pleurodesis:</strong> If recurrent malignant effusion (talc, doxycycline, bleomycin). Prevents reaccumulation</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Light's Criteria rules in exudate:</strong> Sens 98%, but 20% false positives (transudate called exudate). Use serum-albumin gradient if doesn't fit clinically</li>
                    <li><strong>CHF effusions are bilateral/symmetric:</strong> If unilateral or asymmetric, tap it (could be empyema, malignancy, PE)</li>
                    <li><strong>pH <7.2 or glucose <60 = drain it:</strong> Complicated parapneumonic/empyema. Won't resolve with antibiotics alone. Needs chest tube</li>
                    <li><strong>TB effusion is lymphocytic:</strong> >50% lymphs. ADA >40 suggestive. Pleural biopsy ‚Üëyield (culture + granulomas)</li>
                    <li><strong>Don't remove >1.5L at once:</strong> Risk re-expansion pulmonary edema (chest pain, cough, hypoxia after thoracentesis). Stop if patient develops symptoms or pressure drops >20 cm H2O</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="pneumothorax" class="condition-page">
            <div class="page-header">
                <h2>39. PNEUMOTHORAX</h2>
                <div class="subtitle">Primary ‚Ä¢ Secondary ‚Ä¢ Iatrogenic ‚Ä¢ TENSION = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Types:</span></p>
                    <ul>
                        <li><strong>Primary Spontaneous (PSP):</strong> Tall, thin, young men (15-35yo). Smokers. Rupture apical bleb/bullae. No underlying lung disease</li>
                        <li><strong>Secondary Spontaneous (SSP):</strong> Underlying lung disease - COPD (most common), CF, PCP pneumonia, necrotizing pneumonia, TB, Marfan's</li>
                        <li><strong>Iatrogenic:</strong> Central line placement (subclavian>IJ), thoracentesis, transbronchial biopsy, mechanical ventilation (barotrauma), CPR</li>
                        <li><strong>Traumatic:</strong> Blunt/penetrating chest trauma, rib fractures</li>
                    </ul>
                    
                    <p><span class="label">Presentation:</span> Acute-onset pleuritic chest pain, dyspnea. Exam: Decreased breath sounds, hyperresonance to percussion, decreased tactile fremitus on affected side. Tracheal deviation toward affected side (simple PTX) or AWAY (tension PTX)</p>
                    
                    <p><span class="label">TENSION PNEUMOTHORAX - EMERGENCY:</span></p>
                    <ul>
                        <li><strong>Pathophys:</strong> One-way valve ‚Üí air enters pleural space but can't escape ‚Üí ‚Üëpressure collapses lung, shifts mediastinum, compresses contralateral lung + great vessels ‚Üí ‚Üìvenous return ‚Üí shock</li>
                        <li><strong>Presentation:</strong> Severe respiratory distress, hypotension, tachycardia, JVD, tracheal deviation AWAY from affected side, absent breath sounds, hyperresonance, cyanosis</li>
                        <li><strong>CLINICAL DIAGNOSIS - DON'T WAIT FOR CXR!</strong></li>
                        <li><strong>Treatment:</strong> Immediate needle decompression: 14-16 gauge angiocath, 2nd intercostal space, midclavicular line (or 4th-5th ICS anterior axillary line). Insert needle over rib (avoid neurovascular bundle under rib). Rush of air = confirms diagnosis. THEN get CXR and place chest tube</li>
                    </ul>
                    
                    <p><span class="label">CXR Findings:</span> Visceral pleural line (edge of collapsed lung), absent lung markings peripherally. Upright film more sensitive. Deep sulcus sign on supine (air collects anteriorly). Quantify size: Measure distance from chest wall to lung edge at hilum level. Small <2cm, Large >2cm</p>
                    
                    <p><span class="label">Treatment Algorithm (Non-Tension):</span></p>
                    <ul>
                        <li><strong>Small (<2cm or <20%), stable, minimal symptoms:</strong>
                            <ul>
                                <li>Observation + supplemental O2 (hastens resorption - 4√ó faster with O2)</li>
                                <li>Repeat CXR in 6hr. If stable/improving, discharge with outpatient follow-up CXR 1-2 weeks</li>
                                <li>PSP: Resorbs ~1-2% per day (10-14 days). SSP: Higher risk progression, lower threshold to place tube</li>
                                <li>Instruct: Return if increased dyspnea, chest pain. No flying until resolved (pressure changes expand PTX)</li>
                            </ul>
                        </li>
                        <li><strong>Large (>2cm or >20%) OR symptomatic:</strong>
                            <ul>
                                <li><strong>Aspiration (PSP, first episode, age <50, stable):</strong> 16-18 gauge IV catheter, 2nd ICS midclavicular line or 4th-5th ICS midaxillary line. Aspirate with 60 mL syringe + 3-way stopcock. Max 2.5L (if not successful, place chest tube). If successful (PTX <2cm, symptoms improved), observe 4hr, repeat CXR. Discharge if stable. Success ~60-80% PSP</li>
                                <li><strong>Chest tube (SSP, large PSP failing aspiration, recurrent, bilateral, hemodynamic instability):</strong> 16-28Fr pigtail (small) or 28-32Fr tube (large). 4th-5th ICS, anterior axillary line, directed posteroapically. Connect to water seal +/- suction (-20 cm H2O). Keep tube until no air leak √ó 24hr + lung re-expanded on CXR</li>
                            </ul>
                        </li>
                        <li><strong>Recurrent PTX (20-50% recur within 2 years):</strong> Video-assisted thoracoscopic surgery (VATS) with bleb resection + pleurodesis. Reduces recurrence to <5%. Consider after 1st SSP or 2nd PSP</li>
                    </ul>
                    
                    <p><span class="label">Special Situations:</span></p>
                    <ul>
                        <li><strong>Mechanical ventilation:</strong> If PTX develops, place chest tube immediately (positive pressure worsens). Don't wait/observe</li>
                        <li><strong>Bilateral PTX:</strong> Higher risk respiratory compromise. Usually place bilateral tubes</li>
                        <li><strong>Persistent air leak (tube in, still bubbling >7 days):</strong> Bronchopleural fistula. Consult thoracic surgery</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Tension PTX is clinical diagnosis:</strong> Don't wait for CXR! Respiratory distress + hypotension + absent breath sounds + hyperresonance = needle decompression NOW</li>
                    <li><strong>Tracheal deviation:</strong> Simple PTX ‚Üí toward affected side (volume loss). Tension PTX ‚Üí away from affected side (mass effect pushing mediastinum)</li>
                    <li><strong>PSP = tall thin young men:</strong> "Walking around with time bombs." Apical blebs. Smoking ‚Üërisk 20√ó. Often rupture at rest. Recurrence 20-50%</li>
                    <li><strong>SSP more dangerous than PSP:</strong> Underlying lung disease ‚Üí less reserve. Lower threshold to place chest tube. Higher morbidity/mortality</li>
                    <li><strong>O2 speeds resolution 4√ó:</strong> Creates nitrogen gradient ‚Üí resorption. Give O2 even if saturating well</li>
                    <li><strong>No flying until resolved:</strong> Pressure changes at altitude expand PTX. Wait 1-2 weeks post-resolution before flying</li>
                    <li><strong>Aspiration vs tube:</strong> PSP, young, stable ‚Üí try aspiration first (60-80% success, less invasive). SSP ‚Üí chest tube (higher failure rate, don't waste time)</li>
                    <li><strong>Recurrent PTX needs surgery:</strong> VATS pleurodesis after 1st SSP or 2nd PSP. Reduces recurrence <5%</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<div id="syncope" class="condition-page">
            <div class="page-header">
                <h2>40. SYNCOPE</h2>
                <div class="subtitle">Vasovagal ‚Ä¢ Cardiac ‚Ä¢ Orthostatic ‚Ä¢ Neurologic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Transient loss of consciousness (LOC) with loss of postural tone, followed by spontaneous complete recovery. Caused by global cerebral hypoperfusion. Duration typically <20 seconds</p>
                    <p><span class="label">Classic:</span> Sudden LOC, fall, rapid spontaneous recovery without intervention. Patient recalls events before and after (vs seizure with postictal confusion)</p>
                    
                    <p><span class="label">Key Historical Questions:</span></p>
                    <ul>
                        <li><strong>Prodrome:</strong> Nausea, diaphoresis, tunnel vision, lightheadedness = vasovagal. No warning = cardiac</li>
                        <li><strong>Position:</strong> Standing ‚Üí orthostatic or vasovagal. Supine ‚Üí cardiac (very concerning!)</li>
                        <li><strong>Activity:</strong> Exertional syncope = cardiac until proven otherwise (HOCM, AS, arrhythmia, PE)</li>
                        <li><strong>Triggers:</strong> Pain, emotion, standing, prolonged standing, hot environment = vasovagal. Post-micturition/defecation = situational</li>
                        <li><strong>Recovery:</strong> Immediate = syncope. Confusion/lethargy = seizure or stroke</li>
                        <li><strong>Witnesses:</strong> Tonic-clonic movements? (can occur in syncope but brief <15sec, vs prolonged in seizure). Tongue biting/incontinence more typical of seizure</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations by Etiology:</span></p>
                    <ul>
                        <li><strong>Vasovagal (Neurocardiogenic):</strong> Most common (40-50%). Prodrome of nausea, diaphoresis, visual changes. Triggered by emotional stress, pain, prolonged standing, hot environment. Young patients. Benign</li>
                        <li><strong>Orthostatic Hypotension:</strong> Syncope upon standing from sitting/supine. Elderly, autonomic dysfunction, medications (Œ±-blockers, diuretics, vasodilators), volume depletion. BP drop ‚â•20/10 mmHg within 3 minutes of standing</li>
                        <li><strong>Cardiac Arrhythmia:</strong> No warning, sudden collapse. Palpitations before/after. High-risk: age >60, exertional, supine, no prodrome, heart disease. Bradyarrhythmias (sick sinus, AV block) or tachyarrhythmias (VT, SVT)</li>
                        <li><strong>Structural Cardiac:</strong> Aortic stenosis (exertional syncope, systolic murmur), HOCM (young athletes, exertional, family history sudden death), cardiac tamponade, myxoma, PE (dyspnea, pleuritic chest pain)</li>
                        <li><strong>Neurologic (RARE cause):</strong> Vertebrobasilar TIA (diplopia, ataxia, vertigo), subclavian steal, seizure (postictal confusion differentiates from syncope)</li>
                        <li><strong>Situational:</strong> Specific triggers - micturition (post-void), defecation, cough, swallow. Vasovagal-mediated</li>
                        <li><strong>Carotid Sinus Hypersensitivity:</strong> Elderly men, triggered by tight collar, head turning, shaving. Bradycardia/hypotension with carotid massage</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ALL Patients Must Have:</span></p>
                    <ul>
                        <li><strong>Detailed History:</strong> Events before/during/after, position, activity, prodrome, recovery time, witnesses, prior episodes, medications, cardiac history</li>
                        <li><strong>Physical Exam:</strong> Complete cardiac exam (murmurs, JVD, edema), neurologic exam (focal deficits?), orthostatic vitals (supine ‚Üí standing at 1 and 3 min)</li>
                        <li><strong>ECG (MANDATORY for ALL):</strong> Look for: prolonged QT (>480ms = high risk for Torsades), Brugada pattern (ST elevation V1-V3), pre-excitation (WPW = short PR, delta wave), epsilon wave (ARVC), pathologic Q waves (old MI), heart block, SVT/VT</li>
                    </ul>
                    
                    <p><span class="label">Risk Stratification - San Francisco Syncope Rule (HIGH RISK if ANY):</span></p>
                    <ul>
                        <li><strong>H</strong>istory of CHF</li>
                        <li><strong>E</strong>CG abnormal (any non-sinus rhythm or new changes)</li>
                        <li><strong>A</strong>nemia (Hct <30%)</li>
                        <li><strong>R</strong>espiratory - Shortness of breath</li>
                        <li><strong>T</strong>riage systolic BP <90 mmHg</li>
                        <li>If ANY present ‚Üí 7-10% risk of serious outcome at 30 days ‚Üí ADMIT</li>
                    </ul>
                    
                    <p><span class="label">Labs (Based on Clinical Suspicion):</span></p>
                    <ul>
                        <li><strong>Basic:</strong> CBC (anemia?), BMP (electrolytes - hypokalemia can cause QT prolongation), glucose (hypoglycemia?)</li>
                        <li><strong>If cardiac suspected:</strong> Troponin (ACS?), BNP (heart failure?), D-dimer if PE suspected</li>
                        <li><strong>If volume depletion suspected:</strong> BUN/Cr ratio, orthostatic vitals</li>
                        <li><strong>Pregnancy test:</strong> All women of childbearing age (ectopic pregnancy can present as syncope)</li>
                    </ul>
                    
                    <p><span class="label">Advanced Testing (If Indicated):</span></p>
                    <ul>
                        <li><strong>Echocardiography:</strong> If structural heart disease suspected (murmur, abnormal ECG, exertional syncope, known heart disease). Assess for AS, HOCM, RV strain (PE), tamponade, LV function</li>
                        <li><strong>Telemetry/Holter Monitor:</strong> If arrhythmia suspected. Admit for telemetry if high-risk features. Outpatient Holter (24-48hr) or event monitor (30 days) for recurrent syncope</li>
                        <li><strong>Exercise Stress Test:</strong> If exertional syncope (evaluate for ischemia, arrhythmias). Contraindicated if severe AS suspected</li>
                        <li><strong>Tilt Table Test:</strong> If recurrent syncope, no cardiac cause found. Reproduces vasovagal response. Positive = BP drop >25mmHg or HR <60 with symptoms</li>
                        <li><strong>Electrophysiology Study (EP Study):</strong> For unexplained syncope with structural heart disease or high suspicion for arrhythmia. Can induce/document VT, assess sinus/AV node function</li>
                        <li><strong>CT Head:</strong> Only if focal neurologic deficits, head trauma, persistent altered mental status. Syncope alone does NOT require head CT</li>
                        <li><strong>Carotid Ultrasound:</strong> Generally low yield. Consider if carotid bruit or vertebrobasilar symptoms</li>
                        <li><strong>CT PE Protocol:</strong> If dyspnea, pleuritic chest pain, hypoxia, tachycardia, RV strain on ECG</li>
                    </ul>
                    
                    <p><span class="label">Orthostatic Vitals Technique:</span></p>
                    <ul>
                        <li>Supine √ó 5 minutes ‚Üí measure BP/HR</li>
                        <li>Stand immediately ‚Üí measure at 1 minute and 3 minutes</li>
                        <li><strong>Positive:</strong> SBP drop ‚â•20 mmHg OR DBP drop ‚â•10 mmHg OR HR increase ‚â•30 bpm (or HR >120)</li>
                        <li>Symptoms (lightheadedness, presyncope) with standing = clinical orthostasis even if BP criteria not met</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li>Treatment depends on underlying cause</li>
                        <li>Admit if high-risk features (see San Francisco Syncope Rule, cardiac cause suspected)</li>
                        <li>Discharge if low-risk and clear benign etiology (young, vasovagal, normal ECG, normal exam)</li>
                    </ul>
                    
                    <p><span class="label">Vasovagal Syncope (Reflex/Neurocardiogenic):</span></p>
                    <ul>
                        <li><strong>Reassurance:</strong> Benign condition, excellent prognosis. Explain pathophysiology</li>
                        <li><strong>Trigger Avoidance:</strong> Avoid prolonged standing, hot environments, dehydration, emotional stress. Sit/lie down at first prodromal symptom</li>
                        <li><strong>Hydration:</strong> Increase fluid intake to 2-3 L/day. Liberal salt intake (6-10g/day) if no contraindications</li>
                        <li><strong>Physical Counterpressure Maneuvers:</strong> At first sign of prodrome: leg crossing + tensing, squatting, arm tensing. Can abort episode</li>
                        <li><strong>Tilt Training:</strong> Gradual exposure to prolonged standing (start 5 min, increase to 30+ min)</li>
                        <li><strong>Pharmacologic (Refractory cases only):</strong>
                            <ul>
                                <li>Midodrine 5-10mg TID (Œ±-agonist, increases BP) - first-line medication</li>
                                <li>Fludrocortisone 0.1-0.2mg daily (volume expansion)</li>
                                <li>Œ≤-blockers (metoprolol) - controversial, limited evidence</li>
                            </ul>
                        </li>
                        <li><strong>Pacemaker:</strong> Very rarely indicated. Only if severe cardioinhibitory response (asystole >3 sec) on tilt table and failed medical therapy</li>
                    </ul>
                    
                    <p><span class="label">Orthostatic Hypotension:</span></p>
                    <ul>
                        <li><strong>Identify and Address Causes:</strong>
                            <ul>
                                <li>Volume depletion ‚Üí IV fluids, oral hydration</li>
                                <li>Medications ‚Üí stop/reduce Œ±-blockers, diuretics, vasodilators, antihypertensives, antidepressants</li>
                                <li>Autonomic dysfunction ‚Üí treat underlying (diabetes, Parkinson's, amyloidosis)</li>
                            </ul>
                        </li>
                        <li><strong>Non-Pharmacologic:</strong>
                            <ul>
                                <li>Rise slowly from supine/sitting (sit at edge of bed √ó 1 min before standing)</li>
                                <li>Increase fluid intake (2-3 L/day) and salt (6-10g/day if no CHF)</li>
                                <li>Compression stockings (waist-high, 30-40 mmHg) - wear before rising</li>
                                <li>Elevate head of bed 10-20 degrees at night (reduces nocturnal diuresis)</li>
                                <li>Avoid large meals (can cause postprandial hypotension)</li>
                                <li>Physical counterpressure maneuvers</li>
                            </ul>
                        </li>
                        <li><strong>Pharmacologic:</strong>
                            <ul>
                                <li>Midodrine 2.5-10mg TID (last dose before 6 PM to avoid supine hypertension)</li>
                                <li>Fludrocortisone 0.1-0.3mg daily (watch for hypokalemia, edema, supine hypertension)</li>
                                <li>Droxidopa 100-600mg TID (norepinephrine precursor, for neurogenic OH)</li>
                                <li>Pyridostigmine 60mg TID (if autonomic failure)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Cardiac Syncope - ADMIT for Telemetry:</span></p>
                    <ul>
                        <li><strong>Arrhythmia Management:</strong>
                            <ul>
                                <li>Bradycardia (sick sinus, AV block) ‚Üí Cardiology consult, consider pacemaker</li>
                                <li>Tachyarrhythmia (VT, SVT) ‚Üí Antiarrhythmics, ablation, ICD evaluation</li>
                                <li>Long QT syndrome ‚Üí Remove offending drugs, electrolyte repletion (Mg, K), Œ≤-blockers, ICD if high risk</li>
                                <li>Brugada, ARVC ‚Üí EP study, ICD placement</li>
                            </ul>
                        </li>
                        <li><strong>Structural Disease:</strong>
                            <ul>
                                <li>Aortic stenosis ‚Üí Cardiology/CT surgery referral for valve replacement if severe + symptomatic</li>
                                <li>HOCM ‚Üí Œ≤-blockers, avoid volume depletion/vasodilators. ICD if high risk. Septal reduction if refractory</li>
                                <li>Pulmonary embolism ‚Üí Anticoagulation, thrombolytics if massive PE</li>
                                <li>Cardiac tamponade ‚Üí Pericardiocentesis</li>
                            </ul>
                        </li>
                        <li><strong>Ischemia:</strong> If syncope due to ACS ‚Üí treat per ACS protocol (aspirin, heparin, cath lab)</li>
                    </ul>
                    
                    <p><span class="label">Situational Syncope:</span></p>
                    <ul>
                        <li>Micturition syncope ‚Üí Sit to void, avoid straining, stay hydrated</li>
                        <li>Defecation syncope ‚Üí Avoid straining (stool softeners), adequate hydration</li>
                        <li>Cough/swallow syncope ‚Üí Treat underlying cause (GERD, cough), maneuvers to reduce triggering</li>
                    </ul>
                    
                    <p><span class="label">Neurologic Syncope (Rare):</span></p>
                    <ul>
                        <li>Vertebrobasilar TIA ‚Üí Neurology consult, antiplatelet therapy, imaging (MRA/CTA neck)</li>
                        <li>Subclavian steal ‚Üí Vascular surgery referral</li>
                        <li>Seizure (if postictal confusion suggests) ‚Üí Neurology consult, antiepileptics, EEG</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>ECG is MANDATORY for ALL syncope patients:</strong> Single most important test. Can diagnose Brugada, long QT, WPW, ARVC, heart block, old MI. Never discharge syncope patient without ECG</li>
                    <li><strong>Syncope while supine = cardiac until proven otherwise:</strong> Vasovagal almost never occurs supine. If patient syncopizes lying down, think arrhythmia and admit for telemetry</li>
                    <li><strong>Exertional syncope = high-risk:</strong> Think HOCM (young athletes), AS (elderly), VT, coronary ischemia. These patients need echo, stress test, and cardiology evaluation</li>
                    <li><strong>Red flags for cardiac syncope:</strong> Age >60, exertional, supine position, no prodrome, known heart disease, abnormal ECG, family history sudden cardiac death. Admit these patients</li>
                    <li><strong>Vasovagal has a prodrome, cardiac doesn't:</strong> If patient describes nausea, diaphoresis, tunnel vision before passing out = vasovagal (low risk). No warning, sudden collapse = cardiac (high risk)</li>
                    <li><strong>Don't confuse syncope with seizure:</strong> Syncope = brief LOC (<20 sec), rapid complete recovery, may have brief myoclonic jerks (<15 sec). Seizure = prolonged LOC, tonic-clonic movements, tongue biting, incontinence, postictal confusion/lethargy. But can be tough to distinguish!</li>
                    <li><strong>Head CT rarely useful:</strong> Only if focal neurologic findings, head trauma, or persistent altered mental status. Syncope is due to global hypoperfusion, not focal brain lesion. Don't reflexively order head CT</li>
                    <li><strong>San Francisco Syncope Rule is your friend:</strong> If none of the 5 criteria (CHF, abnormal ECG, Hct <30%, SOB, SBP <90), patient is low-risk (<1% serious outcome) and can likely be discharged with outpatient follow-up if vasovagal etiology clear</li>
                    <li><strong>Orthostatic vitals technique matters:</strong> Must be supine √ó 5 min first, then check at 1 and 3 minutes standing. Immediate standing without adequate supine time can give false positives</li>
                    <li><strong>Young healthy patient with classic vasovagal story needs minimal workup:</strong> Prodrome, triggered by standing/heat/emotion, quick recovery, normal ECG = can discharge with reassurance and anticipatory guidance. Don't over-test these patients</li>
                    <li><strong>Medications are a common culprit:</strong> Œ±-blockers (BPH meds), diuretics, antihypertensives, TCAs, antipsychotics, PDE5 inhibitors. Always review medication list carefully</li>
                    <li><strong>Carotid massage to diagnose carotid sinus hypersensitivity:</strong> Only perform if safe (no carotid bruits, no recent stroke/TIA). Massage one side √ó 5 seconds. Positive = >3 sec asystole or >50 mmHg BP drop. Never massage both sides simultaneously!</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Syncope with ongoing chest pain suggesting acute MI</li>
                        <li>Hemodynamically unstable (persistent hypotension, shock)</li>
                        <li>Malignant arrhythmia (sustained VT/VF requiring cardioversion)</li>
                        <li>High-grade AV block (Mobitz II, complete heart block) requiring pacing</li>
                        <li>Massive pulmonary embolism with hypotension</li>
                        <li>Cardiac tamponade</li>
                        <li>Aortic dissection</li>
                        <li>Ruptured ectopic pregnancy with hemorrhagic shock</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clear benign etiology identified (vasovagal, orthostatic)</li>
                        <li>NO high-risk features (San Francisco Syncope Rule negative)</li>
                        <li>Normal or unchanged ECG</li>
                        <li>Normal vital signs and orthostatics</li>
                        <li>No concerning cardiac exam findings</li>
                        <li>Labs normal (if obtained)</li>
                        <li>No recurrent episodes during observation</li>
                        <li>Able to ambulate safely without recurrence</li>
                        <li>Patient counseled on trigger avoidance (if vasovagal)</li>
                        <li>Close follow-up arranged (PCP within 1 week, Cardiology if needed)</li>
                        <li>Clear return precautions: recurrent syncope, chest pain, palpitations, dyspnea</li>
                        <li>Driving restrictions discussed (varies by state, typically 3-6 months abstinence after cardiac syncope)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Syncope Episode:</strong> Trauma from fall (head injury, fractures, lacerations), motor vehicle accidents (if driving), sudden cardiac death (if malignant arrhythmia), prolonged cerebral hypoperfusion causing ischemia (rare)</p>
                    <p><strong>From Underlying Cardiac Cause:</strong> Sudden cardiac death (VT/VF, complete heart block), acute MI/ACS, cardiac arrest, stroke from arrhythmia with thrombus formation, progression of structural heart disease (AS, HOCM)</p>
                    <p><strong>From Recurrent Episodes:</strong> Injury from repeated falls, impaired quality of life, anxiety/depression, loss of driving privileges, loss of employment (especially if operate machinery), social isolation</p>
                    <p><strong>From Treatment:</strong> Supine hypertension (midodrine, fludrocortisone - can cause nocturnal HTN), hypokalemia (fludrocortisone), edema (fludrocortisone), bradycardia (Œ≤-blockers), pacemaker complications (infection, lead malfunction), ICD shocks (appropriate or inappropriate)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

</div>


        <!-- PAGE 41: PERICARDITIS -->
        <div id="pericarditis" class="condition-page">
            <div class="page-header">
                <h2>41. PERICARDITIS / PERICARDIAL EFFUSION / CARDIAC TAMPONADE</h2>
                <div class="subtitle">Acute Pericarditis ‚Ä¢ Effusion ‚Ä¢ Tamponade</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad of Acute Pericarditis:</span> Chest pain, pericardial friction rub, diffuse ST elevations on ECG</p>
                    <p><span class="label">Chest Pain:</span> Sharp, pleuritic, worse lying flat, better sitting up leaning forward. Radiates to trapezius (highly specific). Not exertional</p>
                    <p><span class="label">Beck's Triad (Tamponade):</span> Hypotension, elevated JVP, muffled heart sounds. Pulsus paradoxus >10mmHg</p>
                    <p><span class="label">Etiologies:</span> Viral (most common 80-90%), post-MI, uremic, malignancy, autoimmune, TB, drugs, radiation, trauma</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> ESR/CRP (elevated), troponin (if myopericarditis), BMP, blood cultures if febrile</p>
                    <p><span class="label">ECG:</span> Stage 1: Diffuse ST elevation + PR depression. Stage 2: Normalization. Stage 3: T wave inversion. Stage 4: Resolution</p>
                    <p><span class="label">Echo:</span> Assess effusion size, tamponade signs (RA/RV collapse, IVC plethora, respiratory variation >25%/40%)</p>
                    <p><span class="label">Cardiac MRI:</span> If diagnosis unclear or assessing for myopericarditis</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Acute Pericarditis:</span></p>
                    <ul>
                        <li><strong>NSAIDs:</strong> Ibuprofen 600-800mg PO TID √ó 1-2 weeks, taper over 2-4 weeks OR Aspirin 750-1000mg TID</li>
                        <li><strong>Colchicine:</strong> 0.6mg BID √ó 3 months (reduces recurrence 50%). ALWAYS add to NSAIDs</li>
                        <li><strong>PPI:</strong> GI protection</li>
                        <li><strong>Avoid Steroids:</strong> Increase recurrence risk unless autoimmune/uremic/contraindication to NSAIDs</li>
                        <li><strong>Activity Restriction:</strong> No strenuous exercise until symptoms resolve and CRP normalizes (3 months for athletes)</li>
                    </ul>
                    <p><span class="label">Cardiac Tamponade (EMERGENCY):</span></p>
                    <ul>
                        <li>STAT cardiology/cardiac surgery</li>
                        <li>Aggressive IV fluids (500-1000mL NS bolus)</li>
                        <li>URGENT pericardiocentesis under echo/fluoro guidance</li>
                        <li>Remove even 50-100mL can dramatically improve hemodynamics</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>PR
<!-- ============================================ -->
<!-- CONDITION 51: ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE -->
<!-- ============================================ -->
<div class="condition" id="ild">
    <h2>Acute Exacerbation of Interstitial Lung Disease (ILD)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 52: HEMOPTYSIS (MASSIVE) -->
<!-- ============================================ -->
<div class="condition" id="hemoptysis">
    <h2>Hemoptysis (Massive)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 53: ACUTE HYPERCAPNIC RESPIRATORY FAILURE -->
<!-- ============================================ -->
<div class="condition" id="hypercapnic-failure">
    <h2>Acute Hypercapnic Respiratory Failure</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 54: TRANSIENT ISCHEMIC ATTACK (TIA) -->
<!-- ============================================ -->
<div class="condition" id="tia">
    <h2>Transient Ischemic Attack (TIA)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 55: GUILLAIN-BARR√â SYNDROME -->
<!-- ============================================ -->
<div class="condition" id="gbs">
    <h2>Guillain-Barr√© Syndrome</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 56: MYASTHENIA GRAVIS CRISIS -->
<!-- ============================================ -->
<div class="condition" id="myasthenia">
    <h2>Myasthenia Gravis Crisis</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 57: ACUTE DELIRIUM (NON-ALCOHOL) -->
<!-- ============================================ -->
<div class="condition" id="delirium">
    <h2>Acute Delirium (Non-Alcohol)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 58: INCREASED INTRACRANIAL PRESSURE -->
<!-- ============================================ -->
<div class="condition" id="increased-icp">
    <h2>Increased Intracranial Pressure (ICP)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 59: SPINAL CORD COMPRESSION -->
<!-- ============================================ -->
<div class="condition" id="cord-compression">
    <h2>Spinal Cord Compression</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 60: INFLUENZA/SEVERE VIRAL PNEUMONIA -->
<!-- ============================================ -->
<div class="condition" id="influenza">
    <h2>Influenza/Severe Viral Pneumonia</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 61: COVID-19 SEVERE DISEASE -->
<!-- ============================================ -->
<div class="condition" id="covid">
    <h2>COVID-19 Severe Disease</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 62: CLOSTRIDIOIDES DIFFICILE COLITIS -->
<!-- ============================================ -->
<div class="condition" id="cdiff">
    <h2>Clostridioides difficile Colitis</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 63: UTI/PYELONEPHRITIS (COMPLICATED) -->
<!-- ============================================ -->
<div class="condition" id="pyelo">
    <h2>Urinary Tract Infection/Pyelonephritis (Complicated)</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 64: SKIN/SOFT TISSUE INFECTIONS -->
<!-- ============================================ -->
<div class="condition" id="ssti">
    <h2>Skin/Soft Tissue Infections (Cellulitis, Necrotizing Fasciitis)</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 65: TUBERCULOSIS (ACTIVE) -->
<!-- ============================================ -->
<div class="condition" id="tb">
    <h2>Tuberculosis (Active)</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 66: HIV/AIDS COMPLICATIONS -->
<!-- ============================================ -->
<div class="condition" id="hiv-aids">
    <h2>HIV/AIDS Complications</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 67: OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED HOST -->
<!-- ============================================ -->
<div class="condition" id="opportunistic">
    <h2>Opportunistic Infections in Immunocompromised Host</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 68: HYPERTHYROIDISM/THYROTOXICOSIS -->
<!-- ============================================ -->
<div class="condition" id="hyperthyroid">
    <h2>Hyperthyroidism/Thyrotoxicosis (Non-Storm)</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 69: HYPOTHYROIDISM -->
<!-- ============================================ -->
<div class="condition" id="hypothyroid">
    <h2>Hypothyroidism (Non-Myxedema)</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 70: DIABETIC FOOT INFECTION -->
<!-- ============================================ -->
<div class="condition" id="diabetic-foot">
    <h2>Diabetic Foot Infection</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 71: SIADH -->
<!-- ============================================ -->
<div class="condition" id="siadh">
    <h2>SIADH (Syndrome of Inappropriate ADH)</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 72: DIABETES INSIPIDUS -->
<!-- ============================================ -->
<div class="condition" id="diabetes-insipidus">
    <h2>Diabetes Insipidus</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 73: PHEOCHROMOCYTOMA CRISIS -->
<!-- ============================================ -->
<div class="condition" id="pheo">
    <h2>Pheochromocytoma Crisis</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 74: BOWEL OBSTRUCTION -->
<!-- ============================================ -->
<div class="condition" id="bowel-obstruction">
    <h2>Bowel Obstruction (Small/Large)</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 75: SEVERE ACUTE DIARRHEA/VOLUME DEPLETION -->
<!-- ============================================ -->
<div class="condition" id="acute-diarrhea">
    <h2>Severe Acute Diarrhea/Volume Depletion</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 76: INFLAMMATORY BOWEL DISEASE FLARE -->
<!-- ============================================ -->
<div class="condition" id="ibd">
    <h2>Inflammatory Bowel Disease (IBD) Flare</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 77: DIVERTICULITIS (COMPLICATED) -->
<!-- ============================================ -->
<div class="condition" id="diverticulitis">
    <h2>Diverticulitis (Complicated)</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 78: CIRRHOSIS COMPLICATIONS -->
<!-- ============================================ -->
<div class="condition" id="cirrhosis-complications">
    <h2>Cirrhosis Complications (Variceal Bleeding, Hepatorenal Syndrome)</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 79: ACUTE-ON-CHRONIC LIVER FAILURE -->
<!-- ============================================ -->
<div class="condition" id="aclf">
    <h2>Acute-on-Chronic Liver Failure</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 80: ISCHEMIC BOWEL/MESENTERIC ISCHEMIA -->
<!-- ============================================ -->
<div class="condition" id="mesenteric-ischemia">
    <h2>Ischemic Bowel/Mesenteric Ischemia</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 81: CHRONIC KIDNEY DISEASE COMPLICATIONS -->
<!-- ============================================ -->
<div class="condition" id="ckd-complications">
    <h2>Chronic Kidney Disease Complications</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 82: UREMIC SYNDROME -->
<!-- ============================================ -->
<div class="condition" id="uremia">
    <h2>Uremic Syndrome</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 83: RHABDOMYOLYSIS -->
<!-- ============================================ -->
<div class="condition" id="rhabdo">
    <h2>Rhabdomyolysis</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 84: TUMOR LYSIS SYNDROME -->
<!-- ============================================ -->
<div class="condition" id="tls">
    <h2>Tumor Lysis Syndrome</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 85: HYPOCALCEMIA -->
<!-- ============================================ -->
<div class="condition" id="hypocalcemia">
    <h2>Hypocalcemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 86: HYPERMAGNESEMIA/HYPOMAGNESEMIA -->
<!-- ============================================ -->
<div class="condition" id="magnesium">
    <h2>Hypermagnesemia/Hypomagnesemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 87: HYPERPHOSPHATEMIA/HYPOPHOSPHATEMIA -->
<!-- ============================================ -->
<div class="condition" id="phosphate">
    <h2>Hyperphosphatemia/Hypophosphatemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 88: METABOLIC ALKALOSIS -->
<!-- ============================================ -->
<div class="condition" id="metabolic-alkalosis">
    <h2>Metabolic Alkalosis</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 89: THROMBOCYTOPENIA (ITP, HIT, TTP/HUS) -->
<!-- ============================================ -->
<div class="condition" id="thrombocytopenia">
    <h2>Thrombocytopenia (ITP, HIT, TTP/HUS)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 90: DISSEMINATED INTRAVASCULAR COAGULATION (DIC) -->
<!-- ============================================ -->
<div class="condition" id="dic">
    <h2>Disseminated Intravascular Coagulation (DIC)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 91: SICKLE CELL CRISIS -->
<!-- ============================================ -->
<div class="condition" id="sickle-cell">
    <h2>Sickle Cell Crisis (Vaso-occlusive, Acute Chest)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 92: HEMOLYTIC ANEMIA -->
<!-- ============================================ -->
<div class="condition" id="hemolytic-anemia">
    <h2>Hemolytic Anemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 93: ONCOLOGIC EMERGENCIES -->
<!-- ============================================ -->
<div class="condition" id="onc-emergencies">
    <h2>Oncologic Emergencies (SVC Syndrome, Cord Compression, Hypercalcemia of Malignancy)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 94: ANTICOAGULATION REVERSAL/MAJOR BLEEDING -->
<!-- ============================================ -->
<div class="condition" id="anticoag-reversal">
    <h2>Anticoagulation Reversal/Major Bleeding on Anticoagulants</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 95: ACUTE GOUT/PSEUDOGOUT -->
<!-- ============================================ -->
<div class="condition" id="gout">
    <h2>Acute Gout/Pseudogout (Crystal Arthropathy)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 96: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) FLARE -->
<!-- ============================================ -->
<div class="condition" id="sle">
    <h2>Systemic Lupus Erythematosus (SLE) Flare</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 97: GIANT CELL ARTERITIS/TEMPORAL ARTERITIS -->
<!-- ============================================ -->
<div class="condition" id="gca">
    <h2>Giant Cell Arteritis/Temporal Arteritis</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 98: ANAPHYLAXIS -->
<!-- ============================================ -->
<div class="condition" id="anaphylaxis">
    <h2>Anaphylaxis</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 99: DRUG OVERDOSE/TOXIDROMES -->
<!-- ============================================ -->
<div class="condition" id="overdose">
    <h2>Drug Overdose/Toxidromes (Acetaminophen, Salicylates, TCA, etc.)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 100: OPIOID OVERDOSE/WITHDRAWAL -->
<!-- ============================================ -->
<div class="condition" id="opioid">
    <h2>Opioid Overdose/Withdrawal</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>
        <div class="footer-section">
            <p><strong>Internal Medicine Clinical Reference Guide</strong></p>
            <p>Evidence-based guidelines for hospital medicine</p>
            <p style="font-size: 8pt; margin-top: 15px;">Always consult institutional protocols and current literature. Updated 2025.</p>
        </div>
    </div>
    
    <script>
        // HEART Score Calculator
        function calculateHEART() {
            const history = parseInt(document.getElementById('heart-history').value);
            const ecg = parseInt(document.getElementById('heart-ecg').value);
            const age = parseInt(document.getElementById('heart-age').value);
            const risk = parseInt(document.getElementById('heart-risk').value);
            const trop = parseInt(document.getElementById('heart-trop').value);
            
            const score = history + ecg + age + risk + trop;
            
            let interpretation = '';
            let riskClass = '';
            
            if (score <= 3) {
                interpretation = `Score: ${score}/10 - LOW RISK (0.9-1.7% adverse cardiac events at 6 weeks). Consider outpatient workup.`;
                riskClass = '';
            } else if (score <= 6) {
                interpretation = `Score: ${score}/10 - MODERATE RISK (12-16% adverse cardiac events at 6 weeks). Admit for observation and further evaluation.`;
                riskClass = '';
            } else {
                interpretation = `Score: ${score}/10 - HIGH RISK (50-65% adverse cardiac events at 6 weeks). Admit for aggressive management, consider early invasive strategy.`;
                riskClass = 'high-risk';
            }
            
            document.getElementById('heart-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // TIMI STEMI Calculator
        function calculateTIMI_STEMI() {
            let score = 0;
            
            if (document.getElementById('timi-stemi-age65').checked) score += 2;
            if (document.getElementById('timi-stemi-age75').checked) score += 3;
            if (document.getElementById('timi-stemi-dm').checked) score += 1;
            if (document.getElementById('timi-stemi-bp').checked) score += 3;
            if (document.getElementById('timi-stemi-hr').checked) score += 2;
            if (document.getElementById('timi-stemi-killip').checked) score += 2;
            if (document.getElementById('timi-stemi-weight').checked) score += 1;
            if (document.getElementById('timi-stemi-anterior').checked) score += 1;
            if (document.getElementById('timi-stemi-time').checked) score += 1;
            
            let mortality = '';
            let riskClass = '';
            
            if (score === 0) {
                mortality = '0.8%';
            } else if (score === 1) {
                mortality = '1.6%';
            } else if (score === 2) {
                mortality = '2.2%';
            } else if (score === 3) {
                mortality = '4.4%';
            } else if (score === 4) {
                mortality = '7.3%';
            } else if (score === 5) {
                mortality = '12.4%';
            } else if (score === 6) {
                mortality = '16.1%';
            } else if (score === 7) {
                mortality = '23.4%';
            } else if (score === 8) {
                mortality = '26.8%';
            } else {
                mortality = '35.9%';
                riskClass = 'high-risk';
            }
            
            if (score > 6) riskClass = 'high-risk';
            
            const interpretation = `Score: ${score} - Predicted 30-day mortality: ${mortality}`;
            
            document.getElementById('timi-stemi-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // TIMI NSTEMI Calculator
        function calculateTIMI_NSTEMI() {
            let score = 0;
            
            if (document.getElementById('timi-nstemi-age').checked) score += 1;
            if (document.getElementById('timi-nstemi-risk').checked) score += 1;
            if (document.getElementById('timi-nstemi-cad').checked) score += 1;
            if (document.getElementById('timi-nstemi-asa').checked) score += 1;
            if (document.getElementById('timi-nstemi-angina').checked) score += 1;
            if (document.getElementById('timi-nstemi-ecg').checked) score += 1;
            if (document.getElementById('timi-nstemi-trop').checked) score += 1;
            
            let risk = '';
            let riskClass = '';
            
            if (score <= 2) {
                risk = '5% risk of death, MI, or urgent revascularization at 14 days - LOW RISK';
            } else if (score <= 4) {
                risk = '13% risk of death, MI, or urgent revascularization at 14 days - MODERATE RISK';
            } else {
                risk = '41% risk of death, MI, or urgent revascularization at 14 days - HIGH RISK. Consider early invasive strategy.';
                riskClass = 'high-risk';
            }
            
            const interpretation = `Score: ${score}/7 - ${risk}`;
            
            document.getElementById('timi-nstemi-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // GRACE Score Calculator
        function calculateGRACE() {
            const age = parseInt(document.getElementById('grace-age').value) || 0;
            const hr = parseInt(document.getElementById('grace-hr').value) || 0;
            const sbp = parseInt(document.getElementById('grace-sbp').value) || 0;
            const cr = parseFloat(document.getElementById('grace-cr').value) || 0;
            
            // Age points
            let agePoints = 0;
            if (age < 30) agePoints = 0;
            else if (age < 40) agePoints = 8;
            else if (age < 50) agePoints = 25;
            else if (age < 60) agePoints = 41;
            else if (age < 70) agePoints = 58;
            else if (age < 80) agePoints = 75;
            else agePoints = 91;
            
            // HR points
            let hrPoints = 0;
            if (hr < 50) hrPoints = 0;
            else if (hr < 70) hrPoints = 3;
            else if (hr < 90) hrPoints = 9;
            else if (hr < 110) hrPoints = 15;
            else if (hr < 150) hrPoints = 24;
            else if (hr < 200) hrPoints = 38;
            else hrPoints = 46;
            
            // SBP points
            let sbpPoints = 0;
            if (sbp < 80) sbpPoints = 58;
            else if (sbp < 100) sbpPoints = 53;
            else if (sbp < 120) sbpPoints = 43;
            else if (sbp < 140) sbpPoints = 34;
            else if (sbp < 160) sbpPoints = 24;
            else if (sbp < 200) sbpPoints = 10;
            else sbpPoints = 0;
            
            // Creatinine points
            let crPoints = 0;
            if (cr < 0.4) crPoints = 1;
            else if (cr < 0.8) crPoints = 4;
            else if (cr < 1.2) crPoints = 7;
            else if (cr < 1.6) crPoints = 10;
            else if (cr < 2.0) crPoints = 13;
            else if (cr < 4.0) crPoints = 21;
            else crPoints = 28;
            
            const arrest = document.getElementById('grace-arrest').checked ? 39 : 0;
            const st = document.getElementById('grace-st').checked ? 28 : 0;
            const enzymes = document.getElementById('grace-enzymes').checked ? 14 : 0;
            const killip = parseInt(document.getElementById('grace-killip').value);
            
            const score = agePoints + hrPoints + sbpPoints + crPoints + arrest + st + enzymes + killip;
            
            let risk = '';
            let riskClass = '';
            
            if (score < 109) {
                risk = 'LOW RISK - <1% in-hospital mortality, <3% 6-month mortality';
            } else if (score < 140) {
                risk = 'INTERMEDIATE RISK - 1-3% in-hospital mortality, 3-8% 6-month mortality';
            } else {
                risk = 'HIGH RISK - >3% in-hospital mortality, >8% 6-month mortality. Consider aggressive management.';
                riskClass = 'high-risk';
            }
            
            const interpretation = `GRACE Score: ${score} - ${risk}`;
            
            document.getElementById('grace-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // Wells Score for PE Calculator
        function calculateWells() {
            let score = 0;
            
            if (document.getElementById('wells-dvt').checked) score += 3;
            if (document.getElementById('wells-alt').checked) score += 3;
            if (document.getElementById('wells-hr').checked) score += 1.5;
            if (document.getElementById('wells-immob').checked) score += 1.5;
            if (document.getElementById('wells-prior').checked) score += 1.5;
            if (document.getElementById('wells-hemo').checked) score += 1;
            if (document.getElementById('wells-cancer').checked) score += 1;
            
            let interpretation = '';
            let riskClass = '';
            
            if (score <= 4) {
                interpretation = `Wells Score: ${score} - PE UNLIKELY. Consider D-dimer to rule out PE. If D-dimer negative, PE excluded.`;
            } else {
                interpretation = `Wells Score: ${score} - PE LIKELY. Proceed directly to CTPA or V/Q scan. Do not wait for D-dimer.`;
                riskClass = 'high-risk';
            }
            
            document.getElementById('wells-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // qSOFA Calculator
        function calculateQSOFA() {
            let score = 0;
            
            if (document.getElementById('qsofa-rr').checked) score += 1;
            if (document.getElementById('qsofa-ams').checked) score += 1;
            if (document.getElementById('qsofa-sbp').checked) score += 1;
            
            let interpretation = '';
            let riskClass = '';
            
            if (score < 2) {
                interpretation = `qSOFA Score: ${score}/3 - LOW RISK for poor outcomes. Does not exclude sepsis. Continue clinical assessment.`;
            } else {
                interpretation = `qSOFA Score: ${score}/3 - HIGH RISK for poor outcomes. Strongly consider sepsis. Calculate full SOFA score, obtain lactate, start sepsis bundle immediately.`;
                riskClass = 'high-risk';
            }
            
            document.getElementById('qsofa-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // FENa Calculator
        function calculateFENa() {
            const urineNa = parseFloat(document.getElementById('fena-urine-na').value);
            const serumNa = parseFloat(document.getElementById('fena-serum-na').value);
            const urineCr = parseFloat(document.getElementById('fena-urine-cr').value);
            const serumCr = parseFloat(document.getElementById('fena-serum-cr').value);
            
            if (!urineNa || !serumNa || !urineCr || !serumCr) {
                document.getElementById('fena-result').innerHTML = '<div class="calc-result">Please enter all values</div>';
                return;
            }
            
            // FENa = (Urine Na / Serum Na) / (Urine Cr / Serum Cr) √ó 100
            const fena = ((urineNa / serumNa) / (urineCr / serumCr)) * 100;
            
            let interpretation = '';
            let riskClass = '';
            
            if (fena < 1) {
                interpretation = `FENa: ${fena.toFixed(2)}% - Suggests PRERENAL AKI. Kidney is avidly retaining sodium (underperfused but functioning). Treat with fluids/optimize perfusion.`;
            } else if (fena <= 2) {
                interpretation = `FENa: ${fena.toFixed(2)}% - INDETERMINATE. Could be prerenal or early ATN. Consider clinical context and other findings.`;
                riskClass = '';
            } else {
                interpretation = `FENa: ${fena.toFixed(2)}% - Suggests INTRINSIC AKI (likely ATN). Kidney cannot conserve sodium (tubular damage). Supportive care, avoid nephrotoxins.`;
                riskClass = 'high-risk';
            }
            
            interpretation += '<br><br><strong>Note:</strong> FENa not valid if patient on diuretics. Use FEUrea instead (<35% = prerenal).';
            
            document.getElementById('fena-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
    </script>
    
</body>
</html>
